Research in the News

Keith Thomas broke his neck at the bottom of a swimming pool in the summer of 2020, leaving him paralysed from the chest down. This month his story has been making the rounds again across the news, and for good reason: he can now move his hand, drink on his own, wipe his own face — and feel the fur of his family's dog, Bow, under his fingers.

The technology behind it is called a "double neural bypass," and it's one of the more striking demonstrations of what brain-computer interfaces can do for spinal cord injury. Because the story is resurfacing rather than brand new — the surgery itself took place in 2023 — it's a good moment to look calmly at what's actually been achieved, and what it means.

What a "double neural bypass" is

When the spinal cord is damaged, the problem isn't usually that the brain or the muscles have stopped working. It's that the wiring between them is broken. The brain still forms the intention to move a hand; that signal just can't get past the injury to reach the arm.

A neural bypass builds a detour around the damage. Surgeons at the Feinstein Institutes for Medical Research at Northwell Health in New York, led by Professor Chad Bouton, implanted electrodes in the part of Thomas's brain that controls movement. Those electrodes read his intention to move, a computer interprets it, and the signal is routed — bypassing the injured spinal cord entirely — to stimulators that activate the muscles in his arm and hand.

The "double" part is what makes it stand out. Most systems only handle the outgoing direction: brain to muscle. This one also runs sensation back the other way. Pressure sensors on Thomas's fingertips send touch information back to the sensory areas of his brain, so he doesn't just move his hand — he can feel what he's touching. That two-way loop is why he can register the softness of his dog's fur.

What actually changed for him

Before the implant, Thomas could lift his arms only about an inch. During the trial he was able to move his arm at will and feel touch again. What surprised the research team most was that some improvement lingered even when the system was switched off — suggesting the therapy may be encouraging the nervous system itself to recover a little, not just acting as an external bridge. His gains in arm and wrist strength have carried over into everyday life outside the lab.

The honest caveats

This is genuinely remarkable, and it's also important not to oversell it. This is one participant in an early clinical trial, not an approved treatment you can go and receive. The setup involves major brain surgery — Thomas's operation lasted around 15 hours — and a system that, for now, largely lives in a research lab. It restores specific hand and arm function; it does not reverse paralysis or let him walk. The path from a single extraordinary result to something widely available is long, and honesty about that is part of respecting how hard the work still is.

Still, the direction is real. Every function restored — a hand that grips, a fingertip that feels — is a piece of independence handed back. And the hint that the nervous system might partially heal alongside the technology is exactly the kind of clue researchers build the next decade of work on.

Reader Q&A

Is this available as a treatment? No. It's an experimental system tested in a clinical trial with a small number of participants. It is not an approved therapy you can currently receive.

How is it different from other brain implants I've read about? Most brain-computer interfaces are one-way: they read movement intention and drive a device or muscle. This one is two-way — it also feeds touch sensation from the fingers back to the brain, so movement and feeling are restored together.

Why is the story in the news again now? The surgery took place in 2023, and the system has since been widely recognised as a landmark. Coverage has resurfaced this month, which is why you may be seeing it across several outlets.

Did the improvements last? Some gains in arm and wrist function persisted even when the system was turned off, and carried into daily life — a hint that the therapy may be helping the nervous system recover, not just substituting for it.

One of the most frustrating facts about spinal cord injury is that, in the crucial first days after a severe injury, doctors still have almost nothing to give. Surgery to stabilise the spine, careful management of blood pressure and breathing — yes. But an actual drug that protects the injured cord and improves the odds of recovery? There isn't a widely accepted one. A new Phase III trial published in the Journal of Neurotrauma is part of a long effort to change that.

The drug is hepatocyte growth factor, usually shortened to HGF. Despite the name — it was first identified for its role in the liver — HGF turns out to be a powerful protective and pro-repair signal in the nervous system too. In animal studies it reduces the wave of secondary damage that follows a spinal cord injury and supports the survival of nerve cells. This trial is the culmination of a research programme (led by teams including Kitamura, Nagoshi and colleagues) that has moved HGF step by step from the lab bench toward the clinic.

What the trial tested

The study looked at intrathecal delivery of recombinant human HGF — meaning the drug is injected into the fluid around the spinal cord, so it reaches the injured tissue directly rather than being diluted through the whole body. Timing is central to the design: treatment is given within 72 hours of injury, during the narrow window when limiting secondary damage can matter most.

What stands out is the population. The trial focused on people with AIS grade A injuries — the most severe, "complete" category, where there's no movement or sensation preserved below the level of injury. This is deliberately the hardest group to help and the one where existing treatments have least to offer. Testing a therapy here is ambitious; it's also exactly where a success would mean the most.

How to read a result like this

A couple of honest caveats matter. First, this summary is based on the published abstract rather than the full paper, so the fine detail of how much benefit was seen — and how confidently — needs to be read in the complete results. Second, HGF's earlier human testing was a Phase I/II safety and early-efficacy study, and the reported Phase III work has been a relatively small, focused trial rather than a huge multi-thousand-patient study. That's normal for a condition as specific as acute severe cervical injury, but it means results should be read as an important step, not a finish line.

The reason this is worth flagging at all is the target. Most of the exciting SCI research we cover is about chronic injury — helping people months or years down the line. This is different: it's about intervening in the first hours and days, in the most severely injured people, to change the trajectory before scar and damage set in. If HGF holds up, it would fill one of the biggest gaps in spinal cord injury care.

Reader Q&A

What is HGF in plain terms? Hepatocyte growth factor is a natural signalling protein. In the injured spinal cord it appears to protect nerve cells and limit the "second wave" of damage that follows the initial trauma.

Why inject it into the spinal fluid? Delivering it intrathecally — into the fluid around the cord — gets the drug straight to the injured area at a useful concentration, rather than relying on it travelling through the bloodstream.

Who was this trial for? People with the most severe (AIS grade A) acute cervical injuries, treated within 72 hours. That's the group with the fewest options today.

Does this mean a treatment is coming soon? Not immediately. A published Phase III is a significant milestone, but regulatory approval and real-world availability depend on the full results and on regulators' review. This is an encouraging step, not a treatment you can request yet. (Note: this write-up is based on the abstract.)

If you've been following spinal cord injury news over the past year, the name ARC-EX may already be familiar. It's the non-invasive stimulation system from ONWARD Medical that earned regulatory clearance on both sides of the Atlantic, and we've written before about the wider UK programme testing it in real rehabilitation settings. This week brings a concrete next step: STEPS Rehabilitation, a residential centre in Sheffield, has become one of the first rehab providers in Europe to bring ARC-EX in-house for its clients.

That distinction — a device moving out of the trial and into the day-to-day rehab gym — is exactly the kind of milestone worth paying attention to.

What ARC-EX actually does

ARC-EX is a form of transcutaneous (through-the-skin) spinal cord stimulation. Electrodes are placed on the skin over the back of the neck, and the device delivers gentle electrical pulses to the spinal cord below the level of injury. The idea isn't to override the nervous system but to "wake it up": the stimulation makes the surviving nerve pathways more responsive, so signals from the brain that were once too weak to get through can have more of an effect.

Crucially, it's non-invasive. Unlike epidural stimulators, which require surgery to implant electrodes directly onto the spinal cord, ARC-EX sits on the outside of the body. That lowers the barrier considerably — no operation, no surgical risk — which is a big part of why it's realistic for a rehab centre to offer it as part of a programme rather than only in a hospital research setting.

ARC-EX is the first system to receive a CE Mark in Europe specifically for improving hand and arm strength and sensation in adults living with chronic, incomplete spinal cord injury. The strongest results so far have come when the stimulation is paired with intensive, task-specific rehabilitation — in other words, the device isn't a replacement for the hard work of therapy, it's a way of making that work go further.

Why a rehab centre adopting it matters

There's an important difference between a technology being approved and a technology being available. Regulatory clearance means a device has cleared the safety and evidence bar. Actual availability means a person with a spinal cord injury can walk into a centre and access it as part of their rehab. STEPS bringing ARC-EX into its residential programmes is a small but real example of that second step happening in the UK.

It's worth keeping expectations honest. ARC-EX is aimed at people with incomplete injuries — those who retain some nerve signalling below the injury — and it's about improving hand and arm function, not restoring walking or reversing paralysis. For the right person, better grip and hand strength can translate into meaningful independence: managing a phone, holding cutlery, transferring more safely. That's not a cure, but it's not nothing either.

Reader Q&A

Is this the same as the surgical stimulators I've read about? No. Those are epidural stimulators, implanted onto the spinal cord during surgery. ARC-EX is non-invasive — the electrodes sit on the skin over the neck, so there's no operation involved.

Who is ARC-EX for? It's approved in Europe for adults with chronic, incomplete spinal cord injury, to improve hand and arm strength and sensation. It's not aimed at complete injuries or at restoring walking.

Does it work on its own? The evidence so far suggests it works best combined with intensive, task-specific rehabilitation. Think of it as amplifying the benefit of therapy rather than replacing it.

How do I access it? It's newly available at STEPS Rehabilitation in Sheffield and through the wider UK rollout. Availability is still limited and early, so anyone interested would need to contact providers directly to understand eligibility and cost.

Kenny Salvini was left paralysed after a skiing accident 22 years ago. Out of that came something he now calls his "passion project": the Here and Now Project, a social support network for people with spinal cord injuries and other mobility disabilities, running gatherings up and down Washington's I-5 corridor and on the Olympic Peninsula.

Seattle Sounders FC recently featured the organisation as part of its "Change Champions" initiative, a partnership with Boeing that spotlights local groups making a difference in their communities. The club has a long-running relationship with the Here and Now Project as part of its broader push to make sport, and community life more generally, accessible to people with disabilities.

Why peer support matters this much

Salvini describes the organisation's purpose simply: it's a way to "get knee to knee with people that have been where you've been." That's a distinction worth sitting with. Rehab teams, doctors, and family can offer enormous support after a spinal cord injury, but there's a particular kind of understanding that only comes from someone who has actually lived through it — the practical stuff nobody puts in a discharge pamphlet, the emotional weight of adjusting to a new normal, the small wins that don't seem small at all when you're the one experiencing them.

That's the gap peer-support organisations like this one are built to fill. They don't replace clinical care, but they offer something clinical care often can't: community, on equal footing, with people who simply get it.

A small story with a real point

There's no clinical trial here, no new device or drug. But stories like this matter for a different reason — they're a reminder that quality of life after spinal cord injury isn't just about what medicine can restore physically. It's also about whether people have somewhere to belong. Organisations like the Here and Now Project, and the local partnerships that help amplify them, are part of what makes that possible.

Reader Q&A

What exactly does the Here and Now Project do? It runs regular social gatherings for people with spinal cord injuries and other mobility disabilities across the Seattle area and Pacific Northwest, built around peer connection rather than clinical treatment.

Who runs it? Kenny Salvini, who was paralysed in a skiing accident 22 years ago, leads the organisation as executive director.

Is this only for people in Seattle? The gatherings are regional, focused on Washington State's I-5 corridor and the Olympic Peninsula, so it's most relevant to people in that area — but it's a good example of the kind of peer-support model that exists in many communities.

Why is a football club involved? Seattle Sounders FC's "Change Champions" programme, run with Boeing, spotlights local nonprofits doing meaningful community work — it's a way of using the club's platform to raise awareness and support for groups like this one.

Zebrafish can do something humans can't: fully repair a severed spinal cord and swim normally again within weeks. Scientists have studied this for years hoping to find the "trick" — some magic molecule humans are missing. A new study from Karolinska Institutet, published in *Science Advances*, suggests the real trick isn't a single molecule at all. It's timing.

What the researchers found

The team, led by Konstantinos Ampatzis at Karolinska's Department of Neuroscience, studied adult zebrafish after a complete spinal cord injury. First, they found that neurons near the injury site don't simply die off if they survive the initial trauma — they go quiet for a while, temporarily changing how they fire and how they talk to neighbouring cells, before coming back online.

At the same time, the tissue surrounding the injury changes too. A group of molecules called chondroitin sulphate proteoglycans (CSPGs) — long blamed as one of the biggest obstacles to spinal cord regeneration, because they form a dense barrier around damaged tissue — briefly spike after injury.

Here's the twist: when the researchers used an enzyme to clear away CSPGs early after injury, healing sped up at first, but the fish ended up worse off. Long-term regrowth and swimming ability were both impaired. It turns out CSPGs aren't just a barrier — early on, they protect and stabilise the injured neurons. It's only later that they start getting in the way of regrowth.

Why this matters beyond zebrafish

A lot of experimental spinal cord treatments — including some in human trials — work by trying to clear away CSPGs to "unblock" regeneration. This study suggests that approach might backfire if the timing is wrong. Strip away the protective barrier too soon, and you could be removing something the injured tissue actually needs in those first hours or days.

The researchers now want to identify exactly which cells produce these matrix molecules after injury, and how the process is controlled, with the eventual goal of designing therapies that protect neurons early and only encourage regrowth once that protective phase has done its job.

The honest caveat

This is zebrafish research, not a human trial, and it's early-stage. Human spinal cords are far more complex, and turning "timing matters" into an actual treatment is still a long way off. But it's a genuinely useful piece of the puzzle — it helps explain why some regeneration-focused drugs have underperformed in past trials, and it gives researchers a clearer roadmap for sequencing future treatments rather than just removing barriers all at once.

Reader Q&A

Does this mean a cure is coming soon? No. This is basic biology research in fish, aimed at understanding *why* spinal cord healing succeeds or fails — not a treatment ready for people. But findings like this shape how future human therapies get designed and timed.

Why do scientists study zebrafish for spinal cord injury at all? Zebrafish are one of the few vertebrates that can fully regenerate a severed spinal cord. Because they share a lot of basic biology with humans, studying what makes their repair process succeed can point researchers toward what's missing or going wrong in mammals, including us.

Could "clearing barriers" treatments already in human trials be doing harm? This study doesn't test that directly in humans, so we can't say for certain. But it's a reasonable flag that timing needs more attention in how these treatments are designed and tested going forward.

What happens next in this research? The team plans to figure out exactly which cells are producing the matrix molecules after injury and how that process is controlled, with the long-term goal of designing treatments that protect neurons early and support regrowth later.

Of all the concerns that have surrounded stem cell therapy for spinal cord injury over the decades, the one that matters most is this: could transplanted cells go rogue? Could they multiply out of control and form a tumour in the spinal cord?

That question has held back clinical translation for years. Animal studies were encouraging. Non-human primate studies were encouraging. But no-one had injected iPSC-derived neural cells into a living human spinal cord and watched what happened — until now.

Published today in *Nature Medicine*, a research team from Keio University School of Medicine in Tokyo reports results from a first-in-human Phase 1 trial. Four men with complete cervical spinal cord injuries received transplants of iPSC-derived neural stem/progenitor cells. The primary finding: across two to four years of follow-up, no tumour formed. No graft-related serious adverse events occurred. The cells appear to have been safe.

That's the headline. Everything else — the neurological changes, the grade improvements, the comparison with registry data — is secondary, and the researchers are careful to say so.

What iPSC-NS/PCs are, and why they matter

iPSC stands for induced pluripotent stem cell. The key word is *induced*. Ordinary adult cells — in this case, cells from umbilical cord blood — can be reprogrammed in the laboratory back to a stem-cell-like state, then directed to become the specific cell type you want. In this trial, those stem cells were guided to become neural stem/progenitor cells (NS/PCs): cells that, once in the right environment, can differentiate into neurons, astrocytes, and oligodendrocytes — the main cell types of the nervous system.

The practical advantage of iPSC-derived cells over earlier stem cell approaches is significant. The cell line used in this trial came from a single healthy donor with a common HLA (immune) profile, manufactured under pharmaceutical-grade conditions at Kyoto University's Centre for iPS Cell Research and Application. That single donor's cells, cryopreserved and quality-controlled, can potentially be used for many different patients — a much more scalable and standardised approach than therapies requiring cells from each individual patient.

The cells were prepared with an additional safety step: before transplantation, a γ-secretase inhibitor was applied to suppress a cell-growth pathway (Notch signalling) that had previously been linked to tumour-like overgrowth in preclinical work. This purification step was one of several quality controls that allowed the team to feel confident enough to proceed to human trials.

Who received the treatment

Seven candidates were screened; four met the eligibility criteria. All were male, aged 26 to 66, with complete cervical SCI (AIS grade A — the most severe category, indicating no voluntary motor or sensory function below the injury) at levels between C4 and C6. The injury had to be confirmed complete, confirmed stable, and in the subacute phase (14–28 days post-injury) — a window the researchers had identified in preclinical work as most likely to support cell integration.

Two million cells were injected directly into the injury epicentre under ultrasound guidance during a single surgical procedure. Immunosuppression (tacrolimus) was started the day before transplantation, maintained for six months, and then tapered off by nine months. Standard rehabilitation was continued throughout.

Follow-up ranged from two to four years depending on when each patient was enrolled — patient 1 has now had four years of surveillance.

The safety results

The primary endpoint was safety, and it was met. Serial MRI scans showed no evidence of abnormal cell proliferation at any time point across any participant. FDG-PET imaging at 24 weeks — which would show metabolically hyperactive tissue, a signature of tumour growth — was normal in all four. During long-term follow-up, no imaging or clinical findings suggestive of tumour formation were identified.

Across all participants, 84 adverse events were recorded — most mild, and most attributable to the immunosuppressive drug tacrolimus rather than to the cells themselves. The most frequent issues were hypomagnesemia (low magnesium, a known tacrolimus effect) and urinary tract infections (common after SCI generally, but listed as possibly related to tacrolimus). One serious adverse event occurred: a transient high potassium reading in one patient, based on a single blood test, resolved spontaneously and was considered most likely a sampling artefact. No serious adverse events were linked to the transplanted cells.

Notably, after tacrolimus was withdrawn at nine months, there were no signs of immune rejection or neurological deterioration. The transplanted cells — which came from a different person — appear to have been tolerated over the long term without immunosuppression.

The neurological picture

This is where the results become interesting, with an important caveat: this trial was not designed or powered to test efficacy. It was a safety study. Any neurological changes are exploratory secondary data, and they cannot be attributed to the transplant rather than to natural recovery. The team is explicit about this, and so should any reporting be.

With that said: all four participants improved on neurological scores. Total ISNCSCI motor score (a 100-point scale measuring voluntary movement across muscle groups) increased in all four from baseline to week 52. The median gain was 13 points, with individual improvements ranging from 10 to 40 points.

Two patients changed AIS grade. Patient 1 moved from AIS A to AIS C — meaning they regained both sensory function and some voluntary motor activity below the injury. Patient 3 moved from AIS A to AIS D — meaning they regained substantial motor function below the injury (AIS D is defined as most key muscles below the level having a grade of 3 or higher on the 0–5 scale). Patient 3's total motor score went from 38 at baseline to 78 at 52 weeks — a gain of 40 points. His independence score (SCIM III) also improved meaningfully.

Patients 2 and 4 did not change AIS grade, though both showed numerical improvements in motor and sensory scores. Gains in all patients remained largely stable during long-term follow-up — there was no late regression.

For comparison, the team identified 52 patients in the Japan SCI registry with comparable injuries (same severity, level, and eligibility profile). The median motor score change in this registry cohort was 7 points at 52 weeks in the available-case analysis and 4 points using last-observation-carried-forward analysis. AIS C or above at 52 weeks was achieved by 12–15% of the registry cohort, compared with 50% (2 of 4) of the transplant participants.

These numbers are suggestive. But they come from a trial of four people compared against a registry, not a randomised trial. The researchers use the word "numerically greater" carefully — not "significantly greater." The differences are encouraging rather than conclusive.

What this study does and doesn't tell us

It tells us that injecting iPSC-derived neural cells into the injured human spinal cord is feasible and does not, at least over two to four years, cause tumours or other graft-related serious harm. That is an important finding. The principal concern that has stood between this technology and human trials has been addressed, with real patients and real follow-up data.

It does not tell us that the cells work. Two patients improved substantially — but so do some people with complete SCI without any stem cell treatment. Recovery from complete cervical SCI is rare but not impossible, especially in the first year. Without a randomised control group, it is not possible to know whether the transplant contributed to the recovery in patients 1 and 3, or whether those patients would have improved anyway.

The team also cannot confirm that the transplanted cells survived and integrated. In animals, you can sacrifice the subject and examine the tissue. In living humans, that's not possible. The evidence for graft persistence is indirect — the absence of deterioration after stopping immunosuppression, some parallels with other CNS cell transplant work — but the direct evidence isn't there.

Why it's still a significant moment

Phase 1 trials exist to answer one question: is it safe enough to keep going? This one answers yes. Four patients, up to four years, no tumour growth — that's a meaningful green light for phase 2 trials with actual control groups, larger numbers, and the statistical power to detect whether the treatment works.

The iPSC platform itself is important beyond this specific trial. A quality-controlled cell product derived from a single donor and manufacturable at scale — with no ethical controversy over embryonic tissue sources, no need for patient-specific cell derivation — is a fundamentally more practical foundation for a scalable therapy than most of what came before it. The infrastructure required to move this into controlled trials exists. Keio University's group has been building toward this for over fifteen years.

The next step is a phase 2 trial with a comparator arm. That trial hasn't been announced yet, but the logic and the evidence now point toward it.

Reader Q&A

Does this mean stem cell therapy for SCI is available now?

No. This was a four-person safety trial in Japan. The treatment is not available outside this research setting, and it would not be appropriate to seek it outside a properly regulated trial. Anyone offering iPSC-based SCI treatment outside a clinical trial should be approached with great caution.

What does AIS A to AIS D actually mean in practice?

AIS is the American Spinal Injury Association Impairment Scale, the standard way of classifying SCI severity. AIS A means no voluntary motor or sensory function below the injury level — a complete injury. AIS D means most key muscles below the injury level have voluntary movement with enough strength to work against gravity. The gap between A and D is large. If the transplant contributed to that in patient 3, it would be remarkable. The honest answer is we don't yet know.

Why did only two patients change AIS grade?

The researchers observed that the two who improved most had "relatively preserved spinal cord structure" on MRI. This matches preclinical evidence suggesting that residual neural networks help transplanted cells find something to work with. If there are very few surviving axons and circuits to build on, the cells may have less to integrate with. This might mean that future trials need to think carefully about patient selection, or combine cell therapy with other approaches for the most severe lesions.

Is it safe to stop immunosuppression after nine months?

In this trial, no harmful effects were observed after tacrolimus was withdrawn. The cells appear to have been immunologically tolerated despite coming from a different person — which is somewhat surprising, but is consistent with animal work suggesting that the central nervous system is a relatively immune-privileged site. That said, the optimal duration of immunosuppression isn't yet established, and this will need to be studied further.

When might a proper efficacy trial happen?

No phase 2 trial has been publicly announced as of this writing. Given the phase 1 results, the logical next step is a randomised controlled trial — probably with more participants, a control arm, and standardised rehabilitation. Given the time it takes to design, fund, and recruit for trials of this kind, a phase 2 result is realistically several years away.

Doctors don't always lead with encouragement, and for Nguyen Thi Thanh Loan and Bui Duc Hanh, they didn't. When the Vietnamese couple — both living with the lasting effects of spinal cord injuries — decided they wanted a child, the first response they got was a list of risks.

Two different injuries, one shared reality

Hanh, now 45, was a truck driver until an accident at age 25 left him with a cervical vertebral fracture and lasting effects that make it difficult for him to sit steadily. Loan, 40, was injured in an accident at age three, resulting in a spinal cord injury, a fractured pelvis, and a deformed spine — she has used a wheelchair ever since. When the couple decided to pursue having a child together, doctors flagged a genuinely serious combination of risk factors: Loan's history of pelvic fractures, her spinal deformity, her age over 40, and the general risks of pregnancy layered on top of all of it. They were told that carrying a pregnancy could endanger both her and the baby.

Choosing to try anyway

Rather than treating that warning as a final answer, the couple sought a second, more specialised opinion from fertility specialists. After a full evaluation, the guidance shifted from "don't" to "if you're going to try, don't wait" — Loan's age meant her ovarian reserve would keep declining, narrowing the window for a viable pregnancy.

What followed was a demanding process: repeated trips from their home in Ninh Binh to fertility clinics in Hanoi for consultations, ovarian stimulation injections, egg retrieval procedures, and embryo transfers. Their first IVF cycle didn't go to plan — both mature eggs Loan produced were released naturally before doctors could retrieve them. They didn't stop. In a second cycle, Loan produced eight eggs, though Hanh's sperm quality and motility presented their own obstacles. After embryo culture, the couple had four viable embryos to work with — fewer than many couples going through treatment at the same time, but enough. On 5 December 2023, they welcomed their first child.

Why this story belongs here

Fertility and parenthood after spinal cord injury are rarely discussed openly, and when they are, the framing is often clinical rather than personal. This is a story about two people navigating real medical risk factors, a healthcare system that initially discouraged them, and a fertility process that didn't go smoothly the first time — and choosing to keep going regardless. For a community that's frequently told what it can't do, that's worth telling plainly.

Reader Q&A

Is pregnancy generally considered high-risk for women with spinal cord injuries? It can carry specific risks depending on the level and completeness of injury — including autonomic dysreflexia, altered sensation that can mask labour signs, and mobility-related complications — which is why specialist obstetric involvement is typically recommended. Loan's case involved additional risk factors (pelvic fracture history, spinal deformity, age) on top of her SCI.

Does a spinal cord injury affect fertility for men? It can, depending on the injury, often through effects on ejaculation and sperm quality — which the article notes was a challenge the couple had to work through during IVF.

Why did it take two IVF cycles? The first cycle's eggs were released naturally before retrieval could occur — a recognised risk in IVF timing generally, not specific to SCI. The second cycle produced more eggs and ultimately usable embryos.

Is this an unusual outcome, or does it suggest parenthood is broadly achievable after SCI? Every case depends heavily on individual injury level, associated complications, and access to specialist fertility and obstetric care. This story documents one couple's specific, successful path — not a general guarantee — but it's a meaningful data point for anyone facing similar decisions.

One of the frustrating truths about the adult nervous system is that it's very bad at repairing itself. When the spinal cord is injured, the biological "grow" programs that worked so well when the nervous system was first forming in the womb are largely switched off in adulthood. Scientists have spent years trying to figure out how to flip pieces of that developmental switch back on. A new study, posted as a preprint, adds a promising new tool to that effort.

The problem with retinoic acid

Retinoic acid, a derivative of vitamin A, is one of the best-known signals for triggering nerve growth during development, and it's shown modest regenerative effects when applied after injury too. The trouble is practical, not conceptual: retinoic acid is chemically unstable and breaks down quickly in the body, and it only "docks" with its receptor briefly before disengaging. That makes it a poor candidate for an actual therapy, however promising the underlying biology looks.

Building a more stable stand-in

The research team designed a small synthetic molecule called DM04, engineered to trigger the same downstream effects as retinoic acid — without needing to bind the same way or break down as fast. In lab tests, DM04 encouraged neurons to grow new projections (neurites), switched on the same genes retinoic acid normally activates, and even helped guide human stem cells toward becoming neurons. Notably, it achieved these effects through a different molecular route than retinoic acid typically uses, rather than simply being a more stable copy of the same key.

What happened in mice

When tested in a mouse model of spinal cord injury, DM04 treatment led to improved motor recovery compared to untreated animals. Genetic analysis of the treated tissue showed that DM04 switched on many of the same genes retinoic acid does, but also activated its own distinct set — particularly genes involved in remodelling the extracellular matrix, the structural scaffolding that surrounds cells and can either support or block nerve regrowth depending on how it's organised after injury.

Why a "mimic" molecule matters

The appeal here isn't just replicating what retinoic acid already does — it's building something with the beneficial signalling profile but the chemical durability to actually function as a drug candidate. That combination — mimicking a natural regenerative signal while sidestepping its practical weaknesses — is a common and valuable strategy in translating promising biology into something that could eventually be tested in patients.

Reader Q&A

Is DM04 a treatment people can access? No. This is preclinical research in mice, released as a preprint, meaning it has not yet completed formal peer review. Human trials, if they happen, would be years away.

Did the mice fully recover? The study reports improved motor recovery, not full reversal of paralysis. Preprints in this area rarely claim complete recovery, and this one doesn't either.

What does 'preprint' mean for how much to trust this? A preprint is research shared publicly before undergoing formal peer review by other scientists. The findings are real data from a real experiment, but they haven't yet been independently vetted to the same standard as a published, peer-reviewed paper — worth keeping in mind as a caveat.

Why focus on a vitamin A-related pathway specifically? Retinoic acid signalling is one of the most well-established drivers of nerve growth during embryonic development, which is exactly why researchers keep returning to it as a target — the biological machinery for growth already exists, the challenge is switching it back on safely and durably in an adult nervous system.

Jon Cook has spent years figuring out how to keep doing the sport he loves after his body changed the rules on him. This August, he's turning that adjustment into a fundraising challenge that covers nearly 300 miles.

Cook, a senior oarsman with Dover Rowing Club, is an incomplete paraplegic following treatment for a rare spinal tumour. Rather than stepping back from endurance sport, he's taking on the Para Arch to Arc Challenge — travelling from Marble Arch in London to the Arc de Triomphe in Paris using a hand bike and a rowing boat. At 290 miles, organisers believe it's the first challenge of its kind attempted by a disabled athlete in this format.

Why this kind of story matters

It's easy for spinal cord injury coverage to focus entirely on lab breakthroughs and clinical trials — the "when will there be a cure" stories. But a huge part of life with SCI is what Cook is doing here: adapting a sport, a routine, or a goal to a body that now works differently, and doing it well enough to take on something genuinely difficult. Incomplete paraplegia covers a wide range of ability and Cook's approach — hand bike for the road sections, rowing boat for the water crossing — is a practical example of matching equipment to what the body can do rather than what it used to do.

Cook is raising funds specifically for the organisations that supported him through his own diagnosis and treatment, which gives the challenge a direct, personal throughline: this is fundraising built from lived experience, not a generic awareness campaign.

Reader Q&A

What is incomplete paraplegia? It means some nerve signal function is retained below the level of injury, even though leg function is significantly affected — as opposed to complete paraplegia, where no signal gets through at all. The degree of retained function varies enormously between individuals, which is part of why adaptive sport equipment is so individually tailored.

Why a hand bike and a rowing boat specifically? These are established adaptive sport formats that let an athlete generate power and cover distance using upper body strength and trunk control, without requiring leg-driven propulsion. Combining them lets Cook cover both road and water sections of the London-to-Paris route.

Is this connected to a specific charity? The article identifies the challenge as raising funds for the organisations that supported Cook through his own treatment and adaptation, though it functions as a personal fundraising challenge rather than a single named charity campaign.

Is this the first event of its kind? It's reported as the first challenge of its kind attempted in this specific format (hand bike plus rowing boat, covering this distance) by a disabled athlete.

Back in 2020, a team at Japan's Keio University did something no one had done before: they transplanted neural progenitor cells made from induced pluripotent stem (iPS) cells directly into the spinal cords of people newly injured. It was the world's first clinical study of its kind. This week, they reported the results that matter most in any cell therapy trial — not "did it work," but "was it safe, and did it stay safe."

What actually happened

Between 2020 and 2025, Professor Hideyuki Okano's team transplanted around two million iPS cell-derived neural progenitor cells into each of four patients, all treated within four weeks of their spinal cord injury — the "subacute" window when the injury site is still able to accept new cells but hasn't yet been walled off by scar tissue.

A year after the surgeries, the team reported no major safety concerns, along with some improvements in physical function in a few of the patients. That was encouraging, but short-term safety data only tells you so much. Cell therapies carry a specific long-term risk: because iPS cells are reprogrammed to behave like embryonic stem cells, there's a theoretical risk they could keep dividing uncontrollably and form tumours years after transplant.

This new report addresses exactly that. Two to four years after surgery, none of the four patients has shown tumour formation or any other major safety issue. Just as importantly, none of them has shown a decline in physical function either — the improvements gained appear to have held.

Why this connects to a bigger picture

This is the same Keio University group we covered back on 10 July, when Okano's team presented preclinical data on a related but distinct cell type — gliogenic neural stem/progenitor cells, aimed at chronic (long-standing) SCI rather than fresh injuries. That announcement described this subacute trial as the foundation the newer chronic-injury work is built on. This week's update is effectively the "how did the original patients do" follow-through on that foundation.

With this long-term safety data in hand, the team now plans to launch an investigator-initiated clinical trial as early as next year, moving the subacute approach from four patients under a research protocol toward something closer to routine clinical use.

What this doesn't tell us

Four patients is a very small number, and this update is about safety, not proof that the therapy meaningfully improves recovery across a larger population. Larger trials with control groups will be needed to establish how much benefit the therapy provides and for whom. But in cell therapy, "we didn't see cancer show up two to four years later" is a genuinely important box to tick before scaling up.

Reader Q&A

Does this mean iPS cell therapy is now approved for spinal cord injury? No. This is long-term follow-up on a small, early-stage research trial. Approval for wider use would require larger controlled trials, which the planned 2027 trial is a step toward.

Why does the tumour risk matter so much for iPS-derived cells specifically? iPS cells are adult cells reprogrammed back to an embryonic-like, highly flexible state before being guided into neural progenitors. That flexibility is what makes them useful, but it also means any cells that don't fully mature down the intended path could, in theory, keep dividing. Multi-year monitoring without tumour formation is a strong reassurance, though not an absolute guarantee for all future patients.

Did any patients get worse? The report states no clear deterioration in physical function was confirmed in any of the four patients, two to four years on.

How does this differ from the chronic SCI programme covered here in July? This trial treated patients within four weeks of injury (subacute). The chronic SCI programme covered separately targets people whose injuries are months or years old, using a different cell type aimed at rebuilding myelin rather than replacing neurons. They're related efforts from the same lab, at different stages, for different patient groups.

If you've been through inpatient rehab after a spinal cord injury, you'll know that recovery doesn't look the same for everyone. Some people make significant gains in leg strength; others plateau early. A new study published in the journal Spinal Cord set out to find one of the reasons why — and it points to something measurable at admission: muscle mass.

What they measured

Researchers at a single rehabilitation hospital studied 204 adults with paraplegia (thoracic or lumbar spinal cord injury, meaning the legs are affected but the arms are not) who were admitted within six months of their injury. Using a bioelectrical impedance scan — a quick, non-invasive test similar to some bathroom body-composition scales — they measured each patient's appendicular skeletal muscle mass index, or ASMI. In plain terms: how much muscle mass someone was carrying in their arms and legs relative to their body size, taken at the point they arrived for rehab.

The team then tracked whether each patient achieved a "minimal clinically important difference," or MCID, in their lower extremity motor score during their rehab stay. MCID is a rehab research term for an improvement large enough that patients or clinicians would actually notice it in daily life — not just a statistically detectable blip.

What they found

Just over half the patients (111 of 204, or 54.4%) achieved this clinically meaningful improvement. Higher ASMI at admission was independently linked to a greater chance of reaching that threshold — even after accounting for other factors that affect recovery. The researchers also identified specific cut-off points: above roughly 6.97 kg/m² of muscle mass index for men, and 5.85 kg/m² for women, patients were considerably more likely to show meaningful improvement in leg strength and overall function at discharge. The effect was strongest in women.

Muscle mass alone wasn't a perfect predictor — used by itself, it only modestly separated patients who improved from those who didn't. But combined with other clinical information already collected during rehab, it added meaningfully useful information for predicting who was on track for a good recovery trajectory.

Why this matters beyond the numbers

This isn't a treatment — it's a prediction tool, and prediction tools matter because they change how care is targeted. If a clinician can flag early that a patient's low muscle mass may be working against their recovery, that opens the door to targeted nutritional and strength interventions during the rehab window, when the nervous system is most responsive to physical input. It also gives patients and families a slightly clearer picture of what factors are — and aren't — within their control during recovery.

Reader Q&A

Does this mean building muscle before injury protects you? The study measured muscle mass after injury, at the point of rehab admission, not before injury. It's a snapshot of nutritional and muscular status at a critical recovery window, not a claim about pre-injury fitness.

Can I do anything to change my ASMI during rehab? The study didn't test an intervention — it identified an association. But muscle mass is influenced by nutrition and activity, both things rehab teams already work on. This research strengthens the case for prioritising them early.

Does this apply to tetraplegia (arm and leg involvement) too? This study specifically looked at paraplegia. Whether the same relationship holds for tetraplegia would need separate research.

Is this a cure or a treatment breakthrough? No — it's a predictive marker, not a therapy. Its value is in helping clinicians identify who might benefit from more intensive early support, not in directly improving recovery on its own.

Before he became "Coach" to a generation of kids with physical disabilities, Rodriguez was a 23-year-old learning to survive a gunshot wound that changed the direction of his life. He was shot in 2001, just before he was set to deploy to Afghanistan. The injury damaged his T6 vertebra, and he became a wheelchair user almost overnight.

From patient to peer mentor

Rodriguez had been an athlete since he was young, and he wasn't willing to let that identity go. He started powerlifting in 2004, working his way back into competitive sport from a wheelchair. It was a chance encounter at the gym — with a man he called his "Mr. Miyagi," who turned out to be a priest — that changed his path again. That connection led him to a hospital room, where a woman recovering from a car accident was overwhelmed with fear about her future. Rodriguez, still processing his own trauma, ended up spending hours answering her questions and sharing what his recovery had actually looked like.

He didn't plan to make that a habit. But hospital staff started calling him directly, asking him to visit other patients newly diagnosed with spinal cord injuries — people at the exact moment when a diagnosis feels like the end of the story, not the start of a new one. He kept showing up.

Building something bigger

That informal peer support eventually grew into One Chair at a Time, the nonprofit Rodriguez founded in 2013 to provide adaptive sports opportunities, sports wheelchairs, and education for kids with physical disabilities. The organisation's newest project is a published book collecting true stories of people persevering through the hardest chapters of life-altering injury — turning the same kind of hospital-room conversations Rodriguez started having in the 2000s into something that can reach people who'll never meet him in person.

Why this story belongs here

Peer support is one of the most consistently cited needs in the SCI community, and one of the hardest things to formalise — it depends on people willing to sit with someone at their lowest point and be honest about what recovery and adaptation actually involve. Rodriguez's path from newly injured 23-year-old to founder of a peer-support and adaptive sports nonprofit is a concrete example of how that need gets met in practice, one hospital visit and one wheelchair at a time.

Reader Q&A

What does One Chair at a Time actually provide? Based on its founder's account, the organisation provides adaptive sports opportunities, sports wheelchairs, and education for kids with physical disabilities, alongside informal peer mentoring for people newly navigating spinal cord injury.

Is peer support proven to help recovery outcomes? This article is a human-interest profile, not a clinical study, so it doesn't offer outcome data. But peer support is widely recognised across SCI rehabilitation literature as valuable for psychological adjustment, even where it's hard to formally measure.

What is a T6 injury, roughly? T6 refers to the sixth thoracic vertebra, located in the mid-back. An injury at this level typically affects the legs and lower trunk while sparing arm and hand function, which is consistent with Rodriguez's described ability to return to powerlifting.

Where can people learn more about the book? The article describes it as a recently published collection of true stories about persevering through the hardest parts of injury and disability, produced by the nonprofit; specific purchasing details weren't part of the source article.

After a spinal cord injury, the initial mechanical damage isn't the whole story. What happens in the hours and days afterwards — the so-called secondary injury cascade — accounts for a large portion of the total cell death and tissue loss. Researchers have been trying for years to interrupt this cascade, and a new study from Tianjin Medical University in China targets one of its most damaging components: a process called ferroptosis.

The treatment they've developed involves a specially engineered hydrogel that, when exposed to gentle ultrasound from outside the body, generates molecular hydrogen directly at the injury site. In rats, it worked — reducing cell death, preserving nerve fibres, and improving motor function at eight weeks. The findings were published this week in the journal *Materials & Design*.

The iron problem: what ferroptosis is and why it matters after SCI

Ferroptosis is a form of programmed cell death that was only formally defined in 2012, and understanding it has become one of the more active areas of SCI research. It's driven by iron — specifically by a chain reaction in which excess iron reacts with hydrogen peroxide to produce hydroxyl radicals, a highly destructive form of reactive oxygen species (ROS). These hydroxyl radicals attack lipids in cell membranes, triggering a spreading wave of damage called lipid peroxidation. The cell's membrane breaks down, and it dies.

After SCI, iron overload at the injury site is common. The blood-spinal cord barrier is disrupted, haemoglobin breaks down, and iron floods into the lesion environment. This sets up exactly the conditions for ferroptosis to run unchecked. Cells that might otherwise survive — neurons and supporting glia — die not because of the original impact but because the post-injury chemistry kills them.

The body has a natural defence against ferroptosis: an antioxidant enzyme called GPX4 (glutathione peroxidase 4), which, working alongside glutathione (GSH), neutralises lipid peroxides before they can spread. After SCI, GPX4 and GSH are depleted — leaving cells increasingly vulnerable.

The solution: hydrogen, delivered on demand

Molecular hydrogen (H₂) has an interesting property: it selectively neutralises hydroxyl radicals — one of the most damaging ROS — without interfering with other reactive molecules that cells actually need for normal signalling. This selectivity makes it an attractive therapeutic target. The problem is getting enough of it to the right place at the right time. Hydrogen gas is highly volatile, poorly soluble in biological fluids, and hard to deliver in controlled amounts.

The CSVC hydrogel developed by the Tianjin team addresses this delivery problem through an elegant engineering solution. The gel is made of three components:

- C3N4 nanosheets — a piezoelectric material that generates electrical charge when vibrated by ultrasound. This charge drives a chemical reaction that splits water, producing hydrogen gas. - Vitamin C — which acts as a "hole scavenger" in the chemistry, improving the efficiency of hydrogen generation and extending the reaction. - Methacrylated chitosan (CSMA) — a biocompatible hydrogel matrix that holds the other components together and keeps them localised at the injury site.

In practice: the gel is applied directly to the surface of the injured spinal cord during surgery. Then, over the first three days after injury, low-intensity ultrasound is applied from outside — through the skin — for five minutes per session. The ultrasound activates the C3N4 nanosheets, which generate hydrogen within the gel, which diffuses into the surrounding tissue and scavenges hydroxyl radicals.

What happened in rats

The researchers tested CSVC in a standard rat T10 contusion model — a well-validated approach where a controlled weight drop creates a mid-thoracic SCI. They compared four conditions: injury only, ultrasound only, hydrogel without ultrasound, and hydrogel plus ultrasound (CSVC + US). The key results:

At three days post-injury, tissue analysis showed that CSVC + US significantly increased GPX4 expression and restored GSH levels in neurons at the injury site — markers of ferroptosis suppression. It also reduced lipid peroxidation (measured by MDA and 4-HNE staining). Neither ultrasound alone nor the gel alone produced these effects — both components were needed together.

At eight weeks, the CSVC + US group had significantly better BBB locomotor scores (the standard measure of hindlimb function in rat SCI models) than injury controls from week three onward. They also performed better on swimming tests, sensory testing (hot plate), and detailed gait analysis (CatWalk). Histology showed denser, more continuous axonal fibres at the lesion site, and electrophysiology confirmed better neural conduction across the injury.

What the researchers are honest about

The paper includes a careful limitations section. Ultrasound parameters were not yet optimised — the dose that balances safety and hydrogen output still needs refinement. Hydrogen generation was measured in the lab but not directly in living tissue; the in vivo effects are inferred from the biological markers rather than from direct H₂ measurement. And the hydrogel's long-term degradation in the spinal cord wasn't tracked — an important gap before any human application could be considered.

Vitamin C's contribution is also slightly ambiguous: it's there to improve catalytic efficiency, but it also has independent antioxidant properties. The researchers argue that the control group (gel without ultrasound, which includes the VC) showed minimal protective effect, suggesting the catalytic hydrogen generation is the active mechanism. But they acknowledge this needs cleaner controls.

This is animal model research. The translation to humans — with different anatomy, longer injury-to-treatment windows, and much harder-to-manage logistics — is a significant step that would require extensive further development.

Why it's worth watching

What makes this study interesting beyond the specific result is the design principle. Targeting ferroptosis is mechanistically sound — the pathway is real, well-characterised, and operating in human SCI. The ultrasound-activated delivery system sidesteps the hard problem of getting hydrogen into deep tissue in controllable amounts. And the materials — piezoelectric nanosheets, chitosan, vitamin C — are not exotic; they're relatively accessible and have established biocompatibility track records.

The field of "gas therapy" for SCI (hydrogen being the most studied, but also nitric oxide and carbon monoxide in other contexts) is still young, but the logic is solid and the experimental results are increasingly consistent. This is a study that advances the engineering of the delivery system, which is often the harder part of the problem.

Reader Q&A

What is ferroptosis, and is it definitely happening in human SCI?

Ferroptosis is an iron-dependent form of programmed cell death characterised by runaway lipid peroxidation. It has been documented in human SCI tissue — it's not just a rodent phenomenon. The iron overload conditions that trigger it (disrupted blood-spinal cord barrier, haemoglobin breakdown) are well-established features of human SCI. Whether the scale and timing of ferroptosis is the same in humans as in rat models is less certain, but it is a genuine component of secondary injury.

Does this mean hydrogen gas treatments for SCI are coming?

Not soon, but this is a real research direction. Hydrogen inhalation therapy has been tested in some clinical contexts (stroke, cardiac surgery) and shown some safety signals. The challenge for SCI is targeting the hydrogen to the spinal cord specifically. This study's approach — a localised, surgically implanted gel activated by ultrasound — solves that targeting problem in rats; whether the same approach is practical in humans is a different question.

Is the ultrasound safe? Does it not risk additional damage?

The researchers explicitly checked this. They used low-intensity pulsed ultrasound (0.6 W/cm², well below therapeutic ultrasound levels used in physiotherapy), verified that it didn't cause temperature increases or additional cell death in their models, and found no sonothermal harm. That said, safety in the specific context of acute SCI in humans would need to be established independently.

When would anything like this be tried in humans?

There's no clinical trial for this specific system. For a novel implantable biomaterial in SCI, the typical path involves larger animal studies, rigorous biocompatibility and degradation characterisation, and safety studies before any human phase. Realistically, that's a minimum of five to ten years if development continues without setbacks.

One of the most striking phenomena in spinal cord injury research is the difference in recovery between newborns and adults. An adult with a complete SCI — one where the cord is fully severed — faces persistent paralysis below the injury. But in very young animals, the story can be different. Mice injured in the first days of life can, over weeks, regain the ability to walk.

Why? A new study from Jinan University in Guangzhou, China, has dug into that question with unusual rigour — and found a detailed answer. Published this week in the journal *Biology*, it maps the structural rewiring that happens below the injury site in neonatal mice, and shows that recovery doesn't come from the brain reconnecting. It comes from the spinal cord itself.

First, the crucial question: did the cord actually heal?

Studies of recovery after SCI are sometimes muddied by incomplete injuries — residual fibres that survived the procedure and act as hidden bridges. The Jinan University team went to considerable lengths to rule this out.

They performed complete removal of the T9 spinal cord segment in both newborn (postnatal day 7) and adult mice — not just a cut, but full excision of a section of cord, with the gap packed with a gelatin sponge to prevent reconnection. They then verified the completeness of the injury histologically in all animals. Imaging of the lesion site confirmed: in both adult and neonatal mice, there was a clear gap, no continuous axonal bridge, and no NF200-positive (neurofilament) fibres crossing the injury site.

So the recovery in neonatal mice is not explained by the cord healing or supraspinal axons sneaking through. Whatever is happening, it's happening below the injury.

What the neonatal mice actually achieved

Starting from complete hindlimb paralysis immediately after injury, the P7 (postnatal day 7) mice showed progressive recovery over the following weeks. By week three, they had weight support and stepping. By eight weeks, BMS locomotor scores reached approximately 5 — a level that includes plantar stepping and some coordination. By 16 weeks (about four months after injury), scores had improved further.

Adult mice with the identical injury barely moved at all. Their BMS scores stayed below 1 — ankle movement at best — throughout the entire observation period. The difference between the two groups is stark and consistent across all the measures used: BMS, CatWalk gait analysis, weight-bearing, foot-fault testing (accuracy of paw placement), and swimming.

Forelimb activity was also analysed — to rule out the possibility that front-leg pushing or dragging was artificially boosting the hindlimb scores. It wasn't: forelimb parameters didn't improve in a way that could account for the hindlimb recovery.

What was different in the lumbar cord

The researchers examined the lumbar spinal cord — the section below the injury, which controls hindlimb movement — and compared neonatal versus adult injured mice at multiple time points. The findings at each level of analysis were consistent:

Motor neuron survival was similar in all groups. The injury didn't cause motor neuron death in the lumbar cord for either neonates or adults. So the neurones controlling the legs were alive in both groups — but only in neonatal mice were they driving useful movement.

Synaptic coverage around motor neurones (measured by synaptophysin staining, a general marker of synaptic contacts) was better preserved in neonatal mice and partially recovered over time. In adult mice, synaptic coverage was more severely and persistently reduced.

Excitatory versus inhibitory balance shifted over the recovery period in an informative way. Excitatory inputs to motor neurones (measured by VGLUT1, a marker of glutamatergic synapses) progressively increased in recovering neonatal mice. Inhibitory inputs (VGAT) increased early and then subsided. In adult mice, the pattern was different — inhibitory inputs stayed high and excitatory inputs didn't recover — a pattern associated with poor motor output.

Myelin (the insulating sheath around nerve fibres, marked by MBP) was significantly better preserved in neonatal compared to adult injured mice. Better myelin means better signal conduction in the local circuits.

Neuromuscular junctions — the connections between nerve fibres and muscle — were also more intact in neonatal mice by 16 weeks, with partially recovered EMG (electrical muscle response) amplitudes compared to adult mice.

The big picture: CPGs and developmental plasticity

What the lumbar cord in neonatal mice appears to be doing is something researchers call central pattern generator (CPG) activity. CPGs are networks of spinal cord neurones that can produce rhythmic, coordinated motor outputs — like walking — without instruction from the brain. They're present in all vertebrates and are what allows a human to walk on autopilot while having a conversation, or allows the spinal cord to produce stepping reflexes even in a completely anaesthetised animal.

In adult SCI, these CPG networks survive physically but become functionally suppressed — partly by the collapse of excitatory input, partly by the shift toward excessive inhibition, and partly by the loss of descending signals that normally prime them.

In neonatal SCI, something different happens. The circuits below the injury are young and highly plastic — they haven't yet fully matured into fixed patterns. The loss of descending input arrives before those patterns are locked in. Instead of suppressing the circuits, the injury may trigger them to reorganise around the remaining inputs. The progressive increase in excitatory synapses, the recovery of synaptophysin coverage, the better preservation of myelin — these together describe a cord that is actively reshaping its local network to support locomotor output.

Limitations to be clear about

This is a mouse study, and the neonatal mouse spinal cord is very different from a human infant's — let alone an adult's. The recovery observed here, while striking, was partial: even the 16-week neonatal mice didn't walk normally. The mechanisms identified are structural correlates of recovery, not proven causes — the relationship is associative, not causal.

The study used only female mice at endpoint (male neonatal mice were included in early analyses but excluded from the final structural comparisons for sex-matching). And complete transection at postnatal day 7 doesn't map cleanly onto any common human SCI scenario — it's a model for understanding developmental plasticity, not a clinical analogue.

Reader Q&A

Does this mean something can be done for people injured as infants?

The research is about understanding the biology of why young nervous systems recover better — it's not a clinical finding about human infants. But the mechanisms identified here (synaptic reorganisation, excitatory/inhibitory rebalancing, CPG activation below the injury) are being actively studied in adults too. Understanding why neonatal circuits rewire successfully is one route toward identifying what would need to happen to get adult circuits to do something similar.

Does this have any relevance to rehabilitation in adults?

Indirectly, yes. Rehabilitation approaches like locomotor training, functional electrical stimulation, and epidural spinal cord stimulation are already known to influence CPG activity in adults. The detailed picture of what structural changes accompany successful recovery — better excitatory input, preserved myelin, more synaptic coverage around motor neurones — gives researchers and clinicians a clearer target for what they're trying to produce in adults through rehabilitation.

What are CPGs and why haven't I heard of them?

Central pattern generators are well-known in neuroscience, less so in the broader SCI community. They're networks of spinal interneurones that can produce rhythmic outputs (like walking or breathing) independently. After complete SCI in adults, CPGs persist but are typically too suppressed to produce useful movement. Epidural stimulation research (including work on people re-learning to walk after complete injuries) works partly by activating these circuits. This study adds to the evidence that CPGs are a real therapeutic target — and shows in fine structural detail how they can reorganise in favourable conditions.

Could any of this lead to a treatment?

The specific findings — identify what remodelling allows neonatal mice to recover — could guide the search for interventions that promote similar remodelling in adult animals and, eventually, in humans. Candidates might include drugs that shift the excitatory/inhibitory balance in lumbar circuits, or rehabilitation protocols timed to promote synapse formation. That's years of research away, but the map provided by this study is the kind of knowledge that makes that research possible.

Most people associate creatine with gym bags and protein shakes. It's one of the most widely used sports supplements in the world, popular for boosting short-burst power and muscle recovery. But researchers have been looking at it from a completely different angle: can this molecule, which sits at the heart of cellular energy production, help the nervous system survive and recover from spinal cord injury?

A review paper published this month in the Indonesian journal Intisari Sains Medis brings together the available evidence and tries to answer that question honestly. The short answer: there's a reasonable scientific rationale and some encouraging preclinical results, but the clinical evidence in humans remains thin, and creatine is not yet an established therapy for SCI. Here's where things actually stand.

The energy crisis after SCI

To understand why creatine is being studied in SCI, you need to understand what happens at the cellular level after the injury itself.

The initial mechanical damage — the moment of impact — is called the primary injury. But the majority of cell death and tissue loss happens in the hours and days afterwards, in what's called secondary injury. One of the key drivers of secondary injury is mitochondrial dysfunction: the energy-producing machinery inside cells gets disrupted, and cells start running out of adenosine triphosphate (ATP) — the molecule all cells use as fuel.

When cells can't make enough ATP, a cascade of damaging processes follows. Sodium and calcium ions flood into cells. Oxidative stress builds up. Cells trigger their own death pathways (apoptosis). Inflammatory signals escalate. The result is a zone of damage that extends far beyond the original injury site.

This is where creatine becomes interesting. Creatine's primary biological role is to support rapid ATP regeneration — specifically through a molecule called phosphocreatine, which acts as a fast-access energy reserve. When ATP is depleted, phosphocreatine can donate its phosphate group to replenish ATP almost instantly, buying cells critical time. The question is whether supplementing creatine before or after SCI can shore up this system enough to limit secondary damage.

What the animal studies show

The preclinical evidence is genuinely encouraging. Rat studies using 2% dietary creatine for four weeks after SCI have shown improvements in functional motor recovery measured by the Basso, Beattie, and Bresnahan (BBB) locomotor scale — a standard test of hindlimb function in rodent SCI models. Other animal studies have found that creatine reduces oxidative stress markers, attenuates apoptosis (programmed cell death), and appears to support mitochondrial function in injured neural tissue.

The mechanisms proposed in the research are plausible: creatine may stabilise cell membranes under metabolic stress, reduce the production of reactive oxygen species (damaging molecules generated during the energy crisis), and support the survival of neurons that would otherwise die in the hours after injury.

It is worth noting that this is all animal model evidence. Rat SCI models are useful for understanding mechanisms, but they don't always translate to human outcomes — a challenge that has frustrated many promising SCI research directions.

What the human studies show

Here the picture becomes more cautious. Human clinical trials on creatine in SCI are limited in number and scope. The most relevant evidence suggests that creatine supplementation can improve upper-extremity work capacity in people with cervical SCI — meaning they may be able to sustain arm and shoulder effort for longer during rehabilitation activities. This is a meaningful finding for people whose upper limbs are their primary means of independence and mobility, but it is a functional/performance benefit rather than evidence of neurological recovery or neuroprotection.

No clinical trial has yet shown that creatine supplementation improves neurological outcomes — motor or sensory scores — after SCI in humans. The studies that have been done tend to be small, vary in their methodology, and don't establish creatine as a treatment that changes the trajectory of SCI recovery.

What the review concludes

The authors from Udayana University in Bali are measured in their conclusions. Creatine has a solid scientific rationale, a plausible mechanism of action in secondary SCI injury, and encouraging results in animal models. The early human data on physical performance is positive. But the evidence base is not yet sufficient to recommend creatine as a neurorestorative therapy after SCI. Larger randomised controlled trials are needed, and fundamental questions remain unanswered — including the optimal dose, the best timing (before injury? immediately after? during rehabilitation?), and whether the preclinical neuroprotective effects translate to humans at all.

The review is a useful stocktake of where the field is, not a green light for creatine as an SCI treatment.

Reader Q&A

Should I be taking creatine after my SCI?

This isn't something to start based on this review alone. The human evidence is limited, and there's no established clinical recommendation for creatine as an SCI therapy. That said, creatine is widely considered safe for most people at standard doses, and it has some evidence for improving upper-body exercise capacity. If you're interested in it as a supplement to support your rehabilitation training, it's worth raising with your rehabilitation doctor or physiotherapist — they can advise based on your specific situation, any medications you're on, and your rehabilitation goals.

Is there any harm in taking creatine?

At typical doses used in research (3–5g per day after an initial loading phase), creatine is generally well tolerated. Common side effects are minor — some people experience water retention and a small initial weight gain. People with pre-existing kidney problems should discuss it with their doctor before supplementing, as creatine metabolism places some load on the kidneys. There are no specific safety concerns flagged for people with SCI in the reviewed literature.

If it helps athletes, why wouldn't it help people with SCI?

The mechanism that makes creatine useful for athletic performance — supporting rapid ATP regeneration during short bursts of intense effort — is the same mechanism that theoretically makes it interesting for neuroprotection. But the contexts are very different. Athletic performance benefits are reliably measured; neuroprotective benefits after SCI are far harder to detect and much less certain to occur. The body of evidence just isn't there yet.

What would it take to establish creatine as an SCI therapy?

A well-designed randomised controlled trial: people with acute SCI randomised to creatine versus placebo, with neurological outcomes tracked over at least six months to a year. Ideally multiple such trials from different centres. That kind of evidence doesn't currently exist for creatine in SCI — and building it is the researchers' key recommendation.

When we picture a spinal cord injury, most of us imagine a young person after a car crash or a diving accident. That picture is still partly true, but a new study published today in the Journal of Clinical Medicine suggests it is slowly going out of date. Drawing on ten years of worldwide data, researchers found that the population living with spinal cord damage is getting older — and the health systems built to care for them may not be ready for it.

What the researchers actually did

A team based mainly at the Medical University of Warsaw took a decade of figures — 2014 to 2023 — from the Global Burden of Disease study, the enormous international project that estimates how much illness and disability different conditions cause around the world. They pulled out two categories the project tracks: spinal cord lesions "at neck level" (cervical, the highest and usually most serious injuries) and "below neck level."

Two things are worth knowing up front. First, these are modelled population estimates, not a headcount of individual diagnosed patients, so they capture the broad shape of the problem rather than an exact tally. Second, the researchers looked at two measures: how many people are living with these injuries (prevalence), and how many years of healthy life are lost to the resulting disability each year (a measure researchers call Years Lived with Disability, or YLDs).

The headline: rates down, real numbers flat

On the surface, there is good news. Once you adjust for the world's changing age profile, the rate of spinal cord lesions fell by about 12% over the decade, and the disability rate fell by 14%. Injury-prevention efforts, safer roads and better trauma care are all plausible reasons.

But here is the catch. The *actual number* of people living with these injuries barely moved — from roughly 27.3 million in 2014 to 27.5 million in 2023. In other words, the world is doing a better job of avoiding these injuries relative to its growing, ageing population, yet the total number of people who need care and support has not gone down. For anyone planning services, the real numbers are what matter, and they are stubbornly flat.

The real story is about age

The most striking finding is a split between the young and the old. Among people aged 15 to 49 — the traditional "typical" spinal cord injury patient — the disability burden fell by nearly 12%. But among people aged 70 and over, it rose by 31.5%. The number of older adults living with these injuries jumped by a third.

Why? The study can't prove the cause, but the authors point to an obvious suspect: falls. As populations age, more older people are living long enough to suffer a serious spine injury from a relatively minor fall — the kind of low-energy accident that a younger body might shrug off. By 2023, the over-70s accounted for more than one in ten of all the disability from spinal cord lesions worldwide, up from around one in twelve a decade earlier. And this ageing shift showed up in every region of the world, rich and poor alike.

Neck injuries do the most harm

The study also confirmed something clinicians have long understood: injuries high up the spine, at the neck, cause a disproportionate share of the disability. Cervical injuries made up 63.5% of the global disability burden in 2023, even though they are not the majority of injuries by count. Neck-level injuries can affect the arms, hands, breathing and much more, so each one tends to carry a heavier long-term cost. Interestingly, this share was highest in wealthier countries — likely because better emergency care means more people survive these severe injuries and live for years with the consequences.

Why this matters

This isn't a breakthrough treatment or a new device. It's a map — and maps are how you plan a journey. The message to health systems is that the demand for rehabilitation, long-term care and support is not fading away, and it is increasingly coming from older people whose needs (other health conditions, frailty, different rehab goals) can look quite different from those of a 25-year-old. Fall prevention for older adults turns out to be spinal-cord-injury prevention too.

Reader Q&A

Does this mean fewer people are getting spinal cord injuries? Relative to the size of the population, yes — the rates are falling. But the absolute number of people living with these injuries has stayed essentially flat, because the population is growing and ageing at the same time.

I'm a younger person with an SCI. Is this relevant to me? Very much so. Younger adults still make up the largest group living with these injuries. The study's point is that services will increasingly have to stretch to cover a wider age range, not that younger people no longer matter.

Should older people be worried about falls? Falls are a leading cause of serious injury in later life, and this study adds spine injury to the long list of reasons that fall prevention — good footwear, home safety, strength and balance exercise, medication reviews — is worth taking seriously.

How reliable are these numbers? They come from careful statistical modelling rather than a direct count, so they show trends and broad patterns rather than exact figures. The authors are upfront that the data can't tell us about injury severity, individual causes, or the quality of care people received. It's best read as a big-picture snapshot.

Here's something that might surprise you: your spinal cord already has its own repair cells. They're called ependymal cells, they line the fluid-filled central canal that runs the length of the spinal cord, and under normal circumstances they sit quietly doing very little. But after a spinal cord injury, they wake up.

The problem is that they don't wake up enough, or for long enough, to make a meaningful difference. The repair response they mount is real but limited — far short of what would be needed to close the injury cavity or restore lost function. Scientists have been trying for years to understand what triggers their activation, hoping that if they could identify the switch, they could find a way to turn it up.

A new study from Wenzhou Medical University and Westlake University in China has found that switch — or at least a critical part of it. Published in the journal *Neurobiology of Disease*, the research identifies a metabolic reprogramming process in ependymal cells that drives their activation after SCI, and shows that enhancing this process with a vitamin B6 derivative improves outcomes in mice.

What ependymal cells actually are

The central canal of the spinal cord is a tiny fluid-filled tube that runs from the brain down through the cord. It's lined with ependymal cells — a type of cell that, in adults, behaves somewhat like a dormant stem cell. They have the capacity to divide and differentiate into other cell types (neurons and glia), but in the normal adult spinal cord, they rarely do.

After SCI, ependymal cells partially shed this dormancy. They begin to proliferate — dividing and producing daughter cells — and migrate towards the injury site. They contribute to the formation of the glial scar, which serves as a partial barrier to further damage, and they generate some new cells. But the scale of this response falls well short of meaningful regeneration.

Understanding what drives the activation of ependymal cells — and what limits it — is an important piece of the regenerative medicine puzzle.

What the researchers did

The team used single-cell RNA sequencing — a technology that reads the gene activity of individual cells rather than averaging across thousands — to analyse what happens to ependymal cells in mouse spinal cords after injury. This approach gives a much finer-grained picture of cellular behaviour than traditional methods.

What they found was striking: after SCI, the ependymal cells that went on to activate and proliferate underwent a dramatic shift in their metabolic programme. Specifically, they upregulated a pathway called polyamine metabolism — the production of small molecules called polyamines (putrescine, spermidine, and spermine) that play essential roles in cell growth, division, and survival.

The central enzyme in this switch is called ODC1 (ornithine decarboxylase 1). ODC1 converts ornithine into putrescine, the first step in the polyamine production chain. For ODC1 to work, it requires a cofactor: PLP (pyridoxal 5'-phosphate), which is the biologically active form of vitamin B6.

In cells with high ODC1 activity, polyamine production surges, which in turn supports cell proliferation. In ependymal cells that didn't activate this pathway after SCI, the regenerative response was limited.

What happened when they enhanced the pathway

The researchers tested whether boosting this pathway could improve outcomes after SCI. They gave mice PLP — the active vitamin B6 derivative — after inducing a T10 (mid-thoracic) spinal cord contusion injury, and compared them to untreated mice with the same injury.

The results, at 28 days post-injury, were encouraging:

- Ependymal cells in PLP-treated mice showed significantly higher ODC1 activity and polyamine production - There was more ependymal cell proliferation at the injury site - The injury cavity (the area of lost tissue at the injury site) was smaller in treated mice - Motor function scores (assessed using the BMS locomotor scale, which tests hindlimb movement) were meaningfully better in treated mice

They also confirmed the specificity of the effect: when they used a genetic approach to block ODC1 in ependymal cells specifically, the beneficial effects of PLP disappeared — confirming that the pathway they had identified was genuinely the mechanism at work, not a side effect of something else PLP was doing.

What this doesn't mean yet

This is mouse research. That is not a criticism — mouse SCI models are essential tools for understanding mechanisms, and the experimental design here is rigorous. But the history of SCI research is littered with findings that worked in rodents but didn't translate to humans, for reasons ranging from differences in spinal cord anatomy to timing of the injury response to dose-response issues.

PLP is also not the same as taking vitamin B6 supplements. B6 in food or standard supplements exists in other forms that need to be converted to PLP in the body. The dosing and delivery in this study was direct administration of PLP — not the kind of self-supplementation a person could replicate. Any human application would require careful pharmacological work to establish dose, timing, delivery method, and safety profile.

The researchers are appropriately cautious: they present this as a mechanistic finding that opens a pathway for further investigation, not a treatment ready for clinical translation.

Why it matters

The significance of this research is in the conceptual advance. The spinal cord's own cells are trying to repair the injury — ependymal cells really do respond to SCI and really do have regenerative potential. This study identifies, with unusual molecular precision, the metabolic programme that drives that response and shows it can be enhanced.

That makes it a legitimate candidate for therapeutic development. If PLP or an equivalent agent can be shown to safely enhance ependymal activation in larger animal models, and eventually in humans, it represents a form of treatment that works *with* the spinal cord's own biology rather than imposing something entirely external. That's an appealing strategy — it means the cord's intrinsic repair machinery does the work, just at greater scale.

Reader Q&A

Does this mean vitamin B6 supplements could help after SCI?

No — not based on this research. PLP is the active form of B6, but the study involved direct administration at a controlled dose in an experimental mouse model. Taking B6 supplements as a person with SCI is not the same thing, and there is no human evidence that it affects ependymal cell activity or SCI outcomes. Please don't read this as a reason to take B6 supplements.

What are ependymal cells, and why hadn't they been focused on before?

They have been studied, but they're hard to study — there aren't many of them, they're deep inside the cord, and standard research methods that average across large numbers of cells don't pick up the subtle signals from small populations. Single-cell RNA sequencing has made it much more practical to study rare cell types like ependymal cells in detail, which is partly why this kind of finding is emerging now.

Could this be combined with other SCI repair strategies?

Potentially — and that's one of the reasons it's interesting. Approaches like cell transplantation, growth factor delivery, and electrical stimulation are each working on different aspects of the repair problem. An endogenous approach that amplifies the cord's own stem cell response could, in principle, complement rather than compete with these strategies. That's a long way off, but it's the kind of question researchers will be asking.

When might this be tested in humans?

There's no clinical trial on the horizon yet. The next steps would typically involve larger animal models (non-human primates), safety studies, and dose optimisation before any human trial could be designed. Realistically, that is a pipeline of at least five to ten years if everything goes well — which it often doesn't. But the mechanism is now identified, which is the necessary first step.

One of the frustrating truths of spinal cord repair is that promising cells, injected on their own, often don't stick around long enough to do their job. Put them into an injured spinal cord and many are swept away in the bloodstream within days. A new study from Jinan University in Guangzhou, published in the journal Gels, tries to solve that problem with a simple idea: give the cells a place to stay.

The problem they set out to fix

The cells in question come from what's called the stromal vascular fraction, or SVF — a mixed bag of cells harvested from fat tissue that includes stem cells, immune cells and blood-vessel-forming cells. SVF is attractive because it's relatively easy to obtain and the different cell types seem to work together. The trouble, as the researchers put it, is that after transplantation SVF is "rapidly cleared" and survives poorly, which undercuts any benefit.

The two-part solution

To keep the cells in place, the team built a scaffold: a self-assembling peptide gel (with the unwieldy name HGF-RADA16-IKVAV) that forms a soft, nerve-friendly mesh right at the injury site. Think of it as scaffolding around a building under repair — it holds everything together while the real work happens, and it's laced with a growth factor to encourage nerve tissue to knit back together. The cells were embedded in this gel and implanted into the injured spinal cords of rats.

What happened

In the rats that received the combined treatment, the researchers reported several improvements over the injury alone: the damaging inflammation that follows spinal cord injury was calmed, more neurons survived, and a denser network of nerve fibres (axons) grew across the wound. Crucially, these cellular changes translated into something you can see — better restoration of limb movement — along with reduced signs of neuropathic pain, the burning, hypersensitive pain that plagues many people after spinal cord injury. A protein-level analysis backed this up, showing the treatment shifted the injury's molecular environment, especially in immune and inflammatory pathways.

The all-important caveat

This is a study in rats, not people. That distinction matters enormously, because the history of spinal cord research is full of therapies that worked beautifully in rodents and then failed to translate to humans, whose spinal cords are larger, more complex and injured in messier ways. Nothing here shows that this approach will help a person, and there is a long road — safety testing, larger animals, and carefully designed human trials — before anyone could know. What the study does offer is a well-reasoned strategy and encouraging early evidence that combining cells with a retaining scaffold beats using cells alone.

Why it's still worth knowing about

The interesting thing isn't the specific gel or cell mix — it's the principle. A lot of spinal cord research is converging on the idea that no single ingredient will be enough: you need to protect surviving tissue, calm inflammation, and give new nerve fibres both a reason and a physical structure to regrow. This study is one more careful test of that combination approach, and it adds to a growing body of work suggesting that "cells plus scaffold" is a more realistic recipe than cells by themselves.

Reader Q&A

Could this be a treatment for me or a family member? Not yet, and not for a long time. This is early laboratory work in rats. It's a step in a research direction, not a therapy you could ask a doctor about.

What's special about using fat-derived cells? They're comparatively easy to collect and contain a useful mix of cell types that appear to cooperate. The challenge the study tackles is that these cells don't survive well once transplanted — hence the gel scaffold to hold them in place.

Why does reducing inflammation matter so much? After a spinal cord injury, a second wave of damage from runaway inflammation can harm tissue that survived the initial trauma. Calming that response is one of the main goals of many experimental treatments, because it may preserve function that would otherwise be lost.

Has anything like this reached human trials? Various cell therapies and scaffolds for spinal cord injury are being studied in people, but this particular combination is at the animal stage. Progress in the field is real but slow, and honest reporting means not overstating how close any single study brings us.

Most brain-computer interface stories you read about focus on movement: a person thinks about moving, and a machine translates that thought into action. That is remarkable on its own. But movement is only half of how we actually use our hands. The other half is feeling — knowing how firmly you are gripping a cup so you don't crush it, sensing when your fingers have found the object you're reaching for. Without touch, even a hand that moves is clumsy and unreliable.

A team at the Feinstein Institutes for Medical Research in New York has now reported, in a peer-reviewed paper in Nature Medicine, a system that tackles both halves at once — and produced results that lasted.

The person at the centre of the study

The participant is Keith Thomas, who sustained a spinal cord injury at the C4–C5 level in a diving accident in a swimming pool in 2020. That level of injury left him unable to move or feel his hands and arms. In 2023, surgeons at the Feinstein Institutes carried out a long, complex operation to implant five small microchips into regions of his brain responsible for movement and for the sense of touch.

What followed is what the team calls a "double neural bypass" — a way of routing signals around the damaged spinal cord in both directions.

How the double bypass works

In one direction, the implants read the electrical activity in Keith's motor cortex when he thinks about moving his hand. A computer decodes that activity in a fraction of a second and sends commands to flexible electrode patches on his forearm, which stimulate the muscles to produce the intended movement. This is the "brain to muscle" pathway that restores movement.

In the other direction, pressure sensors on his fingertips detect contact and force. That information is fed back to the touch-processing region of his brain through the implanted electrodes, recreating a sensation of touch and grip. This is the "hand to brain" pathway that restores feeling.

Put together, the two pathways create a closed loop: he intends to move, the movement happens, and he feels the result — all bypassing the injured cord entirely.

What actually improved

After a structured programme of training that ran for around 35 weeks, the changes were substantial. The team reported that strength in his right arm increased by roughly 86% and in his left arm by roughly 62%. His sensation improved markedly too. In everyday terms, Keith was able to drink from a cup unaided, wipe his own face, and handle delicate objects while controlling how hard he gripped.

The most scientifically interesting finding, though, is what happened when the system was switched off. Some of his recovered movement and sensation remained even without the device running. That points to something beyond a machine simply substituting for lost function: the sustained pairing of intention, movement and feeling appears to have encouraged Keith's own surviving neural connections to strengthen and reorganise — a process scientists call neuroplasticity. In other words, the technology may have helped his nervous system partly heal itself.

Why the "lasting" part matters so much

Many assistive technologies work only while they are actively in use. A device that boosts function while switched on but leaves nothing behind when switched off is still valuable, but it is fundamentally a prosthesis. Evidence that a training approach produces durable, device-independent recovery is different in kind — it suggests the intervention is changing the underlying biology, not just compensating for it. That is the direction the whole field hopes to move in.

Important caveats

This is a single-participant study. One person's results, however encouraging, cannot tell us how well the approach will generalise to others with different injury levels, different amounts of surviving tissue, or different amounts of time since injury. The surgery is major — five implanted microchips and a lengthy operation — and the training is intensive and lengthy. The system as it stands relies on laboratory equipment and expert support, not something a person could take home today.

None of that diminishes the achievement. But the honest framing is that this is a landmark proof of concept, not a treatment ready for the clinic. The next steps are to test the approach in more people and to work toward systems that are less bulky and less dependent on constant expert oversight.

Reader Q&A

Does this cure spinal cord injury?

No. The spinal cord itself was not repaired. The system routes signals around the damaged area, and the training appears to have strengthened some of Keith's own neural pathways. That is a meaningful, lasting improvement in function — but it is not a cure, and the study involved one person.

How is this different from other brain-computer interfaces I've read about?

Most restore movement only. The distinctive feature here is that it restores the sense of touch as well, feeding sensation from the fingertips back into the brain — and that the combination produced improvements that partly persisted after the device was turned off.

Could I get this?

Not currently. This is early-stage research carried out with implanted devices and intensive, supervised training. It is not an approved or available treatment, and would require much larger studies before it could become one.

Why did some function remain when the device was off?

The leading explanation is neuroplasticity — the nervous system's ability to reorganise and strengthen connections with repeated, meaningful use. By repeatedly pairing the intention to move with actual movement and genuine touch feedback, the training seems to have reinforced surviving pathways. This is a hopeful sign but still needs to be confirmed in more people.

Fertility after spinal cord injury is a subject that doesn't always get the attention it deserves. SCI affects a lot of young men, and for many of them, the question of whether they can have biological children is one of the most important quality-of-life issues they face. The honest answer is that most men with SCI will need medical help to have children — but the good news, reinforced by this new study, is that help is available and it works.

The problem isn't sperm production. Research consistently shows that the testicles themselves keep working normally after SCI — sperm are still being made. The issue is getting them out. Ejaculatory dysfunction affects the vast majority of men with SCI, particularly those with higher-level injuries. Some men retain the ability to ejaculate with vibration; many do not.

When natural ejaculation isn't possible, there are two main clinical approaches. A new study from the Yazd Reproductive Sciences Institute in Iran — one of the region's most active fertility centres — compared them directly.

The two methods

The first is electroejaculation (EE). This is a non-surgical procedure where a small probe is placed internally and low-voltage electrical pulses stimulate the prostate and seminal vesicles to produce an ejaculation reflex. It works in 85–100% of cases. General anaesthesia isn't required, and the procedure is repeatable. The main clinical caution is autonomic dysreflexia in men with injuries above T6 — a risk that can be managed with proper monitoring.

The second is testicular sperm extraction (TESE). This is a minor surgical procedure under local anaesthesia where a small tissue sample is taken directly from the testicle and examined under a microscope for sperm. It's used when EE either doesn't produce sperm or can't be performed safely.

In both cases, the retrieved sperm is used for ICSI — intracytoplasmic sperm injection — where a single sperm is injected directly into an egg in a laboratory. This is the standard IVF technique used for male-factor infertility.

What the study found

Researchers followed 37 men with SCI who underwent fertility treatment between 2017 and 2023, covering a range of injury levels from C4 to L2. Across 54 IVF cycles, they tracked three outcomes: whether a pregnancy occurred on a blood test (chemical pregnancy), whether a foetal heartbeat was detected on ultrasound (clinical pregnancy), and whether a live birth resulted.

The overall results were encouraging. Around 35% of cycles resulted in a confirmed clinical pregnancy, and the live birth rate across all cycles was just over 20% — comparable to general IVF success rates in this age group.

More importantly for the central question: there was no meaningful difference between the EE and TESE groups on any of these measures. Chemical pregnancy rates were 44.4% for EE vs. 36.1% for TESE. Clinical pregnancy rates were 33.3% vs. 36.1%. Live birth rates were 22.2% vs. 19.4%. None of these differences were statistically significant — in other words, the data don't support one method being better than the other.

Hormone levels — testosterone, FSH, LH — were also similar between the two groups, which the researchers interpret as confirmation that SCI primarily disrupts ejaculatory function while leaving sperm production itself intact.

Why this matters

Previous research had suggested that TESE sperm might be biologically superior for IVF because testicular sperm haven't been exposed to the inflammatory environment of the seminal tract — and men with SCI often have elevated oxidative stress in their semen, which can damage sperm DNA. On paper, this would predict better outcomes with TESE. In practice, this study (and others like it) suggests those biological differences don't translate into better pregnancy rates, likely because modern ICSI techniques are good enough to select the best sperm regardless of source.

The clinical implication is that EE — which is less invasive, avoids surgery, and can be repeated — makes sense as the first approach to try. TESE remains the right option when EE fails to retrieve sperm, when autonomic dysreflexia risk makes EE unsuitable, or based on individual assessment.

Limitations

This is a relatively small study (37 men, 54 cycles) from a single centre, and the groups weren't randomised — which method was used depended on clinical judgement, not a coin flip. The researchers also note that they didn't analyse sperm DNA fragmentation or other molecular measures that might reveal differences not captured in pregnancy rates alone. Larger prospective studies are needed.

Reader Q&A

If I have SCI, what are my chances of having a biological child?

Based on this study and others, IVF using sperm retrieved by either EE or TESE gives roughly a 20% live birth rate per cycle. That's broadly similar to IVF success rates in the general male-factor infertility population. Chances across multiple cycles are higher. The key first step is a fertility consultation at a centre experienced with SCI patients — not all fertility clinics have this expertise.

Which method would I be offered first?

In most centres, EE is the first-line approach because it's non-surgical and repeatable. TESE is typically used if EE doesn't retrieve viable sperm, if there's a high autonomic dysreflexia risk, or based on your specific injury characteristics. Your fertility specialist and SCI team would make this decision together.

Does the level or severity of my SCI affect the chances of success?

The study included men with injuries from C4 to L2 — a wide range — and injury level didn't emerge as a major predictor of IVF outcome. Sperm production is generally preserved regardless of injury level. Time since injury does matter: there's some evidence that sperm quality declines over many years post-injury, which is why earlier fertility evaluation is generally recommended for men with SCI who may want children in the future.

What about fertility preservation — should I bank sperm after injury?

Many clinicians now recommend discussing sperm banking early after SCI, before any potential decline in sperm quality over time. This is a conversation worth having with your medical team, especially if having children is something you want in the future.

One of the most frustrating patterns in regenerative medicine is the therapy that works beautifully in the lab and then disappoints in people. Cells that regrew in a dish fail to regrow in a patient. A growth factor that repaired tissue in an animal model does little in a clinical trial. It happens often enough that researchers have started asking whether something more fundamental is being missed.

A team at the University of Oregon's Knight Campus has proposed an answer that is both simple and unsettling: maybe we have been delivering the right signals in the wrong sequence.

Healing is a sequence, not a switch

When the body repairs an injury, it doesn't fire off all its repair instructions at once. It follows an ordered programme. Certain signals — proteins called growth factors — need to appear first, do their job, and then quiet down so that the next set of signals can take over. Inflammation ramps up and then must resolve. Scaffolding is laid down and then remodelled. The steps overlap, but they have an order, and that order matters.

Most regenerative therapies, by contrast, tend to flood the injury site with a growth factor all at once, or release it steadily over time. If the biology actually depends on a specific sequence — this cue now, that cue later — then dumping everything in simultaneously could blunt the effect or even push the repair process in the wrong direction. The signal is correct; the choreography is not.

What the Oregon team built

To test and exploit this idea, the researchers engineered small proteins called affibodies. An affibody can be designed to grab onto a specific growth factor and hold it — temporarily blocking its activity. By tuning how tightly the affibody holds on, the team can control the rate at which a growth factor becomes available to the surrounding tissue.

In effect, this gives them a dial for timing. Rather than releasing a repair signal all at once, they can delay it, meter it out, or schedule it to become active only after an earlier signal has done its work. That level of control over the sequence of cues is what has been missing from many earlier approaches.

The findings were reported across two papers, in the journals Biomacromolecules and the Journal of Controlled Release.

Where spinal cord injury comes in

The team is applying this timing-control approach to several kinds of repair, including bone healing, muscle repair, and spinal cord regeneration. Spinal cord injury is a particularly hard test case: the injured cord contains a mix of processes that need to be encouraged and processes that need to be held back, and their timing relative to one another is thought to be crucial. A tool that can impose an order on regenerative signals is exactly the kind of thing that could make previously underwhelming spinal cord therapies work better.

It is worth being clear about what this is and isn't. This is foundational bioengineering work — a new method for controlling when regenerative signals act, tested in laboratory and preclinical settings. It is not a spinal cord injury treatment that has been tested in people. Its value for SCI is a well-reasoned hypothesis backed by early evidence, not a clinical result.

Why it's still worth paying attention to

If the central idea holds up, it reframes a lot of past disappointment. Therapies that were written off as ineffective might have been effective all along, just mistimed. That would mean the path forward isn't necessarily finding new signals — it's learning to deliver the ones we already have in the right order. For a field that has spent decades searching for the missing ingredient, the suggestion that the ingredient was there but out of sequence is a genuinely useful shift in thinking.

Reader Q&A

Is this a treatment for spinal cord injury?

Not yet. It is a laboratory method for controlling the timing of regenerative signals, being applied to spinal cord regeneration among other targets. It has not been tested as a therapy in people with SCI.

What is a growth factor, in plain terms?

A growth factor is a signalling protein the body uses to tell cells what to do — for example, to grow, divide, or move to repair damaged tissue. Different growth factors do different jobs at different stages of healing.

What's an affibody and why does it help?

An affibody is a small engineered protein designed to latch onto a specific target — here, a growth factor. By holding onto that growth factor and releasing it in a controlled way, the researchers can decide when and how quickly the signal becomes active, giving them control over the sequence of repair cues.

Why would timing matter so much?

Because healing is a staged process. If a signal that should come second arrives first, it can interfere with the step that was supposed to happen before it. Getting the order wrong can weaken or misdirect the whole repair, even when every individual signal is correct.

Last Sunday, a surgical team at Huashan Hospital — one of China's most prominent neurosurgical centres, affiliated with Fudan University in Shanghai — spent six hours implanting a small array of electrodes into the brain of a 35-year-old man who had lost voluntary use of his hands following a cervical spinal cord injury.

This wasn't an experimental procedure in the usual sense. The device they used — the NEO system, developed by Chinese company Neuracle Technology — had just received commercial approval from China's National Medical Products Administration (NMPA), the country's equivalent of the FDA. This surgery was the first performed under that approval.

If that sounds significant, it is. Until last week, no implantable brain-computer interface had ever been granted commercial approval anywhere in the world. Every previous BCI implanted in a person with paralysis — including those in US Neuralink trials — was done under research exemptions, not as a licensed product a doctor could simply prescribe. We covered the regulatory milestone when it was announced earlier this week; Sunday's surgery is the next chapter.

What the device does

The NEO system is designed for people with cervical SCI — specifically those with injuries between C3 and C7 — who have lost voluntary control of their hands and fingers. The device consists of electrodes implanted into the motor cortex, the part of the brain that controls voluntary movement. It reads the electrical signals the brain generates when the person *thinks* about moving their hand, and translates those signals into commands that can stimulate muscles or control external devices.

The goal is what researchers call "thought-controlled muscle rehabilitation" — restoring functional hand use by creating a new pathway between brain and muscle that bypasses the damaged cord.

Following the surgery, the patient will need to commit to six hours of rehabilitation per day to train the system and rebuild functional connections. That's intensive, and it underscores that this isn't a passive implant — it requires significant sustained effort from the person receiving it.

Why China, and why now

China has an estimated 3.7 million people living with spinal cord injuries — one of the largest SCI populations in the world. Neuracle Technology has been developing the NEO system for several years, with clinical trials demonstrating safety and some functional benefit sufficient for the NMPA to grant commercial approval.

The specific evidence package used to support the approval hasn't been published in full, but the fact that a sovereign national regulator — with its own evidence standards — granted commercial status to an implantable BCI is notable. No other country has done this yet.

What this doesn't mean yet

It would be easy to read "commercially approved BCI" and assume this technology is now broadly available. It isn't. The NEO system is approved in China. It has not been reviewed by the FDA, the European Medicines Agency, or the MHRA. The approval pathway in China, while rigorous, differs from Western jurisdictions, and each regulator will require its own evidence review.

Access will also depend on cost, surgical infrastructure, and — critically — post-surgical rehabilitation resources. Six hours of therapy daily is a serious commitment, one that requires substantial clinical support to sustain.

None of this diminishes what happened on Sunday. For the first time in history, an implantable BCI for paralysis has moved from experimental to commercial, and the first patient has received it. The regulatory door has been opened. The scientific and commercial pressure to bring equivalent devices through the FDA and European processes will only grow.

Reader Q&A

Could someone with SCI get this surgery right now? Not outside China, and even within China, access will depend on cost, clinical eligibility, and availability of surgical centres experienced with the procedure. This is a brand-new commercial product — the first surgery was performed last Sunday.

Is the NEO system the same as Neuralink? No. Neuralink is a US company with its own design still in clinical trials. Neuracle Technology is a separate Chinese company whose device has now received commercial approval — a stage Neuralink has not yet reached.

Does this mean there's a cure for hand paralysis after SCI? No. The NEO system creates a new communication pathway between brain and muscles, but it doesn't repair the spinal cord. It's an assistive technology that, with intensive rehabilitation, may allow some people to regain functional hand use. The extent of recovery will vary by individual.

When might something like this be available in the UK, US, or Europe? Genuinely unknown. It would require separate regulatory submissions, clinical trials acceptable to the FDA or MHRA, and likely several more years of development. The China approval is a significant milestone, but it doesn't shorten any other regulator's pathway.

If you have a spinal cord injury — particularly at a cervical or high thoracic level — the muscles that control your breathing are likely affected. Most people with SCI know this in a general way: reduced lung capacity, difficulty clearing the chest after illness, or shortness of breath with effort. What's been less clear is which training approach actually improves this, and whether the severity of your injury limits what's possible.

New research from the Swiss Paraplegic Centre in Nottwil — one of Europe's leading SCI rehabilitation hospitals — gives a more concrete answer than we've had before. The headline finding is both simple and actionable: train hard, train often, and keep going for at least three months. Almost everything else is secondary.

What the study did

Researchers analysed data from 81 people with SCI who completed respiratory muscle training programmes at the Swiss Paraplegic Centre. Participants spanned a range of injury levels and severities — both complete and incomplete injuries — as well as different ages, body types, and baseline fitness levels. This mix was deliberate: the researchers wanted to understand which factors predicted better respiratory outcomes at the end of training.

The training used inspiratory muscle training (IMT) devices — small handheld tools that add resistance to your breathing, similar in principle to a breathing weight. Participants trained at varying intensities and for varying durations as part of their rehabilitation plans.

What they found

When the researchers modelled which factors predicted improvement in respiratory muscle strength, training intensity and programme duration emerged as the dominant predictors — by a significant margin. Personal characteristics like age, sex, and body weight had comparatively little predictive power. Injury characteristics — level, AIS classification (complete vs incomplete), and time since injury — also mattered far less than the training variables themselves.

The practical implication is striking: someone with a complete C4 injury who trains consistently at high intensity for four months is likely to see more improvement than someone with an incomplete C6 injury who trains at moderate intensity for six weeks. The injury doesn't cap your gains as much as the training approach defines them.

The researchers' specific recommendations: train at the highest intensity you can sustain, three to five times per week, for a minimum of three months.

Why respiratory muscle strength matters so much

Pneumonia is the leading cause of death in people with AIS A (complete motor and sensory loss) and AIS B (complete motor loss, some sensory preserved) spinal cord injuries. The primary reason is that impaired respiratory muscles make it harder to cough forcefully and clear the airways of secretions — a problem that becomes critical during a chest infection.

Stronger respiratory muscles translate directly into a more effective cough, better ability to manage respiratory illness at home, and — critically — a reduced risk of pneumonia requiring hospitalisation or mechanical ventilation. The stakes are high enough that this is one area of rehabilitation where the evidence really matters.

Why this study is worth paying attention to

The Swiss Paraplegic Centre treats around 300 new SCI patients a year and carries one of the largest longitudinal SCI rehabilitation datasets in the world. Research from this centre tends to be grounded in clinical reality rather than tightly controlled experimental conditions — these were real patients doing real rehabilitation, not a highly selected research cohort. That makes the findings more directly applicable to practice.

The study also addresses a question that's been genuinely uncertain: does it matter who you are, or does it matter what you do? The answer, clearly, is the latter. That's useful information for patients deciding whether to invest in a training programme, and for clinicians deciding how to structure one.

Reader Q&A

Should I be doing respiratory muscle training? If you have a cervical or upper thoracic SCI and you ever notice difficulty clearing your chest, shortness of breath, or recurring respiratory illness, then yes — it's worth discussing with your physiotherapist or rehabilitation doctor. The evidence is now reasonably strong that structured training helps, and the risk is low.

What kind of device is used? Inspiratory muscle training (IMT) devices are small handheld tools you breathe through against adjustable resistance. They're available without prescription and relatively inexpensive. Your physiotherapist can advise on the right resistance level and technique for your situation.

Does this apply to incomplete injuries too? Yes. The study included both complete and incomplete injuries, and the key finding — that training intensity matters more than injury characteristics — applied across the range.

What if I've had my SCI for years? Is it too late to benefit? Time since injury was not a strong predictor of training response in this study, which suggests it's never too late to benefit. That said, starting respiratory training earlier in rehabilitation tends to establish better habits and baselines — so earlier is generally better, but later is still worth doing.

Most people with a spinal cord injury know their injury level from the moment they leave the emergency room. A C5 injury is a C5 injury — and while recovery varies in the weeks and months that follow, the basic neurological picture is usually established within the first 24 to 72 hours.

For a small number of people, that picture doesn't stay fixed. In the days after an SCI, their neurological function begins to deteriorate — sometimes dramatically — as the injury level appears to ascend upward in the cord. Someone who initially presented with a T6 injury might, over the following days, develop the deficits of a C5 or C4 injury. This complication is called post-traumatic ascending myelopathy, often abbreviated to SPAM.

SPAM is rare, which makes it hard to study systematically. A new case series published in *Spinal Cord Series and Cases* (a Nature journal) adds to the small body of literature with three carefully documented cases treated at Vall d'Hebron Hospital in Barcelona over seven years.

What is ascending myelopathy?

The spinal cord doesn't always remain stable after a traumatic injury. In some cases, a combination of secondary injury mechanisms — including oedema (swelling), disruption to blood supply, and inflammatory processes — can cause the damage to extend upward from the original injury site. This is distinct from the normal secondary injury cascade that causes some deterioration in the first few days. SPAM involves more pronounced and sustained upward progression that continues beyond the acute phase.

The mechanisms aren't fully understood. Disruption of the anterior spinal artery (the main blood supply to the front of the cord), inflammatory swelling, and syrinx formation (fluid-filled cavities that develop within the cord) have all been proposed as contributors in different cases. The literature reports mortality rates of around 10%, and survivors face the potential for significant additional permanent disability above their original injury level.

The Barcelona cases

The Vall d'Hebron team identified three cases of SPAM from their SCI population between 2018 and 2025 — representing 0.54% of SCI patients treated at the centre during that period. All three presented with progressive neurological deterioration in the days after their initial injury, with the ascent confirmed on imaging.

The clinically interesting part of the paper concerns treatment. Two of the three patients received methylprednisolone, a specific type of corticosteroid. Both showed a pattern of neurological stabilisation and some recovery. The third patient received dexamethasone — a different corticosteroid — with a less favourable outcome.

The authors suggest that methylprednisolone may have properties particularly relevant to SPAM's mechanisms, including effects on membrane stabilisation and oedema reduction that differ from dexamethasone's profile. However, they are explicit that three cases is far too small a sample to draw clinical conclusions. The difference in outcomes could reflect patient factors, injury characteristics, timing, or any number of other variables unrelated to the choice of drug.

What this paper contributes

Case series like this one exist not to provide definitive answers but to document a condition that's difficult to study precisely because it's rare. The value is in the careful clinical description: what SPAM looked like in these cases, how it was identified on imaging, what was tried and what happened. This adds to the handful of published case reports in the literature and helps build the recognition framework that better-powered studies will eventually test.

For clinicians managing an acute SCI patient whose neurological status is worsening beyond what's expected, this kind of documented clinical experience — even from small numbers — matters. For researchers, it reinforces the case for a multicentre SPAM registry that could finally accumulate enough cases to draw meaningful conclusions.

Reader Q&A

How would I know if ascending myelopathy was happening? The key sign is progressive neurological deterioration — new weakness, sensory changes, or respiratory compromise — in the days after an SCI, when imaging shows changes above the original injury level. This is something acute SCI unit teams monitor for specifically; it's not something a patient would typically identify themselves.

Is this something that can happen long after injury? No — post-traumatic ascending myelopathy occurs in the acute and subacute period, typically within the first days to weeks after injury. A separate condition, progressive post-traumatic myelopathy (often due to syrinx formation), can develop months or years later but is a different entity with different mechanisms.

Should I worry about this if I already have a stable SCI? Once past the acute phase with a stable neurological picture, the risk of SPAM is very low. It's a complication of the acute period immediately following injury.

Does this study tell us what treatment to use? Not definitively. It describes three cases and notes that methylprednisolone appeared associated with better outcomes than dexamethasone in this small group — but three cases cannot establish a treatment protocol. The authors are clear that larger, ideally prospective data is needed before firm recommendations can be made.

Every year, United Spinal Association brings wheelchair users to Washington to sit across from their elected representatives and explain, in plain terms, what their daily life actually looks like. This year's Roll on Capitol Hill took a virtual format for its meetings — 176 sessions held online — but the conversations were the same as they've always been: personal, specific, and grounded in the reality of living with a disability.

194 advocates from 37 states participated in ROCH 2026 on July 14. Three issues were on the table.

The bills they came to support

Faster wheelchair repairs. The FAST Repairs for Wheelchairs Act, introduced by Rep. Ayanna Pressley (D-MA), would prohibit Medicare Advantage plans from requiring prior authorisation before approving wheelchair repairs. For people who rely on a wheelchair for everything, a broken chair that can't be fixed without jumping through insurance hoops isn't an inconvenience — it's a health crisis. Minnesota advocate Joey Carlson, attending his fifteenth ROCH since 2012, put it directly: "We shared how disruptions in getting our wheelchairs repaired negatively affected our health."

There was also good news to report here: advocate Gatwiri Mwiti from California noted that the FAST Act passed — in part due to sustained advocacy from events like this one over recent years.

Better coverage for better chairs. The Choices for Increased Mobility Act would create new Medicare billing codes for carbon fibre and titanium wheelchairs. These materials produce chairs that are lighter, stronger, and more responsive than standard aluminium frames — meaningfully better for daily use. But right now, Medicare doesn't recognise them as distinct from standard models. If you want one, you pay the full cost yourself. The bill aims to fix that by acknowledging these chairs as the legitimate clinical equipment they are.

Home care access. The third issue was access to personal support services — the carers and attendants that allow people with disabilities to live in their own homes and communities rather than in institutional settings. This is a persistent pressure point: the supply of qualified carers hasn't kept up with demand, and funding structures vary widely by state.

Why showing up matters

"The real power of an event like Roll on Capitol Hill is that legislative staff get to hear stories from actual constituents on how policies can impact people's everyday life," said Carlson. That's the mechanism. These aren't professional lobbyists — they're people with SCI, families, occupational therapists, and advocates who live these issues. When they sit across from a congressional staffer and explain what it means to wait weeks for a replacement wheelchair part, the abstract policy question becomes a real one.

"As both an occupational therapist and a person with a disability, I see firsthand how policies around home care, medical equipment and assistive technology impact people's everyday lives," said Christie Cyktor, advocacy coordinator for United Spinal Pittsburgh. "It was empowering to help ensure that the voices of wheelchair users were heard."

What's next

United Spinal's Action Center allows anyone to send an email directly to their congressional representatives about both bills — the Choices for Increased Mobility Act and the FAST Repairs Act. Their grassroots advocacy network is approaching 3,000 members. If you're in the US and want to add your voice, it's a five-minute action at unitedspinal.org.

Reader Q&A

Is this only relevant to people in the US? ROCH is a US event focused on US legislation, but the underlying issues — wheelchair repair timelines, equipment funding, home care — are familiar in most countries. The advocacy tactics also translate: showing up, sharing personal stories, and engaging consistently with decision-makers works everywhere.

What happened with the FAST Act? It passed — a win that advocates at events like ROCH have been pushing for over several years. The Choices for Increased Mobility Act is still working through Congress.

How can I get involved? United Spinal's Action Center (unitedspinal.org) lets you send messages to your representatives directly. You can also join their grassroots advocacy network to stay informed about upcoming actions.

Not every spinal cord injury happens in an instant. For one man — we'll call him by the name Aspire shared, though it isn't given — the injury unfolded slowly over six months, a quiet catastrophe that was repeatedly missed before becoming impossible to ignore.

A fracture that hid in plain sight

It started with a fall in November 2024. He'd always been an active, outdoors kind of person — spending much of his time volunteering at Ladybower Reservoir in Derbyshire, rearing fish for a local fly-fishery. After the fall, he developed severe back pain and pins and needles in his legs. His GP prescribed pain medication and physiotherapy and sent him home.

The symptoms seemed to ease, and he kept going to the reservoir. Months passed. Then one day he arrived as usual and had to go home after a couple of hours — the back pain had become unbearable. By the time he got there, he couldn't get out of the car. Both legs had stopped working properly. He took a taxi to A&E, where the driver had to lift him out of the vehicle. The A&E assessment concluded: back pain. He was sent home again.

Shortly afterwards, his condition deteriorated rapidly. An ambulance was called. By that point, he was completely paralysed.

An MRI scan finally revealed what had been happening all along: the fall six months earlier had fractured a vertebra, and it had been slowly grinding against his spinal cord ever since.

Rehabilitation and a different kind of support

He was transferred to Princess Royal Spinal Injuries Centre, where, he says, the staff were fantastic and he began to make some recovery.

It was there that he met Alex, an Aspire Independent Living Advisor (ILA). Alex wasn't a physio or a medic — his role was different. He came to the ward, sat down, and had a conversation.

"Alex first came to see me on the ward and simply stopped by for a chat," the man told Aspire. "We spent a lot of time talking about my life before my injury, my hobbies, and the huge changes I was now facing. Being able to speak openly with someone who genuinely understood what I was going through made an enormous difference."

That conversation — and others like it — helped him start to see a possible future, not just the loss of the life he'd had. Over time, with Aspire's support around practical matters like housing, equipment, and independent living, he worked towards a life that felt like his own again.

He's now back at Ladybower Reservoir, volunteering at the fly-fishery.

Reader Q&A

What does an Aspire Independent Living Advisor actually do? An ILA is typically a peer support worker — someone who has personal experience of spinal cord injury and works with newly injured people on the ward and after discharge. They're not there to provide clinical care, but to offer practical guidance and emotional support: helping people think through housing adaptations, benefits, equipment, and what life after SCI might look like. The peer element — talking to someone who genuinely gets it — is often what people describe as most valuable.

Is it common for spinal cord injuries to develop gradually like this? Most SCI is traumatic and sudden, but gradual or progressive SCI does happen. Conditions like cervical stenosis, tumours, or — as in this case — an unrecognised vertebral fracture can cause the cord to be compressed over time. The symptoms (back pain, weakness, pins and needles) can easily be mistaken for more common musculoskeletal problems, which is part of why delayed diagnosis occurs. If you have persistent neurological symptoms following any injury or trauma, it's worth being specific with medical staff about any earlier fall or incident.

Can people with SCI really return to the activities they loved before? Often, yes — in some form. The nature of the return will depend on the level and completeness of the injury, but adaptive sports, modified volunteering, and accessible outdoor activities are more widely available than many people realise. Organisations like Aspire, Spinal Injuries Association, and local disability sports charities can often help people find pathways back to the things that matter to them.

One of the most frustrating things about spinal cord injury is that the body seems to know how to repair other tissues — skin heals, broken bones knit — but when the nerves that carry signals from your brain to your limbs are damaged, they almost never regrow. Now a team at the University of Cambridge has used a remarkable new laboratory tool to find out exactly why that is, and shown that the block may not be permanent.

What the team built

The Cambridge researchers created what they call a brain-spinal cord organoid model. Organoids are three-dimensional clusters of cells grown in the lab from stem cells — essentially miniature, simplified versions of real organs. By differentiating human embryonic stem cells into both brain tissue and spinal cord tissue, the team coaxed them to self-organise into connected structures that mimic the neural circuits of the human central nervous system.

This is a significant achievement in itself. Creating organoids that model a single organ is already tricky; creating two different tissue types that communicate with each other the way the real brain and spinal cord do is considerably harder. But it gave the researchers a way to study human nerve biology without needing human spinal cord tissue — and, crucially, to observe the same nerves at different stages of development.

The key nerves: corticospinal neurons

The team focused on a specific type of nerve cell: corticospinal neurons. These are the cells that form the long communication highway from your motor cortex (the brain region that controls movement) down through the spinal cord to your muscles. When you decide to pick up a cup of tea, it's corticospinal neurons that carry that instruction. When they're damaged in a spinal cord injury, voluntary movement below the injury site is lost — and unlike many other types of cells, corticospinal neurons are notoriously reluctant to regrow their axons (the long projections that transmit signals).

"When the brain and spinal cord are damaged, the nerve fibres that carry movement signals from the brain to the spinal cord rarely grow back. That's why paralysis is usually permanent," said Dr András Lakatos, senior author of the study and a researcher in the Department of Clinical Neurosciences at Cambridge.

What they discovered

By comparing younger and older versions of their organoids after inducing injury to corticospinal axons, the team found a clear pattern: axons in more mature organoids had a much lower capacity for regrowth than those in younger ones. Something changed during development that switched off the nerves' ability to repair themselves.

The culprit they identified is FGF2 — fibroblast growth factor 2. This is a signalling molecule that plays a key role during normal development. The researchers found that as organoids matured, FGF2 signalling changed in a way that progressively suppressed axon regrowth. When they blocked FGF2 signalling in the mature organoids, regrowth was restored.

In plain terms: the nervous system appears to flip a switch during development that turns off the regeneration programme. And when the researchers found that switch and turned it back, the nerves started growing again.

What this means — and what it doesn't

This is genuinely exciting, but it's important to keep perspective on what stage this research is at.

First, this is a laboratory finding using organoids, not a clinical trial and not a treatment for people living with SCI. There is a long road between identifying a molecular mechanism in a lab model and delivering a therapy to a patient.

Second, FGF2 signalling is one piece of a very complex puzzle. The researchers themselves are clear that many other factors also limit nerve regeneration after spinal cord injury — including the glial scar that forms at the injury site, immune responses, and the physical structure of damaged tissue. Addressing FGF2 alone wouldn't overcome all of those barriers.

What this work does provide is a genuinely useful model — a way to study human corticospinal neuron biology and test potential strategies in a system that reflects human development more closely than animal models do. That's a meaningful tool that the field has lacked.

Dr Lakatos summed it up carefully: "Our model provides a good indication that this block happens during development, and it can still be reversed after this point."

Reader Q&A

Does this mean a cure for paralysis is on the way? Not in any near-term sense. This is foundational research that identifies a mechanism — it's a step toward understanding the problem at a deeper level. Clinical treatments based on this discovery would require many more years of research, safety testing, and trials. The honest answer is that this is promising science that opens a door, not a treatment that's coming soon.

Why is the brain-spinal cord organoid model significant? Most spinal cord research uses animal models (typically rodents) to study nerve biology, which don't always translate well to humans. Human organoids give researchers a way to study human nerve cells and their behaviour directly. They're not perfect representations of the full spinal cord, but they're a much closer approximation for certain types of questions — especially developmental ones like this.

Is FGF2 already targeted by any existing drugs? FGF2 signalling is studied in the context of cancer and wound healing, and there are compounds that modulate it. However, the specific context of corticospinal neuron regeneration is different, and a lot of work would be needed to understand whether any existing drug could be safely used for this purpose — or whether an entirely new approach would be needed.

Could this help people with chronic (long-standing) SCI, or only acute injuries? The study doesn't address this directly. The organoid model investigates the developmental loss of regenerative ability, not the secondary damage that occurs in the weeks and months after injury. Whether this mechanism is relevant specifically to acute or chronic injury — or both — is a question future research will need to tackle.

If you've followed SCI research in recent years, the names Jocelyne Bloch and Grégoire Courtine will be familiar. The two scientists, based at EPFL and CHUV in Lausanne, Switzerland, lead NeuroRestore — a lab that has spent more than a decade working on treatments for spinal cord injury. Their work has resulted in some of the most striking demonstrations in modern neuroscience: patients with complete paralysis of their legs regaining the ability to walk, cycle, and swim, using a technology called a brain-spine interface.

That work has now received major recognition from the French scientific establishment. Bloch and Courtine, together with Guillaume Charvet from CEA-Leti in Grenoble, have been awarded the 2026 Grand Prix scientifique by the Fondation NRJ – Institut de France, carrying a prize of €150,000.

What Is a Brain-Spine Interface?

The brain-spine interface is exactly what it sounds like: a connection between the brain and the spinal cord that bypasses the damaged section.

In a healthy nervous system, movement starts in the brain. The motor cortex sends signals down through the spinal cord to the muscles. When the spinal cord is injured, those signals can't get through. The brain still tries to send them, but they don't arrive.

The brain-spine interface intercepts those signals at the brain and delivers them where they're needed. Specifically, it uses a brain implant called WIMAGINE® — developed at Clinatec (CEA-Leti) — to record electrical activity from the motor cortex in real time. Algorithms then decode this activity to figure out what movement the person is intending. That decoded intention is immediately translated into precisely targeted electrical stimulation of the spinal cord, delivered via an implanted pulse generator below the level of injury.

The stimulation reactivates the circuits in the lower spinal cord that control the muscles for walking. The result is that a person whose brain signal can no longer reach their legs can, in effect, route it around the damage.

More Than a Lab Result

The crucial thing about NeuroRestore's approach is that it doesn't just work in a controlled lab environment. Patients with the system have walked outdoors, on uneven ground, and have continued to improve over time — suggesting that the technology is also prompting neurological recovery beyond what the device alone provides.

This is significant because it means the benefit may compound: the device enables movement, and that movement drives neuroplasticity, which may lead to further gains even when the device is off.

What the Prize Means

The Fondation NRJ – Institut de France focuses specifically on neuroscience. Its Grand Prix scientifique is one of the highest honours in the field in France. That this year's award has gone to a team working on SCI reflects both the scientific quality of the work and the growing recognition that brain-spine interfaces represent a genuinely new class of treatment.

Following more than a decade of work moving from animal models to human clinical trials to real-world demonstration, the technology is now at a stage where serious attention from funding bodies and regulatory agencies is warranted.

Reader Q&A

Who can currently get a brain-spine interface? At present, this technology is available only in clinical research settings. It's not yet a commercially available treatment. The work is progressing toward clinical translation, but a timeline for broader availability hasn't been announced.

Is this the same technology as Neuralink? Both involve brain implants, but they're different systems with different goals. NeuroRestore's brain-spine interface is specifically designed to restore movement in SCI by coupling a brain implant to targeted spinal stimulation. Neuralink is developing a broader platform for brain-computer interfaces with multiple potential applications. The underlying approaches and current stages of development are quite different.

What happens if the device is turned off? Patients who have used the brain-spine interface have reported retaining some of the gains even when the device is not active — likely because the movement enabled by the device is driving neuroplasticity. But this varies by individual, and the device is generally needed for ongoing function.

Why does it matter who wins a science prize? Science prizes are one signal that a body of work is considered credible and important by the scientific community. They also bring funding attention, public awareness, and — in this case — recognition that SCI research is producing real, landmark results worth investing in.

For years, brain-computer interfaces (BCIs) have lived in the research lab. Impressive results in small clinical trials, lots of scientific papers, a handful of landmark demonstrations — but no commercially approved product, and no clear path to reaching patients outside of research programmes.

That changed in March 2026, when China's National Medical Products Administration (NMPA) granted market approval to the NEO device, developed jointly by Neuracle Medical Technology (based in Shanghai) and researchers at Tsinghua University. The NEO is now the world's first invasive brain-computer interface to receive commercial regulatory approval anywhere in the world.

It is specifically designed for people with cervical spinal cord injuries.

How the NEO Device Works

The NEO works by implanting a coin-sized device in the skull that records brain signals in real time. For someone with a cervical SCI, the connection between the brain and the hands is disrupted — they have the intention to move, and the brain sends the signal, but the damaged spinal cord blocks it from getting through.

The NEO picks up those signals from the motor cortex — the part of the brain that controls movement — and decodes them. It then translates that decoded intention into commands that control a pneumatic glove worn on the hand. The glove responds in real time to the person's brain signals, allowing them to perform grasping movements: picking up objects, holding a cup, drinking water.

The brain does the thinking. The device and glove do the moving.

Who It's For

The commercial approval specifically covers adults aged 18 to 60 with quadriplegia caused by cervical SCI at levels C2 to C6 (from the second to the sixth cervical vertebra). To qualify, patients must also have a confirmed injury grading of A to C on the standard ASIA scale, a diagnosis confirmed for at least a year, and documented stability of their condition for at least six months after standard treatments.

These are people who have chronic, established injuries — not acute cases. They have had time for their condition to stabilise, and existing treatments haven't restored hand function.

The Clinical Evidence

The approval was based on a clinical trial involving 36 implant procedures — four feasibility cases followed by 32 multicenter confirmatory cases. Participants were followed for 18 months. The key finding: all patients achieved home-based, brain-controlled grasp assist using the device. There were no serious adverse events related to the device itself.

Eighteen months of follow-up across 36 people is a modest dataset by the standards of most pharmaceutical approvals, but for a first-generation invasive BCI it's meaningful. The safety record across the trial was clean.

What "Commercial Approval" Actually Means

It's worth being precise about what this approval does and doesn't mean. NMPA market approval means the device can be sold and implanted in China as a regulated medical product — hospitals can offer it, it can be reimbursed through health systems, and it doesn't require patients to enrol in a clinical trial to access it.

It does not mean the device is widely available, cheap, or accessible to most people who might benefit. The infrastructure for implanting and supporting BCIs, and the cost of the device and surgery, remain significant barriers. But the regulatory milestone matters: it establishes that this class of device is real enough to be regulated, that the evidence is strong enough to support approval, and that the transition from research tool to medical product is underway.

What This Means for the Broader BCI Field

China's move is likely to accelerate activity globally. The NMPA approval provides a regulatory template that other agencies will study. Companies and academic groups working on BCI technology elsewhere — including in the US and Europe — will be watching closely. Regulatory agencies will now have a reference point for evaluating similar applications.

For people with cervical SCI specifically, who typically have severely limited hand function, a working BCI that enables grasping has profound quality-of-life implications. Hand function is consistently ranked by people with high cervical SCI as one of the things they most want to regain.

Reader Q&A

Is this available outside China? Not yet. The NMPA approval covers China only. BCI devices for SCI are still in clinical trial phases in the US and Europe, and no equivalent commercial approval has been granted in those regions.

Is the NEO the same as Neuralink? No. Neuralink is a US company developing a BCI platform, and its device (the N1) is currently in human trials under FDA oversight. NEO is a different device developed in China and is the first of its kind to receive full commercial approval. The underlying principles are similar — brain implant decodes neural signals — but the companies, devices, approval status, and current applications are all different.

Does this mean the person can move their hand normally? The current technology enables grasping movements via a pneumatic glove — enough to hold objects, pick things up, and drink. It's not full restoration of natural hand movement. But for someone with C3 or C4 tetraplegia who has no hand function at all, this represents a meaningful practical gain.

What are the risks of an implanted BCI? Any brain implant carries risks: infection, bleeding, device failure, and the need for eventual replacement. In the NEO trial, there were no serious device-related adverse events, which is encouraging. But long-term safety data beyond 18 months isn't yet available, and this is an area that will continue to be monitored.

When Anthony Guzman had his spinal cord injury at 13, he didn't leave the house by himself for years. By 19, he had his driver's licence, a job at a movie theatre, and a place at the University of Massachusetts.

True Grit didn't do all of that. But it helped.

What True Grit Is

True Grit is a week-long residential summer camp at Rutgers University in New Jersey, run by Rutgers School of Health Professions in partnership with Children's Specialized Hospital, part of RWJBarnabas Health. It's open to young people aged 16 to 21 with spinal cord injuries.

The camp takes place in accessible campus housing — which matters, because part of the programme is the experience of living away from family. For teenagers and young adults with SCI who haven't had that opportunity, the camp week is often a first.

The schedule is built around activities designed to increase independence and help participants think about what comes next: college, careers, relationships, and life beyond the medical system. Supported by therapists, nurses, and peer mentors, participants work through practical challenges and, perhaps more importantly, spend time with other young people who are navigating the same experiences.

The Peer Mentor Effect

Some of the most important people at True Grit are the peer mentors — several of whom have SCI themselves. This matters more than it might seem. Teenagers and young adults with SCI often spend most of their time around people without SCI: family, teachers, carers, clinicians. True Grit gives them access to people who've been through similar things and come out the other side.

Seeing someone who uses a wheelchair and also has a job, a social life, and plans for the future can shift something that clinical therapy can't. It replaces "people like me don't do that" with "actually, people like me do."

Filling a Gap That Rehab Doesn't Cover

Standard rehabilitation after SCI focuses heavily on the physical: regaining function, learning to use equipment, preventing complications. All of that is essential. But it doesn't always address the social, psychological, and practical challenges of becoming an adult with a disability — which is what True Grit specifically targets.

How do you navigate a college campus in a wheelchair? How do you talk to an employer about your needs? How do you handle the social anxiety of being the only person at the party who uses a chair? These aren't medical questions, but they shape quality of life just as profoundly.

True Grit creates space for those conversations, in a community of people who actually get it.

This Year's Camp

The 2026 camp is running this week — July 13 to 19 — at Rutgers' Livingston Campus in New Brunswick, New Jersey. This is the programme's fourth year in its current form, and applications have continued to grow.

Reader Q&A

Who can attend True Grit? The programme is open to young people aged 16 to 21 with spinal cord injuries. You don't need to be from New Jersey — applications come from across the US. The Rutgers School of Health Professions website has details on how to apply.

Is True Grit the only programme like this? It's described as the first of its kind specifically for teens and young adults with SCI in a residential university setting. There are other camps for people with physical disabilities more broadly, but True Grit's focus on SCI, independence, and the transition to adult life makes it relatively unique.

Does the camp offer clinical rehabilitation? The programme includes therapists and nurses, but it's not primarily a clinical programme. It's more about independence skills, peer community, and preparing for adult life. Clinical rehabilitation happens elsewhere.

What happens if someone can't attend in person? The current programme is residential and in-person. For young people who aren't in a position to attend, the Rutgers School of Health Professions and Children's Specialized Hospital both offer other SCI resources and support.

In 2018, Fergus 'Gussie' Farrell's life changed in an instant. A workplace accident left the former Galwegians and Connacht Rugby player paralysed from the waist down. Doctors gave him a 5% chance of ever walking again.

A few years later, he's planning to walk from New York to Los Angeles.

The Challenge

The "Fergus Walks" challenge — set to begin in August 2026 — will see Fergus cover more than 4,500 kilometres over 75 consecutive days, averaging the equivalent of a marathon and a half every single day. If he completes it, he will become the first person with a spinal cord injury ever to walk coast-to-coast across America, and the first Irishman to make the crossing on foot in over a century.

That's not a marketing line — it's a genuine historic milestone. The route itself is brutal for anyone. For someone who was told they'd never walk again, the undertaking is almost impossible to put into words.

Why He's Doing It

Fergus isn't walking for personal glory. He's walking to raise funds and awareness for Spinal Injuries Ireland, the organisation that supports people rebuilding their lives after SCI. His campaign has also partnered with the Christopher & Dana Reeve Foundation, the leading SCI charity in the United States, to raise the profile of the walk on both sides of the Atlantic.

The money raised will go directly toward supporting SCI survivors — the kind of practical help, peer support, and advocacy that makes a difference long after hospital discharge.

A Story Worth Knowing

What makes Fergus's story particularly striking is the gap between where he was told he would be and where he actually is. Recovery from a serious spinal cord injury is never linear, and most people who have been told they had a 5% chance of walking again do not go on to walk a marathon and a half a day for 75 days. Fergus is the exception — and his willingness to channel that into something for others says a great deal about him.

He's not claiming this is easy. Pushing his body and mind to their absolute limits over two and a half months will take a toll. But he's prepared, supported, and clear about what he's doing and why.

Reader Q&A

Is Fergus fully recovered from his SCI? The story doesn't say he's "fully recovered" — people don't always recover completely after SCI, and each person's outcome is different. What we know is that Fergus can now walk well enough to attempt a coast-to-coast challenge. That's remarkable, but it doesn't mean everyone with a similar injury will have the same outcome.

How can I support the walk? The campaign has its own site at ferguswalks.ie, where you can follow progress and donate. The walk is also supported by Spinal Injuries Ireland and the Christopher & Dana Reeve Foundation.

When does the walk start? Fergus is set to begin in August 2026, with the challenge running for 75 consecutive days.

Does this mean the 5% prognosis was wrong? Not necessarily — a 5% chance is not zero. Prognoses after SCI are statistical averages across many patients, and individual outcomes can vary significantly depending on the exact nature of the injury, the care received, and many other factors. Fergus's outcome is inspirational precisely because it's relatively rare.

For people with spinal cord injuries in Winnipeg, First Steps Wellness Centre was more than just a gym. It was the only local provider of intensive activity-based therapy — a specialised form of rehabilitation that goes beyond standard physiotherapy to focus on what the nervous system can still do, even after a serious injury.

In June 2026, it closed.

The closure left a significant gap for SCI patients in Manitoba who depended on the centre's services. And it left one local mother determined not to let that gap go unaddressed.

What First Steps Offered

Activity-based therapy (ABT) differs from conventional rehabilitation in an important way. Standard physiotherapy after SCI tends to focus on adapting to disability — learning to use a wheelchair, building arm strength, managing the effects of injury. ABT takes a different approach: it focuses on activating the nervous system below the level of injury through repetitive, task-specific movement, even when that movement is assisted or passive.

The theory — backed by growing evidence — is that sustained activation of the circuits below a spinal cord injury can drive neuroplasticity and, in some cases, promote meaningful recovery. Some ABT patients have regained function they were told they wouldn't recover. Others have seen gains in sensation, bowel and bladder control, or pain reduction.

First Steps Wellness Centre provided this kind of therapy in Winnipeg. Its clients included people who, with support, had been able to walk with parallel bars or a walker — gains that depended on continued access to specialised sessions.

A Community Without Services

When a specialised facility like First Steps closes, the impact isn't abstract. It means specific people lose specific appointments. In some cases, it means losing access to the only therapy that was producing results for them.

Manitoba's SCI community faces a particular challenge: the province's main alternative for this kind of intensive therapy has historically been centres in Saskatchewan, requiring families to travel or relocate for care. That's not a realistic option for everyone.

The Winnipeg Free Press report highlights a local mother who has stepped forward to champion the community's needs — working to identify what services can be restored, by whom, and where. Her campaign reflects a pattern seen wherever specialised SCI services are cut: the community mobilises, because it has to.

Why This Story Matters Beyond Winnipeg

The closure of First Steps in Winnipeg isn't an isolated event. Specialist SCI rehabilitation services are expensive to run, often depend on charitable funding, and are vulnerable to financial pressures that don't affect mainstream healthcare. When they close, there's rarely an automatic replacement.

The fight to restore services in Winnipeg is the same fight that happens in cities around the world: SCI patients and their families pushing back against a healthcare system that too often treats spinal cord injury as a condition to manage rather than one to actively rehabilitate.

Reader Q&A

What is activity-based therapy, exactly? ABT is a rehabilitation approach that uses repetitive, task-oriented movement to stimulate the nervous system. Unlike standard physiotherapy, it's specifically designed to activate circuits below the level of a spinal cord injury, with the goal of promoting neuroplasticity and potentially recovering function. It typically involves equipment like functional electrical stimulation bikes, body-weight-supported treadmills, and standing frames.

Is there evidence that ABT works? Yes, though the evidence base is still growing. There's good evidence for benefits in secondary health outcomes (like bone density, cardiovascular health, and pressure sore prevention), and emerging evidence for neurological gains in some patients. Outcomes vary by injury level, completeness, and how soon after injury therapy begins.

What happens to people who lose access to these services? For some, it means a plateau or reversal of gains that took months of work to achieve. For others, it means relying on standard physiotherapy that isn't designed to target neurological recovery. In practical terms, it can mean reduced quality of life, worsening secondary health complications, and loss of function that had been hard-won.

How can people support the campaign? The Winnipeg Free Press article covers the mother's ongoing campaign. Following local SCI advocacy groups and Spinal Cord Injury Canada (SCI Canada) would be the best way to stay informed and show support.

If you live with a spinal cord injury above T6, you've probably heard of autonomic dysreflexia — or you've experienced it. It's a sudden, sometimes severe spike in blood pressure triggered by stimulation below the level of injury that the nervous system can't process properly. Common triggers include a full bladder, catheter problems, constipation, or — critically — surgical procedures on the bladder or urethra. Left untreated, it can cause stroke, seizure, or cardiac events.

Managing anaesthesia in people with high-level cervical SCI during urological procedures is genuinely difficult. General anaesthesia is often used, but it doesn't reliably block the abnormal reflex pathways that drive AD. A team from the China Rehabilitation Research Center in Beijing tried something different: low-dose epidural anaesthesia. The results, published in the Journal of Spinal Cord Medicine, are small in number but striking in their consistency.

The five patients

All five participants had C4–C6 injuries classified as AIS A or B (meaning complete or nearly complete loss of motor and sensory function below injury level). All had documented AD episodes during their regular daily catheterisation — these weren't people with mild or occasional symptoms. They were undergoing urological procedures: four bladder lithotripsies (stone removal) and one bladder neck incision.

Instead of general anaesthesia, the team performed lumbar epidural anaesthesia using ropivacaine at 0.2–0.5% concentration, injecting 4–10 mL depending on the individual. Because sensory testing below the injury level isn't reliable in this population, adequacy of the block was judged indirectly — by observing spasticity control and haemodynamic stability.

What happened

None of the five patients developed intraoperative AD, defined as a systolic blood pressure rise of more than 20 mmHg above baseline in response to surgical stimuli. All five completed their procedures without interruption.

Four of the five had systolic BP that stayed within 20 mmHg of baseline throughout. One patient, who had significant preoperative anxiety, showed a reduction in BP to stable levels (not a dangerous drop — the anxiety itself had elevated it beforehand). One patient required a single dose of atropine for a transient bradycardia (slowing of the heart rate) that resolved quickly.

In the authors' experience, the same procedures under general anaesthesia had previously produced AD episodes in similar patients. That context is important: this isn't a controlled trial, but the comparison to historical experience adds weight.

Why epidural might work better than general anaesthesia

The nerve pathways involved in AD are in the spinal cord, not the brain. General anaesthesia works at brain level — it suppresses consciousness and pain perception but doesn't block the spinal reflex arc responsible for AD. Epidural anaesthesia, delivered into the spinal canal, interrupts signal transmission at the level where the reflex originates. For urological procedures — where the trigger stimulus is coming from the bladder and urethra — a well-placed epidural can block the signal before it ever gets into the ascending pathways that drive the reflex.

The honest limits

Five patients is five patients. This is a retrospective case series — no control group, no randomisation, no blinding. The authors are clear: this is preliminary evidence suggesting epidural anaesthesia warrants further formal investigation. It's not a practice guideline change.

There are also practical challenges. Performing lumbar epidurals in people with severe cervical SCI requires anaesthetists experienced in this population. Positioning may be difficult. And the inability to confirm sensory block level in these patients adds a degree of uncertainty about whether the block is adequate.

Reader Q&A

Does this apply to all SCI, or only cervical injuries? The dysreflexia risk is generally associated with injuries at T6 and above. This study specifically looked at C4–C6, which is among the highest-risk group. The underlying rationale — blocking spinal reflex arcs rather than suppressing brain activity — would theoretically apply across the T6-and-above range, but the study doesn't test that.

Should I ask for epidural rather than general anaesthesia for my next urological procedure? This paper is a starting point, not a prescription. If you have cervical SCI and a history of AD, it's worth discussing your anaesthetic options with your treating anaesthetist and spinal unit team before any urological surgery — and making sure whoever is doing the anaesthetic is familiar with SCI. This paper gives you one more piece of evidence to bring to that conversation.

What's the next step in research? The authors call for prospective studies with larger numbers and, ideally, comparisons between epidural and general anaesthesia in the same population. Given how serious AD can be, and how commonly people with high-level SCI need urological procedures, this feels like an important gap to fill.

When someone sustains a traumatic spinal cord injury, surgeons typically focus on removing bone fragments or disc material pressing on the cord. But there's a second source of pressure that usually gets left alone: the dura, the tough outer membrane that wraps the cord like a sausage casing. After acute SCI, swelling inside this fixed tube can compress the cord further. Some surgeons choose to cut it open — a procedure called a durotomy — to release that pressure. Others don't, for fear of complications.

A new systematic review published in the journal Spinal Cord tries to settle the question by pooling data from eight existing studies. The finding: durotomy is associated with meaningful neurological improvement, and the complication risk appears manageable.

What the numbers show

The meta-analysis included eight observational studies comparing outcomes in patients who received intradural decompression (durotomy, with or without duroplasty — adding a patch to expand the dural space) against those who did not. Pooling the data produced a standardised mean difference in motor recovery of 0.82 — a statistically significant effect (p<0.00001) with a moderately wide confidence interval (0.62–1.02). Translated into clinical terms, this means patients who had durotomy recovered considerably more motor function than those who didn't.

The overall neurological improvement rate pooled across studies was approximately 82%. That sounds high, but it comes with important caveats: heterogeneity between studies was substantial (I²=59–77%), meaning the studies weren't all measuring the same things in the same population at the same follow-up points. The result should be read as "consistent signal in a diverse set of studies," not as a precise prediction.

Who benefits most?

This is where the findings get clinically interesting. Subgroup analysis found a strong effect in people with incomplete or mixed SCI (SMD 1.40, CI 0.05–2.75), but the effect in complete SCI was not statistically significant (SMD 1.21, CI −0.36–2.78). In other words: if there's any preserved function below the injury level, durotomy may offer substantially more benefit.

This makes biological sense. In complete injuries, the cord's circuits below the lesion are already too disrupted for releasing dural pressure to make much difference. In incomplete injuries, preserving the function that remains — by reducing secondary compression — could be the difference between walking and not.

What about complications?

The main concern with cutting the dura is cerebrospinal fluid leakage — the clear fluid that cushions the brain and spinal cord. CSF leaks can cause headaches, infection risk, and wound healing problems. The meta-analysis found no statistically significant increase in CSF-related complications from durotomy (OR 2.29, CI 0.79–6.63). The odds ratio suggests a possible elevation in risk, but the confidence interval crosses 1.0, meaning the evidence doesn't confirm harm.

Sensitivity analyses confirmed the main findings were robust — they held up when individual studies were removed one at a time.

The honest limitations

The review's authors are careful to point out that all eight included studies are observational, not randomised trials. This matters: surgeons didn't randomly assign patients to durotomy or no durotomy. They chose based on injury severity, presentation, and clinical judgment — meaning the groups being compared may not be equivalent. Higher heterogeneity and small study effects were also detected, which can inflate apparent benefits.

The conclusion is appropriately cautious: durotomy *may* improve recovery, particularly in incomplete injuries, but randomised controlled trials are needed before it becomes standard practice.

Reader Q&A

Does this mean I should have wanted a durotomy after my injury? Not necessarily — and this review doesn't change surgical guidelines yet. Many decisions in acute SCI surgery are made under intense time pressure, and durotomy adds surgical complexity and risk. This paper builds the evidence base for a procedure that some neurosurgeons already use selectively; it doesn't tell us it should be universal.

Is this common practice? Durotomy in acute SCI is practised at some specialist centres, particularly in Europe, but it's not a standard of care anywhere. The variation in practice is part of why a meta-analysis is valuable — it aggregates the scattered experience into one picture.

What is 'duroplasty' when mentioned alongside durotomy? Duroplasty means adding a patch (often a synthetic or biological material) after opening the dura, creating extra room inside the membrane rather than just releasing the immediate pressure. Some studies in this review used durotomy alone; others used durotomy with duroplasty. The meta-analysis looked at both together under the term 'intradural decompression.'

When would an RCT happen? This review is partly designed to build the case for exactly that. The authors argue the current observational evidence is strong enough to justify a well-designed prospective trial. Given the logistical complexity of acute SCI surgery research, that could still be several years away.

One of the biggest frustrations with stem cell research in spinal cord injury has been the gap between lab results and actual treatment. Promising findings in animals are common. Approved human trials are not. That gap is closing.

A new trial published in BMJ Open describes a phase I study that has received regulatory clearance from both China's National Medical Products Administration and the US Food and Drug Administration. It will test an off-the-shelf formulation of iPSC-derived motor neuron progenitor cells — shortened to MNPs — in adults with subacute SCI (injury sustained within the past few months). The trial is multicentre, enrolling at two Chinese hospitals, and can take 12 to 24 participants.

What makes this different

Most stem cell therapies under development require cells grown from the patient's own tissue — a time-consuming and expensive process that's hard to scale. This study takes a different approach. The MNPs are derived from induced pluripotent stem cells (iPSCs), which are essentially reprogrammed adult cells that have been wound back to an embryonic-like state. Crucially, the cells are allogeneic — meaning they come from a donor bank rather than from each patient. Think of it like blood typing: with the right preparation, donor cells can be used in multiple recipients without triggering rejection. The result is a standardised product that can be manufactured in advance and stored until needed.

The "motor neuron progenitor" label matters too. These aren't generic stem cells. They're cells that have already been guided partway toward becoming motor neurons — the nerve cells responsible for movement — before being delivered. Preclinical studies suggest they work through two mechanisms: directly replacing lost or damaged motor neurons, and supporting the survival of existing cells by releasing protective signals.

How the trial works

Participants will receive the cells via intrathecal injection — a needle into the spinal canal, the same route used for some anaesthetics and chemotherapy drugs. This puts the cells close to where they're needed without requiring open surgery.

The trial runs in two sequential phases. In the first (single ascending dose, or SAD), each participant gets one injection. In the second phase (multiple ascending dose, or MAD), participants receive four injections spaced two weeks apart. Within each phase, doses step up from 50 million cells to 150 million cells, with safety reviews between each step. The escalation only continues if no serious dose-limiting toxicities emerge in a 28-day window.

The primary goal is safety — the trial is too small to prove effectiveness. Researchers will track adverse events, serious adverse events, and whether any dose causes unacceptable harm. But they'll also collect a rich set of secondary data: ASIA Impairment Scale grades, motor and sensory scores, bladder function, spinal cord imaging, cerebrospinal fluid biomarkers, and neurophysiological measurements. Follow-up visits run to 360 days after the last injection.

Who can join

The study targets adults with subacute SCI — those who sustained their injury within a specific time window that makes cells more likely to integrate and survive (the early months after SCI, before scarring hardens the injury environment). The trial excludes people with complete, long-standing injuries.

Reader Q&A

This is a protocol paper — no results yet. Why is it worth writing about? Because the regulatory approvals are real, the cell manufacturing approach is novel, and the subacute window means people who are currently in early recovery could potentially be eligible — or know someone who is. Knowing a trial exists is the first step to finding out if you qualify. Enrolment is at Third Affiliated Hospital of Sun Yat-sen University (Guangzhou) and Third Hospital of Hebei Medical University.

What does 'off-the-shelf' actually mean for safety? It means the cells are from a donor, not the patient. The team has included immunosuppression protocols to manage any rejection response, but this is a key part of what the safety monitoring is watching for. It's not assumed to be risk-free — that's what phase I is for.

Could this help people with older, chronic SCI? This specific trial is for subacute injury only. The biology of chronic SCI — heavy scarring, years of tissue change — is quite different, and the cell types needed may be different too. There are separate programmes working on chronic SCI (the gliogenic NSPC approach from Dr. Okano's group, for example, which we covered here recently). This trial isn't a path forward for everyone, but it may be a door opening for a subset.

When will we see results? The trial is structured around 360-day follow-up per participant, so published results are likely at least 18 months away. This is normal for phase I — patience is the price of rigour.

Ask people living with spinal cord injury what's hardest about daily life, and pain often features near the top of the list. Not the pain from the injury itself — that acute period passes — but the persistent, often burning or electric-shock-like pain that can develop months or years later. It's called neuropathic pain, and it's the nervous system misfiring: signals being generated, amplified, or misdirected in ways that no longer serve any protective purpose. For many people, it's both debilitating and resistant to conventional pain management.

Spinal cord stimulation (SCS) — the delivery of gentle electrical pulses to the spinal cord via implanted or surface electrodes — has emerged as one of the more effective options. A review published in Neural Regeneration Research pulls together what's known about how it works and what the clinical evidence shows for SCI-related pain specifically.

Understanding SCI-related chronic pain

Chronic pain after SCI comes in several flavours. At-level pain sits at or near the injury site. Below-level pain affects areas where sensation has been lost, which is particularly strange to experience: pain in a limb you can't feel. Above-level pain can develop too, driven by the same rewiring processes. What they have in common is that they're centrally generated — the source is the nervous system itself, not tissue damage at the site you feel the pain.

This is why analgesics that work at injury sites (anti-inflammatories, opioids at lower doses) often fail: there's no peripheral injury to block. The pain is coming from the spinal cord and brain directly.

How spinal cord stimulation intervenes

SCS works through several overlapping mechanisms described in the review:

Gate control. The best-established explanation comes from gate control theory, originally proposed in the 1960s but still holding up well. The spinal cord contains interneurons that act as gatekeepers — when large-diameter sensory fibres are active (the ones that carry touch, vibration, and proprioception), they suppress the transmission of pain signals from smaller C fibres. SCS activates those large fibres electrically, effectively closing the gate before pain signals get through. This is why early SCS users often described a tingling or buzzing sensation replacing the pain — the large-fibre signals were physically competing with the pain pathway.

Neurochemical regulation. SCS also shifts the balance of neurotransmitters in the spinal cord. It increases levels of inhibitory transmitters — GABA (the main 'off switch' in the nervous system), serotonin, and acetylcholine — while reducing excitatory ones. This is a more diffuse effect than gate control, operating across broader circuits rather than at a single point.

Anti-inflammatory and neuroprotective effects. SCS downregulates pro-inflammatory signalling molecules in the spinal cord and upregulates anti-inflammatory responses. It also promotes the release of neurotrophic factors — proteins that support nerve survival and can facilitate axonal repair. These effects may partly explain why some patients report ongoing improvement even after stimulation periods end.

What the clinical evidence shows

The review summarises clinical studies showing that SCS has demonstrated efficacy for below-level SCI pain — the type that develops in anaesthetic regions, which is often the most treatment-resistant. Results for at-level pain are more mixed; some patients respond well, others less so.

Reported outcomes include reductions in pain intensity scores, reduced reliance on opioid medication, and improvements in sleep and daily function. Response rates are not universal — like most neuromodulation therapies, SCS works well for some patients and modestly or not at all for others. Patient selection and programming (the specific pattern of electrical pulses) appear to matter significantly.

Newer SCS approaches — including high-frequency stimulation (which avoids the tingling sensation of conventional SCS) and burst stimulation (a patterned delivery mimicking natural nerve firing) — have shown promising results in chronic pain generally and are beginning to be studied in SCI populations.

How it's delivered

SCS can be delivered in two ways. Epidural SCS involves implanting a small lead under the skin near the spine, connected to a pulse generator (similar to a pacemaker) implanted in the abdomen or buttock. This is the established surgical route, used for decades in chronic pain management. Transcutaneous SCS (tSCS) applies the current through electrodes on the skin surface — non-invasive and reversible, which makes it attractive for research and for patients who aren't surgical candidates. Both appear to reduce pain, though the evidence base is stronger for the implanted route.

Reader Q&A

I already use SCS for pain — am I getting the right kind? SCS is a broad category, and the specific programming matters. Conventional SCS produces a tingling (paresthesia) that overlaps the pain area; high-frequency and burst modes don't. Some pain clinics are still primarily using conventional programming. If your current setup isn't giving you the relief you hoped for, it's worth asking your pain specialist about alternative programming modes or different electrode placements.

Is SCS covered by health insurance / the HSE? In Ireland, implanted SCS for chronic pain is available through the HSE for certain indications, though access varies considerably. In the UK, NICE has guidance supporting SCS for various chronic pain conditions. Whether SCI-related neuropathic pain specifically qualifies depends on the clinical centre and available funding. Your pain specialist or SCI nurse can advise on the pathway in your area.

Could this help with spasticity as well as pain? There's evidence that SCS can reduce spasticity in some SCI patients — this is a separate but related effect, probably driven by similar modulation of spinal interneurons. This paper focuses on pain specifically, but research into the dual benefits of SCS for both pain and spasticity is ongoing.

What if I've tried medications and nothing works? SCS is often considered after medications (gabapentinoids, amitriptyline, duloxetine, opioids at appropriate doses) have been tried without adequate effect. The review supports its use as an effective option for treatment-resistant SCI pain, but the decision should be made with a specialist pain clinic that has SCI experience.

Getting the right care in the acute phase after spinal cord injury matters enormously — that much is accepted. What's less well documented is exactly *how much* it matters, and what the consequences look like over time when people don't get specialist input. A study published in BMC Health Services Research addresses that gap with one of the larger datasets assembled on the question: 1,733 people with incomplete traumatic SCI, followed for up to a year after discharge, drawn from British Columbia health records linked to the Rick Hansen Spinal Cord Injury Registry.

The headline finding: receiving both specialised acute care *and* specialised rehabilitation reduces the odds of an unplanned hospital readmission within a year by roughly half, compared to receiving neither.

How the study was designed

Researchers pulled data on everyone in BC who sustained an incomplete traumatic SCI between 2001 and 2017. They divided participants into four groups based on where they received their acute and rehabilitation care: fully specialised (both acute and rehab in specialist settings), partially specialised in different combinations, and fully non-specialised. The analysis adjusted for differences between groups — age, injury severity, and other factors — to try to isolate the effect of specialised care itself.

The numbers

The fully specialised group (N=421) was the reference point. Against that benchmark:

Non-specialised acute care (regardless of rehab setting, N=810): OR 2.06, p<0.01. Roughly double the odds of unplanned readmission within the year.

Specialised acute care only (no specialist rehab, N=411): OR 1.59, p=0.05. Still elevated compared to full specialist care, though the p-value sits right at the significance threshold.

Specialised rehab only (no specialist acute, N=38): OR 2.54, p=0.02. Interestingly, having specialised rehab without specialised acute care was associated with *higher* odds of readmission than the reverse — possibly because people in this group sustained complications from their initial non-specialist acute management that drove later readmissions.

In total, 536 unplanned readmissions were recorded across the 17-year period.

What people were being readmitted for

This is where the study adds real texture. In the specialised care group, the most common cause of readmission was urinary tract infection (UTI). That's sobering — even with expert management, UTI remains a persistent challenge after SCI.

In the non-specialised group, the most common readmission cause was injury and surgical complications: femur fractures, problems with internal orthopaedic implants or grafts, and similar issues. These are the kinds of secondary complications that specialist SCI centres are specifically trained to prevent — proper positioning, skin monitoring, fall prevention, and the management of spasticity and mobility. Finding them as the dominant readmission driver in non-specialist settings is a direct signal of what specialist input protects against.

The honest limits

This is an observational study based on administrative health records, which means the researchers couldn't randomly assign people to specialist or non-specialist care. There may be unmeasured differences between groups — for example, people with more severe injuries or more complex presentations might have been more likely to reach specialist centres, which could bias the comparison. The study spans 17 years, during which BC's healthcare system evolved, though the researchers note SCI specialisation patterns were fairly stable across the period.

The study focuses only on incomplete injuries, so findings can't be directly applied to complete SCI.

What this means practically

British Columbia isn't unique in having a mix of specialist and non-specialist facilities. The same pattern exists in most countries: a handful of designated SCI centres handling the complex cases, with smaller hospitals managing many others. This study quantifies the cost of that fragmentation in terms of downstream readmissions — and, by implication, quality of life and healthcare spending.

For people who've recently been injured or are supporting someone who has: wherever possible, advocate for access to a specialist SCI unit. The acute phase matters, but so does the rehabilitation phase — and this study suggests missing specialist input at *either* stage carries a measurable cost.

Reader Q&A

Does this study cover Ireland or the UK? No — it's a Canadian dataset from British Columbia. But the principles apply wherever you are. Ireland has the National Rehabilitation Hospital in Dún Laoghaire and a small number of spinal units. Access to those services isn't equal across the country, and studies like this make the case for pushing to change that.

What counts as 'specialised' care in this study? The researchers used the Rick Hansen SCI Registry to classify whether each participant's acute and rehabilitation care was delivered at a designated SCI specialty centre. In BC, this means centres with specialist neurosurgical and rehabilitation expertise, SCI-specific nursing protocols, and dedicated therapy teams.

If I'm already past the acute phase, is it too late? The study is about early-phase care, but it doesn't mean later specialist input is useless. What it shows is that the foundation matters: complications established in the acute phase (poor pressure care, UTI management, surgical complications) can have ripple effects that last a year or more. If you're in ongoing care, pushing to see an SCI-specialist team — even years after injury — is always worthwhile.

There's a particular moment in Ian Burkhart's story that researchers are still trying to make sense of. Burkhart became the first quadriplegic person to regain hand movement using a brain implant. He's been living with a neural interface for years. And somewhere along the way, the relationship between him and the device stopped feeling like a person using a tool.

A new paper published in *Neuroethics* captures that shift. Titled *"The Brain-Computer Interface is Changing Me,"* it's based on a first-in-human trial in which a Brain-Computer Interface (BCI) was implanted into a quadriplegic patient — and the research team then followed him closely, not just to measure what his hands could do, but to document what the experience was doing to his sense of self.

Burkhart is one of the paper's co-authors, which is itself significant. This isn't a study *about* a patient. It's a study that includes the patient as an investigator — someone with standing to interpret their own experience.

What is a BCI, exactly?

A Brain-Computer Interface records electrical signals from neurons in the brain and translates them into commands for an external device. In the case of intracortical BCIs like the one used here, a small electrode array is surgically implanted into the motor cortex — the part of the brain that controls movement. The signals it picks up are decoded in real time and used to drive things like a robotic limb or, in Burkhart's case, functional electrical stimulation of the muscles in his own paralysed hand.

The loop doesn't run just one way. As the patient tries to move, the system responds. That response feeds back into how the patient learns to use the system. Over time, the brain and the device begin to adapt to each other — a process that makes the boundary between "person" and "technology" surprisingly hard to locate.

The unexpected finding

The study's central finding is that this sustained feedback loop does something beyond restoring function. Participants described an enhanced sense of empowerment and ownership — feeling that the device was becoming part of them, not merely attached to them. The sense of agency, of being the author of your own movements, was amplified rather than diminished.

But the researchers — neuroethicist Frederic Gilbert, Ian Burkhart, and J. Morrill — were careful to document the other side too. There are complex ethical tensions at work. When you become deeply integrated with a machine that decodes your neural signals, questions arise about who is really in control. The device is learning from you. You are learning to use it. The line between "I decided to move my hand" and "the algorithm decoded my intention and executed it" is harder to draw than it sounds.

For someone whose identity has already been reshaped by injury, adding another layer of technological transformation raises real questions about continuity, autonomy, and what it means to remain yourself.

Why does this matter for SCI?

BCIs are moving — slowly but steadily — from research settings into real-world use. Neuralink, Synchron, and academic programmes worldwide are now trialling devices in humans with paralysis, ALS, and stroke. The published literature has focused heavily on what these systems can do: how many electrode channels, how accurately they decode intent, what functions they restore.

This paper asks a different question: what does it do *to* the person?

Ian Burkhart has been unusually candid about his experience over the years, co-founding the BCI Pioneers Coalition specifically to ensure that people who actually live with these devices help shape how they're designed and deployed. His role as a co-author here positions him not as a study subject but as a scientist — someone whose experiential knowledge is treated as legitimate evidence.

That shift in framing matters. As BCIs get closer to clinical use, the question of what they do to identity, agency, and wellbeing will need answers that come from people living with these devices, not just researchers observing them.

Reader Q&A

Does this mean a BCI can "change your personality"? Not in any dramatic science-fiction sense. What the paper describes is more subtle: a shift in how the user understands their own agency and bodily ownership. Most participants reported this as positive — a feeling of empowerment, a greater sense of being the author of their movements. But the researchers are appropriately cautious, noting that prolonged integration with a device that reads and responds to your neural signals raises questions that haven't been fully answered.

Is this relevant to most people with SCI right now? Intracortical BCIs — the kind requiring surgery to implant electrodes in the brain — are only available through research trials at a small number of specialist centres. Most people with SCI won't have access to this technology for some years yet. Non-invasive BCIs and transcutaneous spinal stimulation are further along for most users. But this research shapes the trajectory of where the technology is heading.

Who is "in control" when a BCI executes a movement? This is the most interesting tension the paper surfaces. The patient initiates an intention; the algorithm decodes and executes it. Over time, users often feel that *they* are doing the moving, even though the machine is doing the decoding. Whether that's a psychologically accurate account or a useful construct is one of the core questions neuroethics is now grappling with.

Will we see more research like this? Almost certainly. As more people enter BCI trials, researchers are starting to treat the experiential and psychological dimensions as seriously as the engineering. This paper is part of a growing body of work that positions the human experience of living with a neural device as evidence worth collecting — and people like Ian Burkhart as co-investigators, not just participants.

There's a version of coping after spinal cord injury that can fool almost everyone — including the clinical teams treating it.

Writing on KevinMD, a physician draws on years of experience treating veterans with SCI at a hospital in Puerto Rico. What they noticed during their residency was striking: many young veterans had, by any conventional measure, adapted remarkably well to life in a wheelchair. They were engaged, socialising, meeting rehabilitation goals. Outwardly, they looked like success stories.

And then, sometimes, something would shift.

The gap between looking adjusted and being adjusted

The article describes what this physician came to recognise as a kind of protective performance — not dishonesty, but a genuine effort by patients to show the world (and sometimes themselves) that they were managing. Depression, when it arrived, didn't always announce itself. It hid behind the very resilience that made these young men and women so impressive to care for.

This pattern matters because SCI depression is common and chronically underdiagnosed. Studies consistently find that rates of clinical depression in people with spinal cord injuries run at roughly two to four times the rate in the general population — yet it's routinely missed in clinical settings, partly because the signs can overlap with the normal grief and adjustment that follow a life-changing injury, and partly because people with SCI often have strong reasons — social, personal, and cultural — to present as coping.

Why younger patients may be at higher risk

One of the article's key observations is that depression can hit younger SCI patients particularly hard, even when they appear most resilient. This aligns with research suggesting that the very qualities that help someone look adjusted — a strong pre-injury identity, high activity levels before the accident, a presentation of control — can also make it harder for depression to surface or be acknowledged.

The veteran context adds a further layer. Military culture has historically stigmatised mental health difficulties, and a young soldier who adapted physically and publicly to his injury might find it significantly harder to admit that, internally, he was struggling. The very success of his visible adjustment could work against him in clinical encounters.

What to do with this

The article is a physician's reflection rather than a clinical protocol — but it carries a clear practical implication: routine screening for depression in SCI care should not be scaled back because someone seems fine. Seeming fine, in this context, is not sufficient evidence that someone is fine.

For anyone in the SCI community — whether living with injury, or as a family member, partner, or carer — the piece is a useful reminder that resilience and distress are not mutually exclusive. They can share the same face. Checking in regularly, and making it genuinely normal to talk about mental health, is not the same as looking for trouble. It's attentiveness.

Reader Q&A

How common is depression after SCI? Common. Studies consistently estimate clinical depression in the SCI population at two to four times the general population rate, though exact figures vary by study design and population. Depression can occur acutely after injury or emerge months to years later — and it can recur. It is one of the most significant contributors to reduced quality of life after SCI.

Are there effective treatments? Yes. Both psychological therapies — particularly cognitive behavioural therapy (CBT) and acceptance and commitment therapy (ACT) — and medication have evidence behind them for post-SCI depression. Peer support and social connection also have consistent evidence. The challenge is identification, which is precisely what this article addresses.

Should I be worried if someone close to me with SCI seems to be coping well? Not necessarily — but "seeming fine" shouldn't be taken as conclusive on its own. Regular, genuine checking-in matters more than watching for obvious signs of distress. If you're genuinely concerned, a conversation with their clinical team is worth having. You don't need certainty to raise a concern.

Does this apply only to veterans? No. The article is set in a VA context, but the pattern it describes — depression hiding behind apparent resilience — applies across the SCI population regardless of how the injury occurred. Veterans may face additional barriers because of military culture, but the phenomenon isn't confined to that group.

The world's largest annual wheelchair sports event started earlier this week, and it's running until Sunday in Detroit.

The 45th National Veterans Wheelchair Games (9–14 July 2026) has brought together more than 600 US military veterans from across the country. To participate, veterans need a qualifying condition — spinal cord injury, amputation, multiple sclerosis, or other neurological conditions requiring a wheelchair for athletic competition — and a service record. That's it. Elite athletic background is not a requirement.

The sports on offer span a wide range: wheelchair basketball, track and field, archery, air rifles, hand-cycling, boccia, billiards, swimming, and more, with events designed to accommodate different levels of function and different types of injury. For many participants, competing here isn't simply about winning. It's about what happens to a person's sense of themselves when they compete.

From 77 athletes to 600

The Games were launched by the Department of Veterans Affairs in 1981, starting small: seven events, 77 athletes. Paralyzed Veterans of America (PVA) joined as co-organiser four years later, and the event has grown steadily every decade since. Today it's one of the most visible proof points that wheelchair sport at scale works — that competition, community, and physical challenge are meaningful parts of life after serious injury.

The underlying philosophy is about mindset as much as movement. Veterans who enter the Games as patients often leave thinking of themselves differently — as athletes, competitors, teammates.

Rehabilitation through competition

There's a solid evidence base linking adaptive sports participation to improved psychological wellbeing, reduced depression, better pain management, and stronger social connection in people with SCI and related conditions. The Games are one of the most sustained institutional expressions of that principle.

Uniti, which manufactures wheelchairs and mobility equipment, has supported the Games for the sixth consecutive year in 2026, contributing to the equipment and logistics that allow veterans from across the country to participate.

The Michigan Paralyzed Veterans of America is the host chapter for this year's event, and the state's disability sport infrastructure has been a visible part of the build-up.

Reader Q&A

Can civilians with SCI attend or participate? The National Veterans Wheelchair Games are open only to US military veterans with qualifying conditions. But many of the sports featured have civilian equivalents — through organisations like US Paralympics, Wheelchair Basketball USA, and others. In the UK and Ireland, organisations including the British Wheelchair Basketball Association, Wheelchair Sports Ireland, and ASPIRE run equivalent programmes.

What's the difference between the Wheelchair Games and the Paralympics? The Paralympics is an elite competition for the world's best adaptive athletes. The Veterans Wheelchair Games prioritise participation and rehabilitation over elite performance — any veteran with a qualifying condition can enter, regardless of athletic ability or experience. It's closer in spirit to a community games than to the Olympics, though some participants do go on to compete at Paralympic level.

Is this just a US thing? The National Veterans Wheelchair Games are US-specific, but comparable events exist in other countries. The Invictus Games, which also focuses on military veterans with injuries, has an international format. The Cybathlon (based in Switzerland) takes a different approach, using assistive technology as the competitive medium.

Is there any connection to SCI research at these events? Indirectly, yes. Adaptive sports events generate interest in assistive technology, wheelchair design, and rehabilitation science. They also provide a pipeline of participants for research studies, and several academic partnerships operate in and around events like this. Visibility matters: what's seen as achievable tends to expand what researchers and clinicians try to make possible.

Most spinal cord injury research focuses on the acute phase — the hours, days and weeks just after injury. But the majority of people living with SCI were injured years or even decades ago, and for them, the research picture has historically looked bleak. That may be starting to change.

At the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, Dr. Hideyuki Okano from Keio University in Japan presented new preclinical efficacy data for a stem cell-based approach targeting chronic incomplete SCI — along with plans for a physician-initiated clinical trial expected to begin recruiting patients in 2027.

Why myelin matters

When a spinal cord injury occurs, several things go wrong at once: nerve fibres are severed, inflammation damages surrounding tissue, and the insulating sheath around surviving nerve fibres — called myelin — breaks down. Those demyelinated fibres are at the heart of Okano's approach.

The key insight is that in many people with incomplete SCI, the underlying nerve fibres are still physically present — they just lack adequate insulation. Without myelin, nerve signals can't travel properly, even if the fibre itself is intact. Restore the myelin, and those dormant fibres might start working again.

A different kind of stem cell

Many stem cell approaches in neurology try to replace lost neurons — an extremely difficult task. Okano's team took a different route. Their cells are called gNS/PCs (gliogenic neural stem/progenitor cells), and the word "gliogenic" is the important part. Rather than generating neurons, these cells are specifically designed to produce the nervous system's support cells: oligodendrocytes (which make myelin) and astrocytes (which maintain the neural environment). It's a more targeted strategy — rebuilding the infrastructure around surviving nerve fibres rather than trying to regenerate severed connections from scratch.

Critically, these are clinical-grade cells — produced under the standards required for human use — which brings them closer to the clinic than earlier experimental formulations.

Building on a first-in-human milestone

This isn't the team's first step in humans. Okano's group previously completed what they describe as the world's first first-in-human clinical study of gNS/PCs in patients with subacute SCI (injury within weeks). That study demonstrated a promising safety profile, which is a crucial foundation before moving to a harder clinical problem.

The new work extends the approach to chronic SCI — injuries that are months or years old. The cellular environment changes significantly over time after injury: scar tissue forms, inflammation subsides, and the window for certain interventions narrows. Developing a strategy that works in that chronic environment is a separate (and more difficult) scientific challenge from the subacute case.

Who would this help?

The planned clinical trial will focus on people with chronic, incomplete SCI who retain dormant but demyelinated nerve fibres. This is an important distinction: the approach is specifically designed for patients who still have surviving fibres that could potentially transmit signals if their myelin were restored. It is not expected to benefit people whose fibres are largely severed.

This profile — chronic, incomplete, with demyelinated but surviving fibres — applies to a significant proportion of the people currently living with SCI.

Reader Q&A

Is a treatment available now? No. The preclinical data is promising and a clinical trial is planned to start recruiting in 2027, but this is still in early stages for chronic SCI specifically. The timeline from a Phase 1 safety trial to a widely available therapy typically spans several more years.

How is this different from other stem cell approaches for SCI? Most previous approaches have tried to regenerate neurons — a very difficult goal. This strategy targets remyelination: rebuilding the insulating sheath around nerve fibres that survived the original injury. It's a different biological target, and arguably a more achievable one for a significant subset of patients.

Would someone with a complete injury benefit? The approach as described focuses on patients with incomplete injury who still have surviving fibres. For complete injuries, where most fibres are severed, the biological challenge is different and this strategy as currently designed may not apply directly.

Is this connected to earlier Keio University SCI research? Yes. The same group made news in early 2025 for work on stem cell treatment in acute/subacute SCI patients. This July 2026 announcement represents the next logical step — applying the approach to chronic patients, which is the larger and harder population.

In the long road from promising biology to approved treatment, pharmacokinetics and immunogenicity data are not the most dramatic milestone — but they matter. A new paper in Future Science OA provides that data for E3112, a recombinant human hepatocyte growth factor (HGF) that has been in clinical development for acute spinal cord injury in Japan for several years.

The drug is also referred to as KP-100IT, its development-programme name. It has been studied in Phase 2 trials in people with acute SCI, where earlier results suggested some improvement in motor function. This paper is not a new efficacy readout — it focuses on how the drug behaves in the body (pharmacokinetics, or PK) and whether the immune system produces antibodies against it (immunogenicity).

Why pharmacokinetics and immunogenicity matter

When a drug is a protein — which recombinant HGF is — two questions become important that are less relevant for small-molecule drugs. First: how does it move through the body, how long does it stay active, and how consistently does it do so across different patients? Second: does the body's immune system recognise it as foreign and mount an antibody response against it?

These questions matter for safety and for understanding whether the drug works as intended. If a protein drug provokes an immune response, those antibodies can neutralise the drug's effect or, in some cases, cause adverse reactions. The published data here provides the clinical assessments of both — showing how E3112 behaves pharmacokinetically and what the immunogenicity profile looks like in the patient population studied.

Background: what HGF does in SCI

Hepatocyte growth factor is a naturally occurring protein that has multiple roles in the body, including promoting cell survival, reducing inflammation, and supporting nerve growth and repair. Its potential relevance to SCI comes from preclinical evidence that it supports neural survival and regeneration after injury, and that it may reduce the secondary injury cascade that extends damage in the hours and days after the initial trauma.

The idea behind KP-100IT/E3112 is to deliver recombinant HGF directly to the spinal cord — via intrathecal administration — during the acute injury window, when the cord is still in the process of secondary damage and when interventions have the best chance of preserving function.

Earlier clinical data from the Japanese programme suggested motor function improvements in some patients, which was enough to support continued development. The PK/immunogenicity paper represents the kind of detailed characterisation needed to understand how to dose the drug correctly and what to watch for in larger trials.

Where this sits in the development timeline

E3112/KP-100IT has been in development for longer than many SCI drugs, and the fact that it has reached the stage of publishing PK and immunogenicity characterisation suggests the programme is moving forward methodically. Japan has been a relatively active space for SCI drug development — several programmes including cell therapies have originated there and progressed to clinical testing.

This paper is not a signal of a breakthrough, and it does not provide new evidence that the drug works. It is the kind of characterisation data that sits behind the scenes of any serious drug development programme, filling in the picture that regulators and future trial designers will need.

Reader Q&A

Is this drug available?

No — E3112/KP-100IT is in clinical development in Japan and is not commercially available.

Has it been shown to work in SCI?

Earlier Phase 2 data from Japan showed some motor improvement in patients with acute SCI. That was encouraging, but Phase 2 trials are not definitive — they are designed primarily to assess safety and gather preliminary evidence of effect. Larger, controlled trials would be needed to confirm efficacy.

What is intrathecal administration?

Intrathecal means delivered directly into the space around the spinal cord and brain (the subarachnoid space), rather than taken orally or given intravenously. It is used for drugs that cannot cross the blood-brain barrier effectively and where direct delivery to the spinal cord is important. It requires a lumbar puncture or similar procedure.

For people with cervical spinal cord injury, regaining upper limb and hand function is often the single change that would most improve daily independence. Two rehabilitation technologies — transcutaneous spinal stimulation (TSS) and robotic exoskeleton training — have each shown promise on their own. A new study asked whether combining them is better, and more importantly: for whom, and why.

The paper, published in the Journal of NeuroEngineering and Rehabilitation on 29 June 2026, was led by J. Oh, M.S. Scheffler, S.T. King, E.E. Mahan, M. Lee and colleagues working with the research group of David A. Friedenberg. Eleven participants completed the full study: five with chronic stroke and six with chronic SCI affecting upper limb function.

The two technologies explained

Transcutaneous spinal stimulation (TSS) is a non-invasive technique that uses electrode patches placed on the skin over the spine to deliver mild electrical currents. These modulate the activity of spinal cord circuits without surgery — which makes TSS more accessible and lower-risk than implanted (epidural) stimulation systems. It doesn't directly move the limb; instead it primes or modulates the spinal networks that control movement, potentially making them more responsive to training.

Robotic exoskeleton training uses wearable mechanical devices that guide the arm through controlled movements. The repetitive, assisted practice supports motor learning — the process by which the brain and spinal cord reorganise to regain function after injury. These systems can perform far more consistent repetitions than a human therapist can manage, and can precisely track force and range of motion over time.

Both approaches leverage a core principle of neurorehabilitation: neuroplasticity — the nervous system's capacity to reorganise and adapt in response to experience.

How the study worked

The trial used a crossover design, meaning each participant received both treatments in sequence (with a washout period between), rather than being randomly assigned to just one. This allows each person to serve as their own control — a useful design when participant numbers are small.

Over 14 weeks, each participant went through: four weeks of assessment, four weeks of robotic training with sham (non-active) TSS, a two-week washout, and then four weeks of the same robotic training with active TSS (or vice versa — the order was randomised). Sessions lasted one hour and ran three days per week, combining robotic exoskeleton-assisted arm movements and hand grip training while receiving either real or sham stimulation.

Individual responses — the key finding

The title of the paper flags something important: "individual neurophysiological and clinical responses." Rather than reporting a single averaged treatment effect, the researchers examined how each participant responded — both in the nervous system (neurophysiological changes, such as alterations in nerve signal patterns) and in function (clinical changes, such as grip strength or arm movement scores).

This reflects a reality well-known in SCI and stroke rehabilitation: responses vary considerably between individuals. What significantly helps one person may have little effect on another. By examining individual-level patterns rather than group averages alone, studies like this help build the evidence base for matching specific interventions to specific patients — the goal of personalised rehabilitation.

What this adds to the field

Several previous studies have looked at TSS for lower limb or gait recovery in SCI. Research on TSS for upper limb function is more recent and less extensive. This study specifically addresses upper extremity recovery — the priority for many people with cervical SCI — and pairs TSS with robotic training rather than testing either in isolation.

The combination matters because the two approaches may work better together than apart: TSS may make the spinal circuits more receptive to the motor learning that robotic training drives. Understanding when and for whom that synergy is real is the work that studies like this begin to answer.

Reader Q&A

Is this combination available to me now? Robotic exoskeleton programs exist at some specialist rehabilitation centres, but combining them with TSS is not yet standard clinical practice. If you're interested, a physiatrist or rehabilitation specialist at a larger SCI centre would be the right person to ask about research programmes or emerging clinical access.

How is transcutaneous stimulation different from the epidural stimulation I've read about? Epidural stimulation involves surgically implanting electrodes near the spinal cord, delivering a more precise and powerful signal. Transcutaneous stimulation uses skin-surface pads and requires no surgery — it's weaker and less targeted, but much more accessible and carries no surgical risk, making it well-suited for use during outpatient rehabilitation.

Is this relevant to people with cervical SCI? Yes — the study focused on upper limb impairment, which is the defining challenge of cervical SCI. All six SCI participants in this study had upper extremity involvement.

Why is the title so focused on "individual responses"? Because it's an important finding in itself. If the response to TSS + robotics were uniform, you could simply recommend it to everyone with upper limb impairment after SCI. The fact that responses vary suggests there are meaningful differences between individuals — possibly related to injury level, completeness, how long ago the injury happened, or underlying neurophysiology — that future research can use to predict who will benefit most.

One of the less-discussed consequences of spinal cord injury is what happens to sensation below the injury level. Motor function — movement — tends to get most of the attention in research and in public conversation. But sensory loss can be just as disabling in practical terms. If you cannot feel when your foot is touching the ground, or where the pressure is, walking and balance become far harder — even if your muscles are working.

A team at the Georgia Institute of Technology has been working on this problem directly, and a new interview published by The Naked Scientists gives a detailed look at what they have built and where it has reached.

What the device does

Matthew Flavin, who runs a wearable bioelectronics lab at Georgia Tech, describes the approach as sensory substitution. The idea is that if one part of the body has lost its ability to receive sensory information, you can route that information to another part of the body where sensation is intact — and the brain can learn to interpret it.

The system has two main components. First, pressure-sensing insoles sit inside the shoe and capture what is happening at the foot in real time: where pressure is being applied, how much, and from what part of the sole. Second, a set of small actuator devices — wearable units that can vibrate and generate heat — are placed on the forearm, where sensation is typically preserved after many SCI and stroke injuries.

The mapping is designed to be spatially intuitive. Pressure at the toe produces vibration near the wrist. Pressure at the heel produces vibration near the elbow. The brain can learn to read those signals as information about the foot.

Who might benefit

The conditions Flavin identifies as target populations are stroke, spinal cord injury, and diabetic neuropathy — three conditions that can each damage the sensory pathways from the feet, through different mechanisms. In SCI, the injury interrupts the spinal pathways that carry sensory signals from the lower limbs to the brain. In stroke, the damage occurs higher up. In diabetic neuropathy, the peripheral nerves themselves degrade over time.

What they have in common is the practical consequence: the person cannot reliably feel what is happening at their feet, and that affects balance, gait, and confidence in movement. Falls become more likely. Going outside becomes more effortful.

What the early testing showed

The team tested the system in two groups: twelve neurotypical adults with normal sensation, and eight participants with lower-limb sensory impairments from stroke or spinal cord injury.

The core test was a sensory matching task. The researchers applied different patterns of vibration to the forearm actuators and asked participants to identify which part of their foot corresponded to each pattern — essentially testing whether the signal-to-meaning mapping was working. Both groups — neurotypical participants and those with SCI or stroke — performed well on this task.

Flavin is careful about what this means. The study was designed as a proof-of-concept test of the system itself: can the devices deliver the signals reliably, and can people interpret those signals? Those questions were answered. The next step — showing that the system improves balance and gait outcomes in real-world conditions, in controlled trials — has not yet been done.

The balance application

One concrete example Flavin gives is balance recovery in people with stroke. When the stimulation is working and a person can feel where their foot pressure is, they can use that feedback to shift their weight distribution — putting more balance in the centre of their stance. That is the kind of functional change that would matter day-to-day.

For people with SCI, particularly those with incomplete injuries who retain some lower-limb motor function, the same principle applies: knowing where and how the foot is in contact with the ground is important for walking, and losing that information is a real obstacle to rehabilitation.

What is not yet known

The study is early stage. It has not yet shown that the sensory substitution system actually improves walking or balance outcomes compared to not using it — that comparison would require a controlled trial with outcome measures like gait speed, step length, or fall rates. The participants in the current study had a range of different conditions (stroke and SCI are quite different), and the number of participants with sensory impairments was small (eight people).

Flavin also notes that one of the design challenges is the variability between patients. Even among people with SCI at the same injury level, the pattern of motor and sensory loss can differ significantly — which means a device intended to help a broad population may need to be adaptable. That adaptability is something the team is working toward.

Reader Q&A

Does this restore sensation, or is it a workaround?

It is a workaround — a substitute, not a restoration. The foot itself is still not feeling anything; the device is taking the information the foot would have transmitted and rerouting it to a part of the body that can. The brain receives the signal, but it arrives through a different pathway and a different body location. The hope is that with training, the brain learns to use that signal effectively. It does not repair the damaged sensory pathways.

Is this already available?

Not commercially. This is a research prototype being tested at Georgia Tech. The researchers describe a commercially available, adaptable version as the "aspirational goal" — something they are working toward, but not something that exists yet.

Could this help with motor rehabilitation as well?

Not directly — the device is designed for sensory symptoms, not motor function. But sensation and motor control are linked. If a person with incomplete SCI can feel where their foot is during walking practice, that feedback can help them walk more safely and potentially make rehabilitation more effective. Whether using this kind of sensory substitution during motor rehabilitation would lead to better outcomes is a question for future trials.

What about diabetic neuropathy?

Flavin specifically mentions diabetic neuropathy patients as a group who could benefit but have not yet been tested. A well-known problem in diabetic neuropathy is that patients can't feel small wounds or pressure sores developing on their feet, leading to serious infections. A device that routes foot-contact information to a place the patient can feel could, in principle, help with this — though again, that specific application has not been tested yet.

Most people who have been living with spinal cord injury for some time are aware of the pressure sore risk, the bladder complications, the muscle changes. But one consequence that gets less attention — even though it affects nearly everyone with a complete injury — is what happens to bone.

After SCI, bones stop being loaded the way they normally would through walking and standing. Without that mechanical stimulus, bone mass drops rapidly and continuously. The lower limbs are worst affected, and the distal femur — the part of the thigh bone just above the knee — is particularly vulnerable. Fractures at this site, sometimes triggered by something as minor as a transfer or a fall from a wheelchair, are a serious and common complication. They are difficult to treat surgically in people who lack sensation, and they extend disability significantly.

Several approaches to maintaining bone mass after SCI have been explored over the years — electrical stimulation to activate muscles, functional electrical stimulation cycling, standing frames. Some show modest effects, but none are widely used, partly because they are burdensome and partly because results have been inconsistent.

A team at the University of Strathclyde and the Scottish Centre for Innovation in Spinal Cord Injury is taking a different approach: applying very high-frequency, very low-amplitude vibrations directly to the bone itself, using a device worn around the knee.

Why vibration, and why at that frequency?

The physics of bone stimulation by vibration is not new research. Laboratory and animal studies have shown that very small vibrations — at the nanometre scale in terms of actual displacement — at frequencies around 1,000 Hz can activate bone cells and stimulate the processes involved in maintaining and building bone density. The key is that the vibration needs to be delivered at the right frequency, at a consistent amplitude, and to the right location.

Previous work on vibration therapy for SCI bone loss has typically applied vibration through the feet or to larger body segments. The Strathclyde team reasoned that the distal femur — the most at-risk site — could be targeted more precisely and more effectively by applying vibration directly at the knee.

What the device does

The device is a wearable unit that straps around the knee. It delivers 1,000 Hz vibrations to the skin surface overlying the distal femur. The vibrations are at nanoscale amplitude — far smaller than what you can feel as conventional vibration — generated by a specialised transducer. A gel interface between the device and the skin helps transmit the vibration into the underlying tissue, including the bone.

Before settling on the knee as the target, the team compared three different placement sites — the distal femur (front of the knee), the proximal tibia (just below the knee at the front of the shin), and the ankle. They measured how consistently and reproducibly they could deliver vibration to each site, and how well it transmitted through to the bone, using laser interferometry to measure vibration at the bone surface. The distal femur site came out ahead on both consistency and signal quality, and that became the target for further testing.

What the feasibility study showed

The main part of the study tested the device in a single participant: a person with a motor-complete spinal cord injury. The participant completed 61 sessions over 14 weeks, with each session lasting approximately two hours. In total, just under 120 hours of device use was accumulated.

The primary goal of this phase was to assess whether the device was safe and tolerable over repeated use — not whether it improved bone density. That is a question for a future, larger trial. On the safety side, there was no skin damage over the entire course of testing. The participant was able to use the device for the planned session durations without adverse events.

The gel interface was found to help transmit vibration more consistently compared to direct skin contact, even though it reduced the overall amplitude slightly. That trade-off appears to be worth it for reliability.

Practical limitations the team is working on

The researchers are candid about the practical challenges that emerged. The device can slip during sessions as the participant moves or adjusts position, which affects vibration delivery. The 1,000 Hz frequency produces an audible hum that may be noticeable and potentially distracting or intrusive over a two-hour session. And the current electronics unit is bulky — it needs to be made substantially smaller and more portable before the device could be used easily in everyday life.

These are engineering problems rather than fundamental barriers, and the team identifies them as the priority for the next development phase.

Where this sits

This paper is a preprint — it has not yet been through the peer review process. That means its methods and conclusions have not been independently scrutinised and may change. The study is also a single-participant feasibility trial: it was designed to show the device can be used safely and consistently, not to show that it improves bone. Whether vibration at this site, at this frequency, actually prevents or reverses SCI-related bone loss in the distal femur is the key scientific question — and answering it will require a larger randomised trial with bone density measurements over time.

Reader Q&A

Does this device currently prevent bone fractures in SCI?

That has not been tested yet. This study showed that the device can be worn safely over many sessions. The actual clinical question — whether it maintains or improves bone density, and whether that translates to fewer fractures — is for a future trial to answer.

How bad is bone loss after SCI, and why does it matter?

Very bad, and it matters a lot. Within the first year or two of a complete SCI, people can lose 30–50% of bone mass in the lower limbs. The distal femur and proximal tibia are the areas most severely affected. This makes fractures far more likely from relatively low-energy events — a fall from a wheelchair, an awkward transfer, even vigorous physiotherapy. Fractures are painful even without sensation in the usual sense, difficult to treat, and often extend hospital stays significantly.

Is this device available to use?

No. It is a research prototype and is not commercially available. The researchers are working on engineering improvements before a larger efficacy trial.

Could this work for people with incomplete injuries too?

The study only included a person with a motor-complete injury. People with incomplete injuries also experience bone loss, though typically less severe. Whether the device would be appropriate or beneficial for that group has not been tested.

Spinal cord stimulation has become one of the most actively researched areas in SCI rehabilitation over the past decade. Studies have shown that delivering electrical stimulation to the spinal cord — either through surgically implanted epidural leads or through non-invasive surface electrodes — can reactivate circuits below an injury and help people with incomplete injuries walk, stand, or move their arms. Some results have been striking.

But most of these systems share a fundamental limitation: the stimulation is essentially constant. It runs at a fixed rate and pattern, regardless of what the person is doing at that moment. That works up to a point, but it is not how the nervous system naturally operates. The body's own neural circuits constantly adjust their activity in response to feedback — from muscle sensors, from joint position sensors, from the vestibular system, from vision. To get the full benefit of spinal stimulation, the stimulation itself needs to become responsive in the same way.

That shift — from open-loop (fixed) to closed-loop (adaptive) stimulation — is the subject of a detailed review just published in the journal Sensors by researchers at the University of Louisville's Kentucky Spinal Cord Injury Research Center.

What closed-loop means in practice

In a closed-loop system, sensors detect what is happening in the body or environment in real time, and that information is fed back to adjust the stimulation parameters — the timing, intensity, or pattern of the electrical pulses — on the fly. The idea is that stimulation should be active when it is needed, at the right level, and timed to the right phase of movement or activity.

The review identifies five distinct categories of sensors being used or explored for this purpose in SCI rehabilitation.

The first category is kinematic sensors — devices like inertial measurement units (IMUs) and accelerometers that detect the position and movement of limb segments. These can identify what phase of a movement cycle the person is in (for example, the swing phase versus the stance phase of walking) and trigger stimulation accordingly.

The second category is force and pressure sensors — sensors placed in shoe insoles or under foot pads that detect when and where the foot is in contact with the ground and how much weight is being borne. This kind of information is central to controlling walking and balance.

The third category is electromyography (EMG) — measuring the electrical activity of muscles themselves. When a muscle fires (or tries to fire), that signal can be detected and used to trigger or modulate stimulation in real time. Surface electrode arrays that cover larger areas of muscle are making this more practical.

The fourth category is vision-based sensing — using cameras to detect features of the environment (a step, an obstacle, a change in terrain) and trigger adjustments in stimulation before the person encounters them, rather than reacting after the fact.

The fifth category is neural interfaces — recording directly from nerves or the spinal cord to detect the state of neural circuits below the injury. This is the most technically demanding approach and the furthest from routine clinical use, but it offers the most direct window into what the nervous system is doing.

What has been achieved so far

The review discusses where these technologies have reached in research settings, referencing several landmark studies.

In walking recovery, perhaps the most striking demonstration was the work published in Nature in 2023 by Lorach and colleagues — the so-called "digital bridge" study — in which a person with a complete thoracic SCI walked with the aid of a brain-spine interface that decoded his movement intentions and translated them into precisely timed epidural stimulation. That system used both neural recording (brain signals) and stimulation timing calibrated to gait phases. It demonstrated the principle that closed-loop systems timed to intended movement can produce functional walking in a way that continuous stimulation cannot.

Other studies have used EMG activity and body position sensors to create "activity-specific" stimulation programs — different patterns of stimulation for standing, for walking, for transitioning between the two — triggered automatically by the body's own movements. Research from Rowald and colleagues and from groups led by Grégoire Courtine and Jocelyne Bloch has demonstrated these approaches in people with incomplete injuries.

For upper limb function, a study from the Moritz group (referenced as a multicenter tSCS trial in the review) has shown that non-invasive spinal stimulation of the cervical spinal cord can improve hand and arm function after SCI. A very recent study from 2026 (Tazoe et al., published in Brain) demonstrated that EMG from the hand — recorded non-invasively — could be used to control stepping through spinal stimulation, creating a cross-limb closed loop that is novel and clinically interesting.

Why this matters beyond the lab

The review's central argument is that the sensor and control design — how stimulation is triggered and adjusted — is becoming the critical variable in whether these systems work outside of a research laboratory. Getting the hardware to work is increasingly well understood. Getting it to respond intelligently to the complexity of real-world movement and the individual variability between patients is the harder problem.

The authors make the point that each sensor type has trade-offs: IMUs are convenient but don't tell you about muscle state; EMG is informative but harder to use reliably in all conditions; neural interfaces are powerful but require surgery and careful implant management. The field is moving toward combining multiple sensor types to build a more complete picture.

Reader Q&A

Is closed-loop stimulation available clinically now?

In a limited sense, yes — some commercial epidural stimulation systems (like Medtronic's Intellis platform) offer basic adaptive stimulation features. But the kind of sophisticated, movement-responsive, multi-sensor closed-loop systems described in this review are still largely in research settings. A few clinical trials are underway.

Does this work for complete injuries as well as incomplete?

Much of the most dramatic walking recovery demonstrated with closed-loop stimulation has been in people with incomplete injuries — where some neural connections below the injury remain. The digital bridge study (Lorach 2023) was in a person with a complete injury and achieved walking with the assistance of the closed-loop brain-spine system. Results are more variable in complete injuries, and what is achievable depends heavily on the person, the injury level, and the system being used.

This sounds complicated — is there a risk of systems becoming too complex to actually use?

That is a real concern the review addresses. More sensors and more complex algorithms mean more things that can go wrong, more calibration required, and more technical expertise needed. A key challenge for the field is building systems that are robust and user-friendly enough to be operated by patients at home, not just in a clinic with a research team. The review identifies this as one of the central unsolved problems.

When researchers want to build a brain-computer interface (BCI) that lets a paralysed person control their hand, the most obvious place to put the electrodes is the motor cortex — the part of the brain that directly commands muscle movement. And that has been the dominant approach. It works, up to a point.

But grasping something — really picking up an object, shaping your hand to it, applying the right grip — is not just a motor cortex activity. The brain has a whole network of areas involved in planning, visually guiding, and coordinating reaching and grasping. Those areas encode information that motor cortex alone doesn't capture.

A team at the Cleveland Clinic and Case Western Reserve University, working within a broader clinical trial called ReHAB (Restoration of Hand and Arm function after tetraplegia), have been exploring what happens when you implant electrodes into those additional brain regions — and how to figure out, before surgery, exactly where in a given person's brain those regions are.

Their results, published in Neuroimage: Reports, describe the approach they used and what they found when they put it into practice in one participant.

The challenge of finding the right spots

The brain regions involved in grasping are well mapped at a population level — we know roughly where they sit in most brains. But "roughly" isn't good enough when you're implanting electrode arrays. Brains vary significantly from person to person, and after a spinal cord injury, the brain can reorganise in ways that shift where functional regions are located. A target identified purely from anatomy or standard brain atlases might land in the wrong neighbourhood.

There's an additional complication: several of the brain areas most important for grasping are very close to areas involved in speech and language. For someone who relies on their voice to communicate, accidentally impairing speech in the course of a surgery aimed at restoring hand control would be a serious harm.

And then there are the practical surgical constraints: current electrode arrays (including those from Blackrock Neurotech, which is what was used here) can only be implanted on the exposed surface of the brain — not in the folds (sulci). This rules out a number of otherwise-attractive targets.

The solution: map first, operate second

The team built a multi-step planning process centred on brain imaging.

Three months before surgery, the participant — a 47-year-old man with C5-level SCI, who had motor but not sensory impairment, from a car accident 2.5 years earlier — underwent an extensive MRI session. This included standard structural scans, diffusion-weighted imaging (which shows how different brain regions are connected to each other through white matter tracts), and a contrast scan to map the blood vessels on the brain surface (important for avoiding vasculature during surgery).

The team also used a software platform called Quicktome that aligns a person's individual brain anatomy with a large population database (the Human Connectome Project) to estimate where specific functional regions are likely to be, based on how this brain's structure compares to thousands of others.

But the most important step was a task-based fMRI session: the participant lay in a scanner and imagined grasping or reaching toward objects while the scanner measured blood flow across the brain. Regions that became more active during imagined grasping lit up. Separately, an auditory fMRI task was run — listening to reversed speech — to map out the speech and audio processing regions to be avoided.

The fMRI revealed something critical: the anatomical region that sulcal landmarks would suggest for one key target (the anterior intraparietal area, or AIP — a region involved in hand pre-shaping during grasping) actually contained two neighbouring sub-regions. One responded to grasping. The adjacent one responded to audio. Without the fMRI, anatomy alone would have pointed at the same general location and there would have been no way to know which sub-region was which. The team placed the electrode specifically in the grasp-responsive sub-region, away from the audio-responsive one.

A 3D-printed model of the participant's skull and brain — made to exact scale from the MRI data — was used to let the surgical team physically rehearse the electrode placement, including the craniotomy (the opening in the skull) and the routing of electrode leads.

Where the electrodes went

The team implanted eight electrode arrays (Blackrock Utah arrays, 96 channels each, 768 total channels). In addition to the standard primary motor cortex (M1) and primary somatosensory cortex (S1) placements — which are part of the standard ReHAB protocol — two additional arrays went into the putative AIP region, and two into the ventral premotor cortex (PMv), specifically into sub-regions called 6V and 6R.

The inferior frontal gyrus (IFG), another grasp-related area, showed grasp activation on fMRI but was excluded: the relevant sub-region sat mostly inside a sulcus and was largely obscured by blood vessels, making it surgically inaccessible.

What the electrodes recorded

Starting four weeks after surgery, the team began recording from all the implanted arrays while the participant attempted five different arm and hand movements: raising his right arm, moving his hand sideways, making a pinch grip, bending his wrist down, and rotating his wrist outward. Even though he could not physically complete these movements (his injury had paralysed his hand), his brain still generated movement signals as he tried.

Each individual brain region decoded the movements with accuracy ranging from 62% (for one PMv sub-region, 6V) to 92% (for AIP). Chance performance for five movements would be 20%.

When signals from all regions were combined, accuracy rose to 96%. Importantly, combining didn't just average things out — each region added information that the others didn't fully capture. This confirms that different parts of the grasp network encode complementary aspects of movement, not just redundant copies of the same signal.

Performance was stable across three recording sessions (one in April 2025, two in July 2025), with combined accuracy remaining between 85% and 96% across sessions.

Reader Q&A

How is this different from existing BCI systems?

Most existing human intracortical BCI systems record from motor cortex only. This study adds three additional brain regions (AIP, and two sub-regions of PMv) that are involved in higher-level aspects of grasping — planning, object shape recognition, visuomotor coordination. The result is a richer signal that can be decoded more accurately, and which encodes more information about what the person intends to do.

Can this person now use their hand?

Not reported in this paper — the paper focuses on the electrode targeting methodology and the decoding accuracy. The ReHAB trial's broader aim is to connect this decoded brain signal to a functional electrical stimulation system that would activate the hand muscles. That work is ongoing.

Why is this a single-participant study?

Clinical trials of implanted brain devices necessarily proceed carefully and slowly, with intensive study of each participant. This paper reports the planning methodology and initial results for one person. More participants will need to be enrolled to establish whether the approach generalises.

Is the fMRI mapping necessary every time?

That's an open question. The researchers argue it was essential in this case because it revealed that the AIP region contained both grasp-responsive and audio-responsive sub-regions that anatomy alone couldn't distinguish. Whether every person would show similar variability is not known. The authors suggest fMRI mapping should be standard for targeting non-primary motor regions.

One of the reasons spinal cord injury is so difficult to treat is that the cord is not just a bundle of nerve fibres — it has a specific, carefully organised architecture that is essential for how it works.

If you look at a cross-section of the spinal cord, you see two distinct zones. The outer ring — the white matter — is where long axons run in parallel bundles, carrying signals up and down the cord between the brain and the body. The inner region, shaped a bit like a butterfly, is the gray matter, where the cell bodies of neurons cluster together in circuits that process signals and coordinate movement.

After a spinal cord injury, this organised structure is destroyed. Scar tissue fills the injury site in a disorganised way. Even if axons try to regrow, they run into a chaotic environment with no clear direction to follow. The result is that reconnection across the injury rarely happens spontaneously.

Researchers at several institutions in China — including Shenzhen University and Guangzhou Medical University — have been working on a scaffold designed to restore that organisation at the injury site, giving axons the physical and chemical guidance they need to grow back in the right direction. Their results, just accepted in the journal Biofabrication, show this approach can make a meaningful difference in an animal model of complete spinal cord transection.

The scaffold's two-zone design

The core idea is to replicate the anatomy. The researchers built what they call a Gray/White Matter Zoned Scaffold (GWZS), constructed from two materials arranged to match the spinal cord's natural zones.

For the outer white matter region, they used aligned silk fibres — individual filaments drawn from silkworm cocoons and arranged so they run parallel to each other along the length of the scaffold, in the same direction axons would naturally travel. These fibres do two things: they act as physical guide rails for growing axons (which tend to follow aligned surfaces), and they give the scaffold mechanical structure.

For the central gray matter region, they used a hydrogel — a water-containing gel incorporating hyaluronic acid, a laminin-derived peptide, and collagen type VI. Hyaluronic acid is a natural component of the spinal cord's extracellular environment and helps reduce scar formation. The collagen type VI component specifically promotes neurons to cluster together and form network-like structures — something the gray matter normally does.

The two materials are integrated, not simply placed side by side: the hydrogel fills the spaces between the silk fibres in the white matter region, binding them in position and preventing them from moving. The central hydrogel-only region has no fibres at all, leaving it open for neuron clustering.

The researchers used anatomy directly to determine how many silk fibres to place in each region, using the actual proportions of white matter at the T10 level of the rat spinal cord as their blueprint.

What happened in cell culture

Before testing in animals, the researchers grew neurons and supporting cells inside the scaffold to see whether the two-zone design actually produced two different types of neural organisation.

It did. In the silk fibre region, 83% of axons grew aligned with the fibres — following the physical guidance. In the central hydrogel region, neurons formed clusters and network-like structures, more resembling gray matter. The scaffold produced something that looked structurally like a miniature spinal cord in a dish.

What happened in rats with complete spinal cord injury

The main test was in rats that had the spinal cord completely cut across at the T10 level — a 2mm gap created and then bridged with either the GWZS scaffold, a plain hydrogel alone, or nothing.

After 16 weeks, the GWZS group showed substantially better outcomes on two measures. On the BBB scale — a standard 21-point scoring system for rat hindlimb movement, where 21 is normal and 0 is no movement — the GWZS group averaged 11.4. The hydrogel-only group averaged 9.8. The untreated SCI group averaged 4.7. A score of around 11 indicates consistent weight-bearing walking, though not fully normal coordination.

Motor evoked potentials — the electrical signals that travel from the motor cortex down the cord to the muscles — were also measured at 16 weeks. In the GWZS group, signal amplitude recovered to 44.3% of what is seen in healthy animals. In the hydrogel-only group, it recovered to 30.4%. In the untreated SCI group, no signal was detectable at all.

What didn't work as well

The researchers are straightforward about the limitations. While the white matter zone showed axon regeneration that matched the scaffold's structure, the central gray matter zone did not regenerate well — only sparse neural tissue grew there. The researchers believe this is because the adult spinal cord doesn't have enough stem cells or regenerative capacity to repopulate that region without additional help, and the scaffold in this study did not include any added stem cells.

The silk fibres also degraded very slowly — at 8 weeks post-implant, they were largely intact. This might create long-term problems if the fibres remain while the cord is trying to remodel itself around them.

This is also an animal study in rats, using a complete transection model. Most human SCI involves crushing or bruising rather than a clean cut, and the human spinal cord is very different in scale from a rat's. Translation to humans is a long way off.

Reader Q&A

Why does it matter that the scaffold mimics the gray/white matter zones?

Because the structure of the spinal cord is not incidental to how it works — it is how it works. The axons in the white matter need to run in parallel bundles along the length of the cord to carry signals efficiently. If they grow back in random directions, the signal connections don't re-establish properly even if the axons physically cross the injury. Providing physical guidance that matches the cord's natural anatomy gives regenerating axons the best chance of connecting up in a functionally meaningful way.

Is this anywhere near clinical use?

No. This is animal model research — the experiments were all conducted in rats. Many promising scaffold approaches in rodents have not translated to humans, for a range of biological and mechanical reasons. The researchers themselves identify the need for primate studies before any consideration of clinical application.

Could stem cells be added to improve the gray matter result?

Yes, and that is exactly what the researchers propose as the next step — loading the central hydrogel region with neural progenitor cells (cells that can develop into neurons) to drive repopulation of the gray matter zone.

Something significant happened in the world of SCI rehabilitation this week. Spinal Research, the UK's leading charity focused on curing paralysis, has launched a programme to place Onward Medical's ARC-EX system in a network of specialist rehabilitation centres across the country. It's the first time a treatment specifically approved by UK regulators for paralysis — not just pain or other conditions, but paralysis — has been deployed in a real-world setting.

What is the ARC-EX system?

ARC-EX, developed by Onward Medical, combines two components: targeted electrical stimulation of the spinal cord (applied non-invasively through the skin) and structured rehabilitation exercises. The idea is that electrical stimulation can help "wake up" dormant neural pathways, and pairing it with active therapy gives those pathways something useful to do.

In clinical trials, the ARC-EX system demonstrated improvements in hand strength and sensation in people with chronic cervical spinal cord injuries. Chronic here matters — these were participants who had been living with their injuries for an extended period, not people in the acute phase where some natural recovery would be expected anyway.

The device received approval from UK regulators, making it the first dedicated treatment for paralysis to clear that bar. Until now, most devices used in SCI rehabilitation have been approved for adjacent indications — pain management, for example — and then applied to paralysis care. ARC-EX was approved specifically for what it's being used for.

What is the Spinal Research programme doing?

Rather than simply making the device available for purchase, Spinal Research is creating a structured network of approved rehabilitation centres and loaning ARC-EX systems to them for a 12-month period. The idea is to gather real-world data — not just from controlled clinical trial conditions, but from day-to-day rehabilitation practice with a range of clients.

The first centre to join is the Matt Hampson Foundation's Get Busy Living Centre near Melton Mowbray in Leicestershire. The Foundation was set up by Matt Hampson, a former England Under-21 rugby player who was paralysed from the neck down in a training accident at age 20. It provides expert physical and emotional rehabilitation for young people following life-changing injuries.

Three more centres in Yorkshire, the North East, and the South West are set to follow. A fourth centre is being funded through a partnership with the Injured Jockey's Fund.

This programme is part of a broader initiative called the Spinal Research Recovery Alliance — an effort to bring together researchers, clinicians, industry partners, charities, and the SCI community to accelerate the path from laboratory discovery to real-world impact. The vision is ambitious: a nationally connected, data-driven ecosystem for spinal repair.

Why does this matter?

Two things make this particularly significant.

First, it brings an approved, evidence-based treatment to rehabilitation centres that might not otherwise have access to it. For people with SCI, the quality of rehabilitation available can vary enormously depending on where they live and which centre they attend. A national network helps address that inequality.

Second, the data gathered will be different from what clinical trials produce. Trials are tightly controlled, with selected participants, rigid protocols, and frequent monitoring. Real-world data reflects what actually happens when a technology meets a diverse population of people with SCI, across varied clinical settings, as part of their ordinary rehabilitation journey. That information matters for shaping future research and best practice.

"We have been part of Onward's journey from the start, and it's incredible to see that hope is now turning into real progress," said Spinal Research Chief Executive Louisa McGinn at the launch. "The next few years could change everything for people with spinal cord injuries."

One of the programme's first participants is Sophie Wilson, Head of Operations at the Matt Hampson Foundation, who was paralysed herself in a diving accident eight years ago. She is already using the ARC-EX system as part of the real-world programme.

Reader Q&A

Can I access the ARC-EX system myself? For now, the programme is being delivered through the four approved rehabilitation centres. If you're based in the UK, contacting Spinal Research directly would be the best way to find out if you're eligible and whether a centre near you is participating or planned. The charity is also launching a fundraising campaign to expand the network nationwide.

Is this available outside the UK? Onward Medical, the company behind ARC-EX, has been pursuing regulatory approval in multiple markets. The UK approval is a significant milestone, but availability in other countries will depend on local regulatory processes.

How does it compare to invasive epidural stimulation? The ARC-EX system delivers stimulation transcutaneously — through the skin — rather than through surgically implanted electrodes. This makes it far less invasive and more accessible, though it may also mean the stimulation is less targeted than implanted systems. For many people, a non-surgical option that can be used as part of regular rehab is a significant advantage.

What does "chronic cervical SCI" mean in this context? Cervical injuries affect the neck region of the spinal cord, which typically means both arm and leg function are affected. "Chronic" means the injury occurred more than six months ago — the period in which natural spontaneous recovery is most likely. Showing improvement in chronic injury is significant because it means the device is doing something beyond allowing natural healing to proceed.

When researchers talk about the scar that forms after spinal cord injury — the glial and fibrotic scar that blocks axon regeneration and is one of the central obstacles to recovery — they have largely described it as a chemical and cellular problem. The wrong cells are in the wrong place. The wrong proteins are blocking the wrong pathways. The wrong signals are suppressing the wrong growth factors.

A new preprint changes the frame. It asks: what if the scar is also a mechanical problem? And what if the changing stiffness of the tissue after injury is not just a consequence of what cells are doing, but is itself an active signal that tells cells what to do next?

The paper, from researchers at Cleveland State University and the University of Akron, used two powerful techniques — atomic force microscopy (AFM) and bulk RNA sequencing — to track how the spinal cord changes physically and genetically at one month and six months after a severe thoracic contusion injury in an animal model.

First: what the tissue does physically

The headline finding is straightforward to describe, even if the technique behind it is not. Using a nanoscale probe to measure tissue stiffness at the injury site — a technique called nanoindentation — the researchers found that spinal cord tissue gets dramatically softer in the weeks after injury, reaching its softest point at around one month. Then, over the following months, it gets progressively stiffer, eventually becoming harder than normal uninjured tissue by six months, as the scar matures.

This softening-then-stiffening pattern has been observed in other tissue injuries — scar tissue in skin, liver, and heart tends to become stiffer over time. But the detail here, and the techniques used to map it, are more precise than what has been published for spinal cord injury before. The researchers also measured viscoelasticity — essentially, how the tissue behaves when you apply and then release pressure, which reveals information about its composition at a structural level.

What they found was that chronic scar tissue is not just stiffer — it also has a slower relaxation response, meaning it stays stiff longer when compressed. This, the researchers argue, reflects the physical consequence of dense collagen deposition and the accumulation of proteoglycans: the two main structural components of fibrotic scar.

Then: what the cells do because of it

Here is where the study becomes more than an account of what scar looks like under a probe. Using RNA sequencing of tissue samples taken at the same time points, the researchers mapped which genes were active in the spinal cord at one month and six months post-injury.

The pattern was telling. During the early softening phase — the first month — the most active pathways were inflammation and matrix degradation. The tissue is in crisis, breaking down its normal structure, recruiting immune cells, and beginning the wound-healing process that will eventually produce scar.

During the later stiffening phase — by six months — the active pathways had shifted to collagen synthesis, ECM organisation, and fibrotic remodelling. The tissue was rebuilding, but in a way that locks in stiffness and locks out regeneration.

And critically: the genes governing mechanotransduction — the cellular machinery through which cells sense and respond to the mechanical properties of their environment — were active at both time points, and their activity patterns were coordinated with the changing stiffness of the tissue.

Mechanotransduction: cells listening to the scar

This is the concept that sits at the heart of what makes this preprint significant, and it is worth explaining.

Cells do not just exist in a mechanical environment — they sense it and respond to it. A cell sitting on stiff tissue behaves differently from the same cell on soft tissue. Stiffness signals can change which genes a cell expresses, how it moves, whether it proliferates, and whether it produces proteins that build up or break down the tissue around it.

This is well understood in other contexts — tumour biology, wound healing, cardiac fibrosis. It is much less studied in spinal cord injury.

What this preprint suggests is that the evolving mechanical stiffness of the spinal cord after injury is not simply a reflection of what cells are doing — it is also an active instruction to cells. The scar stiffens, and cells in that stiffening environment receive signals that tell them to produce more collagen, reorganise the matrix in fibrotic patterns, and maintain the stiff, restrictive microenvironment.

In other words: the scar may be partly self-reinforcing through its own mechanical properties. The tissue gets stiff, cells respond by making it stiffer, and that stiffer environment continues to suppress the conditions under which axons might regrow.

What this is not

This is a preprint — it has not yet been through peer review. It is an animal study, in a thoracic contusion model. The findings need to be replicated and extended before drawing clinical conclusions. The mechanotransduction story, while compelling and consistent with a lot of parallel research in other tissues, still needs causal experiments to confirm that the mechanical signals are driving the gene expression changes rather than just correlating with them.

The study also does not offer a treatment. It is mechanistic science — it describes a process and proposes a framework for understanding why the scar is so resistant to repair. The translation from "here is how the scar reinforces itself mechanically" to "here is a drug or intervention that interrupts that process" is a long road.

Why tracking this matters

Mike's approach to SCI science on this site has always included following the basic science — not just the trials and the approvals, but the upstream biology that eventually determines what becomes a target and what becomes a drug or device.

The mechanical biology of the SCI scar is one of those upstream questions. If it turns out that stiffness-driven mechanotransduction is a significant contributor to regenerative failure, then the therapeutic targets it opens up are distinctive from the cytokine and growth factor pathways that have dominated the field. Stiffness itself can be modified — through scaffold materials, through targeted enzyme delivery, through biomaterials that compete with fibrotic ECM. None of those are available treatments today. But the science describing why the scar fails axons mechanically is the foundation on which those approaches will eventually be built.

Reader Q&A

What is a preprint?

A preprint is a research paper that has been posted publicly before peer review — the formal process in which independent experts check the methods and conclusions before a journal publishes it. Preprints allow researchers to share findings quickly, but they should be treated with slightly more caution than peer-reviewed publications because they have not yet passed that external check.

What is AFM (atomic force microscopy) and why does it matter here?

AFM is a technique that uses a nanoscale probe — essentially a very fine tip attached to a flexible arm — to feel the surface of a material at a level of detail far beyond what light microscopy can achieve. In biology, it can measure the stiffness of individual cells or tissue samples with extraordinary precision. That is what makes it useful here: you can map stiffness changes in spinal cord tissue at the same sites you are measuring gene expression, correlating the two directly.

Does this mean scar stiffness is the main reason regeneration fails?

Not necessarily — and the authors do not claim that. The scar is a multi-layered problem: it includes chemical inhibitors like chondroitin sulphate proteoglycans (CSPGs), cellular barriers, immune regulation failures, and many other factors. Mechanical stiffness is one more dimension of that problem, and this study suggests it may be more actively involved in maintaining the scar than previously appreciated. How large that contribution is relative to other factors is still an open question.

What would a treatment targeting this look like?

Research in other fields has explored materials designed to match or progressively match the mechanical properties of target tissue (biomimetic scaffolds), enzymes that break down fibrotic ECM components, and pharmacological targets in the mechanotransduction pathways themselves. None are approved for SCI. But the science described in this preprint helps define what such a treatment would need to do.

A piece of news from the stroke rehabilitation world is worth tracking here, because the technology at its centre is exactly the same technology that SCI researchers have been developing for years — and what works (or does not work) in stroke recovery has direct implications for understanding how spinal cord stimulation could be used in SCI.

MindMaze Therapeutics has announced that its precision neurotherapy platform is being used in a University of Pittsburgh study testing a combination approach to post-stroke arm recovery. The trial is now enrolling.

The background: what cervical SCS already showed in stroke

The University of Pittsburgh has been one of the leading centres for epidural spinal cord stimulation research in both SCI and stroke. Earlier this year, results published in Nature Medicine showed that cervical epidural spinal cord stimulation can meaningfully improve arm and hand movement in people with chronic stroke — and that these gains could appear after just a few hours of training.

That is a striking finding. But it came with an important asterisk: the gains were largely assistive. The improvements in arm movement were present while the stimulation was active. When the stimulation was off, many of the gains faded.

The new University of Pittsburgh study is specifically designed to tackle that problem.

What the new trial is testing

The question the study is asking: if you pair the same cervical spinal cord stimulation with a high volume of intensive, intent-driven practice, can the gains outlast the stimulation itself?

The rationale is grounded in how the nervous system relearns movement. When spinal cord stimulation is active, it amplifies the pathways in the cord that drive the muscles — making movements that were barely possible suddenly achievable. If the patient is simultaneously making a deliberate effort to move, that intent pairs with the stimulation-driven activity. Repeat that pairing many times, and the theory is that the connections responsible for the movement get stronger and more stable — durable rather than transient.

Volume is key. The nervous system needs repetition to consolidate these changes. The question is whether MindMaze Therapeutics' platform can deliver that volume.

What MindMaze Therapeutics does

MindMaze Therapeutics (listed on the Swiss exchange as MMTX) develops precision neurotherapy platforms — essentially software and hardware systems designed to deliver structured, high-intensity, intent-driven rehabilitation exercises at scale. The claim the company makes is that their platform can provide the volume and specificity of practice that recovery requires without placing a proportional burden on clinical staffing — meaning patients can complete more therapy sessions than a purely therapist-delivered model would typically allow.

In this trial, MindMaze's system pairs with the stimulation: the cervical SCS creates a window in which arm movement is more achievable, and MindMaze's platform provides the intensive practice to drive during that window.

Why this is relevant to SCI

The primary patient population in this trial is stroke, not SCI. But the technology and the scientific question are identical to central questions in SCI rehabilitation research.

Cervical epidural spinal cord stimulation has been used in SCI with similar rationale: stimulation plus intent plus practice. The challenge of making gains durable — of moving from assistive stimulation to lasting recovery — is the same challenge in both conditions. What the Pittsburgh team learns about the right dose of practice, the right timing, and the right combination will feed directly into how the approach is refined for SCI.

This is part of why it is worth following. Stroke research and SCI research are not the same, but they share the same nervous system. When a study as carefully designed as this one tests a combination of stimulation and intensive practice in the stroke context, the SCI research community will be watching closely.

What comes next

The trial is now enrolling. It will take time before results are available. MindMaze Therapeutics describes this as part of its broader strategy of positioning its platform alongside medical devices and pharmaceutical products to deliver combination therapies — not just standalone neurotherapy.

Whether this trial eventually shows that the combination makes gains durable where stimulation alone did not is still unknown. But the fact that it is being designed and run at all reflects how far the field has come from thinking of spinal cord stimulation as a simple pain-management tool.

Reader Q&A

Is this trial open to people with SCI?

No — this specific trial is enrolling people with post-stroke arm weakness, not SCI. The technology is the same, but the patient population is different.

Could the results change how SCS is used in SCI?

Potentially, yes. The central question — can intensive practice paired with stimulation produce durable gains? — is the same in both conditions. If Pittsburgh shows a clear answer in stroke, it will inform how researchers design the next generation of SCI stimulation trials.

What is MindMaze Therapeutics' relationship to the University of Pittsburgh?

MindMaze is supporting the trial by providing its neurotherapy platform. The University of Pittsburgh is the sponsor and research site. The press release describes this as MindMaze Therapeutics supporting the study, not running it independently.

Is cervical epidural SCS the same approach used in SCI rehabilitation?

Yes. Cervical epidural SCS targets the cervical spinal cord — the region that controls arm and hand function. It has been studied for both upper-limb recovery in cervical SCI and arm recovery after stroke. The electrode placement and stimulation parameters differ between applications, but the basic approach is the same.

For decades, the medical consensus on spinal cord injury was brutally simple: once nerves are damaged, they don't come back. But that consensus is cracking. A peptide drug called NVG-291, developed by the Canadian biotech company NervGen, has just completed a Phase Ib/IIa clinical trial with results that are turning heads — and giving a lot of people with SCI genuine reason for hope.

What is NVG-291 and where did it come from?

NVG-291 — also known as ISP, short for intracellular sigma peptide — traces its origins to the lab of the late Jerry Silver, a neuroscientist at Case Western Reserve University who spent his career asking a question most of his colleagues thought was pointless: what if paralysed nerves could regrow?

Silver's team identified a key culprit in why injured nerves fail to recover: a family of molecules called chondroitin sulfate proteoglycans, or CSPGs. Think of CSPGs as a molecular wall. After a spinal cord injury, the body rushes in to stabilise the damage, and one way it does that is by laying down CSPGs around the injury site. The problem is that these molecules don't just stabilise — they actively block nerve fibres from growing back through the damaged area.

Silver's lab developed ISP as a way to unlock that wall. The peptide binds to a specific receptor on nerve cells, essentially disabling the "stop signal" that CSPGs send. In animal studies, rats given ISP after a spinal cord injury showed dramatic recovery: hind legs that had been dragging began to function again, tails lifted, bladder control returned. A 60–80% response rate. The results were published in Nature, Nature Communications, and the Journal of Neurotrauma.

When NervGen licensed the ISP patents from Case Western, they renamed it NVG-291 and moved it into human testing. Jerry Silver, who passed away in January 2025, served as an advisor and saw the early human data before his death.

What did the Phase II trial show?

NervGen's Phase Ib/IIa trial (NCT05965700) wrapped up in late 2025 and early 2026. Ten participants with cervical spinal cord injuries received NVG-291 as a subcutaneous injection — the same delivery method used for insulin and GLP-1 weight-loss drugs. Participants could inject it themselves at home.

The team measured outcomes using GRASSP — the Graded Redefined Assessment of Strength, Sensibility, and Prehension. GRASSP tests fine motor skills: things like picking up a key, turning it in a lock, holding a cup. After 12 weeks on the drug, participants who received NVG-291 showed an average 3.7-point improvement in GRASSP quantitative prehension.

In clinical terms, this kind of improvement translates into tangible daily-life changes: the ability to brush your teeth, button a shirt, zip up a jacket, open a water bottle. For people who have lost fine hand function, these aren't small things — they're the difference between dependence and independence.

Perhaps the most striking finding came after the trial ended. In blinded exit interviews conducted almost a year after participants stopped taking the drug, those who had received NVG-291 reported that their improvements had continued — a stepwise increase in function even after discontinuing treatment. The drug appears to have kickstarted nerve regrowth that then kept going on its own.

"When you interview these individuals almost a year out from the study, those individuals that received the drug, their report was, 'Look, I stopped the drug and I continued to see a stepwise improvement,'" said NervGen CEO Adam Rogers. Five participants were so pleased with their results that they appeared on local television news to share their stories.

Why does this matter for the SCI community?

Most approaches to SCI rehabilitation work around the damage — teaching the body to compensate for what's missing. NVG-291 is attempting something different: it's trying to get damaged nerve pathways to actually reconnect and function again. The preliminary results suggest this isn't just a theoretical possibility.

The subcutaneous delivery is significant too. Many experimental SCI treatments require surgery or hospital procedures. If NVG-291 proves effective in larger trials, it's the kind of drug someone could manage at home, much like the millions of people who self-inject insulin or Ozempic.

NervGen went public on 21 May 2026, raising $60 million to fund their next phase of development. Phase III is planned to begin in mid-2026. The company is also exploring whether NVG-291 could have a role in other conditions where nerve damage is a factor, including Alzheimer's disease and ALS.

Reader Q&A

This sounds incredible — why haven't I heard about it before? Phase II trials involve small numbers of participants and aren't designed to prove effectiveness — they're primarily about finding the right dose and confirming early signs that a drug is working. NervGen's Phase II had just ten people on the drug. That's exciting for a signal, but it's a very small sample. Phase III, with hundreds of participants across multiple sites, will be the real test.

Will this work for complete injuries, or only incomplete ones? The Phase II trial included participants with cervical spinal cord injuries, but the trial report doesn't specify completeness of injury for all participants. The drug's mechanism — unlocking blocked nerve pathways — in principle applies to both complete and incomplete injuries, but complete injuries involve more extensive damage and may respond differently. Phase III will likely help answer this.

What are the risks? Phase I safety data cleared NVG-291 for human testing, and the Phase II trial didn't raise red flags. As with any drug, side effects are possible, and the long-term profile isn't yet fully established. The company will continue monitoring participants and gathering safety data in Phase III.

When could this be available? If Phase III results are positive, NervGen would then seek regulatory approval — a process that typically takes several years after the trial concludes. A realistic optimistic timeline might be 2029–2031, but that depends on how quickly Phase III enrols and what the results show. Rogers has said the company plans to start their Phase III study in mid-2026.

One of the most intuitive fears about experimental stem cell therapy for spinal cord injury is the idea of injecting cells directly into the spinal cord itself. The spinal cord is a delicate, critical structure. Interfere with it and you risk making things worse. The thought of needles going in — even to deliver potentially healing cells — raises obvious concerns about safety.

A new review published in the journal *Cell Transplantation* takes a careful look at the accumulated evidence and reaches a somewhat reassuring conclusion: the procedure appears to be safer than its reputation suggests.

What is intramedullary transplantation?

"Intramedullary" literally means "within the spinal cord" — as opposed to injecting cells into the spinal fluid or around the spinal cord. It's the most direct approach to getting therapeutic cells to the site of injury, but it's also the most intimidating. The review authors — Caroline Nonnarath and Nicolas Serratrice — assessed evidence from multiple early-phase clinical studies that used this approach, looking at a range of cell types including bone marrow stem cells, mesenchymal stromal cells (MSCs), and neural stem cells.

What did they find on procedural safety?

Despite the heterogeneity across the studies — different cell types, different doses, different delivery methods — a consistent picture emerged on procedural safety. Severe complications after injection were uncommon. Adverse events that did occur were predominantly mild and transient. Most importantly, the review found no reproducible signal of neurological deterioration caused by the procedure itself.

In plain terms: across multiple clinical studies, injecting cells directly into the spinal cord did not reliably make people worse. That's not the same as saying it's risk-free — no procedure involving the spinal cord is — but it does challenge the assumption that intramedullary delivery is inherently dangerous.

What about the risk of tumours?

This is the concern that many people in the SCI community will have heard about. Stem cells are, by definition, cells that can multiply and differentiate. In theory, if something goes wrong during that process, you could end up with abnormal cell growth — a tumour.

The review takes this concern seriously and doesn't dismiss it. It notes that theoretical risks of tumorigenesis, clonal selection, and genomic instability — particularly with MSCs that have been grown in the lab before transplantation — remain real biological possibilities.

However, the review also notes an important distinction: the clinical data gathered so far has not identified confirmed cases of cancer caused by these cell transplantation procedures, within the follow-up periods reported. The concern is theoretically grounded but has not yet been confirmed empirically in patients.

The authors also discuss an alternative approach: freshly isolated stromal vascular fraction (SVF), which uses cells taken directly from a patient's own fat tissue without laboratory expansion. Because SVF cells haven't been grown and multiplied in the lab, they don't carry the same theoretical risks associated with ex vivo expansion. This "minimally manipulated autologous" approach (using your own cells, minimally processed) is highlighted as a potentially safer route with its own interesting properties.

What does this mean for the SCI community?

Stem cell therapy for SCI is one of the most frequently asked-about topics in the community — and one of the most misunderstood. Countless clinics around the world offer stem cell treatments of dubious quality, often at enormous financial cost, targeting people who are desperate for any sign of improvement. The field has been muddied by this, and genuine scientific progress has sometimes struggled to cut through the noise.

This review is a piece of legitimate science doing what science should do: taking stock of what we actually know. Its message is nuanced. Yes, direct spinal cord injection of stem cells appears to be procedurally safer than we assumed. No, we don't have long-term cancer data yet. Yes, some approaches (like SVF) may carry lower theoretical risk. No, this is not a green light to seek unverified treatments.

The authors call for harmonised reporting standards, longer follow-up, and collaborative datasets to build the evidence base properly. That's the kind of careful, systematic work that will eventually give us real answers.

Reader Q&A

Does this mean stem cell treatments for SCI are safe? This review addresses one specific aspect of safety: the procedure of injecting cells directly into the spinal cord in carefully conducted clinical studies. It doesn't cover the wider landscape of stem cell clinics, which often operate outside rigorous clinical protocols and use uncharacterised cell products. The safety reassurance in this review applies to legitimate, regulated early-phase clinical trials — not commercial clinics.

Have any patients actually benefited from intramedullary stem cell transplantation? Early-phase studies are primarily designed to test safety, not effectiveness. Some participants in these trials have reported improvements, but the studies are too small and varied to draw firm conclusions about efficacy. Larger, properly controlled trials are needed to answer whether — and for whom — these approaches work.

What types of stem cells are being used? The review covers three main types: bone marrow mononuclear cells (mixed cells from bone marrow), mesenchymal stromal cells (MSCs, often from bone marrow or fat), and neural stem cells. Each has different properties, different theoretical risks, and different evidence bases.

Should I try to access a stem cell treatment based on this? The authors are specifically reviewing legitimate clinical studies, not commercial treatments. If you're interested in stem cell trials for SCI, the right route is through registered clinical trials — the ClinicalTrials.gov database lists registered studies. Seek advice from your spinal consultant before pursuing anything, and be very cautious of clinics charging large sums for unproven treatments.

Water has been used in rehabilitation for a long time, but rigorous clinical evidence for its specific benefits in spinal cord injury has been slow to accumulate. A new study from Spain fills in a piece of that gap — and the results are encouraging enough to warrant the larger controlled trials the researchers themselves are now calling for.

The study, published in the Journal of Spinal Cord Medicine, tested a structured programme called Water Specific Therapy (WST) in twelve people with subacute incomplete spinal cord injury — all of them injured between thoracic level 1 and lumbar level 5, and all within six months of their injury.

What is Water Specific Therapy?

WST is not simply swimming or gentle movement in a pool. It is a structured therapeutic approach in which a trained physiotherapist works with the patient in water, using the physical properties of the aquatic environment — buoyancy, resistance, hydrostatic pressure, and warmth — in a deliberate and planned way.

The programme in this study involved 18 sessions of 40 minutes each, structured into warm-up, balance training, aerobic exercises, and a cool-down phase. Effort was monitored throughout using the Rating of Perceived Effort scale, which lets patients and therapists track exercise intensity in real time.

The participants all had motor incomplete injury — meaning they retained some voluntary movement below their injury level — and all were in the subacute phase, within six months of injury. This window matters: it is when the nervous system is often most responsive to rehabilitation input.

What did the study measure?

The primary question was about feasibility: can this programme actually be delivered to people with incomplete SCI, and will they stick with it? Feasibility studies answer questions like: do people drop out? Is it safe? Do patients feel it's worthwhile?

On all three counts, the answer was yes. Adherence reached 83% — a strong figure for a rehabilitation study. There were only two dropouts, and both left for reasons unrelated to the therapy itself. Crucially, no adverse effects were recorded. The treatment was deemed safe.

And 88.9% of participants reported subjective improvement across three domains: balance, gait, and lower limb strength. That is a high figure — nearly all participants felt they were getting something from the therapy.

What did the objective measures show?

Beyond what participants reported, the study used five validated outcome measures to track gait and balance objectively:

The Berg Balance Scale (BBS) measures a person's ability to maintain balance during various tasks. The Timed Up and Go test measures how quickly someone can stand, walk a short distance, turn, and sit back down. The 10-metre walk test and 6-minute walk test assess walking speed and endurance. The Walking Index for Spinal Cord Injury II (WISCI-II) ranks how much assistance a person needs to walk.

All four of the last measures reached statistical significance — meaning the improvements were large enough to be unlikely to have happened by chance. Balance improved. Walking speed improved. Walking endurance improved. Independence in walking improved.

What the study could not show

One honest limitation: this was a feasibility study, not a randomised controlled trial. There was no control group — no matched group of participants doing conventional land-based therapy at the same time — so the study cannot prove that the water therapy caused the improvements rather than the natural recovery that can happen anyway in the subacute phase after SCI.

The researchers are clear about this. Their conclusion is that WST is feasible and safe, and that the improvements are promising enough to now justify a properly controlled study to test whether the therapy itself is responsible for what they saw.

The physiotherapists in the study also noted that it was sometimes difficult to push participants to higher intensity levels in water — the resistance is present, but it is distributed differently from land-based exercise, and some participants needed programme adaptations to reach their targets. That is a practical note for therapists implementing similar programmes.

Why this matters for the SCI community

Water-based rehabilitation is already used in some SCI rehabilitation centres, but not universally, and the evidence base for its specific use in SCI has been thinner than the clinical intuition that supports it. Studies like this one — structured, published, peer-reviewed — add to the evidence that justifies investing in aquatic therapy resources and training.

For people with incomplete SCI in the subacute phase, the specific appeal of water therapy is that the buoyancy reduces the effort required to move, potentially allowing people to practise movements — upright balance, stepping, arm movement — that would be impossible or unsafe on land at that stage of recovery. If the nervous system is in its most plastic, most responsive window in the first six months after injury, being able to practise more movement earlier could matter.

This study did not prove that case definitively. But it showed the approach is safe, well-tolerated, and associated with real improvements. That is a meaningful step forward.

Reader Q&A

Is this available in SCI rehabilitation centres now?

Some centres, particularly those with hydrotherapy pools, already incorporate water-based sessions into SCI rehabilitation. Whether a structured WST programme specifically is offered depends on the centre and the therapist's training. If you are in rehabilitation and interested, it is worth asking whether aquatic sessions are available.

Does this only apply to incomplete injuries?

This study looked specifically at motor incomplete SCI (T1-L5). People with complete injuries or cervical injuries were not included. Aquatic therapy is used more broadly, but whether it produces the same measurable outcomes in other injury profiles is a separate question.

Why subacute? What about chronic SCI?

The subacute phase — roughly the first six months after injury — is when the nervous system tends to be most responsive to rehabilitation input, and when spontaneous recovery is also ongoing. This makes it both the most important window to intervene and the hardest to study (because it is difficult to separate therapy effects from natural recovery). Aquatic therapy for chronic SCI is a different question with different considerations.

What is the next step for this research?

The authors explicitly call for controlled studies — ideally randomised controlled trials — to determine whether the improvements seen here are caused by the therapy or would have happened anyway. Until that evidence exists, the current study is best understood as proof that the approach is worth studying properly, not proof that it works definitively.

Brain-computer interface research has come a long way. There are now devices that let paralysed people control robotic arms, move cursor pointers, type text using only their thoughts, and in some cases stimulate their own muscles into movement. The technology is advancing fast.

But here is the question that does not get asked often enough: what do people living with high cervical spinal cord injury actually want from it?

A study published in the Annals of Rehabilitation Medicine set out to find exactly that. Researchers at Seoul National University Hospital ran a structured focus group with four individuals who all had chronic high cervical SCI — neurological levels of C4 or above. All four were living with paralysis that affected the majority of their voluntary movement.

The results are worth paying attention to, not just for what they reveal about patient priorities, but for what they suggest about how BCI research should be shaped going forward.

What they found: digital freedom first

When asked what they most wanted BCI to help them with, the participants were consistent: digital independence.

Specifically, they highlighted messaging, online banking, internet use, and smart home control as the things they most wanted to regain control over. Being able to send a text message without assistance. Managing their own finances without needing someone to type for them. Controlling the lights and temperature in their own home without depending on a carer to do it.

This is significant because a lot of BCI research focuses on restoring physical movement — the dramatic demonstration of a paralysed person moving a robotic arm or walking with exoskeletal support. Those are genuinely important goals. But for the people in this study, the daily reality was different. Digital access and independence in routine tasks came first.

The researchers organised their findings into five major themes: digital accessibility, offline physical activity, social interactions and psychological health, usability, and acceptance. Each one reflects a different dimension of what life with high cervical SCI actually involves.

Reducing reliance on caregivers

Beyond digital access, participants expressed a strong interest in BCI as a way to reduce how much they depended on caregivers. This was both a practical priority and an emotional one.

People with high C-SCI typically require round-the-clock assistance for many basic tasks. Even small gains in autonomy — being able to initiate a phone call, navigate to a website, adjust the heating — can have an outsized impact on quality of life and self-determination.

What the participants described was not necessarily a desire to do things physically, but a desire to be in charge: to initiate, decide, and act independently, even if the mechanism is a thought-controlled interface rather than a hand.

What people were willing to do — and what they worried about

The study also asked about acceptance of BCI technology, including invasive procedures like implanted electrodes. Most participants were open to training. Some were open to invasive options.

One of the more interesting findings was a shift that happened during the focus group itself. After the structured discussion — which was facilitated by experts in rehabilitation medicine and biomedical engineering — participants' willingness to undergo invasive procedures increased, while their expected functional outcomes became more realistic.

Put simply: talking it through with others who shared their experience and with knowledgeable facilitators changed how they thought about the technology. This is a point the researchers flag as important for how clinical education and shared decision-making around BCI should work.

Concerns were also clearly expressed. Surgical safety, device maintenance, reliability, and practical usability were all raised frequently. The enthusiasm for what BCI could offer was genuine — but so was the scepticism about whether current technology could actually deliver it consistently in daily life.

Why user-centred design matters in BCI development

This kind of research — qualitative, small, built around listening to patients — is not the kind that makes headlines about a breakthrough. But it does something important.

It documents the gap between what researchers are building and what users actually want and need. It asks: if this technology eventually works reliably, will it solve the right problems?

For the four participants in this study, the answer is: yes, but only if it prioritises daily independence and digital access alongside (or even ahead of) motor restoration.

The authors conclude that BCI should be seen as a pathway to greater independence, participation, and autonomy for people with high C-SCI — and that lived experience should actively guide assistive neurotechnology development. That is not a radical idea, but it is one that gets underweighted when research funding and attention follows the most visually dramatic applications.

How many people does this represent?

Four. This study has four participants. That needs to be said clearly. Qualitative focus group research is not designed to be statistically representative — it is designed to explore themes, capture nuance, and generate questions for larger research. That is valuable. But it is not a clinical trial, and four voices cannot speak for the full diversity of experience among people with high cervical SCI.

What this study offers is a starting point: a structured, expert-facilitated conversation about what matters to patients, published and peer-reviewed so it can inform future, larger research.

Reader Q&A

Is BCI available for people with high cervical SCI right now?

Some non-invasive systems exist that let people with high C-SCI control computers or communication devices using electrical signals from the brain or muscles. Invasive implanted BCIs, like those trialled by companies such as Synchron and Neuralink, are still in early clinical trial phases. Wide availability is still some years away, but the field is moving quickly.

What is the difference between invasive and non-invasive BCI?

Non-invasive BCIs sit on or near the skin — EEG caps and similar devices pick up brain signals without entering the body. Invasive BCIs involve implanting electrodes directly into or on the brain surface. They generally produce cleaner, more reliable signals, which is why some participants in this study became more open to the idea during the focus group discussion. The trade-off is surgical risk and device maintenance.

Why only four participants?

Finding people with chronic high cervical SCI willing and able to take part in a research focus group is not straightforward. The study is best understood as a carefully documented qualitative exploration rather than a definitive survey. That is still useful — but it is one of the reasons findings should be treated as preliminary.

Does this affect how I should think about BCI news?

Possibly. When you read BCI research coverage, it is worth asking whether the headline capability — moving a robotic arm, typing at speed — maps onto the things that would actually make the biggest difference to daily life. This study suggests the answer for high-level SCI is often: digital access and autonomy. Not just walking.

Something significant happened quietly in the world of spinal cord injury this week. A treatment that has already been approved by UK regulators is now being trialled in real rehabilitation centres across the country — and the organisation behind it wants to turn that into a national network.

The charity Spinal Research has launched what it is calling a pioneering programme: lending the ARC-EX system, developed by Onward Medical, to specialist rehabilitation centres so they can use it with their clients and gather data on how it actually performs in the real world.

This matters because there is often a long gap between a treatment being approved and it actually reaching people with SCI. This programme is designed to close that gap.

What is the ARC-EX system?

ARC-EX stands for Activity-based Rehabilitation with Cervical Electrical Stimulation. It is a non-invasive device that delivers targeted electrical stimulation to the spinal cord in the cervical region — the neck area — while the person is engaged in rehabilitation exercises.

The idea is that the electrical stimulation "wakes up" pathways in the injured spinal cord that are still present but not firing effectively. When that stimulation happens at the same time as active rehabilitation movement, it may help the nervous system relearn and strengthen those connections.

In clinical trials, it has been shown to improve hand strength and sensation in people with chronic cervical spinal cord injury. And crucially, it has been approved by UK regulators — making it the first dedicated treatment for paralysis to receive that approval.

What the programme actually involves

Spinal Research is loaning the ARC-EX system to a small number of approved specialist rehabilitation centres on a twelve-month basis. The centres use it with clients who have spinal cord injuries, alongside their normal activity-based therapy.

The trailblazer centre is the Matt Hampson Foundation Get Busy Living Centre, near Melton Mowbray in Leicestershire. Matt Hampson, the former England Under-21 rugby union player who was paralysed from the neck down in a training accident at age 20, founded the centre to support young people following life-changing injury.

Three more centres are set to join — one each in Yorkshire, the North East, and the South West — with a fourth being funded in partnership with the Injured Jockeys Fund.

Why this is different from a clinical trial

Clinical trials test whether a treatment works under controlled conditions. Real-world programmes test something different: does it actually work when used in the messy, variable reality of everyday rehabilitation?

The people using ARC-EX through this programme will vary in their injuries, their history, their goals, and their abilities. Collecting data across all of them will show something clinical trials cannot — how the device performs across the full range of people who might genuinely benefit from it.

That data feeds back into research and best practice, helping shape how the technology is eventually rolled out more widely.

The bigger picture: the Spinal Research Recovery Alliance

The programme is part of a wider initiative called the Spinal Research Recovery Alliance. This brings together researchers, clinicians, industry partners, and people with spinal cord injuries, with the goal of speeding up progress from the laboratory to real-world impact.

Louisa McGinn, Chief Executive of Spinal Research, put it plainly: "The next five years present an unprecedented opportunity to change what's possible for people living with spinal cord injuries. Breakthrough therapies are nearing clinical reality, and frontier technologies — from AI and robotics to gene therapy — are creating bold and quicker new pathways toward repair and recovery."

The ARC-EX programme is described as a first step in building a national network of community rehabilitation centres connected by shared data, research, and outcomes.

Why this matters for the SCI community

For many people with cervical SCI, improving hand and arm function is one of the most important goals they have. Even small gains can change independence: being able to hold a phone, press a switch, use a wheelchair joystick, or manage personal care are all tasks that depend on hand and arm strength.

ARC-EX is not a cure. It does not repair the spinal cord. But it is a tool — now approved and being tested in real rehabilitation settings — that may help some people with chronic cervical SCI make functional gains they would not otherwise make.

The fact that it is already approved, already in use, and now being systematically studied in real-world conditions is genuinely good news. Not the dramatic kind, but the steady, building kind that tends to matter most.

Reader Q&A

Is ARC-EX available to me right now?

It is being used through this specific programme at four selected rehabilitation centres in the UK. It is not yet widely available through the NHS. If you are interested, it may be worth contacting Spinal Research or the Matt Hampson Foundation to find out more about access.

Is it safe?

Yes. It is non-invasive — no surgery or implants — and it has already passed the UK regulatory approval process. The programme is now collecting further real-world safety and effectiveness data.

What is the Injured Jockeys Fund's involvement?

The Injured Jockeys Fund, which supports jockeys who have been seriously injured in racing, is co-funding one of the four centre placements — a nice example of different SCI communities working together.

Could this expand nationally?

That is the goal. Spinal Research has launched a fundraising campaign to expand the programme to more centres across the UK.

One hundred years ago, Gertrude Ederle became the first woman to swim the English Channel. This summer, a relay team of women decided to do it again in her honour — and raise money for people living with spinal cord injury while they were at it.

Louise, a triathlete from Torquay, is part of 10IronWomen, an all-female triathlon community whose motto is essentially that incredible things are within reach if you put your mind to them. When someone in the group floated the idea of crossing the Channel on the centenary of Ederle's swim, it stuck.

"When looking for my 2026 challenge my lovely 10IronWomen group had a mad idea — it's the 100 year anniversary of the first woman to swim the Channel, so why don't we do it too, in her honour!" Louise wrote for Aspire's blog.

The Aspire Dragonflies

The team swam as the Aspire Dragonflies, with Aspire as their chosen charity. Aspire is a UK charity that provides practical support to people who have been paralysed by spinal cord injury — help with housing, welfare benefits, assistive technology, independent living, and more. It is the kind of organisation that quietly changes lives in concrete ways.

The connection to 10IronWomen came through a team member called Bryony, who is taking on a solo Channel swim this year and recommended Aspire. Once the team heard about the charity and the work it does, the fit was obvious.

The swim itself

A relay Channel swim means the team members take turns in the water — each swimming for roughly an hour at a time — until the full 22-mile crossing from England to France is complete.

Louise was first into the water, which meant starting from a Dover beach in the dark at 2am. She ended up swimming three sections: the opening stretch out of Dover, a spell through the busy separation zone where cargo ships pass, and the final approach that landed the team on the French shore.

The conditions started choppy overnight but settled into something much more pleasant as the day progressed. "The sea was warm, not too choppy and we had glorious sunshine and blue skies," Louise wrote.

The crossing was not without its difficulties. One of Louise's teammates was seriously seasick — unable to keep anything down — but kept getting back in the water anyway. "She was swimming on pure empty. Both her swims were super tough for her but all of us were on the side keeping her going and she absolutely knuckled down and got us forward on the most crucial bit of the swim."

That, in a lot of ways, is the kind of thing that makes these challenges worth reading about.

What it means

Louise had not met anyone with a spinal cord injury before this challenge. But she heard Paula Craig MBE speak at an Aspire information day early in the process and it changed how she thought about the whole endeavour.

"The thought that one day this fitness and ability could suddenly be gone, and yet the dedication and motivation she had to carry on literally brought me to tears," she wrote.

"We are lucky and privileged to get to do this and we shouldn't forget it. If we can help to make someone's life that bit easier or that bit more fun we should."

Get involved

Aspire runs a range of swimming and endurance events throughout the year, including relay and solo Channel swims, Solent swims, and River Arun events. If you are an able-bodied swimmer looking for a challenge with meaning, or if you simply want to donate in support of someone already taking one on, Aspire's event calendar is the place to start.

You can find out more at aspire.org.uk, or sponsor Louise directly at the link below.

If you live with a spinal cord injury, you probably already know that bowel problems are one of the most persistent and frustrating consequences. What you may not know is that researchers are increasingly finding that the relationship runs the other way too — that what happens in your gut after SCI may actually be making the secondary damage to your spinal cord worse.

A review paper published this week in Frontiers in Cellular Neuroscience lays out the current state of knowledge on what scientists are calling the gut–spinal cord axis. The short version: after SCI, your gut changes, and those changes send signals that your spinal cord's immune cells pick up and respond to — in ways that can fuel further inflammation.

First, what happens to the gut after SCI?

The gut is not just a passive tube. It is controlled in large part by the autonomic nervous system — the part of the nervous system that handles automatic functions like heart rate, blood pressure, and digestion. After a spinal cord injury, this autonomic control is disrupted.

What follows is a chain of events. Bowel movements slow down. Gut motility — the movement that keeps food and waste travelling through the intestines — is reduced. The balance of bacteria in the gut (the microbiome) shifts. The lining of the intestine, which normally acts as a barrier keeping gut contents separate from the bloodstream, becomes leaker.

Most people with SCI are familiar with neurogenic bowel dysfunction as a daily management issue. This review is suggesting it may also be a secondary injury pathway — one that continues feeding inflammation into the already-injured spinal cord long after the initial trauma.

What gets through the leaky gut?

When the intestinal barrier is compromised, things that should stay in the gut start getting into the bloodstream. The review focuses on several key signals:

LPS (lipopolysaccharide) is a molecule from the outer wall of certain gut bacteria. When it gets into the bloodstream, it is a powerful trigger for the immune system. In the context of SCI, it can cross into the spinal cord and activate the cells there.

Short-chain fatty acids (SCFAs) are normally produced by healthy gut bacteria breaking down fibre. They have anti-inflammatory and protective properties. After SCI, with the microbiome disrupted, levels of SCFAs tend to fall — removing a natural brake on inflammation.

Tryptophan metabolism gets disrupted too. Tryptophan is an amino acid found in food. Healthy gut bacteria process it into compounds that help regulate immune responses. After SCI, that processing goes wrong, shifting the balance towards more inflammatory outcomes.

TMAO (trimethylamine N-oxide) is another gut-derived molecule that tends to rise when the microbiome is disrupted. Elevated TMAO has been linked to immune dysfunction and may affect the integrity of the protective barrier around the spinal cord itself.

What does this do to the spinal cord?

Inside the injured spinal cord, three types of cells play a major role in the immune response: microglia (the spinal cord's resident immune cells), astrocytes (support cells that help regulate the local environment), and infiltrating macrophages (immune cells that move in from the bloodstream after injury).

The gut-derived signals described above appear to influence all of these cells — pushing them towards more inflammatory states and helping sustain the local inflammatory environment in the injured cord rather than allowing it to settle down.

The review identifies several molecular pathways through which this happens, including TLR4/NF-κB signalling (essentially, a key that unlocks inflammatory responses when LPS arrives) and the NLRP3 inflammasome (a molecular alarm system that, when triggered, amplifies inflammation significantly).

In plain terms: the disrupted gut is sending signals that keep these immune cells stirred up in ways that may slow recovery and worsen secondary damage.

Is this a proven treatment target yet?

Not yet — and the review is honest about that.

The authors note that most existing studies have looked at correlations: people with SCI tend to have certain gut changes, and people with those gut changes tend to have worse outcomes. But correlation is not the same as causation, and most of the evidence comes from animal models rather than clinical trials in humans.

The review calls for studies that establish causal, cell-specific, and stage-specific mechanisms. In other words: we need to understand exactly which gut changes matter, at which point after injury, and for which cells in the spinal cord.

That is the scientific work still to be done before gut-targeted interventions — like specific probiotic strains, dietary changes, or drugs that target these pathways — can be prescribed with confidence.

Why this is still worth paying attention to

Even in its current early state, the gut–spinal cord axis research matters for a few reasons.

First, it reframes something SCI people already deal with. Neurogenic bowel is not just an inconvenient symptom to manage. It may be an active part of secondary injury that deserves the same attention as any other aspect of recovery.

Second, it opens a therapeutic window that does not require surgery or highly invasive interventions. If future studies confirm that improving gut health after SCI reduces secondary neuroinflammation, the tools to address it — diet, targeted probiotics, gut barrier support — are relatively accessible compared to many other SCI research directions.

Third, the biology described here fits with a growing understanding in neuroscience that the gut and brain (and by extension spinal cord) communicate constantly. SCI disrupts that communication in ways that are only now starting to be mapped properly.

Reader Q&A

Should I be taking probiotics after SCI?

There is not enough human evidence yet to make a specific recommendation. The research here is promising but mainly from animal studies. If you are interested, it is worth discussing with your healthcare team — but this is not a proven treatment.

Does this research change anything right now?

Not directly. But it does add scientific weight to the importance of bowel management after SCI. Managing neurogenic bowel well is already important for quality of life; this research suggests it may also matter for the broader recovery environment in the spinal cord.

What does "secondary neuroinflammation" mean?

After the initial spinal cord injury (the primary damage), a second wave of damage begins — driven by swelling, dying cells, and the immune system's response. This is called secondary injury. Neuroinflammation is the inflammation part of that process. The point of this research is that the gut may be contributing to that ongoing inflammation.

This is a company-reported result from NervGen Pharma on its Phase 1b/2a CONNECT SCI study of NVG-291 — a neuroreparative drug that targets the CSPG-PTPσ pathway (the molecular 'brake' scar tissue uses to block nerve regrowth after spinal cord injury). It is worth being clear up front: this is a small, early-phase trial with 10 patients on the drug and 10 on placebo, and the analysis, while independently conducted and blinded, is a company press release rather than a peer-reviewed publication.

The data released here is the biomechanical gait analysis, which tackles a long-standing problem in SCI research. When someone walks better after an incomplete injury, it is hard to tell whether their nerves are healing or whether they have simply learned compensation strategies — using momentum or extra muscle effort to mask the loss. To separate the two, NervGen used Newton Tech, an independent AI motion-capture company, to measure three hallmarks of genuine recovery: coordination, mechanical effort, and postural stability.

The headline finding: across a combined measure of all three, 100% (10/10) of NVG-291 patients were classified as 'responders', versus just 10% (1/10) of placebo patients (p=0.0001). The most telling result is what scientists call 'speed-effort dissociation.' Placebo patients who walked faster only did so by exerting much more effort — the textbook signature of compensation. NVG-291 patients walked faster *without* that spike in effort, consistent with genuinely restored neural control rather than muscling through.

In related company news: NervGen reached FDA alignment in April 2026 on the design of its Phase 3 trial, RESTORE, on track to begin mid-2026 across up to 60 sites in the US and Canada, and priced a US$60 million public offering in May 2026 to help fund it.

For people with cervical spinal cord injury, hand function is not a small detail. It can be the difference between needing help for almost everything and being able to control a little more of your own world.

A current recruiting trial is now testing Battelle's NeuroLife EMG-FES Sleeve System, a wearable forearm sleeve designed to help people with tetraplegia practise grasp and release movements.

The basic idea is simple but powerful. The sleeve tries to detect tiny muscle signals in the forearm when a person attempts to move their hand. These signals are called EMG, short for electromyography. Even when the hand does not visibly move, there may still be weak electrical activity showing that the person is trying.

The second part is FES, or functional electrical stimulation. This uses small electrical pulses through the skin to activate muscles. In the NeuroLife system, the sleeve can both listen for attempted movement and stimulate the muscles needed to help carry out that movement.

Source:

ClinicalTrials.gov study NCT06087445, Battelle's NeuroLife technology page, and previous NeuroLife research involving Ohio State University and Battelle.

What is being tested

The current study is testing the NeuroLife EMG-FES Sleeve System in adults with chronic tetraplegia due to spinal cord injury.

The system is non-invasive. It is worn on the forearm and uses surface electrodes rather than surgery or implanted parts. Trial descriptions say the sleeve can include up to 160 electrodes that record muscle activity and deliver stimulation.

Participants complete a 12-week rehabilitation programme, usually three in-person sessions per week. During these sessions, a therapist works with the participant while they wear the sleeve and practise functional hand and forearm activities.

Where this comes from

This device has a longer backstory than a typical new trial listing.

Battelle and Ohio State University were involved in the earlier NeuroLife neural bypass work, best known through Ian Burkhart. That earlier system used a brain implant, computer decoding, and a forearm stimulation sleeve to help restore voluntary hand movement in a laboratory setting.

That was an important proof of concept, but it was not a practical everyday solution for most people. It required brain surgery and specialist lab equipment.

The newer sleeve approach is different. Instead of reading movement intention directly from the brain, the current NeuroLife EMG-FES system aims to read intention from the forearm muscles themselves. This could make the technology much more practical if future trials show that it is safe and useful.

There was also an earlier completed SCI study, NCT05128994, focused on hand grasp after spinal cord injury. Public final results from that study do not appear to be fully posted yet, but the current recruiting trial suggests the programme has continued into a more structured rehabilitation study.

Why this matters in SCI

A small change in hand function can be a big change in daily life.

Being able to grasp a cup, release an object, use a phone, press a switch, type a few keys, or control a wheelchair joystick can all matter hugely after cervical SCI.

That is why this trial is interesting. It is not promising a cure. It is not claiming to repair the spinal cord overnight. It is asking a more practical question: can a wearable sleeve help people with tetraplegia turn attempted movement into assisted movement?

If the answer is yes, even modest gains could be meaningful.

What this does not prove yet

This remains investigational technology.

Battelle states on its NeuroLife page that the technology is not commercially available and has not been approved or cleared by the FDA for treatment.

The current trial is also small, with a planned enrolment of around 12 participants. It is mainly looking at safety, feasibility, early functional effects, and whether EMG signals could be used as a marker of recovery over time.

In other words, this is promising research, not an available treatment.

Reader Q&A

Is this recruiting now?

Yes. The current ClinicalTrials.gov study is NCT06087445.

Does the sleeve require surgery?

No. This version is non-invasive and uses surface electrodes on the forearm.

Is this the same as the original NeuroLife brain implant system?

No. It comes from the same wider NeuroLife research story, but this version aims to avoid brain surgery by using muscle signals from the forearm instead.

Could it restore normal hand function?

That is not proven. The realistic goal at this stage is to test whether the system is safe, usable, and shows early signs of helping hand and arm function after chronic cervical SCI.

Spinal cord stimulation is often discussed as a movement technology. But for many people with SCI, movement is not the only problem. Spasticity, pain, stiffness, clonus, and involuntary muscle activity can be just as limiting.

A new preprint study looked at a dual-mode epidural spinal cord stimulation approach designed to do two jobs: calm spasticity and support voluntary movement.

The idea is straightforward but important. One stimulation mode used high-frequency stimulation, around 1.2 kHz, to suppress spasticity. The other used lower-frequency stimulation, 30 to 60 Hz, to help motor facilitation during rehabilitation.

Instead of asking stimulation to do one thing, the researchers used different electrical settings for different nervous-system goals.

Author(s):

Yandong Fan, Mangsuer Nuermaimaiti, Hangfei Guo, Manli Zhu, Lei Ren, Yirizhati Aili, Mamutijiang Muertizha, Aihemaiti Aierken, and Kun Luo.

Source:

First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, and Second Affiliated Hospital of Xinjiang Medical University. Posted as a Research Square preprint.

What was tested

The study included 30 people with traumatic spinal cord injury. Participants were randomised to either epidural spinal cord stimulation plus physical therapy, or physical therapy alone.

The stimulation group received a 16-contact epidural electrode implanted close to the injury, one to two spinal segments above the lesion. The authors describe this as lesion-proximal placement.

This differs from many earlier stimulation approaches that mainly targeted intact lumbar circuits below the injury. Here, the researchers aimed to modulate the region nearer the damaged segment.

The stimulation was adjusted during surgery and then reviewed monthly.

Why two modes?

Spasticity and movement facilitation can pull in opposite directions.

Low-frequency stimulation may help activate motor circuits and support voluntary movement. But if someone has severe spasticity, making the nervous system more excitable can sometimes worsen stiffness, spasms, clonus, or unwanted co-contraction.

High-frequency stimulation can be used differently: to dampen overactive reflex pathways.

A simple analogy is driving a car with both a throttle and a brake. If the brake is stuck, pressing the throttle harder does not give smooth movement. This dual-mode approach tries to release the brake first, then support useful movement.

What the study reported

At 30 days, the stimulation plus physical therapy group showed better outcomes than physical therapy alone in several areas:

- Sensory improvement: 93.3% versus 60.0%. - Spasticity control: 73.3% versus 26.7%. - Pain reduction: 60.0% versus 20.0%.

At six months, the stimulation group showed sustained gains. ASIA sensory scores increased, motor scores improved, Modified Ashworth Scale scores fell, and pain scores improved.

The authors report that 80% of the stimulation group achieved clinically meaningful functional improvement, including recovery involving ankle dorsiflexors and gait-related muscles.

For readers, ankle dorsiflexion matters because it helps lift the front of the foot during stepping. Even partial improvement in that movement can be functionally meaningful.

Why this is relevant to spasticity

Spasticity is not just tight muscles.

It can include exaggerated reflexes, increased tone, clonus, involuntary spasms, and muscles firing against each other during attempted movement. That can make transfers, sitting, sleep, hygiene, bladder and bowel routines, and exercise harder.

Many drug treatments can help but may cause side effects such as weakness, tiredness, low tone, dizziness, or withdrawal problems. For some people, spasticity remains difficult to control.

This study is interesting because it treats spasticity as a central part of recovery, not as a side issue.

What this does not prove yet

This is a preprint, meaning it has not completed final peer review.

The study is also relatively small, with 30 participants. The results are promising, but they need independent confirmation, clearer reporting of safety outcomes, and longer-term follow-up.

Epidural stimulation also requires surgery. That means risks, screening, specialist implantation, programming, and rehabilitation support. It is not comparable to a simple external device.

The paper also sits in an interesting context. Other recent stimulation research warns that waveform, frequency, electrode placement, and target fibres all matter. High-frequency stimulation may help with some goals, such as suppressing spasticity, but it should not be assumed to be automatically useful for every recovery target.

Why this matters in SCI

The most useful part of this study is the treatment logic: one stimulation setting may not fit every symptom.

People with SCI may need stimulation programmes that change depending on the goal: relaxing spasticity, supporting stepping, assisting voluntary movement, reducing pain, or stabilising autonomic function.

If future trials confirm these findings, dual-mode stimulation could help move SCI neuromodulation toward personalised programming rather than fixed, one-size-fits-all settings.

Reader Q&A

Could this help someone with severe spasticity?

Possibly in the future, but this is still a preprint and involves implanted epidural stimulation. It should be viewed as promising clinical research, not an available general treatment.

Does high-frequency stimulation restore movement?

Not by itself. In this study, high-frequency stimulation was used mainly to suppress spasticity, while lower-frequency stimulation was used to support motor facilitation.

Why place electrodes near the injury?

The authors argue that placing electrodes close to the lesion may help modulate the injured segment itself, rather than only stimulating intact circuits below the injury. This needs further validation.

Some spinal cord injury breakthroughs are not treatments. They are better tools.

A new Scientific Reports paper describes a method for growing human spinal cord organoids from induced pluripotent stem cells, or iPSCs. These organoids were guided toward a lumbar spinal cord identity, meaning they resemble the lower spinal cord region more than previous models that often lean toward cervical or thoracic identity.

That matters because the lumbar spinal cord contains motor circuits involved in the legs. For SCI, ALS, spinal muscular atrophy, and other motor neuron conditions, researchers need better ways to study human spinal cord tissue in the lab.

Author(s):

Li Jun Loh, Pratibha Panwar, Shila Ghazanfar, Kwaku Dad Abu-Bonsrah, Forough Habibollahi, Joel Mason, Brett J. Kagan, Bradley J. Turner, and Samantha K. Barton.

Source:

Florey Institute of Neuroscience and Mental Health, University of Melbourne, University of Sydney, Charles Perkins Centre, Sydney Precision Data Science Centre, and Cortical Labs. Published in Scientific Reports.

What is an organoid?

An organoid is a tiny 3D tissue model grown in the lab.

It is not a full organ. It does not think, feel, or work like a complete spinal cord. But it can contain several cell types arranged in a more natural 3D structure than flat cells grown on a dish.

A useful analogy is the difference between studying a city from a list of buildings versus looking at a small 3D neighbourhood model. A flat cell culture can tell researchers a lot about one cell type. An organoid can show more of the relationships between cells.

Why lumbar identity matters

The spinal cord is not the same from top to bottom.

Cervical regions help control the arms and hands. Thoracic regions are involved in trunk and autonomic functions. Lumbar regions are important for lower limb circuits.

Many previous spinal cord organoid systems have been more cervical or thoracic in character. This new protocol aimed to push the organoids toward a caudal, or lower-spinal, fate. The researchers used developmental signals to increase HOXC10, a marker linked to lumbar identity, while reducing more anterior spinal cord identity.

In plain English, they tried to tell the stem cells: "do not become generic nervous-system tissue; become more like lower spinal cord tissue."

How the organoids were made

The team started with human iPSCs. These are adult-derived cells reprogrammed into a stem-cell-like state, meaning they can be guided to become many different cell types.

The researchers then used a sequence of chemical signals to mimic development. These included signals that help establish nervous-system fate, caudal spinal identity, ventral patterning, and motor neuron development.

Over time, the cells formed 3D spheres containing spinal cord-like cell populations.

What the researchers found

The organoids contained an enriched neuronal population along with several glial cell types.

Glia are support cells of the nervous system. They are not just background helpers. Astrocytes, oligodendrocyte-lineage cells, and other glial populations influence survival, inflammation, myelin, metabolism, and how neurons function.

That is important because SCI is not just a neuron problem. Injury affects neurons, glia, myelin, blood vessels, immune responses, and the tissue environment.

Single-cell RNA sequencing showed that the organoids contained diverse cell populations and better recapitulated ventral spinal cord identity than standard 2D motor neuron cultures.

The organoids also showed spontaneous electrical activity, suggesting that the cells were forming functional neural networks.

Why this could help SCI research

Animal models remain essential in SCI research, but they are not human.

Human spinal cord tissue is difficult to study directly, especially during early disease or injury processes. Organoids can help bridge that gap. They allow researchers to study human cells in a controlled environment, test drugs, explore disease mechanisms, and compare patient-specific cell lines.

For SCI, lumbar organoids could be useful for studying:

- How human motor neurons mature and connect. - How glial cells affect motor neuron survival. - How injury-like stress affects spinal cord cell networks. - How candidate drugs influence human spinal cord cells. - Why some motor neuron populations are more vulnerable than others.

This does not replace animal studies or clinical trials. It gives researchers another tool before moving into those harder and more expensive stages.

What this does not mean yet

These organoids are not transplant-ready tissue.

They are a model system. They do not contain the full structure of a spinal cord, long-distance body connections, blood supply, immune system, pain pathways, movement circuits, or the mechanical environment of an injured spine.

They also model development more than adult injury. Researchers would still need to adapt and validate them for specific SCI questions.

Why this matters in SCI

SCI research needs better human models. Too many potential therapies look promising in animals or simple cell cultures and then fail later.

A more realistic human lumbar spinal cord organoid could help screen ideas earlier and more accurately. It may also support personalised research in the future, where organoids made from a person's own cells are used to understand disease risk or test treatment responses.

This is not a cure story. It is a better-map story.

Reader Q&A

Could these organoids be implanted into someone with SCI?

No. This study is about creating a lab model, not a transplant therapy. Implantation would require a completely different level of safety and functional testing.

Why is this relevant if it is not a treatment?

Better lab models help researchers choose better treatments to test. They can reduce false starts and make it easier to study human spinal cord biology.

Why focus on the lumbar spinal cord?

The lumbar region contains circuits important for lower limb function. A lumbar-like model may be more relevant for studying leg-related motor neurons and lower spinal cord disease mechanisms.

One of the big problems after spinal cord injury is that the adult central nervous system is not very welcoming to regrowth.

Nerve fibres may try to sprout, but the injured spinal cord contains many stop signals. One of those stop signals is called Nogo-A. The name is unusually clear: it helps tell nerve fibres "no go", limiting growth inside the brain and spinal cord.

NG101 is an antibody designed to block Nogo-A. The hope is that by blocking this growth brake, the injured spinal cord may become more permissive to repair.

A new Nature Communications study looked at MRI data from the phase 2b NISCI trial to ask a more detailed question: does NG101 change the structure of the injured spinal cord in ways that can be measured?

Author(s):

Lynn Farner, Paulina S. Scheuren, Kiomars Shari, Tim M. Emmenegger, Maryam Seif, Michele Hubli, Martin Schubert, Marc Bolliger, Rudiger Rupp, Norbert Weidner, Rainer Abel, Doris Maier, Klaus Ruhl, Michael Baumberger, Margret Hund-Georgiadis, Marion Saur, Jesus Benito, Kerstin Rehahn, Mirko Aach, Andreas Badke, Jiri Kriz, Tim Killeen, Alan J. Thompson, Nikolaus Weiskopf, Martin E. Schwab, Armin Curt, Patrick Freund, and the Nogo Inhibition in Spinal Cord Injury Study Group.

Source:

Multicentre NISCI trial group, led by Balgrist University Hospital/University of Zurich and collaborating European spinal cord injury centres. Published in Nature Communications.

What is Nogo-A?

Nogo-A is a protein found in central nervous system myelin and nerve cell membranes. Myelin is the insulating layer around nerve fibres. After SCI, myelin damage is part of the injury environment, but myelin also carries molecules that can suppress new nerve growth.

A simple way to imagine Nogo-A is as a roadblock sign placed in front of damaged nerve fibres. Even if a nerve fibre has some ability to grow, Nogo-A helps tell it to stop.

NG101 is a recombinant antibody, meaning a lab-made immune protein, designed to neutralise Nogo-A. It does not replace lost spinal cord tissue. It aims to reduce one of the biological brakes on plasticity and sprouting.

What the researchers measured

This study analysed spinal cord MRI scans from 106 participants with acute traumatic cervical SCI who took part in the phase 2b NISCI trial. Participants received either NG101 or placebo.

The researchers tracked several MRI measures over six months:

- Lesion volume: how large the damaged area appeared. - Tissue bridges: strips of spared tissue crossing the injury site. - Cross-sectional cord area: a measure of spinal cord shrinkage or atrophy. - MTsat: an MRI marker sensitive to myelin and microstructure in specific spinal pathways.

They also looked at electrophysiology, including somatosensory evoked potentials, or SSEPs. These tests check whether sensory signals can still travel through the nervous system.

What they found

Compared with placebo, people treated with NG101 showed faster reduction in lesion volume over time.

They also showed a slower decline in spinal cord cross-sectional area and MTsat in important pathways, including the corticospinal tracts and dorsal columns.

In everyday language, the MRI signs suggested less ongoing structural loss in parts of the spinal cord important for movement and sensation.

The authors are careful about what this means. The findings could reflect reduced degeneration, better preservation of tissue, sprouting of nerve fibres, or a mix of biological changes around the injury.

The key point is that MRI detected treatment-related structural differences that may not always be obvious from clinical scores alone.

Why patient selection matters

SCI trials are difficult because no two injuries are exactly alike.

Two people can both have cervical SCI but differ in how much tissue is spared, which pathways remain connected, how swollen the cord is, how severe the injury is, and how much spontaneous recovery is possible.

This study found that combining MRI and electrophysiology helped identify subgroups where treatment effects were easier to detect. In particular, people with preserved tissue bridges and preserved sensory pathway signals showed clearer upper extremity motor recovery differences.

That matters because future trials may be smaller and more informative if they enrol people most likely to show a measurable biological response.

Why this is important for hand and arm recovery

Cervical SCI often affects hand and arm function. For many people with tetraplegia, even small improvements in hand control can change independence: feeding, phone use, wheelchair control, transfers, bladder management, pressure relief, and personal care.

NG101 has already shown exploratory signals that it may improve upper extremity motor function in motor-incomplete cervical SCI. This new imaging study adds another layer: it suggests the treatment may also be changing the spinal cord's structure in measurable ways.

That does not mean NG101 is proven as a standard treatment. It means the biological case is becoming stronger and more measurable.

What this does not prove yet

This was an MRI biomarker analysis from a phase 2b trial, not a final proof that NG101 restores function for all people with SCI.

The treatment was given early after injury, between 4 and 28 days after cervical SCI, through intrathecal injections into the spinal fluid. That makes it an acute SCI treatment approach, not a therapy for long-established chronic injuries at this stage.

The results also suggest that responders may need to be carefully selected. People with different injury patterns may not benefit equally.

Why this matters in SCI

This story matters for two reasons.

First, it keeps the Nogo-A pathway alive as a serious human SCI repair target. Blocking a growth brake is not science fiction anymore; it has reached multicentre human trial analysis with measurable MRI changes.

Second, it shows how future SCI trials may improve. Instead of judging treatments only by broad clinical scores, researchers can use MRI and electrophysiology to see whether the spinal cord itself is changing.

That kind of measurement is essential if the field is going to separate treatments that truly affect repair biology from those that only look promising in small or noisy datasets.

Reader Q&A

Could NG101 help someone with chronic SCI?

This study does not show that. NG101 was tested early after acute cervical SCI. Chronic SCI would need separate trials because the injury environment is very different once scarring and long-term degeneration are established.

Is this a cure?

No. It is a targeted attempt to reduce one biological brake on nerve sprouting and plasticity. It may support recovery in selected people, but it does not rebuild the spinal cord by itself.

Why are MRI and electrical tests so important?

They help researchers see what is happening inside the spinal cord, not just what a person can do on a clinical exam. That can reveal treatment effects earlier and help identify who is most likely to respond.

This is the microrobot story.

A new paper in the International Journal of Extreme Manufacturing reports a striking approach to acute spinal cord injury: use living immune cells as tiny treatment carriers, add magnetic nanoparticles so they can be guided, and steer them toward the injured spinal cord using an external rotating magnetic field.

The researchers call these "DC robots". DC stands for dendritic cell, a type of immune cell that helps organise immune responses.

The goal is not simply to move tiny machines around the body. The goal is to solve a real SCI problem: after injury, the spinal cord environment becomes inflamed, hostile, and short of growth-supporting signals. Treatments injected into the bloodstream often fail to reach the injury site in high enough amounts, while direct injection into the cord can risk extra damage.

Author(s):

Jiawen Niu, Chenlu Liu, Weiwei Zhang, Fawang Zhang, Chuanhua Li, Kunrong Xie, Sikai Wang, Zexuan Wu, Guanglei Li, Xuefeng Li, Jinglong Yan, Jing Li, Chengchao Song, Yan Shi, Jianing Zu, Fengtong Ji, Jie Zhao, Yufu Wang, and Tianlong Li.

Source:

The Second Affiliated Hospital of Harbin Medical University, Harbin Institute of Technology, University of Cambridge, Zhengzhou University, and collaborating laboratories. Published in International Journal of Extreme Manufacturing.

What are dendritic cells?

Dendritic cells are immune system organisers. They help show pieces of biological material, called antigens, to T cells and help shape how the immune system reacts.

In cancer research, dendritic cell vaccines have been studied as a way to train the immune system to attack tumours. In SCI, the idea is different. The goal is to push the immune response toward protection and repair rather than uncontrolled inflammation.

After spinal cord injury, inflammation is not automatically bad. The body needs immune activity to clean up damage. But if the response becomes too aggressive or prolonged, it can worsen tissue loss and block regeneration.

How the microrobots were built

The researchers created biohybrid microrobots using dendritic cells combined with magnetic iron oxide nanoparticles, Fe3O4.

They also incorporated components designed to support immune modulation and neurotrophic factor delivery. Neurotrophic factors are support signals that help nerve cells survive, grow, and maintain connections. Two important ones in this study were BDNF and NT-3.

In simple terms, each DC robot acts like a tiny immune-guidance vehicle:

- The dendritic cell provides the biological immune-regulating function. - Magnetic nanoparticles allow external steering. - Therapeutic cargo and cell signalling help shift the injury environment. - A rotating magnetic field helps guide the microrobots toward the spinal cord lesion.

How they were delivered

In the mouse experiments, the researchers created a T10 spinal cord contusion injury. Two hours after injury, they injected the DC robots through the tail vein.

Then they applied an external rotating magnetic field for 30 minutes to help guide the microrobots toward the injury site.

That matters because SCI disrupts the blood-spinal cord barrier, the protective boundary between blood and spinal cord tissue. During the early injury period, this barrier becomes more permeable. The researchers used that temporary opening as a window to help the microrobots enter the injured area.

Imaging suggested that magnetically guided DC robots accumulated at the injury site more effectively than unguided treatments.

What they changed at the injury site

The treated spinal cord environment shifted toward a more protective immune state.

The paper reports reduced pro-inflammatory signals such as IFN-gamma, GM-CSF, TNF-alpha, IL-1, IL-6, IL-12, and IL-17, alongside increased anti-inflammatory or repair-associated signals such as IL-4 and IL-10.

The DC robots also encouraged immune-cell patterns linked to repair, including more Th2 and Treg-type responses and more anti-inflammatory macrophage/microglial features.

A plain-language way to put this is: the microrobots helped change the injury site from a shouting, destructive immune environment into a calmer clean-up and repair environment.

Growth support: BDNF and NT-3

The study also found higher levels of BDNF and NT-3 at the injury site.

These are neurotrophic factors: molecules that support nerve cell survival and growth. They do not magically rebuild the spinal cord, but they can make the environment more supportive for axons, the long nerve fibres that carry signals.

The authors argue that the benefits came from both sides working together: immune modulation plus growth-factor support.

That is important because SCI repair probably needs combination effects. Reducing inflammation alone may not be enough. Delivering growth factors alone may not be enough. The injury site has to become less hostile and more supportive at the same time.

What happened in the mice

In mouse models of SCI, the magnet-guided DC robot group showed several repair-associated changes.

MRI suggested reduced lesion signal and smaller lesion volume compared with control injury groups. Diffusion tensor imaging suggested more organised nerve-fibre structure at the lesion site. Tissue analysis showed signs of more nerve fibres, less glial scarring, more remyelination-related activity, and improved myelin structure.

Functional testing also improved. The DC robot group showed better hindlimb movement measures, better gait-related CatWalk results, and improved activity measures compared with control groups.

These are promising findings, but they remain preclinical mouse results.

What this does not prove yet

This is not ready for human treatment.

The work was done in mice, in an acute injury window, with careful laboratory control over timing, injection, magnetic guidance, imaging, and analysis. Human SCI is larger, more variable, and medically more complex.

Safety also needs much more work before translation. The authors assessed organ safety and iron clearance in mice, but human use would require major testing around immune reactions, blood flow, clotting, infection risk, dosing, manufacturing, magnetic targeting accuracy, and long-term fate of the cells and nanoparticles.

The study also used female mice only, which the authors acknowledge as a limitation. Future work needs to test whether responses differ by sex.

Why this matters in SCI

This study is interesting because it combines three major SCI treatment ideas:

- Targeted delivery. - Immune reprogramming. - Growth-factor support.

Instead of flooding the whole body with drugs or directly injecting the spinal cord, the researchers used magnetically guided living cell-based carriers to concentrate treatment near the injury.

The bigger lesson is that future SCI therapies may need to be both smart and local. The right treatment has to arrive at the right place, at the right time, and change the injury environment in more than one way.

This does not mean microrobots will be treating people with SCI soon. But it is a creative and serious step toward precision medicine for acute spinal cord injury.

Reader Q&A

Are these real robots?

They are not robots like metal machines with motors. They are biohybrid microrobots: living dendritic cells combined with magnetic nanoparticles so they can be influenced by an external magnetic field.

Could this help chronic SCI?

Not based on this study. The treatment was given two hours after injury and is aimed at the early inflammatory phase. Chronic SCI would need different testing.

Why use magnets?

The magnetic field helps guide the treatment toward the injury site. That could improve targeting and reduce the need for risky direct injection into the spinal cord.

Spinal cord stimulation research can sometimes sound like a miracle story. The truth is more interesting and more useful: stimulation does not simply "make walking happen". It changes how the nervous system responds, and training may help the body learn how to use that changed state.

A new Scientific Reports paper looked at what happens when percutaneous spinal cord epidural stimulation, exoskeleton-assisted walking, and resistance training are combined in people with chronic motor-complete spinal cord injury.

The study was very small, involving four participants, but it asks an important question: when stimulation appears to help after SCI, is the change happening in the brain and spinal cord, in the peripheral nerves and muscles, or both?

The authors describe this as "partitioning" the nervous system. In simpler terms, they were trying to separate which parts of the movement system were adapting.

Author(s):

Ashraf S. Gorgey, Momal Ahmad Wasim, Jakob N. Deitrich, Muhammad Uzair Rehman, Carrie Peterson, and Robert Trainer.

Source:

Richmond VA Medical Center, Virginia Commonwealth University, and collaborating departments. Published in Scientific Reports.

What the study tested

Four people with chronic spinal cord injury took part. Their injuries ranged from C8 to T11, and all were motor-complete, AIS A or AIS B. They were 6 to 24 years post-injury, so this was not early recovery.

Each participant underwent permanent implantation with percutaneous spinal cord epidural stimulation. Percutaneous means the leads are placed through the skin rather than using a larger paddle electrode. Epidural means the stimulation is delivered near the spinal cord, outside the protective covering of the cord.

Participants trained for up to 12 months. The programme involved exoskeleton-assisted walking, stimulation in some phases, and later resistance training for three participants.

The researchers then measured several things:

- Whether participants could intentionally generate knee force with stimulation on. - Electrical signs of peripheral nerve and muscle response. - Muscle activation patterns during exoskeleton walking. - Ten-metre exoskeleton walking performance. - Spasticity changes.

The positive finding: intentional force appeared in some participants

The most important positive signal was that some participants could generate intentional knee torque when stimulation was on.

Torque simply means turning force around a joint. In this case, the researchers looked at knee extension or flexion force. For a person with motor-complete SCI, being able to intentionally produce measurable knee force during stimulation suggests that stimulation may be making the spinal motor system more accessible.

Two participants generated knee extensor torque with stimulation on and active effort. A third generated torque in the flexion direction. One participant did not generate measurable intentional torque.

That variation matters. It shows both the promise and the complexity. Stimulation may open a door for some people, but not everyone responds the same way.

Why this does not mean walking was restored

The walking results were more cautious.

During exoskeleton walking with stimulation on, participants walked with less assistance from the exoskeleton, which sounds positive. But the ten-metre walking test took longer and was slower than when the exoskeleton provided full assistance with stimulation off.

That does not make the stimulation result meaningless. It means the body was being asked to do more of the work. A slower walk with less robotic assistance may reflect a different training challenge rather than a simple performance win.

Still, from a reader's point of view, the caveat is important: this study did not show faster exoskeleton walking.

Central and peripheral changes

The study found signs of both central and peripheral nervous system adaptation.

"Central" here refers to the brain and spinal cord. "Peripheral" refers to nerves and muscles outside the spinal cord.

The central side was suggested by the ability of some participants to generate intentional knee force when stimulation was on. The peripheral side was suggested by changes in H-reflex and M-wave measures, along with improved neuromuscular electrical stimulation-induced knee extensor force in both groups by the end of the study.

A useful analogy is a dimmer switch and a motor. Epidural stimulation may raise the background excitability of the spinal cord, like turning up the dimmer so weak signals can be seen. Training and muscle work may also improve the motor, meaning the peripheral nerves and muscles are better able to respond.

The result is not one system changing alone. It may be a body-wide retraining effect.

What about spasticity?

Spasticity decreased modestly after the first six-month phase, with reported reductions across different movement speeds. But that effect was not maintained in the same way after the second phase.

That means spasticity remains an open question. Stimulation may influence tone, but it is not yet clear how durable or predictable that effect is in this kind of combined programme.

What this study does not prove

This was a proof-of-concept pilot study with only four participants.

The participants were very different from one another, which is normal in SCI research but makes strong conclusions difficult. The study also did not include direct brain imaging or tests such as TMS to prove exactly how much of the intentional torque came from preserved descending pathways versus spinal or peripheral mechanisms.

Lead placement and lead migration also matter. The authors note that spinal mapping and stable lead anchoring are major practical challenges.

So the right conclusion is not "stimulation restores walking". The right conclusion is that epidural stimulation combined with long-term training may help uncover and strengthen remaining motor-system function in some people with chronic motor-complete SCI.

Why this matters in SCI

The study supports a more realistic and useful view of stimulation. The goal is not simply to turn on an electrical device and expect movement. The goal is to tune the nervous system, train repeatedly, and understand which parts of the system are responding.

For people with SCI, that matters because future stimulation therapies will need to be personalised. Injury level, completeness, time since injury, remaining sensory pathways, muscle condition, spasticity, electrode position, waveform, training dose, and goals all likely matter.

This study is positive because it shows measurable intentional force in some chronic motor-complete participants. It is also careful because it shows that better nerve signals do not automatically equal better walking performance.

Reader Q&A

Could this help someone with chronic SCI?

Possibly in the future, but this was a very small specialist study. It involved implanted epidural stimulation, intensive training, and careful testing. It is not a standard therapy yet.

Does this mean exoskeleton walking plus stimulation restores walking?

No. The study found improved intentional force in some participants, but exoskeleton walking speed did not improve. The main value is understanding how stimulation and training change the nervous system.

Why is this still encouraging?

Because it suggests that even years after injury, some motor circuits may still be recruitable when stimulation and training are combined. The next step is learning who responds, why they respond, and how to make the response more useful.

Spinal cord stimulation is not just about applying electricity. The details matter: where the electrodes are placed, how strong the current is, how long each pulse lasts, and what waveform is used.

A new Nature Biomedical Engineering paper is an important cautionary story for spinal cord injury research. It does not say stimulation is bad. It says that not every stimulation pattern reaches the nervous system in the same way.

That is good news in the long run. It means the field is moving from "try a zap and see what happens" toward understanding exactly which nerve fibres are being recruited, and why.

Author(s):

Rodolfo Keesey, Ursula Hofstoetter, Zhaoshun Hu, Lorenzo Lombardi, Rachel Hawthorn, Noah Bryson, Abdallah Alashqar, Andreas Rowald, Karen Minassian, and Ismael Seez.

Source:

Washington University in St. Louis, Medical University of Vienna, Swiss Federal Institute of Technology/NeuroRestore-associated collaborators, and partner institutions. Published in Nature Biomedical Engineering.

The basic issue

Transcutaneous spinal cord stimulation, or tSCS, delivers electrical stimulation through pads on the skin over the spine.

In motor recovery research, many scientists believe one important target is the proprioceptive afferent fibres. These are sensory fibres that carry information from muscles and joints back into the spinal cord. They help the spinal cord know where the body is and how it is moving.

That feedback matters because movement is not only a command from the brain to the muscle. Movement also depends on the spinal cord receiving constant sensory information from the body.

If stimulation recruits those sensory fibres, it may help engage spinal circuits in a way that supports training and recovery. If stimulation mostly activates motor efferent fibres, it may make muscles twitch directly while bypassing some of the spinal circuitry researchers are trying to train.

Afferent versus efferent, in plain English

Afferent fibres carry information into the spinal cord. Think "arriving".

Efferent fibres carry commands out from the spinal cord to muscles. Think "exiting".

For rehabilitation, the distinction matters. Activating a muscle directly may create movement, but it is not the same as engaging the spinal cord's sensory-motor networks.

A useful analogy is learning to ride a bike. If someone simply moves your legs for you, your legs move, but your nervous system may not learn as much. If your body is receiving and using feedback from the pedals, balance, joints, and muscles, the learning system is more engaged.

What kilohertz-frequency carriers are

Some tSCS approaches use kilohertz-frequency carrier waveforms. These are very fast alternating currents, often in the 5 to 10 kHz range, wrapped into a stimulation pulse.

They have gained attention partly because they have been claimed to make stimulation more tolerable or more effective. But the exact nerve fibres they recruit have not always been carefully tested.

This study looked directly at that question.

What the researchers did

The team studied 28 participants using human electrophysiology and computational modelling.

They first stimulated the mixed tibial nerve in the leg. This is useful because researchers can distinguish between two responses:

- The H-reflex, which reflects recruitment of sensory afferent pathways. - The M-wave, which reflects direct recruitment of motor efferent fibres.

They then used computational modelling to understand why different waveforms behaved differently.

Finally, they tested whether the same ideas translated to lumbar and cervical transcutaneous spinal cord stimulation.

What they found

Kilohertz-frequency waveforms increased the stimulation threshold. In simpler terms, they made it harder to trigger the desired nerve response.

They also biased recruitment toward motor efferent fibres rather than proprioceptive afferent fibres.

The modelling helps explain why. A kilohertz waveform rapidly alternates between depolarising and hyperpolarising phases. One part pushes the nerve toward firing, while the next part partly pulls it back. That can interrupt the build-up needed to activate the fibre.

The effect seems especially important because proprioceptive afferent fibres respond better to longer, lower-amplitude pulses, while shorter pulses can favour motor fibres. A kilohertz waveform can behave like a rapid series of very short pulses.

Lumbar and cervical stimulation were not the same

One of the most important findings was that body region mattered.

Lumbar tSCS still tended to preferentially recruit proprioceptive afferent fibres, even though kilohertz waveforms were less effective than conventional ones.

Cervical tSCS was different. In the cervical region, both conventional and kilohertz stimulation appeared to favour motor efferent recruitment.

This is especially relevant because cervical stimulation is being explored for upper-limb and hand recovery after tetraplegia. If the goal is to train spinal circuits using sensory feedback, researchers need to know whether the chosen waveform and electrode placement are actually reaching the intended fibres.

Why this is not anti-stimulation

This study should not be read as "spinal stimulation does not work".

It is more precise than that. It says the waveform matters. The spinal level matters. The nerve target matters. And researchers should not assume that a more complex or higher-frequency waveform is automatically better.

That is an important sign of progress. SCI stimulation research is becoming more like pharmacology: dose, timing, route, target, and mechanism all matter.

What this means for patients and readers

For someone with SCI reading about stimulation, this can feel frustrating. One study says stimulation helps. Another says a certain waveform may not recruit the right fibres. But this is how the field matures.

The real message is that stimulation therapies need to become more personalised and more evidence-based. It is not enough to say "electricity near the spine". Clinicians and researchers need to know which pathway they are trying to activate and which settings best do that.

What this does not prove yet

This was not a clinical recovery trial testing whether one waveform improves walking or hand function better than another over months of rehabilitation.

It was a mechanism study. It tested recruitment patterns in unimpaired participants and tSCS experiments, supported by modelling. It gives strong reasons to be careful with kilohertz carriers, especially for cervical tSCS, but clinical outcomes still need direct testing.

Why this matters in SCI

SCI therapies should not be built on vague stimulation recipes. If the goal is to restore function, researchers need to know whether stimulation is activating sensory feedback loops, motor outputs, or both.

This paper helps sharpen that map. It warns that kilohertz carrier waveforms may make proprioceptive afferent recruitment harder and may shift stimulation toward motor fibres. That could matter if the intended therapy depends on spinal circuit engagement rather than direct muscle activation.

For people with SCI, the takeaway is not pessimistic. It is that better science should lead to better-tuned stimulation.

Reader Q&A

Does this mean kilohertz stimulation is useless?

No. It means kilohertz waveforms may not be ideal for every goal. If the aim is to recruit proprioceptive sensory fibres for rehabilitation, they need careful testing and may be less suitable in some settings.

Why do sensory fibres matter for movement recovery?

Sensory feedback helps the spinal cord and brain know where the limbs are and how they are moving. Training motor circuits without that feedback may be less effective.

Should patients worry if a trial uses a different waveform?

Not automatically. But it is reasonable to ask what waveform is being used, what nerve target is intended, and why the researchers believe those settings are appropriate.

Spinal cord injury happens in two broad waves.

The first wave is the physical impact: the cord is crushed, stretched, bruised, cut, or compressed. That immediate damage is the primary injury.

The second wave comes afterward. Inflammation, immune-cell activity, swelling, chemical stress, and tissue breakdown can continue damaging the spinal cord for days or weeks. This is called secondary injury.

A new abstract from researchers at the University of Michigan and the University of California, Irvine looked at whether tiny polymer nanoparticles could reduce that second wave after contusion SCI in mice.

The study is early and preclinical, but the idea is important: if we cannot undo the original impact, can we reduce the damage that follows?

Author(s):

Samantha Schwartz, Samantha R. Schwartz, Brooke M. Smiley, Sarah E. Hocevar, Brian C. Ross, Aileen J. Anderson, Brian J. Cummings, and Lonnie D. Shea.

Source:

University of Michigan, Ann Arbor, and University of California, Irvine. Published as an abstract in the Journal of Clinical and Translational Science 2026 Abstract Supplement.

What are these nanoparticles?

The treatment used poly(lactide-co-glycolide) nanoparticles, often shortened to PLG or PLGA nanoparticles.

They are tiny biodegradable polymer particles. Polymer simply means a material made from repeating molecular building blocks. Biodegradable means the body can break it down over time.

A useful analogy is a microscopic sponge or messenger bead. These particles are small enough to move through the bloodstream after injection. Previous work suggests they can help change immune responses after injury, which may reduce secondary damage.

In this study, the nanoparticles were injected into the bloodstream through the tail vein within two hours of injury, then given daily for seven days.

Why the researchers tested different injury severities

Not all spinal cord injuries are the same.

A mild contusion, moderate contusion, and severe contusion create very different biological environments. In a severe injury, there may be less tissue left to rescue. In a milder injury, there may be more spared tissue that can benefit from reducing inflammation.

The researchers therefore tested three contusion severities in mice:

- Mild injury. - Moderate injury. - Severe injury.

They then compared nanoparticle-treated mice with control mice that received a PBS vehicle solution.

What they found

In the mild injury group, nanoparticle-treated mice had better Basso Mouse Scale scores starting three days after injury. That difference persisted through week four, and the control mice remained slightly lower through the end of the study.

In the moderate injury group, nanoparticle-treated mice showed significantly better scores starting six weeks after injury and continued to perform better through the end of the study.

In the severe injury group, the nanoparticles did not produce a significant difference in BMS scores. The animals also did not recover enough function to be tested on the ladder beam task.

This pattern is important. It suggests that immune-modulating nanoparticle therapy may help when there is enough tissue left to protect or support, but may be overwhelmed when the injury is too severe.

What the BMS score means

The Basso Mouse Scale is a standard way to rate hindlimb movement after SCI in mice. It looks at things like ankle movement, stepping, coordination, paw position, and trunk stability.

It is not the same as human walking recovery. But it gives researchers a structured way to compare motor function between treatment groups.

In this study, better BMS scores suggest better hindlimb motor recovery in the mild and moderate injury groups.

Why this matters for secondary damage

The immune response after SCI is not simply good or bad. The body needs immune cells to clean up damaged tissue and fight infection. But too much or poorly controlled inflammation can damage tissue that might otherwise survive.

Nanoparticles may help redirect the immune response away from destructive inflammation and toward a more controlled repair environment.

This is different from trying to regrow the spinal cord directly. It is more like trying to stop the injury site from becoming even more hostile after the first impact.

What this does not prove yet

This is an abstract, not a full peer-reviewed paper with all detailed methods, figures, and long-term safety data.

It was also a mouse study. Human SCI is more complex, and people vary widely in injury level, severity, timing, health, medication, infection risk, and rehabilitation access.

The treatment was given very early, within two hours of injury, and repeated for seven days. That makes it most relevant to acute emergency treatment, not chronic SCI.

Why this matters in SCI

The study supports a practical idea: secondary injury is a treatment window.

For mild and moderate contusion injuries, there may be enough surviving tissue that reducing inflammation early can improve outcome. For severe injuries, the same treatment may not be enough by itself.

That matters for future trials because SCI treatments may need to be matched to injury severity. A therapy that helps one group may fail in another, not because the idea is useless, but because the injury biology is different.

Reader Q&A

Could this help someone with chronic SCI?

Probably not in this form. The treatment was given very early after injury to reduce secondary damage. Chronic SCI would likely need different approaches.

Why did it help mild and moderate injuries but not severe injuries?

The most likely explanation is that mild and moderate injuries leave more tissue that can be protected. Severe injury may cause too much primary damage for this immune-modulating approach to make a measurable difference on its own.

This is a News + story. The study is about limb and digit regeneration, not spinal cord injury. But it belongs on the radar because SCI research shares the same big question: why do some animals rebuild complex tissues while adult humans usually scar instead?

A new ScienceDaily report from Wake Forest University describes research published in the Proceedings of the National Academy of Sciences. The team studied axolotls, zebrafish, and mice to look for shared genetic programmes involved in regeneration.

Axolotls can regrow entire limbs. Zebrafish can regrow damaged fins and repair several organs. Mice are much more limited, but they can regenerate the very tips of digits under certain conditions. Humans also have a tiny version of this ability: some fingertip injuries can regrow if the nailbed is preserved.

The researchers found that a pair of genes, SP6 and SP8, appear to be part of a shared regeneration programme across these very different animals.

Author(s):

David A. Brown, Katja K. Koll, Erin Brush, Grant Darner, Timothy Curtis, Thomas Dvergsten, Melissa Tran, Colleen Milligan, David W. Wolfson, Trevor J. Gonzalez, Sydney Jeffs, Alyssa Ehrhardt, Rochelle Bitolas, Madeleine Landau, Kendall Reitz, David S. Salven, Leslie A. Slota-Burtt, Isabel Snee, Elena Singer-Freeman, Sayuri Bhatia, Jianhong Ou, Aravind Asokan, Joshua D. Currie, and Kenneth D. Poss.

Source:

Wake Forest University, Duke University, and the University of Wisconsin-Madison. Published in Proceedings of the National Academy of Sciences.

The basic discovery

The researchers compared regeneration in three animals with very different abilities.

Axolotls are famous for regrowing limbs, tails, parts of the spinal cord, and some organs. Zebrafish can repeatedly regrow fins and repair tissues such as heart, brain, spinal cord, retina, kidney, and pancreas. Mice are mammals, like humans, but their regeneration is much more limited.

Across these animals, the team found that the regenerating epidermis, the outer skin-like layer covering the wound area, activated SP6 and SP8.

That matters because regeneration is not just about the deep tissue underneath. The wound covering itself can send important instructions. In a normal adult mammal, a wound often closes and scars. In a regenerative animal, the wound covering can act more like a command centre, sending signals that tell the body to rebuild the missing structure.

Why SP8 stood out

The team used CRISPR gene editing to remove SP8 from axolotls. When SP8 was missing, the animals could no longer properly regenerate limb bones.

Similar problems were seen in mice when SP6 and SP8 were missing from regenerating digits. That suggests these genes are not just markers of regeneration. They help control part of the process.

In plain English, SP6 and SP8 appear to be part of the instruction set that tells a wound, "do not just close over; rebuild."

The gene therapy experiment

The researchers then tested whether they could replace part of the missing regenerative signal.

Duke researcher David A. Brown's team designed a viral gene therapy inspired by zebrafish biology. The treatment delivered FGF8, a signalling molecule normally linked to SP8 activity.

In mice, the treatment encouraged bone regrowth in injured digits and partly restored regeneration that had been lost when the SP genes were absent.

This does not mean scientists can regrow human arms or legs now. It does show that researchers may be able to borrow pieces of regeneration biology from animals that heal better than we do and use them to push mammalian tissue toward repair.

Where this connects to SCI

Spinal cord injury and limb loss are different problems. A spinal cord is not a finger bone, and nerve repair involves many obstacles: cell death, inflammation, myelin debris, scar formation, lost connections, and long-distance axon growth.

But the wider lesson is relevant. Adult humans usually respond to major tissue damage by sealing it off. That is useful for survival, but it often blocks regeneration.

SCI researchers are also trying to shift the body from a scar-first response toward a repair-friendly response. That includes work on growth factors, gene therapy, biomaterial scaffolds, stem cells, extracellular vesicles, immune reprogramming, and electrical stimulation.

The SP6/SP8 study adds another piece to that field. It shows that the outer wound environment can carry powerful instructions, and that changing those instructions may help mammalian tissue rebuild more than it normally would.

What this does not prove yet

This is early regenerative biology. It is not a human therapy, and it is not an SCI treatment.

Regrowing a digit tip in a mouse is still far from regrowing a human limb or reconnecting a damaged adult spinal cord. Human tissues are larger, more complex, slower to regenerate, and often respond to injury with scarring and inflammation.

The realistic value today is scientific direction. The study helps identify genes and signals that researchers can test further, refine, and possibly combine with other regenerative strategies.

Why this matters in SCI

SCI research needs more than one breakthrough. It likely needs a combination of approaches that make the injury site cleaner, more permissive, and more growth-supportive while also guiding new nerve connections safely.

This study supports the idea that regeneration is not magic. It is a controlled biological programme. If researchers can understand the programme well enough, they may eventually learn how to switch parts of it back on in adult mammals.

Reader Q&A

Does this mean limb regrowth or spinal cord regrowth is close?

No. This is early animal research. It identifies important genes and shows partial effects in mice, but it does not translate directly into a human treatment yet.

Why cover this on an SCI website?

Because SCI repair is part of the wider regeneration field. Discoveries about why some animals rebuild complex tissue can help researchers understand why adult mammals scar instead.

Could SP6, SP8, or FGF8 be used in spinal cord injury?

Not based on this study alone. These signals would need specific SCI testing. The spinal cord has different cell types, risks, and repair challenges compared with digits or limbs.

The 2026 Wings for Life World Run has delivered another major year for spinal cord injury research.

According to Red Bull's event report, 346,527 registered participants took part across 173 countries. Runners, wheelchair users, walkers, joggers, solo app users, and organised event groups helped raise EUR9.2 million for spinal cord injury research.

That brings the event's all-time fundraising total to EUR69.7 million since the first Wings for Life World Run in 2014.

Author(s):

Lucy Debenham for Red Bull.

Source:

Red Bull report: "Wings for Life World Run 2026 raises EUR9.2M and breaks participation record."

A global race for SCI research

The Wings for Life World Run is unusual because everyone starts at the same time worldwide. There is no fixed finish line. Instead, a moving Catcher Car gradually catches participants. When it catches you, your race is over.

That format allows elite runners, casual walkers, wheelchair users, families, teams, and app participants to take part in the same global event. In 2026, the event included seven Flagship Runs, 648 App Run Events, and thousands of solo app users.

The message is simple: run, walk, or roll for those who cannot.

The numbers from 2026

The 2026 event broke the previous participation record.

Key figures:

- 346,527 registered participants. - 173 countries involved. - 648 App Run Events. - EUR9.2 million raised in 2026. - EUR69.7 million raised since 2014. - 344 research projects funded to date.

Red Bull reports that every entry fee and donation goes directly toward spinal cord injury research and clinical trials through Wings for Life.

Why this funding matters

Spinal cord injury research is expensive, slow, and technically difficult. Promising ideas need years of work before they can move from a laboratory finding to a tested human therapy.

Funding can support many stages of that process: basic biology, drug testing, biomaterials, stimulation research, rehabilitation studies, clinical trial preparation, and early human trials.

The Red Bull report highlighted Alejandro Arriero-Cabanero, a PhD researcher at Spain's Hospital Nacional de Paraplejicos in Toledo, who is funded by Wings for Life. His work involves chitosan nanoparticles designed to provide regenerative support in the spinal cord.

That is the kind of research pipeline this event helps power. Not every funded project will become a treatment, but each serious project adds knowledge and moves the field forward.

The people behind the event

The 2026 event included participants from across the world, including wheelchair users, first-time participants, elite ultrarunners, older participants, and well-known athletes.

Former Pittsburgh Steelers linebacker Ryan Shazier, who sustained a spinal cord injury in 2017, took part in Pittsburgh and spoke about the importance of community and research support. His presence matters because it connects the event back to lived experience, not just fundraising numbers.

The race also drew support from athletes and public figures including Yuki Tsunoda, Dominic Thiem, Jurgen Klopp, Anna Gasser, Adam Malysz, Loic Bruni, Scotty James, Mari Fukada, and others.

The winners

In the men's competition, Jo Fukuda of Japan won his fourth global title and set a new record distance of 78.9 km in Fukuoka before being caught by the Catcher Car.

Poland's Dariusz Nozynski finished second with 67.9 km, and Austria's Andreas Vojta finished third.

In the women's competition, Mikky Keetels of the Netherlands won the global title and set a new world record of 62.2 km in Breda. Germany's Esther Pfeiffer finished second, and Imke Salander finished third with a personal best of 52.5 km.

Why this belongs in SCI news

This is not a laboratory paper, but it is directly connected to SCI progress.

Research does not move without sustained funding. Events like Wings for Life create public attention, bring the community together, and fund projects that may otherwise struggle to get support.

For people living with SCI, the most important point is not the running itself. It is that hundreds of thousands of people showed up for spinal cord injury research on the same day.

What comes next

The next Wings for Life World Run is scheduled for May 9, 2027. Registration is due to open on November 4, 2026 at 11:00 UTC.

Reader Q&A

Does the money really go to spinal cord injury research?

Red Bull's report states that every entry fee and donation goes directly to funding spinal cord injury research and clinical trials through Wings for Life.

Why does fundraising matter if cures come from science?

Science needs long-term funding. Laboratory work, safety testing, animal studies, manufacturing, ethics approvals, and human trials all cost money before a treatment can reach patients.

Can wheelchair users take part?

Yes. The event includes runners, wheelchair users, walkers, joggers, app participants, and organised local events. The format is built around participation rather than a single fixed-distance race.

One of the most striking facts in spinal cord injury research is that age changes everything.

Adult mammals usually respond to spinal cord injury with inflammation, tissue breakdown, scar formation, and long-term loss of function. But very young neonatal mice, around two days old, can repair spinal cord damage in a much cleaner way. Their injured spinal cords can heal with far less scarring.

A new study in Bioactive Materials asked a simple but powerful question: what if part of that newborn repair ability is carried in the blood?

The researchers focused on tiny particles called small extracellular vesicles, or sEVs. These are microscopic packages released by cells. They travel through body fluids, including blood, and carry instructions such as proteins and microRNAs. You can think of them like biological text messages: small parcels carrying information from one cell to another.

In this study, the team found that sEVs from neonatal mouse blood, which they call NCEs, could shift the injured adult spinal cord environment away from scarring and inflammation and toward repair.

Author(s):

Feifei Yuan, Chaoran Shi, Xisong Liang, Jiaqi Xu, Yiming Qin, Sheng Xu, Yong Chen, Tian Qin, Yinghe Ding, Zhiyu Hu, Chengjun Li, Hongbin Lu, Jianzhong Hu, and Yong Cao.

Source:

Xiangya Hospital, Central South University, the Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, the National Clinical Research Center for Geriatric Disorders, and collaborating departments in China. Published in Bioactive Materials.

The problem: adult SCI gets trapped in a damage loop

After a spinal cord injury, the first hit is the physical trauma itself. But much of the long-term damage comes from what happens next.

The injury breaks myelin, the fatty insulation around nerve fibres. That broken myelin becomes debris inside the injured cord. The body tries to clean it up, but in adult mammals the clean-up process can become overloaded and messy.

In this paper, the researchers focused on spinal cord microvascular endothelial cells. These are cells that line tiny blood vessels inside the spinal cord. They are not usually the first cells people think about in SCI repair, but they are important because blood vessels help control oxygen delivery, inflammation, immune-cell entry, and tissue survival.

The study suggests that after adult SCI, these blood-vessel lining cells take up myelin debris and become stressed by the fat-like material. Instead of calmly processing the debris, they start storing excess lipid droplets, their internal machinery becomes strained, and they begin shifting into a more scar-forming state.

That change also sends out chemical signals that attract inflammatory immune cells, especially a macrophage population linked to CXCR4. Those macrophages release further damaging signals, including inflammatory factors that can injure nerve fibres and worsen the vessel-cell changes.

In plain English, the injured spinal cord can get caught in a loop:

- Myelin debris stresses blood-vessel cells. - Stressed blood-vessel cells call in more inflammatory immune cells. - Those immune cells release signals that cause more tissue damage. - More damage creates more debris. - The cycle continues and scarring becomes harder to stop.

The researchers describe this as a destructive feedback loop between blood-vessel cells and immune cells.

Why newborn mice are different

Newborn mice appear to handle spinal cord injury very differently from adults. Previous research has shown that two-day-old neonatal mice can repair spinal cord injury with much less scar formation.

This study found that neonatal mice also handled lipid debris in the injured spinal cord more cleanly. Their blood-vessel cells did not stay stuck in the same overloaded, scar-promoting state seen in adults.

The researchers then asked whether something circulating in neonatal blood could help explain that difference. Their attention turned to small extracellular vesicles.

Compared with vesicles from adult mouse blood, neonatal circulating sEVs had a stronger ability to calm the harmful response in adult spinal cord blood-vessel cells. The key cargo appeared to include a microRNA called miR-487b-3p.

A microRNA is a small genetic regulator. It does not build a protein itself. Instead, it helps turn other genes up or down, more like a dimmer switch than a blueprint.

The key message: miR-487b-3p helps break the loop

The study found that neonatal vesicles delivered miR-487b-3p into the injured environment. This microRNA appeared to reduce two important parts of the damaging chain reaction: IRS1 and CXCL12.

Those names are technical, but the everyday meaning is easier:

IRS1 was linked to an overactive internal stress-and-metabolism pathway in blood-vessel cells after they swallowed myelin debris. When this pathway was too active, the cells stored too much fat-like material and became dysfunctional.

CXCL12 acted more like a distress signal that helped recruit inflammatory immune cells into the injury site.

By reducing both signals, the neonatal vesicles helped blood-vessel cells process the injury environment in a healthier way and reduced the recruitment of damaging immune cells.

Put simply, the vesicles did not just target one cell type. They helped quiet the conversation between stressed blood vessels and inflammatory immune cells.

Why the hydrogel matters

Tiny vesicles are promising, but getting them to the right place and keeping them there is a major challenge.

To solve that, the researchers loaded the neonatal vesicles into a sticky hydrogel called GelNB. A hydrogel is a water-rich material, a little like a soft biological gel, that can sit at an injury site and slowly release useful cargo.

The team called the final material a "Microenvironment-Reprogramming Potent Hydrogel". The name is long, but the idea is straightforward: place a repair-instructing gel at the injured spinal cord so it can deliver neonatal vesicles directly into the damaged environment.

This matters because SCI is not only a problem of broken nerve fibres. It is also a problem of the surrounding environment becoming hostile to repair. A delivery gel may help keep the treatment concentrated where the damage is happening.

What happened in the mice?

In adult mouse spinal cord injury models, the neonatal-vesicle-loaded hydrogel improved several repair markers.

The treated mice showed less harmful lipid buildup in blood-vessel cells, less inflammatory macrophage infiltration, better blood-vessel structure, more nerve fibre growth near and beyond the lesion area, and signs of improved myelin repair.

Functional testing also improved. Mice treated with the neonatal vesicle hydrogel performed better on locomotor scoring from around two weeks after injury onward. The researchers also reported better motor evoked potentials, which are electrical tests used to assess whether signals can travel through motor pathways more effectively.

Movement analysis at 28 days showed improvements in measures such as hindlimb movement pattern, stride length, and toe extension.

These are encouraging results, but they remain animal-study results. They do not mean the treatment is ready for people with SCI.

What this could mean for SCI research

This study is interesting because it does not simply say "newborn animals heal better". It tries to identify a transferable part of that healing ability.

The important idea is that neonatal vesicles may carry instructions that help adult injured tissue behave more like a repair-friendly environment. Instead of forcing nerve regrowth alone, the treatment tries to change the soil around the injury so regrowth has a better chance.

That matters because many SCI therapies fail not because nerve cells have no growth potential, but because the injury site becomes toxic, inflamed, scarred, and poorly vascularised.

If future work confirms this pathway, researchers may be able to develop more practical therapies based on engineered vesicles, synthetic vesicles, or specific microRNA delivery rather than needing blood-derived material from newborn animals.

What this does not prove yet

This is preclinical research in mice. It does not prove safety or benefit in humans.

There are several major steps before this could become a therapy. Researchers would need to show that the approach works in larger animals, define safe dosing, understand long-term effects, prove that the gel does not create new risks, and develop a realistic human-grade source or manufactured version of the vesicles.

Timing also matters. This study is most relevant to acute or early SCI because it targets the early injury environment: myelin debris, inflammation, blood-vessel stress, and scar formation. It is not yet clear whether the same approach would help chronic SCI where the scar and tissue structure are already established.

Why this matters in SCI

The study gives researchers a new way to think about repair after spinal cord injury. Instead of focusing only on nerve cells, it highlights the blood-vessel and immune environment as a major control point.

For people with SCI, the most important takeaway is that scarring is not just a passive wall that appears after injury. It is driven by active biological conversations between damaged tissue, blood vessels, immune cells, and debris. If those conversations can be changed early enough, repair may become more possible.

This is still early science, but it points toward a future where SCI treatments may combine biomaterials, vesicle medicine, and immune reprogramming to stop the injury site from becoming hostile to regeneration.

Reader Q&A

Could this help someone who already has a chronic SCI?

We do not know yet. The study mainly targets early injury processes such as debris handling, inflammation, and scar formation. That makes it most relevant to acute SCI for now. Chronic SCI may need different or additional strategies because the injury site has already changed over time.

Are these stem cells?

No. The treatment uses small extracellular vesicles, not whole stem cells. Vesicles are tiny packages released by cells. They can carry biological instructions without becoming new tissue themselves.

Why use a hydrogel instead of injecting the vesicles alone?

The hydrogel acts like a local delivery pad. It helps keep the vesicles near the spinal cord injury site and may release them in a more controlled way, instead of letting them quickly spread away through the body.

This is a News + story. The research is not specifically about spinal cord injury, but it may matter to many people with SCI because itching can be a real and under-discussed problem.

Some people with SCI describe itchy scalps, itching in areas with altered sensation, itching linked to dry skin or sweating changes, itching from medication, pressure, clothing, circulation changes, nerve irritation, or reasons that are never fully explained. Whatever the cause, persistent itch can be more than annoying. It can interrupt sleep, damage skin, increase infection risk, and make daily life harder.

A new report from the Biophysical Society highlights research into a simple but important question: how does the nervous system know when to stop scratching?

The answer may involve a tiny sensory channel called TRPV4.

Author(s):

Research from the laboratory of Roberta Gualdani, professor at the University of Louvain in Brussels. Reported by the Biophysical Society for the 70th Biophysical Society Annual Meeting.

Source:

Biophysical Society news release: "Scientists Discover Why We Know When to Stop Scratching an Itch." Also reported by ScienceDaily as "Scientists discover the brain's hidden 'stop scratching' switch."

What the researchers found

TRPV4 is an ion channel. In plain English, it is a tiny gate on certain nerve cells. When the right physical or chemical signal arrives, the gate opens and lets charged particles move through. That helps the nerve cell send a message.

TRPV4 has been studied before in pain, pressure, temperature, and tissue-stress sensing. In this new work, researchers found that it also seems to play an important role in mechanically triggered itch: the kind of itch-and-scratch loop where touch or scratching changes what the nervous system feels.

The team studied mice where TRPV4 was removed only from sensory neurons. That detail matters. Earlier research often removed TRPV4 from the whole body, which made it hard to know whether the effect came from skin cells, nerve cells, or somewhere else.

When the researchers created a chronic itch condition similar to atopic dermatitis, the results looked odd at first. Mice without TRPV4 in sensory neurons scratched less often overall. But when they did start scratching, each scratching episode lasted much longer.

That suggests TRPV4 is not simply an "itch trigger". It may also help create the feeling of relief that tells the nervous system: enough scratching now.

The stop signal

Most people know the pattern. An itch builds. You scratch. For a short time, scratching feels satisfying. Then the body somehow decides the itch has been dealt with and the scratching stops.

The new research suggests that TRPV4 may be part of that stop signal.

A useful analogy is a kettle switch. The itch is the heat building up. Scratching is the response. TRPV4 may help flip the switch that says the job is done. Without that switch, the animal may still scratch, but the satisfying "that's enough" message is weaker.

The researchers describe this as a negative feedback signal. Negative feedback is the body's way of preventing a reaction from going too far. It is like a thermostat switching the heating off once the room is warm enough.

For itch, that feedback may help prevent scratching from becoming excessive and damaging the skin.

Why this is more complicated than simply blocking itch

This finding matters because many future itch treatments aim to block itch signals.

But TRPV4 appears to have two sides. In skin cells, it may help create itch. In sensory neurons, it may help control scratching and produce the relief signal. That means broadly blocking TRPV4 everywhere might reduce some itch pathways while also weakening the body's natural stop-scratching mechanism.

The practical lesson is that future treatments may need to be very targeted. A good treatment would reduce the itch without disabling the nerve feedback that tells someone they can stop scratching.

This is early research, and it was presented as meeting research rather than a finished clinical therapy. But it gives researchers a clearer target: not just "stop itch", but preserve or restore the relief signal.

Where SCI might fit

The study did not investigate spinal cord injury. It did not test people with SCI, neuropathic itch after SCI, medication-related itch, or scalp itching in wheelchair users.

Still, it may be relevant because itch is a nervous-system experience, not only a skin experience. The skin, peripheral nerves, spinal cord, and brain all take part.

After SCI, sensory processing can change. Some sensations may be reduced, exaggerated, misread, or felt in unusual ways. People can experience neuropathic pain, burning, crawling, tingling, or itching sensations that do not behave like ordinary skin itch. Autonomic changes can also affect sweating, skin moisture, temperature control, and circulation, all of which may influence skin comfort.

Scalp itch may have several possible contributors: dry skin, shampoo sensitivity, sweating changes, medication side effects, nerve irritation, pressure and posture, reduced ability to scratch effectively, or altered sensory processing. Often, it may be more than one factor at once.

This TRPV4 research does not solve those causes. But it helps explain why itching can become difficult to shut off. The issue may not only be the itch signal. It may also be whether the nervous system receives a strong enough "relief achieved" signal after scratching.

Why this matters for people with SCI

People with SCI are often told about bladder, bowel, skin, pressure injuries, pain, spasticity, and autonomic dysreflexia. Itch is less often treated as a serious quality-of-life issue, even when it is persistent and miserable.

This kind of research helps validate itch as a real nervous-system problem. It is not simply a lack of willpower to stop scratching. Scratching behaviour is controlled by biological circuits, chemical signals, sensory neurons, the spinal cord, and the brain.

For people with reduced sensation, fragile skin, pressure-risk areas, or slow wound healing, uncontrolled scratching can also become a skin safety issue. That makes better itch science relevant even when the original study is not about SCI.

What this does not mean yet

This is not a treatment recommendation. There is no TRPV4-based scalp itch treatment ready for SCI users because of this report.

It also does not mean all itching after SCI is caused by TRPV4. Itching can come from many sources, including skin irritation, allergy, eczema, medication, kidney or liver issues, nerve injury, infection, pressure, heat, sweating changes, or neuropathic sensory changes.

Persistent or severe itch should be discussed with a clinician, especially if there is rash, skin breakdown, infection, new medication, swelling, jaundice, or a sudden unexplained change.

The research is best understood as a clue: the nervous system has a built-in scratch-stop mechanism, and when that mechanism is weak or disrupted, itch may become harder to control.

Reader Q&A

Could this help itchy scalp after SCI?

Not directly yet. The study did not test SCI or scalp itch. But it may help researchers understand why some itch becomes persistent and why scratching sometimes does not bring normal relief.

Does this mean blocking TRPV4 would stop itching?

Not necessarily. TRPV4 may help trigger some itch signals, but it may also help stop scratching once relief has been reached. A broad blocker could interfere with both sides. Future treatments may need to target TRPV4 carefully by tissue or pathway.

What should someone with SCI do if itching is constant?

Treat it as a real symptom. Check skin, pressure areas, shampoo or product changes, sweating, dryness, medication changes, and infection signs. If it is persistent, severe, new, or causing skin damage, it is worth raising with an SCI-aware clinician or dermatologist.

Autonomic dysreflexia, often shortened to AD, is one of the most frightening secondary complications of spinal cord injury.

It can come on fast. A blocked catheter, full bladder, bowel problem, skin irritation, pressure sore, tight clothing, or another trigger below the injury level can cause a sudden spike in blood pressure. For people with cervical or upper thoracic SCI, this can mean pounding headache, sweating, flushing, goosebumps, anxiety, chest tightness, slow heart rate, and a real medical emergency.

This story is especially relevant for people who live with severe or repeated AD. The study does not offer an immediate home treatment, but it helps explain why non-invasive spinal cord stimulation could become a useful tool for reducing AD in the future.

The research comes from a 2026 University of British Columbia thesis by Hari Prasad Joshi, supervised by Professor Andrei Krassioukov, a leading researcher in autonomic dysfunction after spinal cord injury.

Author(s):

Hari Prasad Joshi. Supervisory and examining contributors included Andrei V. Krassioukov, Ismail Laher, Rahul Sachdeva, Soshi Samejima, Alexander G. Rabchevsky, and Keith E. Tansey.

Source:

University of British Columbia, Faculty of Graduate and Postdoctoral Studies, Experimental Medicine. Thesis title: "Unraveling the Mechanism of Transcutaneous Spinal Cord Stimulation in Mitigating Autonomic Dysreflexia in Experimental Spinal Cord Injury."

What AD is, in plain English

The autonomic nervous system controls automatic jobs: blood pressure, heart rate, sweating, blood vessel tightening, bladder, bowel, temperature regulation, and more.

After a high spinal cord injury, the brain can lose proper control over many of these automatic circuits below the injury. The lower body can still send alarm signals into the spinal cord, but the brain's calming control cannot always get back down properly.

A useful analogy is a smoke alarm that is wired to a sprinkler system but no longer connected to the control room. Something small sets off the alarm, the sprinkler system overreacts, and nobody upstairs can easily switch it off.

In AD, a trigger below the injury level can cause blood vessels below the injury to clamp down hard. Blood pressure rises quickly. The brain senses the high pressure and tries to slow the heart, but it cannot fully relax the blood vessels below the injury because the spinal cord pathway is interrupted.

That is why AD is not just uncomfortable. It can be dangerous.

The idea: use stimulation to restore the spinal cord's brake

The study looked at transcutaneous spinal cord stimulation, or tSCS.

"Transcutaneous" means through the skin. Unlike implanted epidural stimulation, tSCS uses surface electrodes placed on the skin over the spine. The goal is to send electrical pulses into spinal circuits without surgery.

In this rat study, stimulation was delivered over the T7 spinal segment using 30 Hz pulses for 60 minutes. The model involved a high thoracic T3 spinal cord contusion injury. Six weeks later, the researchers triggered AD-like spinal activity using colorectal distension, a standard experimental model because bowel or rectal distension is a common real-world AD trigger.

The big question was not simply "does stimulation reduce AD?" Previous work had already suggested tSCS can reduce AD. This study asked a deeper question: how might it work inside the spinal cord?

The spinal cord after SCI can become too excitable

After SCI, the spinal cord below the injury is not silent. It can rewire itself.

Some rewiring may be helpful. But some becomes maladaptive, meaning it makes symptoms worse. In AD, sensory signals from the bowel, bladder, skin, or other areas below the injury can over-activate spinal circuits that control sympathetic output. Sympathetic output is the "fight or flight" side of the autonomic system, and when it overfires it can drive blood pressure dangerously high.

The key cells in this process include sympathetic preganglionic neurons, or SPNs. These are spinal neurons that help send commands to the sympathetic nervous system. When they become overactive after a trigger, they can contribute to the blood pressure surge of AD.

The thesis found that colorectal distension strongly activated spinal neurons and SPNs after SCI. That fits the AD pattern: a visceral trigger below the injury sends a powerful signal into overexcitable spinal autonomic circuits.

What stimulation changed

When tSCS was applied at the same time as colorectal distension, the overactivation was reduced.

The researchers used markers such as c-Fos to identify activated neurons. They found that the CRD trigger increased neuronal activation across multiple spinal segments. But when CRD was paired with tSCS, that activation was significantly reduced compared with CRD alone.

Most importantly, tSCS reduced activation of the sympathetic preganglionic neurons involved in driving autonomic output.

At the same time, tSCS increased activation of inhibitory spinal interneurons. These are local spinal neurons that help quiet other neurons. The study focused on inhibitory systems involving GABA and glycine, two chemical messengers that act like brakes in the nervous system.

In plain English: stimulation appeared to turn down the overactive alarm circuit and turn up the spinal cord's braking system.

Why GABA and glycine matter

GABA and glycine are inhibitory signals. They help stop nerve circuits from firing too strongly.

In everyday terms, if excitatory signals are the accelerator, inhibitory signals are the brake. AD may partly happen when the accelerator gets stuck and the brake is too weak. This study suggests tSCS may help press the brake at the spinal level.

That does not mean tSCS "cures" AD. It means stimulation may change the balance inside the spinal cord so that bowel or bladder signals are less likely to explode into a dangerous sympathetic reflex.

Why this matters for people who live with AD

For someone who gets severe AD, the practical goal is not abstract. It is fewer dangerous spikes, less fear around bladder and bowel routines, better sleep, less strain on the heart and brain, and more confidence that the body will not suddenly swing into crisis.

Repeated AD episodes may also matter for long-term health. Blood pressure instability after SCI is linked to cardiovascular and cerebrovascular risk, and researchers increasingly worry that repeated highs and lows could affect brain blood flow and cognition over time.

A non-invasive stimulation method would be especially valuable because it could potentially be used repeatedly, adjusted to the individual, and delivered without implanted surgery.

What this study does not prove yet

This was an experimental rat study, not a human clinical trial.

The researchers studied spinal cord tissue and neuronal activation patterns after stimulation. That gives important mechanism information, but it does not by itself prove that the same stimulation settings will safely and reliably prevent AD in people.

The study also used a specific injury model, timing, stimulation site, and stimulation parameters. Human SCI is more varied: injury level, completeness, time since injury, bladder and bowel routines, medications, spasticity, pain, skin triggers, and cardiovascular health all differ between people.

So the fair conclusion is careful but encouraging: tSCS appears to recruit inhibitory spinal circuits that can dampen AD-related sympathetic activation in an animal model. That gives researchers a stronger reason to test and refine tSCS for AD in people with SCI.

Why this matters in SCI

AD is often treated as a management problem: find the trigger, sit upright, loosen clothing, empty the bladder or bowel, check the skin, monitor blood pressure, and use medication if needed. That emergency approach remains essential.

But this research points toward something more preventive: changing the spinal cord circuits that make AD so explosive in the first place.

If future human studies confirm the effect, tSCS could become part of autonomic rehabilitation. Not just rehabilitation for muscles or walking, but rehabilitation for blood pressure control and internal body stability.

For people living with severe AD, that would be a meaningful goal.

Reader Q&A

Could I use a home electrical stimulator to treat AD now?

No. This should not be tried independently. AD can be dangerous, and spinal stimulation settings, electrode placement, and patient selection need clinical testing. Anyone having AD episodes should follow their medical AD plan and speak with their SCI clinician.

Is this only relevant to bowel-triggered AD?

The experiment used colorectal distension because bowel and rectal distension are reliable AD triggers in research and real life. The mechanism may also matter for bladder or other triggers, but that needs direct testing.

Why is this exciting if it was only in rats?

Because it explains a possible mechanism. It suggests tSCS may work by activating inhibitory spinal circuits, not just by generally "stimulating the spine". Mechanism matters because it helps researchers choose better stimulation locations, strengths, and timing for future human trials.

Bladder control is one of the most life-changing problems after spinal cord injury, yet it often receives less public attention than walking.

For many people with SCI, bladder management shapes the entire day. It can mean catheter schedules, fluid planning, infection risk, sleep disruption, social anxiety, skin problems, autonomic dysreflexia, and hospital admissions. It is not a small side issue. It is central to health, independence, and dignity.

A new Medical Xpress story from the University of Southern California highlights research aimed directly at this problem. Instead of focusing on leg movement, the team is targeting a small spinal cord pathway involved in sensing bladder fullness and coordinating bladder emptying.

Author(s):

Medical Xpress story by University of Southern California. The research paper is led by Shan Zhong and colleagues, with Charles Liu and Vasileios Christopoulos described as senior investigators.

Source:

University of Southern California, USC Neurorestoration Center, and USC Viterbi School of Engineering. Research published in IEEE Transactions on Neural Systems and Rehabilitation Engineering.

The problem: bladder signals get cut off

In an uninjured nervous system, bladder control depends on a two-way conversation.

As the bladder fills, sensory signals travel up the spinal cord to the brain. The brain registers that the bladder is getting full. When it is the right time and place to urinate, the brain sends signals back down to coordinate emptying: the bladder muscle contracts while the sphincter relaxes.

After spinal cord injury, that communication loop can be broken. A person may lose the feeling of bladder fullness, voluntary control over emptying, or both. The bladder and sphincter may also become poorly coordinated, which can create high pressures, incomplete emptying, infections, and kidney risk.

In simple terms, the bladder may still be sending information, but the message cannot reliably reach the brain or trigger the right response.

The target: a small pathway called the DLF

The USC team focused on a spinal cord region called the dorsolateral funiculus, or DLF. The name is technical, but the idea is understandable: it is a narrow bundle of nerve fibres near the surface of the spinal cord that carries certain signals upward.

The researchers found that activity in this area changed as the bladder filled in animal studies. When the bladder became fuller, a tiny region of the DLF showed rhythmic nerve activity that tracked that filling state.

The striking part was how precise the signal appeared to be. Nearby electrodes only a very short distance away did not show the same activity. That suggests the bladder-related signal may have a very specific "address" in the spinal cord.

If researchers can find that address reliably, they may be able to stimulate it in a controlled way.

What the researchers did

The team used very small electrode arrays to record spinal cord activity in rats while the bladder was filled in a controlled way. They looked for the spinal location where nerve activity matched bladder filling.

Once they identified the responsive region, they tested whether patterned electrical stimulation at that same location could trigger coordinated bladder emptying.

According to the report, stimulation of the DLF produced coordinated voiding in most trials, and in all trials when the bladder was already filled to the level where natural DLF activity usually begins. Importantly, the stimulation did not appear to activate leg muscles, suggesting the response was bladder-specific rather than a general body movement reflex.

The future idea: BLISS

The proposed system is called BLISS, short for Bladder-Linked Stimulation System.

The idea is a closed-loop bladder neuroprosthesis. Closed-loop means the system would not simply stimulate on a timer. It would sense what is happening, then respond.

A future version might combine:

- A sensor that detects bladder volume or fullness. - A spinal cord stimulation interface that recreates or boosts the fullness signal. - A stimulation system that helps coordinate bladder emptying.

A simple analogy is a smart thermostat. A basic heater turns on when someone presses a switch. A smart thermostat reads the room temperature and responds when needed. For bladder care after SCI, the long-term goal would be a system that responds to the body's bladder state rather than relying only on alarms, schedules, or guesswork.

Why sensation matters as much as emptying

Bladder technology often focuses on getting urine out safely. That matters, but sensation matters too.

Not knowing when the bladder is full can make life harder and less safe. It can lead to overfilling, leaks, autonomic dysreflexia in susceptible people, or over-reliance on fixed catheter schedules. A system that could restore a usable signal of fullness would be meaningful even before perfect voluntary control is achieved.

This is why the USC approach is interesting. It is not only asking, "Can we make the bladder empty?" It is also asking, "Can we restore the missing message that tells the nervous system the bladder is full?"

How close is this to patients?

This is still early-stage research. The main evidence described here comes from animal studies. The team is moving toward larger animal models, which are closer to human anatomy, and the Medical Xpress report notes that early human recordings could potentially begin in the future during already-planned spinal cord tumour surgeries.

That means this is not a treatment available now for people with SCI. It is a research pathway.

The careful way to read this is: researchers have identified a promising spinal cord target and shown that precise stimulation can influence bladder control in animal models. The next steps are to test whether the same target can be recorded and stimulated safely in larger animals and, eventually, humans.

Why this matters in SCI

Bladder dysfunction after SCI is not just inconvenient. It can be medically dangerous and emotionally exhausting. Urinary tract infections, kidney strain, catheter complications, disrupted sleep, anxiety about leaks, and autonomic dysreflexia can all reduce quality of life.

This research matters because it treats bladder control as a major neurotechnology goal in its own right. It also shifts attention from simply bypassing the bladder problem with schedules and catheters toward rebuilding some form of nervous-system communication.

If this line of work succeeds, future bladder devices may become more responsive, more natural, and more protective of long-term health.

Reader Q&A

Could this help people with chronic SCI?

Potentially, but it is much too early to know. The research is aimed at bladder dysfunction after SCI, including people who have lost bladder sensation or coordinated bladder control. Human studies will be needed before anyone knows which injury levels, severities, or time-since-injury groups might benefit.

Would this replace catheters?

Not yet, and maybe not for everyone. The long-term hope would be to reduce reliance on fixed schedules and improve bladder emptying and safety. But even a successful device would need careful testing before it could change catheter routines.

Why is this different from current bladder management?

Current management often works around the broken signal using schedules, catheters, medication, or external routines. This research is trying to interact directly with the spinal cord pathway that carries bladder fullness information, which could eventually allow a more responsive system.

This is a News + story. The main paper is not about spinal cord injury, but it may matter to SCI research because it reveals a body-brain mechanism that has been largely overlooked.

The study, published in Nature Neuroscience, found that the brain is mechanically linked to the abdomen. In awake mice, the brain moved inside the skull during locomotion, and that motion was driven mainly by abdominal muscle contractions. The movement was not primarily tied to breathing or the heartbeat.

That may sound like a small technical finding, but it could matter. The researchers suggest that abdominal pressure can travel to the brain and spinal canal through a hydraulic-like vascular route, probably involving the vertebral venous plexus. Their modelling also suggests that this brain motion may help move interstitial fluid and cerebrospinal fluid, or CSF, through and out of the brain during wakefulness.

For people with spinal cord injury, this raises an important question: if SCI disrupts abdominal muscle control, autonomic blood pressure regulation, upright movement, and cerebral blood flow, could it also alter this newly described abdomen-brain mechanical system?

The answer is not known yet. But the connection is strong enough to deserve attention.

Author(s):

C. Spencer Garborg, Beatrice Ghitti, Qingguang Zhang, Joseph M. Ricotta, Noah Frank, Sara J. Mueller, Denver I. Greenawalt, Kevin L. Turner, Ravi T. Kedarasetti, Marceline Mostafa, Hyunseok Lee, Francesco Costanzo, and Patrick J. Drew.

Source:

Penn State Neuroscience Institute, Penn State Center for Neural Engineering, The Pennsylvania State University, The University of Auckland, Michigan State University, and collaborating departments. Published in Nature Neuroscience.

SCI context source:

Jill M. Wecht and William A. Bauman, James J. Peters VA Medical Center and Mount Sinai School of Medicine. Their review, "Decentralized cardiovascular autonomic control and cognitive deficits in persons with spinal cord injury", was published in The Journal of Spinal Cord Medicine.

What the brain-motion study found

The researchers used high-speed, multiplane two-photon microscopy — a specialist imaging technique that uses laser light to capture movement inside living tissue at very high resolution — to watch the dorsal cortex (the top surface of the brain) move relative to the skull in awake, head-fixed mice. They found that the brain moved mainly rostrally and laterally, meaning forward and sideways.

The movement was tightly linked to locomotion. When the mice moved, the brain moved. But the timing did not match the cardiac cycle or normal respiration. Instead, the key driver appeared to be abdominal muscle contraction.

The team found that abdominal contractions could activate a pressure route between the abdomen and the nervous system. They also showed that applying pressure to the abdomen could induce similar brain motion.

In plain English, the brain may not be as mechanically isolated from the body as we usually imagine. The skull protects it, but pressure changes from the abdomen may still reach the brain through vascular channels connected to the spinal canal.

The vertebral venous plexus: a possible pressure pathway

The vertebral venous plexus is a network of veins around the spine. These veins are valveless, meaning pressure can be transmitted through them more freely than through many other blood vessels.

The Nature Neuroscience paper describes this system as a possible hydraulic link between the abdomen and central nervous system. When abdominal pressure rises, that pressure may be communicated to the spinal canal and brain.

A useful analogy is a connected plumbing system. If pressure rises in one chamber, fluid and pressure shifts can affect another chamber connected to it. In this case, the abdomen, spine, and brain may be mechanically linked more than previously appreciated.

The researchers also suggest that this motion may help drive fluid movement in the brain. That matters because the brain relies on CSF and interstitial fluid movement to help distribute molecules and clear waste. CSF, or cerebrospinal fluid, is the clear liquid that cushions and surrounds the brain and spinal cord. Interstitial fluid is the fluid that fills the tiny spaces between brain cells. Both need to circulate to keep the brain healthy. This is related to the broader field of glymphatic research — the study of the brain's own waste-clearance system, which operates largely during sleep and movement.

Where SCI enters the picture

Spinal cord injury often changes far more than movement and sensation. It can disrupt autonomic control: the body's automatic regulation of blood pressure, heart rate, blood vessel tone, sweating, bladder, bowel, and temperature.

The SCI review by Wecht and Bauman describes how cardiovascular autonomic disruption may contribute to cognitive problems after SCI. People with higher injuries may experience low blood pressure, orthostatic hypotension (a drop in blood pressure when sitting up or standing, causing dizziness or faintness), bradycardia (an abnormally slow heart rate), and episodes of autonomic dysreflexia (a potentially dangerous spike in blood pressure triggered by stimulation below the injury level — something many people with cervical or high thoracic injuries will be familiar with). Some people may have reduced resting cerebral blood flow, or a weaker increase in brain blood flow during cognitive tasks.

The review also notes that cognitive deficits after SCI can include problems with memory, attention, processing speed, and executive function. These problems are often blamed on traumatic brain injury or pre-existing factors, but the authors argue that cardiovascular and cerebral vascular dysfunction may also contribute.

This is where the new brain-motion study becomes interesting. It adds another possible layer: body mechanics and pressure-driven brain movement.

A possible new link: pressure, movement, and brain fluid dynamics

In SCI, several things could plausibly affect abdomen-brain mechanical coupling.

First, trunk and abdominal muscle control may be reduced, depending on injury level and completeness. If abdominal muscle activity helps drive brain motion during movement, altered trunk activation could change that mechanical input.

Second, upright movement is often reduced after SCI. Locomotion and body movement were key triggers of brain motion in the mouse study. Less frequent standing, walking, stepping, or trunk-driven movement could mean less of this movement-linked brain fluid activity, though this has not been tested in SCI.

Third, autonomic blood pressure regulation can be unstable. People with SCI may experience low blood pressure, poor orthostatic tolerance, autonomic dysreflexia, or abnormal vascular responses. These could interact with pressure and flow in the spinal and cranial venous systems.

Fourth, bowel and bladder events are already known to be powerful triggers for autonomic dysreflexia in susceptible people. The brain-motion paper discusses abdominal pressure and notes that voiding or defecation can influence pressure states. In SCI, those same pressure events can be medically risky. That makes the connection relevant, but it also means it must be handled carefully.

What this could mean for brain fog after SCI

Many people with SCI describe brain fog, fatigue, light-headedness, poor concentration, or worse thinking when upright, hypotensive, overheated, sleep-deprived, or after autonomic episodes. The established explanation often focuses on blood pressure and cerebral blood flow.

That explanation still matters. If the brain is not getting stable blood flow, thinking can suffer.

The new paper suggests researchers may also need to ask whether pressure-driven brain movement and CSF dynamics are altered when autonomic control, abdominal pressure, movement, posture, and venous flow are changed.

This does not mean brain fog after SCI is caused by reduced brain motion. That would be too strong. But it does suggest a new research question: could altered body-brain mechanics be one contributor to cognitive symptoms in some people with SCI?

Why this should be written carefully

This Nature Neuroscience study was done in mice, not people with SCI. It did not test spinal cord injury, orthostatic hypotension, autonomic dysreflexia, wheelchair users, abdominal binders, bowel care, bladder routines, or cognitive symptoms.

The SCI review is also not claiming that abdominal pressure drives cognitive deficits. It focuses on cardiovascular autonomic control, blood pressure, cerebral blood flow, arterial stiffness, and cognition.

The link between the two papers is therefore a reasoned scientific connection, not a proven clinical fact.

What researchers could test next

A future SCI study could ask whether people with different injury levels show different brain motion, CSF flow, venous pressure dynamics, or cerebral blood flow during posture changes, trunk movement, abdominal compression, respiratory tasks, or safe rehabilitation activities.

Researchers could also examine whether abdominal binders, standing frames, assisted stepping, breathing training, functional electrical stimulation, bowel/bladder states, or autonomic dysreflexia history change brain blood flow or brain fluid movement.

Importantly, any study would need careful safety monitoring. For people at risk of autonomic dysreflexia, abdominal pressure and bowel/bladder triggers are not casual experimental tools.

Reader Q&A

Q: Does this mean abdominal pressure causes brain fog after SCI?

A: No. The study does not prove that. The more careful idea is that abdominal pressure, movement, venous flow, CSF movement, and brain mechanics may be connected. In SCI, where autonomic control and trunk function can be altered, this could become a useful research direction.

Q: Should someone with SCI try abdominal pressure, straining, or Valsalva manoeuvres (bearing down hard — the kind of effort used to equalise ear pressure or during certain exercises) to improve brain fluid flow?

A: No. That could be dangerous, especially for people at risk of autonomic dysreflexia, blood pressure spikes, dizziness, or cardiovascular complications. This story is about research, not a self-treatment.

Q: What type of SCI might this matter most for?

A: It may be most relevant to people with injuries that affect autonomic control, trunk muscles, blood pressure stability, or upright tolerance. Higher-level injuries are especially important because they are more likely to involve hypotension, orthostatic hypotension, and autonomic dysreflexia, but the idea needs direct testing.

The takeaway

This paper gives researchers a new way to think about the body-brain connection. The brain may be mechanically linked to abdominal pressure and movement through vascular pathways around the spine. For SCI, that could matter because injury can disrupt abdominal muscle control, autonomic blood pressure regulation, venous flow, posture, movement, and cerebral blood flow.

The immediate message is not treatment. The message is possibility: brain fog and cognitive fatigue after SCI may deserve investigation not only through blood pressure and brain blood flow, but also through pressure-driven brain and CSF mechanics.

A new spinal cord injury study asks a practical question: can an existing hospital drug be repurposed to protect the spinal cord during the first dangerous hours after injury?

The drug is dexmedetomidine, often shortened to Dex. It is a sedative already used in intensive care units and during anaesthesia (the controlled sleep state used in surgery). Clinicians use it because it can calm and sedate patients without suppressing their breathing as much as some other sedatives do. In this study, researchers used Dex for a different reason: it can lower body temperature by suppressing shivering and changing the body's temperature-control signals.

That matters because cooling, or therapeutic hypothermia (deliberately lowering body temperature to protect tissue), has long been studied as a way to reduce secondary injury after trauma to the brain or spinal cord. The problem is timing. Physical cooling can be slow, equipment-heavy, and difficult to start during the narrow window when secondary damage is unfolding.

Author(s):

Aytak Khabbaz, Lilesh Kumar Pradhan, Anne Elizabeth Gowan, Samhita Chakraborty, Yihong Zhang, Fang Yuan, Eris Deanai Harris, Wei Li, Christopher Yu, Qigui Yu, Xiang Gao, and Lingxiao Deng.

Source:

Indiana University School of Medicine, Stark Neuroscience Research Institute, and collaborating Indiana University departments. Published in The Journal of Neuroscience.

The problem: the second wave of damage

The first injury in SCI is the mechanical trauma itself: compression, bruising, tearing, bleeding, or crushing of the spinal cord. But the damage does not stop there. Over the hours and days that follow, the injured cord can go through a second wave of harm involving inflammation, loss of blood flow, oxidative stress (a kind of cellular rust caused by unstable molecules damaging tissues), swelling, excitotoxicity (where overactive chemical signals essentially overstimulate and kill nerve cells), immune activation, and cell death.

A useful analogy is a house fire. The initial impact is the flame. Secondary injury is the smoke, heat, water damage, and collapsing structure that spread the loss after the first spark. Neuroprotection tries to limit that spread.

Cooling the nervous system can slow some damaging processes, but conventional cooling is hard to deliver quickly and consistently. Surface cooling is slow and can trigger shivering, which raises metabolic demand. Endovascular cooling can be faster but needs hospital equipment and carries procedural risks.

What the researchers did

Adult mice received a moderate thoracic contusion SCI — a bruising-style injury to the mid-back section of the spinal cord, the most common type in animal SCI research and similar in mechanism to many human injuries. One hour after injury, the researchers gave a single intraperitoneal dose of dexmedetomidine at 100 micrograms per kilogram. Intraperitoneal means injected into the abdomen — a common method in mouse studies.

The team compared Dex-treated animals with untreated SCI animals, animals receiving conventional surface cooling, animals in which Dex cooling was prevented by heating, and animals receiving ERK pathway inhibition. ERK is a cell-signalling pathway involved in survival and stress responses — think of it as one of the cell's internal emergency management systems. They monitored body temperature, vital signs, ECG (heart rhythm), movement recovery, bladder function, tissue sparing, inflammatory cytokines (chemical alarm signals the immune system releases), serotonin-related descending pathways, ERK survival signalling, and RIPK1-associated injury signalling.

What they found

Dex induced rapid and sustained moderate hypothermia. Body temperature fell into the 29 to 32 degrees Celsius range and remained below 32 degrees for around 16 hours, with slow rewarming. The study reports no respiratory compromise or arrhythmia during 24-hour monitoring.

Functionally, Dex-treated mice recovered better than untreated injured mice and better than the conventional surface-cooling group. The gains included locomotor recovery and bladder voiding performance over six weeks after injury.

Tissue analysis also supported a protective effect. Dex preserved more perilesional tissue, supported neuronal survival, protected axonal integrity, and helped preserve descending serotonergic input. Serotonergic pathways are important because they help regulate spinal circuits involved in movement and autonomic function.

Mechanistically, the study suggests that Dex worked in two ways. First, it created early pharmacological hypothermia (drug-induced cooling). Second, it had intrinsic neuroprotective effects — meaning the drug itself appeared to reduce cell damage independently of the cooling alone. The treatment suppressed early pro-inflammatory cytokines (the chemical signals that drive harmful inflammation), increased the anti-inflammatory cytokine IL-10 at later time points, activated early ERK-dependent survival signalling, and reduced acute RIPK1-associated injury. RIPK1 is a protein involved in triggering cell death — dampening it can help preserve tissue. When hypothermia or ERK signalling was blocked, the benefits were reduced.

Why this is interesting

The strongest part of this story is timing. Acute SCI treatment is a race against biology. By the time a person reaches specialist care, secondary damage may already be underway. A drug that can be given early in a monitored emergency setting, and that induces cooling without external cooling equipment, is a practical idea.

Dex is also already familiar to clinicians. That does not make it automatically safe or effective for SCI, but it lowers some early translation barriers compared with a completely new drug.

The bladder results are worth highlighting. SCI research often focuses on walking, but bladder control is one of the functions that can dominate daily life after injury. A treatment that protects both locomotor and bladder-related circuits would be more meaningful than one that only improves a lab movement score.

What this does not mean yet

This was a mouse study, not a human trial. It tested acute treatment after a controlled contusion injury, given one hour after trauma. That makes it most relevant to new injuries, not chronic SCI.

It also does not mean people with SCI should seek cooling or Dex outside medical supervision. Dex affects sedation, heart rate, blood pressure, and body temperature. Any human SCI trial would need strict monitoring, careful dosing, and clear safety rules.

Reader Q&A

Q: Could this help someone who has lived with SCI for years?

A: Probably not in the way this study tested it. This is an acute neuroprotection strategy aimed at reducing secondary damage soon after injury. It is designed for the early hours after SCI, before more tissue is lost.

Q: Does this mean dexmedetomidine is ready as an SCI treatment?

A: No. It is promising because Dex is already used clinically, but the SCI result is still preclinical. Human trials would need to test safety, dose, timing, cooling depth, and whether functional benefits appear in people.

Q: Why focus on cooling instead of regeneration?

A: Regeneration tries to rebuild or reconnect after damage. Neuroprotection tries to save as much tissue as possible before it is lost. In SCI, both may be needed. Protecting tissue early may give later regeneration, stimulation, and rehabilitation more surviving circuitry to work with.

The takeaway

This study is an acute SCI protection story. Dex did not regrow the spinal cord, but it reduced parts of the secondary injury cascade and improved recovery in mice. The practical appeal is that it uses an existing monitored-care drug to start a protective cooling effect quickly, without relying on slow external cooling equipment.

Spinal cord injury is often described in terms of movement and sensation. But for many people living with SCI, some of the hardest daily problems are less visible: getting tired quickly, feeling short of breath, having poor exercise tolerance, struggling with blood pressure regulation, or finding that the body does not recover well after effort.

A new study in Neuromodulation: Technology at the Neural Interface looked at one possible way to support those body-wide systems after chronic spinal cord injury. The researchers studied an implanted electrical stimulation approach called the LION procedure, used alongside regular rehabilitation. In one group, it was also paired with extra cardiorespiratory physiotherapy: structured training aimed at the heart, lungs, breathing muscles, and physical stamina.

The main message is not that this is a cure, and not that it restores walking by itself. The important point is more practical: when the nervous system is injured, rehabilitation may work better when it supports the whole body, not only the muscles we can see moving.

Author(s):

Wellington Contiero, Augusta Ribeiro Morgado, Victor Croos-Bezerra, Cristiano Soares Simoes, Joao Angelo Ferres Brogin, Jean Faber, and Nucelio Lemos.

Source:

Federal University of Sao Paulo, Increasing Institute of Care and Rehabilitation in Neuropelveology and Gynecology, University Hospital/academic collaborators in Sao Paulo, Brazil, and the University of Toronto. Published in Neuromodulation: Technology at the Neural Interface.

What is the LION procedure?

LION stands for Laparoscopic Implantation of Neuroprosthesis. In plain English, it is a keyhole-surgery procedure where electrodes are implanted near nerves in the pelvis and legs. These electrodes can then deliver controlled electrical stimulation.

This is different from surface electrical stimulation pads placed on the skin. It is also different from stimulation that simply makes a muscle visibly contract. The authors describe LION as a form of continuous, low-level nerve stimulation that may influence both movement-related and automatic body systems.

A useful way to think about it is this: after SCI, many body systems still exist below the injury, but the communication between them and the brain is badly disrupted. Electrical stimulation may act like a repeated signal into those circuits. It does not rebuild the whole cable, but it may help the remaining network become more active, organised, and responsive during training.

Who took part?

The study included 37 people with chronic thoracic spinal cord injury between T1 and T12. All were described as motor-complete injuries, AIS A or AIS B. That means voluntary movement below the injury was absent, although some people may still have some preserved sensation depending on AIS grade.

Participants were divided into three groups:

- A control group received neuromotor rehabilitation alone. - A LION group received the implanted stimulation procedure plus neuromotor rehabilitation. - A LION plus CRP group received LION, neuromotor rehabilitation, and extra cardiorespiratory physiotherapy.

All groups received regular neuromotor rehabilitation for 60 minutes, five times per week. The LION plus CRP group also received two extra 60-minute cardiorespiratory physiotherapy sessions each week.

What did the researchers measure?

The team followed participants over 12 months. They measured how the heart, lungs, breathing muscles, and fatigue levels responded over time.

Some of the tests were technical, but the basic idea is simple. The researchers wanted to know whether a person could produce more physical effort with less strain on the body.

They measured things such as:

- Heart rate at rest and after effort. - Blood pressure and cardiac workload. - Estimated aerobic capacity. - Fatigue during wheelchair-based effort. - Breathing muscle strength. - Peak expiratory flow, which is how strongly someone can blow air out.

These measures matter after SCI because breathing and cardiovascular control can be affected, especially when trunk muscles, respiratory muscles, and autonomic pathways are disrupted.

What did the study find?

The strongest results were seen in the group that received both LION and cardiorespiratory physiotherapy.

Compared with rehabilitation alone, and compared with LION without the extra breathing and fitness programme, the LION plus CRP group showed earlier and more sustained improvements across several areas. They had signs of better heart efficiency, lower fatigue, stronger breathing performance, and better coordination between cardiovascular and respiratory measures.

In everyday terms, the body appeared to do the same kind of work with less strain. That is important because life with SCI often requires high physical effort for ordinary tasks: transfers, wheelchair use, dressing, showering, pressure relief, bowel and bladder routines, and exercise.

The LION-only group also showed benefits, but they were generally more moderate and appeared later. That suggests the implanted stimulation may help, but the structured training may be what turns that stimulation into a stronger whole-body rehabilitation effect.

Why breathing and heart fitness matter after SCI

Breathing is not just about the lungs. It also depends on muscles, posture, trunk stability, cough strength, and automatic nervous system control.

After SCI, especially higher injuries, some of those systems can be weakened or poorly coordinated. Even in thoracic injuries, reduced trunk and abdominal muscle control can affect breathing mechanics, stamina, cough strength, and exercise tolerance.

Heart and blood pressure control can also change after SCI because the autonomic nervous system is disrupted. That is the part of the nervous system that automatically adjusts blood vessel tone, heart rate, sweating, digestion, bladder function, and other background jobs.

This is why a treatment that improves cardiorespiratory efficiency could matter even if it does not directly restore movement. Better stamina and better breathing can mean more capacity for rehabilitation and daily life.

What this does not prove yet

This study is promising, but it should be read carefully.

It was a small study with 37 participants. It was quasi-randomized and observational, not a large blinded trial. Some data came from a trial setting and some from a clinical setting, although the researchers used harmonized protocols. The aerobic capacity measure was estimated rather than measured with full laboratory gas-analysis testing, because that was not practical for the participants.

The treatment also involves an implanted device and surgery. That means it is not comparable to a simple exercise programme or wearable stimulator. Any future use would need careful patient selection, surgical expertise, long-term safety monitoring, and stronger trial evidence.

So the fair conclusion is this: LION plus cardiorespiratory physiotherapy may help improve heart, lung, fatigue, and rehabilitation-related measures in chronic thoracic SCI, but it is still a specialist intervention needing more evidence before it becomes widely available.

Why this matters in SCI

The study points toward a broader idea in spinal cord injury rehabilitation: recovery is not only about trying to move a limb. It is also about improving the body's support systems so a person has more energy, better breathing reserve, better circulation, and better tolerance for daily activity.

If future studies confirm these findings, implanted neuromodulation combined with targeted training could become part of a more complete rehabilitation strategy for some people with chronic SCI. It may be especially relevant for people whose main goals include stamina, respiratory strength, exercise tolerance, and general physiological function rather than only visible movement.

Reader Q&A

Could this help someone with a long-term spinal cord injury?

Possibly, but only in a specific setting. The people in this study had chronic thoracic motor-complete SCI, and the treatment involved an implanted stimulation system plus a structured rehabilitation programme. This is not something someone can access as a standard therapy yet.

Is this mainly for walking recovery?

No. This story is more about the body's engine room: breathing, heart workload, fatigue, and physical endurance. Those improvements could support rehabilitation and daily function, but the study was not mainly a walking-restoration trial.

Why did the exercise programme matter if the device was doing the stimulation?

Stimulation may help wake up or organise nervous-system circuits, but training gives the body a task to adapt to. A simple analogy is tuning a radio and then playing music through it. The device may improve the signal, but repeated training is what teaches the system how to use it.

Many spinal cord injuries are contusions — a medical term for a bruising or crushing injury, as opposed to a clean cut or complete severing of the cord. This is actually the most common type of SCI in humans. It matters because contusion injuries often leave some spared tissue. The injury is not a simple gap. It is a damaged, inflamed, partially connected landscape where some pathways may still be present but too weak or poorly organised to restore useful function.

Professor Dr. Dietmar Fischer and colleagues at the Institute of Pharmacology II, University Hospital Cologne, are pursuing a circuit-based approach for this kind of injury. Instead of placing a treatment directly into the spinal lesion, their study delivers a gene therapy vector into the brain's motor cortex to trigger repair signals in connected descending pathways.

The study is titled "Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity" and was published in Neurobiology of Disease.

Author(s):

Marco Leibinger, Igor Moskaliov, Chinonso-John Ani, Dalia Halawani, and Dietmar Fischer.

Source:

Center for Pharmacology, Institute for Pharmacology II, Medical Faculty and University Hospital Cologne, Germany. Published in Neurobiology of Disease.

The treatment idea

The therapy uses an AAV2 vector carrying instructions for a designer cytokine called hyper-interleukin-6, or hIL-6. AAV (adeno-associated virus) vectors are a type of modified, harmless virus commonly used in gene therapy research as a delivery vehicle — think of them as a biological postman that carries genetic instructions into cells. A cytokine is a signalling molecule that cells use to communicate — they are essentially the body's chemical messaging system. In this case, hIL-6 is a lab-engineered version of a naturally occurring cytokine, modified to be a stronger pro-regenerative signal.

The clever part is the delivery route. The vector is injected into the motor cortex (the part of the brain that controls voluntary movement), where it transduces layer V neurons — the deep brain cells whose long fibres reach down through the brainstem and into the spinal cord. Those neurons have connections that communicate with subcortical and brainstem circuits, including serotonergic raphe nuclei in the medulla (clusters of neurons in the lower brainstem that produce serotonin and send signals down the spinal cord).

"Transneuronal delivery" means the signal can travel through connected neurons across neural circuits, rather than staying in the injection site. In plain language, it is like sending a repair instruction into one relay station so that connected stations further down the route become activated too.

Why serotonergic pathways matter

Serotonergic neurons from the raphe nuclei send long descending fibres down into the spinal cord. Serotonin is usually associated with mood, but in the spinal cord it plays a critical role in modulating movement circuits — helping to excite or inhibit the motor neurons that control muscles. After SCI, strengthening or reorganising spared descending pathways like these may improve how the lower spinal cord responds to movement commands.

This is different from trying to regrow the main corticospinal tract (the primary direct pathway from the brain's motor cortex to the spinal cord) all the way through the lesion. The study found that hIL-6 reduced corticospinal tract axon retraction (stopping nerve fibres from pulling back from the injury site) but did not drive corticospinal axons beyond the lesion. Recovery instead depended on serotonergic circuit remodelling.

That point is important. It suggests functional gains may come from rerouting and strengthening surviving networks, not only from rebuilding the exact original wiring.

What the study found

The researchers tested AAV2-hIL-6 in mouse models of mild, moderate, and severe spinal cord contusion. Across all injury severities, treated mice showed significantly better locomotor function than AAV2-GFP control mice.

The treatment did not reduce lesion size or neuronal loss. Those measures still tracked with how severe the contusion was. This means the therapy was not simply making the injury smaller.

Instead, AAV2-hIL-6 increased the number and length of descending serotonergic axons in the lumbar spinal cord, below the injury. When the researchers selectively ablated serotonergic neurons, the functional gains disappeared. That strongly supports the idea that serotonergic pathways were essential for the recovery effect.

The team also found sustained STAT3-linked transcriptional activation in medullary brainstem circuits after cortical hIL-6 delivery. STAT3 is an internal cell signalling pathway — essentially a molecular switch — that is associated with growth responses and regenerative competence in neurons. When STAT3 is activated in nerve cells, they are generally more capable of growing and surviving.

What this means in plain English

Imagine the original motorway from the brain to the lower spinal cord has been badly damaged. This treatment does not rebuild the motorway exactly as it was. Instead, it appears to improve side roads and relay routes that still connect parts of the system.

The important message is that spared pathways matter. Even when a contusion is severe, some neural tissue may remain. If researchers can make those surviving routes more plastic, more active, and better connected, functional recovery may improve.

Why this story is promising

The study is stronger than a single mild-injury experiment because it tested mild, moderate, and severe contusion models. That gives a better sense of whether the approach might work across clinically relevant injury severities.

It also focuses on a real-world type of SCI. Many human spinal cord injuries are incomplete contusions rather than complete transections. A therapy that depends on spared pathways may be especially relevant to incomplete injuries.

What this does not mean yet

This is still preclinical mouse research. It is not a human treatment and not ready for clinical use. Gene therapy in the brain raises major safety, dosing, targeting, durability, and reversibility questions.

It is also likely to be more relevant where some pathways remain. The authors describe promise for SCI with spared pathways. For a truly complete injury with no usable tissue bridge, the strategy may face different limits.

Reader Q&A

Q: Would this help acute or chronic SCI?

A: The study tested treatment in mouse contusion models, not a human acute or chronic clinical trial. The mechanism is circuit plasticity, so it may eventually be relevant beyond the earliest injury window, but timing still needs to be studied carefully.

Q: Is this aimed at complete or incomplete injury?

A: The study is especially relevant to contusion injuries with spared pathways. That usually points toward incomplete or anatomically incomplete injuries, where surviving circuits can potentially be strengthened or rerouted.

Q: Why did recovery improve if the lesion did not shrink?

A: Because function can improve through circuit remodelling. The treatment increased descending serotonergic axons below the injury. The spinal cord may have used surviving or reorganised pathways more effectively, even though the physical lesion size was unchanged.

The takeaway

This study is a circuit-repair story. AAV2-hIL-6 did not erase the injury site. Instead, it appears to make connected descending networks more growth-capable, especially serotonergic pathways that can influence locomotor circuits below the lesion. For SCI research, that is important because recovery may depend as much on rewiring spared circuits as on regenerating the original ones.

A spinal cord injury happens in the spinal cord, but the whole body responds. A new bioinformatics study puts the liver in the spotlight as one of the organs that may help explain why some people improve neurologically after SCI while others with similar starting injuries do not.

The paper reanalysed existing plasma proteomics datasets from rat SCI models and from people with spinal cord injury. Proteomics means measuring many proteins at once — rather than testing for one specific thing, researchers run a broad scan of hundreds or thousands of proteins simultaneously. Plasma is the liquid part of blood (separate from the red blood cells). Together, plasma proteomics is like taking a broad molecular snapshot of what the body is releasing into the blood after injury.

The headline finding is striking: many proteins linked to injury severity and neurological recovery were also linked to liver function.

Author(s):

Morgan Godwin, Sharon J. Brown, Gabriel Mateus Bernardo Harrington, Srinivasa C. Budithi, John S. Riddell, Charlotte H. Hulme, and Karina T. Wright.

Source:

Centre for Regenerative Medicine Research at Keele University, Robert Jones and Agnes Hunt Orthopaedic Hospital Foundation Trust, Cardiff University Dementia Research Institute, and University of Glasgow. Published in Livers.

Why the liver matters after SCI

The liver is often thought of as a detox organ, but it does much more. It produces many blood proteins, regulates metabolism, manages lipids, helps control inflammation, and contributes to clotting and complement pathways.

After SCI, the nervous system is not the only system under stress. The immune system changes. Metabolism changes. Hormones and autonomic control change. The liver sits at the centre of many of those whole-body responses.

A useful analogy is an emergency control centre. The spinal cord injury is the local disaster, but the liver helps coordinate supplies, inflammation, repair signals, clotting proteins, and metabolic fuel. If that control centre remains stuck in a prolonged inflammatory state, recovery may be affected.

What the study analysed

The authors reanalysed published proteomic datasets from rat SCI models and human SCI blood samples. The human datasets included people with AIS grade C injuries whose blood was sampled within two weeks after injury and again around three months after injury. AIS stands for the American Spinal Injury Association Impairment Scale — a standard classification where A is a complete injury with no movement or sensation below the level, and C means there is some motor function preserved below the injury level, but most key muscles are still too weak for practical use.

The key comparison was between "improvers" and "non-improvers." Improvers were people who converted from AIS C to a better AIS grade (meaning they regained more function) by 12 months. Non-improvers remained AIS C at 12 months.

This is important because AIS C patients can look similar early after injury, yet their long-term recovery can diverge significantly. A blood signature that helps distinguish those trajectories would be valuable for prognosis (predicting outcomes) and trial design.

What they found

Across species, a high proportion of recovery-associated and severity-associated proteins were linked to liver function. In the human datasets, after filtering for meaningful changes, more than 70 percent of differentially abundant proteins were associated with liver-related processes or origins.

Non-improvers showed a prolonged subacute pro-inflammatory response. The changes were not limited to obvious acute-phase proteins. They also involved liver metabolic and synthetic pathways, meaning the liver's broader output appeared altered.

Pathway analysis repeatedly highlighted Liver X Receptor/Retinoic X Receptor activation, complement system or cascade activity, and DHCR24 signalling. In plain terms: these are molecular switches that regulate how the body handles fats and cholesterol, how the immune system attacks threats, and how cells respond to stress. They are pathways linked to lipid metabolism (fat processing), inflammation, cholesterol biology, immune response, and cell stress.

The authors also identified proteins such as alpha-2-HS-glycoprotein (AHSG) and afamin (AFM) as commonly dysregulated across species datasets. These are liver-produced proteins that circulate in blood — their presence at unusual levels may reflect conserved biological links between SCI, inflammation, lipid metabolism, and liver function.

Why this could matter for future treatment

The study does not say the liver alone determines recovery. But it suggests that liver-associated proteins could help identify biological differences between improvers and non-improvers.

That has two possible uses.

First, these proteins could become biomarkers. A biomarker is a measurable signal that helps predict what is happening inside the body. If validated, a blood test might help researchers stratify patients earlier, identify who is more likely to recover spontaneously, and design better clinical trials.

Second, these pathways could point to candidate treatment targets. If non-improvers remain in a prolonged inflammatory or altered hepatic metabolic state, future research could test whether adjusting those pathways improves the recovery environment.

How this connects to extracellular vesicles

The attached extracellular vesicle review adds a useful layer. EVs are tiny membrane-bound particles — essentially microscopic bubbles — released by cells as a way of sending signals and cargo to other cells or into the bloodstream. They carry proteins, microRNAs (small molecules that regulate gene activity), and other material that can reflect cellular stress, inflammation, injury severity, and repair activity.

In SCI, EVs may act like liquid biopsy packages — biological parcels floating in the blood that contain clues about what is happening inside tissues. Instead of only measuring free-floating blood proteins, researchers may eventually measure cell-derived vesicle cargo from neurons, glia (the brain's support cells), immune cells, endothelial cells (the cells lining blood vessels), and other tissues.

Combining liver-associated plasma proteomics with EV-based liquid biopsy could be powerful. The liver study may identify whole-body recovery pathways. EV profiling may help show which cells are sending signals, when they are sent, and whether those signals are damaging, protective, or predictive of recovery.

In practical terms, this combination could help answer three hard questions: who is likely to improve, when is the best treatment window, and which biological pathway should be targeted.

What this does not mean yet

This is a bioinformatics reanalysis, not a treatment trial. It does not prove that changing liver function will turn a non-improver into an improver. It also does not yet provide a clinically approved blood test for prognosis after SCI.

The human group sizes were modest, and the findings need validation in larger, multicentre studies with standardised sampling and long-term outcomes.

Reader Q&A

Q: Could this help someone currently living with SCI?

A: Not directly today. This is biomarker and target-discovery research. Its main value is helping researchers understand why recovery differs between people and how future trials might be better targeted.

Q: Does this mean liver disease causes poor SCI recovery?

A: The study does not prove that. It shows that liver-associated blood proteins and pathways are linked with recovery status. The liver may be part of the recovery biology, but cause and effect still need to be tested.

Q: Why is this exciting if it is not a treatment?

A: Because SCI trials often struggle with timing and patient selection. If blood and EV biomarkers can identify biological subgroups, researchers may be able to test the right treatment in the right patient at the right time.

The takeaway

This paper reframes SCI as a whole-body injury with a measurable liver-associated blood signature. For the SCI community, the promise is not an immediate therapy, but a smarter map: one that may help researchers identify who is recovering, who is not, and which biological pathways might be worth targeting next.

A new animal study is putting mitochondria back in the spotlight for spinal cord injury repair.

The paper, published in Neurochemistry International, was led by Zengtao Song, Zhaoliang Ban, Haosen Zhao, and Xifan Mei at Jinzhou Medical University in China. The team tested elamipretide, also known as SS-31, in a mouse model of thoracic spinal cord contusion.

Why mitochondria matter

Mitochondria are often described as the power plants of the cell because they help produce the energy cells need to survive. After SCI, they can become damaged very quickly. When that happens, injured nerve cells may struggle to make energy, produce more harmful reactive oxygen species, and activate cell-death pathways.

That is important because the first mechanical injury is only part of SCI. A second wave of damage follows, involving inflammation, oxidative stress, energy failure, and apoptosis. Apoptosis means a controlled form of cell death. In the spinal cord, too much of it can mean more neurons and support cells are lost after the original trauma.

SS-31 is a small mitochondria-targeting peptide. It is designed to protect the inner mitochondrial membrane, partly through interaction with cardiolipin, a fat-like molecule that helps mitochondria maintain their structure and energy-producing machinery.

What the study found

In the mouse study, SS-31-treated animals showed better locomotor recovery and gait performance compared with untreated SCI controls. The researchers used behavioural tests over 28 days, including Basso Mouse Scale scoring, oblique board testing, rotarod performance, and footprint-style gait assessment.

Tissue analysis also pointed in the same direction. The SS-31 group had reduced lesion pathology and better neuronal preservation in the injured spinal cord. Early after injury, the treatment was linked with lower levels of cell-death markers such as cleaved caspase-3 and Bax, and higher levels of Bcl-2, a protein associated with cell survival.

By the chronic stage of the experiment, SS-31 was also associated with less astrogliosis and stronger signs of axonal and synaptic remodelling. Astrogliosis is the reaction of astrocytes, a support-cell type in the central nervous system. Some astrocyte response is protective, but too much can contribute to scar-like barriers that make repair harder.

The team also ran cell experiments using oxidatively stressed PC12 cells. In those cells, SS-31 helped preserve mitochondrial membrane potential, reduced reactive oxygen species, and supported proteins involved in oxidative phosphorylation, the process mitochondria use to generate usable cellular energy.

What this means in plain English

This study suggests that protecting mitochondria early after SCI may reduce some of the secondary damage that normally follows the injury. If more cells survive, and the injury environment becomes less hostile, the spinal cord may have a better chance of preserving tissue and supporting limited repair.

That does not mean SS-31 restored the spinal cord or cured paralysis in mice. The result is more modest but still interesting: treated mice performed better on movement tests, and the biological markers lined up with a story of less early cell death and better mitochondrial stability.

Why SCI readers should be cautious

This is a preclinical mouse study, not a human trial. Mouse contusion models are useful, but they do not capture the full complexity of human SCI, including injury severity, rehabilitation, age, complications, chronicity, and the scale of spinal cord damage.

It is also not yet clear how SS-31 would need to be delivered in people, what treatment window would matter most, what dose would be safe, or whether the benefits would translate into meaningful daily function. A therapy that improves scores in mice still has a long path before it can be considered a treatment for people with SCI.

Even so, the study fits an important direction in SCI research. Rather than trying only to regrow axons after the damage is established, researchers are also looking at how to protect the tissue early enough that more of the nervous system remains available for repair.

The takeaway

SS-31 is not a new SCI treatment for patients today. But this paper adds to the case that mitochondrial protection is a serious target in spinal cord injury research. For future therapies, keeping cells alive and energetically stable in the early injury period may be one of the pieces needed before regeneration and rehabilitation can have their best chance to work.

Hydrogels are becoming one of the most active areas of spinal cord injury repair research. A new review in Smart Medicine pulls the field together in a useful way, not by focusing on one single experimental gel, but by asking a bigger question: what should a hydrogel be doing at each stage after SCI?

The review was written by Ruixing Shui, Fan Ding, Dapeng Li, and Guoqing Pan, with authors based at the Affiliated Hospital of Jiangsu University and the School of Materials Science and Engineering at Jiangsu University in Zhenjiang, China. It was accepted on 27 March 2026 and published as an open-access review by Wiley.

What hydrogels are

A hydrogel is a soft, water-rich material with a three-dimensional structure. That matters for SCI because injured spinal cord tissue is also soft and water-rich. In theory, a well-designed hydrogel can sit inside or around the damaged area more naturally than a hard implant.

The simplest way to think about it is as a temporary support scaffold. After SCI, the injury site can contain damaged tissue, inflammation, fluid-filled cavities, scar-forming cells, and molecules that make nerve regrowth harder. A hydrogel can be designed to fill some of that space, carry cells or drugs, and slowly release helpful signals.

Why timing matters

One useful part of this review is the way it links hydrogel design to the different phases of SCI.

In the acute phase, the first 48 hours, the priority is limiting the secondary injury cascade. That includes oxidative stress, inflammation, cell death, swelling, and chemical changes that make the injury worse after the original trauma.

In the subacute and intermediate phases, the challenge shifts. Scar-forming astrocytes and other support cells become more active. Some scarring can protect the tissue, but too much scar can block axon growth. Hydrogels are being studied as a way to reduce harmful scar formation while giving nerve fibres a more organised path to grow through.

In the chronic phase, more than three months after injury, the problem is no longer just protection. The spinal cord may have cystic cavities, mature scar tissue, damaged myelin, and disrupted circuits. The review argues that future hydrogels may need to help with longer-term circuit rebuilding, not just early tissue rescue.

What these materials can do

The paper describes three broad jobs for hydrogels in SCI research.

First, they can provide physical support. This means filling a lesion cavity and giving cells a structure to attach to, rather than leaving them in a hostile, disorganised space.

Second, they can regulate the injury environment. Some experimental hydrogels are designed to reduce reactive oxygen species, calm inflammation, change macrophage behaviour, or reduce cell death. In plain English, they try to make the injury site less toxic and more repair-friendly.

Third, they can deliver treatments locally. This is important because drugs given through the bloodstream may not reach the injured spinal cord in the right amount, at the right time, or for long enough. A hydrogel can potentially release growth factors, anti-inflammatory drugs, stem cells, nanoparticles, or other therapeutic molecules directly at the injury site.

The review also discusses newer "intelligent" hydrogels, including responsive systems that react to the local injury environment, conductive hydrogels that may support electrical signalling, and future 4D-printed materials that could change their shape or function over time.

Why this matters for people with SCI

For people living with SCI, the key point is that hydrogels are not just another lab material. They are being developed because the injured spinal cord has several problems at once: inflammation, oxidative stress, scar formation, tissue loss, poor drug delivery, and lack of a growth-friendly structure.

A hydrogel can potentially combine several jobs in one treatment platform. That makes it attractive for SCI, where one single drug is unlikely to solve the whole repair problem by itself.

But this is still mostly preclinical research. The review is not reporting that a hydrogel treatment is ready for routine clinical use. It is showing how quickly the field is becoming more sophisticated, and why future SCI repair may involve smart materials that deliver multiple biological signals in a timed and local way.

The main caution

The review is clear that translation remains difficult. A hydrogel that works in a small animal model still has to clear major hurdles before human use: safety, sterilisation, reliable manufacturing, degradation timing, surgical delivery, long-term effects, and whether improved tissue repair actually becomes meaningful functional recovery.

The realistic takeaway is that hydrogels are promising building blocks for future combination therapies, not a standalone cure today. Their value may be in making the injured spinal cord a better place for other repair strategies, such as cells, growth factors, drugs, stimulation, or rehabilitation, to do their work.

Lineage Cell Therapeutics is back in the news with a financial calendar announcement rather than new trial results. The company said on 5 May 2026 that it will report its first-quarter 2026 financial and operating results after U.S. markets close on Tuesday, 12 May 2026, followed by a management conference call and webcast at 4:30 p.m. Eastern Time.

That is important to state clearly: the Q1 results have not been released yet. This is an announcement of when the results and business update will be presented.

Who Lineage are

Lineage Cell Therapeutics is a clinical-stage biotechnology company based in Carlsbad, California. Its focus is "off-the-shelf" allogeneic cell therapies. In plain English, that means treatments made from donor-derived or lab-grown cell lines, manufactured in advance, rather than custom-made from each individual patient.

The company's broader pipeline includes OpRegen for geographic atrophy, a form of advanced age-related macular degeneration, as well as programs in hearing loss, eye disease, type 1 diabetes-related cell manufacturing, and spinal cord injury.

Why this matters for SCI

The SCI-relevant program is OPC1. Lineage describes OPC1 as an allogeneic oligodendrocyte progenitor cell therapy designed to improve recovery after spinal cord injury.

Oligodendrocytes are support cells in the central nervous system that help maintain myelin, the insulating layer around nerve fibres. After SCI, myelin and other support systems can be damaged, which affects how well nerve signals travel. OPC1 is intended to replace or support cells in the injured spinal cord that are absent or not working properly after traumatic injury.

OPC1 has already been studied in earlier clinical trials, including a small Phase 1 thoracic SCI safety study and a Phase 1/2a cervical SCI dose-escalation study. Lineage says the program has long-term safety follow-up from those studies and has received RMAT and Orphan Drug designations from the U.S. Food and Drug Administration.

What is happening now

Lineage is currently enrolling the DOSED study, short for Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device. The study is evaluating a delivery system designed to place OPC1 directly into the injury area.

The important new direction is that DOSED includes both subacute SCI patients, between 21 and 42 days after injury, and chronic SCI patients, between 1 and 5 years after injury. That makes it especially relevant for the SCI community, because many experimental cell approaches have focused mainly on the early post-injury window.

The realistic takeaway

Financial updates are not the same as clinical breakthroughs, but they can still matter. Small biotechnology companies depend on funding, partnerships, manufacturing progress, and trial execution. For people following SCI research, Lineage's 12 May update may provide more detail on the pace of the OPC1 program, clinical site activity, cash runway, and what the company expects next.

For now, this is a watch-this-space story. OPC1 remains investigational. It is not an approved SCI therapy, and the upcoming financial report should not be read as evidence of new clinical benefit unless Lineage releases actual trial data.

A new paper in Andrology highlights a health issue that can be easy to miss in spinal cord injury care: low testosterone in men with chronic SCI.

The study was led by D. Tienforti and colleagues from the University of L'Aquila, the San Raffaele Sulmona Institute, and IRCCS Neuromed in Italy. It looked at 152 adult men with chronic traumatic SCI who were admitted to a rehabilitation centre between 2017 and 2023. The men were followed until death or December 2024, with a median follow-up of 62 months.

What the researchers measured

The team focused on calculated free testosterone, often shortened to cFT. This is the portion of testosterone estimated to be available for use by tissues, rather than bound tightly to carrier proteins in the blood.

That matters because total testosterone alone can be misleading, especially in people with chronic illness, inflammation, altered nutrition, or changes in proteins such as albumin and SHBG. In SCI, those factors can be common.

The researchers also measured age, injury history, body mass index, comorbidities, inflammation, albumin, HDL cholesterol, functional independence, autonomic dysreflexia, and other health markers.

What they found

During follow-up, 24 of the 152 men died. Those who died had much lower calculated free testosterone at baseline than survivors: 48.9 pg/mL compared with 85.4 pg/mL.

Severe androgen deficiency was also far more common in the men who died, affecting 83.3% of deceased participants compared with 19.5% of survivors.

After adjusting for age, comorbidities, inflammation, functional independence, injury duration, autonomic dysreflexia, BMI, HDL cholesterol, and testosterone-binding factors, lower calculated free testosterone still independently predicted mortality. In simpler terms, the association was not explained away by the usual health differences between the groups.

The researchers also found that serum albumin was strongly linked with mortality. Albumin is often used as a marker of nutrition, inflammation, and overall medical frailty. Importantly, free testosterone still appeared to carry information beyond albumin alone.

What this means in plain English

This does not prove that low testosterone causes death after SCI. It also does not prove that testosterone treatment would reduce mortality.

What it suggests is that low free testosterone may be a useful warning marker in men with chronic SCI. It may reflect a wider pattern of frailty, metabolic stress, inflammation, reduced muscle mass, altered body composition, and endocrine disruption.

That is highly relevant because men with SCI are known to have increased risk of metabolic problems, cardiovascular disease, reduced lean mass, increased visceral fat, and chronic inflammation. Testosterone deficiency may sit inside that bigger health picture rather than being a separate issue.

Why SCI readers should care

For men living with SCI, this paper supports the idea that hormone health is not a side topic. It may be part of long-term medical monitoring, especially in people with fatigue, low muscle mass, worsening body composition, reduced sexual function, low mood, osteoporosis risk, or signs of metabolic disease.

But testing and treatment decisions need proper medical supervision. Testosterone therapy can have risks and is not appropriate for everyone. The study itself calls for prospective multicentre research before its findings are used to guide major clinical decisions.

The takeaway

Low calculated free testosterone appears to be independently associated with long-term mortality risk in men with chronic SCI. The practical message is not "take testosterone." It is that endocrine health, nutrition, inflammation, and metabolic monitoring deserve more attention in long-term SCI care.

Not every important SCI news story comes from a laboratory paper. Some matter because they bring spinal cord injury into public view, raise research funding, and remind people that SCI is not a rare abstract condition. It is something people live with every day.

A new Red Bull feature focuses on Brandon Beack, a South African Wings for Life ambassador who sustained a complete spinal cord injury in a gymnastics accident in 2012. Beack is preparing to take part in the Wings for Life World Run on 10 May 2026 in Green Point, Cape Town.

What the event is

The Wings for Life World Run is a global running and wheelchair event that raises money for spinal cord injury research through the Wings for Life Foundation. The format is unusual because there is no traditional finish line. Instead, participants start together and keep going until a virtual Catcher Car catches them.

The 2026 event is the 13th edition. In South Africa, participants can join organised app runs in Cape Town and Gqeberha, while others can take part anywhere using the app. Red Bull reports that Beack has set himself a race-day goal of 7.6 km.

Why Brandon Beack's story matters

Beack's story is partly about sport, but it is also about visibility. Before his injury, he had Olympic ambitions as a gymnast. After injury, he went on to represent South Africa as a para athlete and competed at two World Championships.

For SCI readers, that matters because public stories often shape how the wider world understands disability. Beack's message is not that SCI is easy, or that attitude replaces science. It is that people with SCI can still take part, set goals, and be visible in events built for both runners and wheelchair users.

The clinical voice in the story

The article also includes Professor Robert Dunn, the orthopaedic spinal surgeon who operated on Beack. Dunn has worked in spinal surgery in both private and public healthcare and helped develop the Acute Spine Injuries Unit in South Africa.

His comments add useful balance. He notes that people with SCI can often have meaningful lives after injury, but he is also clear that complete injuries with no sensation or power are much less likely to return to normal function than incomplete injuries where some spinal cord function remains.

That distinction is important for lay readers. SCI outcomes vary enormously depending on the level and completeness of injury, early care, complications, rehabilitation, and the amount of preserved nervous system function.

The takeaway

The Wings for Life World Run is not itself a treatment. Its role is different: it raises money and attention for research that aims to improve future outcomes after SCI.

For a field where many therapies are still experimental, public fundraising and awareness can still be part of the research ecosystem. They help keep spinal cord injury visible, fund projects, and connect the science to the people it is supposed to serve.

Brain-computer interfaces usually get described as a way to move things by thought: a cursor, a robotic arm, a wheelchair, or an exoskeleton. But real movement is not just command output. The nervous system is a two-way loop. You try to move, the body moves, and sensory information flows back to the brain so you know where the limb is, whether weight has shifted, and whether the movement is safe.

A new paper in Brain Stimulation, led by researchers at the University of California, Irvine, takes aim at that missing half of the loop. The team tested a bidirectional brain-computer interface, or BDBCI, that could both decode leg movement intent from the brain and deliver artificial leg sensation back to the sensory cortex while a robotic gait exoskeleton stepped.

What was actually tested

This was a proof-of-concept human engineering study, not an SCI treatment trial. One 50-year-old female epilepsy patient was recruited while she already had temporary clinical brain electrodes implanted for epilepsy evaluation. Those electrodes were placed in a rare and valuable location for walking research: the interhemispheric fissure, the space between the two brain hemispheres where the leg areas of the motor and sensory cortex are found.

That location matters. Many earlier BCI systems recorded from the outer surface of the brain, where hand and arm areas are easier to reach. For leg control, however, the brain's leg map sits deeper along the inner wall between the hemispheres. The UC Irvine team's idea is that recording from the actual leg motor area should give a cleaner walking-intent signal, while nearby sensory areas can be stimulated to create leg-like sensations.

The participant did not have SCI, and she did not personally walk in the exoskeleton. For safety, she remained in bed and performed seated stepping-like leg movements. An experimenter wore the Ekso GT robotic gait exoskeleton. The participant's brain signals were decoded in real time, sent wirelessly to the exoskeleton interface, and used to trigger steps. When the exoskeleton leg swung, the system stimulated the participant's sensory cortex to create a matching artificial leg percept.

How the system worked in plain English

The system had two main jobs.

First, it listened to the motor cortex. The researchers used ECoG, which means electrocorticography. These are electrodes placed on the surface of the brain, under the skull, rather than outside the scalp like EEG or penetrating into brain tissue like some other BCI systems. The decoder looked for brain-signal changes linked to the participant's intention to move the legs. In simple terms, it asked: is the brain in an IDLE state or a MOVE state?

Second, it talked back to the sensory cortex. The researchers used direct cortical electrical stimulation, or DCES. That means carefully controlled electrical pulses were delivered through selected brain-surface electrodes over the leg sensory area. The participant felt these as tingling sensations in the lower leg or heel region.

A custom embedded BDBCI device handled the work onboard. That is important because many laboratory BCIs depend on a full external computer for heavy processing. Here, the base station was mainly for configuration and logging. The actual online decoding and stimulation ran on the portable embedded system, which is a step toward a future fully implantable version.

What the team found

The main performance number was strong for a first demonstration. Across 10 online runs of BDBCI-controlled exoskeleton operation with sensory feedback, the system achieved a mean decoding performance of rho = 0.92 +/- 0.04, with an average lag of 3.5 +/- 0.5 seconds.

The artificial sensory feedback was also measurable rather than just anecdotal. In a blind step-counting task, the participant identified the number of triggered leg percepts with 92.8% overall accuracy. In another blind test, she identified right-leg, left-leg, and no-stimulation events with high accuracy. The reported percepts were not vague whole-body feelings; they were mapped to lower-leg areas, such as posterior lower leg to heel tingling.

The researchers also ran control experiments to make sure the decoder was not being fooled by electrical stimulation artifacts or by watching the exoskeleton. Performance remained similar when exoskeleton control was used without stimulation and when stimulation was delivered without exoskeleton control, supporting the idea that the decoder was tracking intended motor activity rather than noise.

No adverse events were reported during cortical mapping, sensory tasks, or BDBCI procedures. The team also avoided electrode pairs that produced painful sensations during clinical mapping.

Why this matters for spinal cord injury

For people with paraplegia, the spinal cord injury blocks or damages the pathway between the brain and the legs. A BCI does not repair that pathway. Instead, it tries to bypass it. The brain still produces movement-intent signals, and a machine reads those signals to control an external device.

Exoskeletons already exist, but most are controlled manually through buttons, weight shifts, preset modes, or therapist support. That can make them useful for rehabilitation and upright mobility, but they are not the same as natural voluntary control. Adding a BCI could make the device respond more directly to the user's intention.

The sensory side may be just as important. Walking without sensation is not just strange, it can be unsafe. The paper notes that sensory impairment is linked with slower gait and increased fall risk. If a future user could receive artificial feedback about leg swing, weight transfer, or foot contact, that could make BCI-controlled walking more intuitive and potentially safer.

This is the key novelty here: not just brain-to-exoskeleton control, but a two-way system where the exoskeleton also sends information back to the brain.

What this does not show yet

This study does not show that people with SCI can walk using this system. It does not show independent community walking, long-term home use, or recovery of natural spinal cord function. It also does not show that the participant could feel real legs again. The sensation was artificial, produced by stimulating the sensory cortex.

The participant was an able-bodied epilepsy patient, not someone with paraplegia. She controlled an exoskeleton worn by an experimenter, while she made seated stepping-like movements in bed. That is a clever and safe first test, but it is still several steps away from the real target use case.

The system also had latency. The average lag was about 3.5 seconds, partly because the robotic gait exoskeleton stepped slowly and because the system paused recording during stimulation to avoid electrical artifacts. Future versions will need faster control, better artifact removal, and ideally true simultaneous recording and stimulation.

The most realistic takeaway

This is not a cure story. It is a neuroprosthetics story.

The important point is that UC Irvine and collaborators have shown a human proof of concept for a portable embedded bidirectional BCI that can control exoskeleton stepping and deliver bilateral artificial leg sensation. For the SCI community, it is worth watching because it addresses a real gap in the field: movement control without sensation is only half a nervous system.

The next big test will be whether a similar system can work in the actual target population: people with paraplegic spinal cord injury, ideally with the person wearing the exoskeleton, walking in a controlled setting, and being measured with practical outcomes such as speed, distance, balance, effort, safety, training time, and user preference.

Not every important SCI-related story is a paper about a new treatment. Some are about the research systems that decide which treatments get built at all.

The Australian Regenerative Medicine Institute, based at Monash University, has just published its Strategy 2030 document. On the surface, this is an institutional roadmap rather than a spinal-cord-specific announcement. But it is still relevant to the SCI community because the strategy explicitly includes spinal cord degeneration, injury, and repair within the institute's research scope.

What ARMI is trying to do

ARMI describes itself as Australia's only research institute dedicated solely to regenerative medicine. Its new strategy argues that the field is moving from possibility to practicality, with cell and gene therapies, stem cell science, and tissue engineering increasingly turning into real clinical products rather than academic concepts.

The key question in the document is not whether regenerative medicine will reshape healthcare, but whether Australia will be positioned to lead or follow. ARMI's answer is to scale up now.

The strategy says that over the next five years the institute plans to grow its group leader cohort to 22, expand research and development pipelines across several disease areas, and advance therapeutics toward first-in-human clinical trials. It also puts strong emphasis on AI, automation, computational biology, and tighter integration between discovery science and translation.

Why this matters for SCI

SCI has lived for decades in the gap between exciting biology and limited clinical reality. There is no shortage of ideas: stem cells, biomaterials, gene therapies, tissue engineering, neuroprotection, immune modulation, stimulation, and rehabilitation combinations. What is often missing is the infrastructure to take these approaches from interesting findings to robust, fundable, clinically testable programmes.

That is why strategy documents like this can matter more than they first appear. A serious regenerative medicine institute setting out a concrete translation agenda means more than general optimism. It means staff recruitment, disease-area prioritisation, grant planning, translational partnerships, preclinical infrastructure, and the kind of institutional focus that can eventually change what reaches patients.

What stands out in the document

One striking feature is how explicitly translational the language is. ARMI is not presenting itself only as a basic science institute trying to understand regeneration in the abstract. It is framing discovery research as the start of a pipeline that should lead to therapeutics and human trials.

The strategy is also unusually direct about scale. It highlights six pillars, including scientific excellence, regenerative medicine research and development at scale, clinical translation of advanced therapies, education, sustainability, and global leadership. In plain terms, the institute is trying to build not just good science, but a durable machine for producing more of it and moving it further.

The document also stresses workforce development. That may sound administrative, but it matters. Regenerative medicine needs scientists, clinicians, engineers, regulatory specialists, translational managers, manufacturing expertise, and trial capability. Without that workforce, even strong discoveries stall.

What this is not

This is not a new SCI treatment announcement, and it is not evidence that specific therapies are about to reach patients. It is a strategic plan. The value lies in what it signals: institutional commitment, prioritised direction, and a framework for translation.

It is also worth noting that strategy documents are promises, not outcomes. They become meaningful only if recruitment happens, funding follows, collaborations work, and therapies actually progress through the hard middle stages between lab discovery and human testing.

Perspective

For SCI readers, this is a background but still important story. Repairing the spinal cord will likely require exactly the kind of long-horizon regenerative medicine ecosystem ARMI is trying to strengthen. So while this document does not offer a therapy today, it does show a serious research institute placing spinal cord injury and repair inside a bigger translational plan for the next phase of regenerative medicine.

One of the biggest barriers to repair after spinal cord injury is not just the initial damage. It is what the injured tissue becomes afterwards.

After SCI, the body rapidly builds a scar around the lesion. Some of that response is protective at first, but dense scar tissue can also become a long-term barrier that blocks regenerating axons from crossing the injury. In particular, fibrotic scar tissue creates a hostile mechanical and biochemical environment that makes reconnection much harder.

A new paper in the Journal of Integrative Neuroscience tested whether a natural compound called atractylodin, often shortened to ATD, could soften that process. ATD is an active constituent from traditional Chinese medicine that has already been studied for anti-inflammatory and anti-fibrotic effects in other disease settings. What had not been clear was whether it could help in spinal cord injury.

What the researchers did

The team used a mouse model of severe compression SCI and treated the animals with ATD after injury. They then assessed recovery using several behaviour-based movement tests, including the Basso Mouse Scale, inclined plane testing, swimming performance, and footprint analysis. They also examined the injured tissue directly to measure scar-related proteins, neuronal survival, and markers linked to axonal regrowth.

Alongside the animal work, the researchers studied spinal-cord-derived fibroblasts in the lab. That matters because fibroblasts are a major driver of fibrotic scar formation. If a treatment can calm down fibroblast activation, it may reduce the build-up of extracellular matrix that turns the injury site into a biological roadblock.

What they found

According to the paper's abstract and results summary, ATD-treated mice showed better motor recovery than untreated SCI mice. The treated animals also had smaller fibrotic scar areas and lower expression of fibrosis-related markers.

Mechanistically, the study points to the TGF-beta/SMAD pathway. This is one of the best-known signalling systems involved in fibrosis across the body. In simple terms, when that pathway is overactive, it encourages fibroblasts to switch into scar-building mode. The paper reports that ATD reduced SMAD2/3 phosphorylation and nuclear translocation, meaning it appears to interrupt the internal signalling steps that tell fibroblasts to keep producing scar tissue.

The authors also report that neuronal survival and axonal regeneration improved in the treated animals. That does not mean the compound repaired the cord completely, but it does support the idea that reducing fibrosis can make the injury environment more permissive for recovery.

Why this matters for SCI

Scar modulation is one of the more important fronts in SCI research. The spinal cord does not fail to repair for one single reason. Regeneration is limited by inflammation, cell death, lack of growth support, myelin-associated inhibitors, and scar tissue acting together. A therapy that weakens one of those obstacles could become more valuable if combined with rehabilitation, neurostimulation, biomaterials, or regenerative cell-based approaches.

This study is especially interesting because it targets the fibrotic scar rather than only the glial scar. Those two are often discussed together, but they are not identical. Fibroblast-driven scar tissue has increasingly been recognised as a specific therapeutic target in SCI, because it contributes heavily to the dense lesion core that axons struggle to cross.

What it does not mean yet

This is still preclinical research in mice, not a human treatment. Many compounds that look promising in rodent SCI models do not make it through translation to patients. Human injuries are more varied, more complex, and often much older by the time any intervention is considered. Dosing, safety, timing, and interactions with standard care would all need much more work.

It is also worth noting that early post-injury biology is delicate. Scar reduction sounds automatically positive, but some aspects of scarring help stabilise tissue in the acute stage. The real challenge is not to eliminate the healing response altogether, but to reshape it so that it protects without permanently blocking repair.

Perspective

The paper presents ATD as a possible anti-fibrotic tool for SCI, with the TGF-beta/SMAD pathway as the likely target. For the SCI community, that makes this a solid early-stage research story rather than a near-term therapy story. The important point is not that a herbal compound has suddenly solved spinal cord injury. It is that researchers are getting more precise about one of the major barriers to regeneration and testing ways to weaken it.

Brain-computer interfaces have long sounded like future technology. The basic idea is simple enough to describe: record brain signals, decode what the person is trying to do, and use those signals to control an external device. In practice, making that safe, stable, and medically useful has been extremely difficult.

A new report from People's Daily says China has now crossed an important regulatory milestone. According to the article, the National Medical Products Administration has approved an implantable brain-computer interface system for medical use, described as the world's first such approval.

The system, called NEO, was jointly developed by Neuracle Technology and Tsinghua University's School of Biomedical Engineering. The aim is not to restore natural nerve pathways directly, but to give people with severe paralysis another route to carry out useful hand actions.

How the system works

The article says the implant is placed outside the dura mater in a minimally invasive procedure. That point matters because many of the most powerful BCI systems involve penetrating the brain more directly, which can increase technical complexity and long-term risk. A system that can capture stable signals without directly entering brain tissue would be an important practical step forward.

Once implanted, the device records and decodes the user's brain signals in real time. Those signals are then used to control a pneumatic glove, allowing the wearer to carry out tasks such as grasping a bottle or lifting a cup to drink.

For the SCI community, that makes this especially relevant. The report explicitly frames the device around people with quadriplegia caused by cervical spinal cord injuries who cannot perform finger grasping movements.

What the report claims has happened so far

According to the article, China has already completed dozens of clinical procedures using implantable BCI systems. It says all participating patients showed some degree of improvement in grasping ability, and that some also showed signs of neural remodelling and partial recovery of additional neural functions.

One example described in the piece is a participant with a high-level SCI who, after training, was reportedly able to grasp a cup and drink independently using thought-controlled commands through the pneumatic glove. The same patient was later able to lift dumbbells and write Chinese characters by hand.

Those are striking results, but they need to be read with some caution. This is a news report, not a peer-reviewed trial paper laying out full methods, patient numbers, control groups, durability, adverse-event rates, or the exact extent of functional gains. It tells us something important happened at the regulatory level, but it does not yet provide the kind of detail needed to judge long-term clinical impact.

Why this matters for SCI

Hand function is one of the highest priorities for many people living with cervical SCI. Even small gains in grasp, pinch, reach, or the ability to handle a cup, phone, toothbrush, or fork can make a major difference to independence. That is why BCIs keep drawing so much interest in paralysis research: they may offer a way to bypass damaged pathways rather than waiting for the spinal cord itself to regenerate.

This system also sits in an important middle ground. It is not simply a lab demo, but it is not the same thing as a cure for paralysis either. It appears to be a function-assistive technology, helping the user carry out specific tasks through an external device. That can still be highly meaningful, especially if it becomes safer, more reliable, and more widely accessible.

What still needs to be answered

The big questions are the same ones that apply to almost every BCI story. How invasive is the surgery in real-world practice? How stable are the signals over months or years? How much training is required? What are the complication rates? How often does the device need recalibration? And how much function does the user gain in ordinary daily life, not just in controlled rehabilitation sessions?

Cost and access will also matter. Even if the technology works well, it will only help large numbers of people if it can move beyond a handful of specialised centres.

Perspective

This is an important BCI milestone story, but it should be understood as a regulatory and translational step, not proof that implantable BCIs have already solved hand paralysis after SCI. The significance is that a device concept many people still associate with experimental neuroscience is now being treated as a real medical product. That shift alone is a major moment.

SCI is usually discussed as an injury to the spinal cord, but the damage does not stay neatly inside the cord itself. After injury, the body enters a wider inflammatory state that can affect immunity, metabolism, the gut barrier, and the microbiome.

That is the idea behind a new paper in the Journal of Inflammation, which examines whether dihydromyricetin, or DHM, can improve recovery after acute SCI by acting through the gut-spinal cord axis.

Why the gut is being studied in SCI

In recent years, researchers have found that spinal cord injury often disrupts the gut microbiota, the community of microbes living in the intestine. That disruption can matter because the gut barrier may become leakier after injury, allowing inflammatory molecules such as lipopolysaccharide, or LPS, to enter the bloodstream more easily. Once that happens, systemic inflammation can worsen and feed back into the injured cord.

In other words, the gut may not just be a bystander after SCI. It may help sustain some of the inflammatory biology that makes secondary damage worse.

What the researchers tested

The team used rats with acute SCI and divided them into sham, untreated SCI, and DHM-treated groups. They measured motor recovery, analysed microbiome changes using 16S rRNA sequencing, and examined markers of intestinal barrier integrity and inflammatory signalling. They also performed faecal microbiota transplantation experiments, which is an important part of the paper because it helps test whether the microbiome changes are actually contributing to the effect rather than just occurring alongside it.

DHM itself is a natural flavonoid compound known for anti-inflammatory and neuroprotective properties in other disease contexts. Here, the question was whether it could work as a microbiome-directed treatment in SCI.

What they found

According to the abstract, DHM improved motor function recovery and reduced the pathological severity of SCI in the rats. At the microbiome level, the treatment shifted the bacterial pattern toward what the authors describe as a more balanced state, increasing Actinobacteria and Bacteroidetes while decreasing Proteobacteria.

The study also reports that DHM promoted recovery of the intestinal barrier, lowered blood LPS levels, and suppressed activation of the TLR4/NF-kappaB pathway and the NLRP3/Caspase-1 inflammasome. Those are important inflammatory routes in SCI and in wider neuroinflammatory disease biology.

The faecal microbiota transplantation results strengthen the central claim of the paper: that the gut microbiota is not incidental here, but a critical part of how DHM exerts its anti-inflammatory effect.

Why the inflammasome angle matters

NLRP3 is part of the inflammasome system, a molecular alarm pathway that helps the body respond to danger signals. In the wrong context, though, it can amplify damaging inflammation. In SCI, inflammasome activation has been increasingly linked to ongoing tissue damage, immune-cell recruitment, and poorer recovery.

If DHM is reducing inflammasome activity indirectly by improving gut barrier function and lowering circulating inflammatory triggers, that gives the study a broader significance. It suggests that some spinal-cord-directed benefits might be achieved by treating the body systems that feed secondary injury, not only the cord tissue itself.

How to think about this result

This is still preclinical research in rats, so it is far too early to treat DHM as a proven therapy for people with SCI. The microbiome is also notoriously complex. A bacterial shift that looks beneficial in one animal model does not automatically translate into a safe or effective human treatment strategy.

Still, the paper is important because it pushes SCI research further into whole-body biology. The message is not that the gut alone explains SCI outcomes. It is that the injury may create a gut-barrier and microbiome problem that then loops back into the spinal cord, and that interrupting that loop may help.

Perspective

For the SCI community, this is one of the more interesting directions in current preclinical research because it expands the treatment map. Instead of focusing only on neurons, scars, or stimulation, it looks at whether inflammation can be reduced upstream through the gut. That does not replace direct spinal therapies, but it could eventually complement them.

Not every important spinal cord story is a lab breakthrough. Some matter because they show how the community around paralysis research keeps moving science forward.

One of those stories comes from Leicestershire, where Pete Linnett and his son Harry are taking on a combined fundraising challenge for Spinal Research. Pete, who was born with spina bifida and is a former Britain's Strongest Disabled Man title holder, is handcycling 106 miles from Leicester to Buckingham Palace across Thursday and Friday. Harry is then running the London Marathon on Sunday.

Together, the challenge is being framed as a family double-marathon effort in support of Spinal Research, the UK charity focused on funding treatments and therapies for paralysis after spinal cord injury.

Why this story stands out

Pete Linnett is not new to physically demanding fundraising. According to the report, he has previously completed sponsored bench press and handcycle challenges and has competed internationally in disability sport. But this event adds another layer: it is clearly about family as much as fundraising.

Harry's role matters to the emotional force of the piece. He describes his father as someone who was once told he would never walk, never have children, and never live a normal life, yet went on to build a life and sporting record that directly contradicted those predictions. That gives the story a message many people in the wider paralysis and disability community will recognise immediately: medical expectations can be real, but they are not the full measure of a person.

Why it matters to SCI research

Fundraising stories can sound softer than science headlines, but they are part of the machinery that makes serious research possible. Clinical translation in SCI is expensive. Preclinical work, device development, rehabilitation studies, early human trials, regulatory steps, and long follow-up periods all cost time and money. Charities often help bridge the gap between early academic discoveries and the larger-scale investment needed to move a therapy toward patients.

The article also includes an important reminder from Spinal Research: paralysis can happen suddenly, and its effects extend far beyond the moment of injury. For many people in the SCI community, the consequences are lifelong and involve far more than loss of movement alone. They can include bladder and bowel dysfunction, chronic pain, infections, cardiovascular issues, pressure injuries, loss of independence, and major social and financial disruption.

A wider community story

Although this piece is not about a new published study, it still belongs in an SCI news feed because it connects research to the people who help sustain it. Stories like this remind readers that progress in paralysis research depends not only on scientists and clinicians, but also on campaigners, families, donors, and people willing to keep the issue visible.

It also broadens the picture of who shows up in spinal research stories. Pete's experience is not the same as traumatic SCI, and the article is careful to frame the challenge around spinal cord injury research rather than claiming his own diagnosis is identical to paralysis after injury. But his involvement still reflects the overlap between disability communities that support mobility research, access, rehabilitation, and function-restoring treatments.

Perspective

For SCI readers, this is a community and fundraising story rather than a technical research story. But it is still a useful one. If we want more therapies to move out of the lab and toward people living with paralysis, the ecosystem around that science has to stay funded, visible, and motivated. This challenge is a good example of that effort in action.

One of the reasons spinal cord injury is so hard to treat is that the first mechanical insult is followed by a cascade of secondary damage. Free radicals build up, inflammation spreads, mitochondria fail, and different cell-death programmes are activated. By the time the tissue stabilises, much more damage has occurred than the original trauma alone caused.

A new paper tackles that secondary injury phase using a biomaterial delivery system built around mesenchymal stem cell lysate rather than live stem cells.

Why stem cell lysate is interesting

Mesenchymal stem cells have been studied in SCI for years, largely because they release a broad mix of factors that may calm inflammation and support tissue repair. But giving live cells has obvious complications: survival, consistency, immune issues, tumour concerns, and manufacturing complexity.

Stem cell lysate tries to keep some of the useful biology while removing the cells themselves. In simple terms, it is the bioactive material obtained from breaking open the cells and harvesting what they contain. That can make the treatment concept safer and more controllable, but it also creates a new challenge: how to stop those factors being degraded or cleared too quickly in the harsh SCI environment.

What the researchers built

The team created a sustained-release composite called DL@ZIF-8@PF-127, combining dental-pulp-derived mesenchymal stem cell lysate with ZIF-8 nanocarriers and a PF-127 hydrogel. The goal was to protect the lysate, hold it locally at the injury site, and release it in a more controlled way rather than losing it rapidly.

This is a common theme in newer SCI biomaterials. The science is no longer only about what the therapeutic ingredient is. It is also about how to package it so it survives the lesion environment and reaches tissue in a useful way.

What the study found

In the paper's animal and cellular models, treatment with the composite system significantly reduced signs of ferroptosis and mitochondrial intrinsic apoptosis. Those two mechanisms are important because both are strongly implicated in the secondary injury wave after SCI.

Ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation and oxidative stress. It has become a major topic in SCI research because iron overload, reactive oxygen species, and membrane damage all rise after injury. Mitochondrial intrinsic apoptosis is another key pathway, reflecting the collapse of the cell's internal energy and survival machinery.

According to the paper, the hydrogel treatment also reduced inflammatory cell infiltration, lessened tissue damage, preserved more neurons, increased Nissl body counts, reduced gliosis, and improved functional readouts such as BBB locomotor scores and gait analysis.

Mechanistically, the authors link the effect to regulation of the Nrf2/HO-1/P65 pathway, suggesting that the treatment is working through oxidative stress control and inflammatory modulation rather than through one single narrow mechanism.

Why this matters

This study is part of a larger trend in SCI research toward multi-function therapies. The injury environment is too complex for many single-target ideas to succeed on their own. A treatment that can reduce oxidative damage, calm inflammation, protect mitochondria, and improve delivery at the same time is much more aligned with the biology of SCI.

It also reflects the shift away from simple "stem cells yes or no" thinking. More researchers are now asking whether the therapeutic value of stem cells may lie less in the cells themselves and more in the molecular cargo they release, especially if that cargo can be delivered in a smarter way.

What still needs caution

This is still preclinical work in mice and cell models. It does not show that the treatment is safe, scalable, or effective in humans. The fact that it appears in the International Dental Journal also reflects the authors' stem-cell source and institutional background, not that this is somehow a dental treatment for SCI.

As with many biomaterial papers, the concept is promising but translation remains the hard part. Manufacturing consistency, local delivery, long-term safety, and the challenge of matching animal lesion models to real human SCI are all still major hurdles.

Perspective

This is a serious and technically interesting SCI biomaterials paper. It does not mean stem cell lysate hydrogels are close to clinic, but it does show how the field is evolving: less focus on a single magic ingredient, more focus on engineered systems that can influence several damaging pathways at once.

Reconstructive surgery for tetraplegia is one of the clearest examples of how function can be rebuilt even when the spinal cord itself is not repaired.

Instead of waiting for damaged spinal pathways to recover, surgeons can sometimes reroute working nerves and tendons so that muscles with preserved control take over functions that were lost after cervical SCI. The goal is practical: improve grasp, pinch, elbow extension, and other actions that make daily life more independent.

A new Cureus case report looks at one patient over the longer term after this kind of hybrid reconstruction, using both nerve transfer and tendon transfer techniques together.

What happened in the case

The patient, a man in his 30s, had a C7 spinal cord injury after a fall, along with fractures including a right olecranon fracture and a left distal radius fracture. After initial trauma surgery and fixation, he was left with major loss of digital flexion and extension and marked weakness in the right elbow.

Two years after the injury, surgeons performed a complex combined reconstruction. The procedures included a right biceps-to-triceps tendon transfer, tendon transfers to support thumb and finger flexion and extension, and a left supinator-to-anterior interosseous nerve transfer.

According to the report, the result was significant postoperative improvement in right elbow flexion and in bilateral pinch and grasp function. For the tetraplegia field, that is the key reason these procedures matter. Restoring hand and elbow actions can have a very large effect on dressing, transfers, feeding, phone use, wheelchair management, and self-care.

Why combining nerve and tendon transfers matters

Tendon transfers have been used in tetraplegia surgery for many years. Nerve transfers are newer in this context and can offer different advantages, including more selective reanimation of specific muscles when suitable donor nerves are available.

Using both approaches together can potentially give surgeons more flexibility. Tendon transfers can provide more immediate mechanical rerouting, while nerve transfers may allow a more biologically integrated recovery over time if reinnervation succeeds. The hybrid strategy aims to get the strengths of both.

What makes this case especially useful

The report does not stop at the early success. Four years after the original trauma, the patient returned with a new loss of thumb interphalangeal flexion caused by rupture of the flexor pollicis longus tendon. The cause was hardware from the earlier distal radius fixation, and the problem required further surgery including hardware removal and tendon reconstruction.

That complication is important because it shows the long tail of care in tetraplegia reconstruction. These procedures are not one-and-done miracle fixes. They sit inside a larger surgical history, and older hardware, altered biomechanics, tendon wear, and the need to preserve already gained function all matter.

Why SCI readers should care

This is a case report, so it should not be treated as broad proof that all combined nerve-tendon transfers will produce the same results. But it is still valuable because it offers a realistic picture of the field. It shows both the upside and the complexity.

The upside is meaningful function. For many people with cervical SCI, a stronger pinch or the return of useful grasp can matter more than very large but less practical changes elsewhere. The complexity is that these reconstructions are highly individual, depend on remaining muscle and nerve function, and may require long rehabilitation plus long-term follow-up.

Perspective

The most useful lesson from this case is that upper-limb reconstruction after tetraplegia is becoming more sophisticated, not simpler. Surgeons are increasingly combining techniques to maximise function, but success also depends on managing the downstream complications that can threaten those gains. It is not a cure for tetraplegia. It is a strong example of reconstructive medicine trying to return specific abilities that matter in everyday life.

One of the hardest things about repairing the injured spinal cord is that the tissue environment becomes actively hostile to recovery.

After the initial mechanical trauma, a second wave of damage takes over. Oxidative stress surges, inflammatory pathways stay switched on, mitochondria are damaged, neurons die, and scar-forming processes make the lesion harder to rebuild. That means a useful therapy may need to do more than one job at once. It may need to protect cells, calm inflammation, and give the tissue some kind of repair-friendly scaffold.

A new paper in Materials Today Bio takes exactly that approach. The researchers built a ROS-responsive hydrogel, meaning a gel designed to react to the high levels of reactive oxygen species found at the injury site. They combined quaternized chitosan and tannic acid to form the hydrogel, then loaded it with copper-zinc metal-organic framework particles, or Cu/Zn MOFs.

Why ROS matters

ROS stands for reactive oxygen species. These are chemically reactive molecules produced during normal biology, but after SCI they can build up to damaging levels. In excess, ROS harms lipids, proteins, DNA, and mitochondria. It also feeds inflammation, which in turn can generate even more oxidative damage. That is one reason researchers often describe oxidative stress and inflammation as a vicious cycle after SCI.

The hydrogel in this study is designed to respond to that abnormal chemistry. In effect, the injury environment itself helps trigger the release and activity of the therapeutic components.

What the material is supposed to do

The authors describe the system as an injectable, self-healing scaffold that can be delivered locally into the lesion. The Cu/Zn MOF particles are meant to behave like nanozymes, engineered materials with enzyme-like activity. In this case, the goal is to mimic antioxidant enzymes such as superoxide dismutase and catalase, helping the injured tissue neutralise excess reactive oxygen species.

According to the abstract and opening sections of the paper, the material did more than just mop up ROS. It also protected mitochondrial function, reduced neuronal apoptosis, and shifted macrophages away from a pro-inflammatory M1 state and toward a more reparative M2 phenotype.

That immune shift matters because macrophages and related inflammatory cells can either worsen tissue damage or help support repair, depending on how they are activated. A treatment that both reduces oxidative stress and nudges inflammation toward a more helpful state is aiming at two major parts of the secondary injury cascade at once.

What happened in the animal study

In vivo, the paper reports that the Cu/Zn MOF-loaded hydrogel reduced astrogliosis, supported axonal regeneration and remyelination, and improved both electrophysiological conduction and locomotor recovery. In other words, the treatment was associated not just with cleaner molecular markers but with better nerve signal transmission and improved movement in the injured animals.

That does not prove full functional restoration, but it is the kind of multi-layered result researchers look for in preclinical SCI repair: changes in the biochemical environment, changes in tissue structure, and changes in behaviour.

Why this kind of biomaterial is interesting

There is a growing shift in SCI biomaterials away from passive fillers and toward smart scaffolds. A passive scaffold can support tissue physically, but a responsive scaffold can sense the environment and act accordingly. That is a more sophisticated concept: instead of delivering one static material, you deliver a system that reacts to the lesion biology itself.

This is particularly attractive in SCI because the lesion environment changes over time. Oxidative stress, inflammation, barrier failure, and immune-cell behaviour evolve across the acute and subacute phases. Materials that can engage with those changes dynamically may be better suited to the real biology of injury.

What still needs caution

This is still a rat study, not a clinical therapy. Biomaterials that perform well in animal models often face major translational hurdles in humans, including long-term safety, reproducibility, manufacturing, sterility, implantation logistics, and the challenge of scaling the material to larger and more complex lesions.

There is also the broader SCI problem that improving the lesion environment is only one part of recovery. Human outcomes will still depend on spared tissue, rehabilitation, chronicity of injury, and whether regenerating axons form meaningful connections rather than disorganised growth.

Perspective

Even with those caveats, this is a strong example of where SCI biomaterials research is heading. The aim is no longer simply to fill a cavity. It is to engineer a material that behaves more like a therapeutic system: antioxidant, immunomodulatory, structurally supportive, and responsive to the biochemistry of injury. That is still early-stage work, but it is serious and technically ambitious early-stage work.

Multiple sclerosis is not a spinal cord injury, but it is highly relevant to people interested in spinal cord function, neuroinflammation, and neurological disability. MS damages myelin in the brain and spinal cord, disrupting the signals that allow movement, sensation, balance, and coordination to work properly.

A new University of Colorado Anschutz news story highlights research that may help explain one of the long-standing questions in the disease: why women are more likely to develop MS than men.

The answer the team is exploring is not simply hormones or lifestyle, but immune biology at the protein level.

What the study looked at

The researchers used proteomics, which means measuring large numbers of proteins at once, to compare cerebrospinal fluid samples from women with MS against samples from healthy controls. Proteins matter because they are the working molecules of cells. If you want to know which pathways are active, inflamed, suppressed, or failing to repair, proteins often tell you more directly than genes alone.

According to the university report, the study analysed more than 120 proteins and found a pattern pointing in two directions at once: more immune activation and less support for neuronal repair.

What they found

Women with MS showed higher levels of proteins associated with activated microglia and macrophages. Microglia are the resident immune cells of the brain and spinal cord. They are essential for clearing debris and maintaining nervous tissue, but when they become chronically overactive they can contribute to inflammation and tissue damage.

The report also says the MS group showed lower levels of proteins linked to neurogenesis and neuron function, suggesting that repair processes may be less effective at the same time inflammatory activity is rising.

Several proteins were highlighted as possible therapeutic targets, including FABP5, APOC3, and CD99. The researchers suggest these may help predict or drive disease processes in women with MS and might eventually point to more tailored treatments.

Why SCI readers may care

MS and traumatic SCI are different conditions, but they overlap in an important way: both involve the spinal cord, inflammation, myelin biology, and the challenge of restoring function after damage to central nervous system pathways.

For people in the SCI community, this story reinforces a broader point about neurodisability research. Recovery is not only about neurons surviving injury. It is also about the surrounding immune environment and whether support cells are helping repair or driving further harm. That same logic shows up repeatedly in SCI research, where microglia, macrophages, astrocytes, and inflammatory signalling are major treatment targets.

What this does and does not show

This is not a new cure, and it does not show that one single protein causes MS in women. It is a mechanistic study that helps map the biology more clearly. That matters because diseases like MS are complicated systems problems. Understanding which proteins rise and fall in the disease state can improve biomarker discovery and guide future drug development.

It is also worth separating the timing of the story from the timing of the underlying science. The university article was published on 21 April 2026, but the linked paper appears to have been published earlier, in 2025. So this is best understood as a fresh institutional write-up of research that may already have been in the literature.

Perspective

For the SCI audience, this is an adjacent neuroscience story rather than a direct SCI therapy story. Still, it is a useful one because it shows how modern neuro research is becoming more precise: less about broad labels like "inflammation" and more about exactly which immune pathways and proteins may be driving disability, and in whom.

When spinal cord injury is discussed publicly, the focus is usually on movement. But for many people, some of the most dangerous and disruptive consequences are autonomic rather than motor.

Injuries at or above T6 can severely disrupt the nervous system pathways that regulate blood pressure, heart rate, bladder function, bowel function, and other internal body processes. These problems can be life-threatening. They also shape daily quality of life in ways that are often underestimated outside the SCI community.

A new PLOS One paper takes aim at that problem, but in an important way: it is not reporting successful treatment results yet. It is a pilot clinical trial protocol, setting out how researchers plan to test whether non-invasive spinal cord stimulation can safely and feasibly support autonomic recovery in people with subacute SCI.

What the study is testing

The intervention is transcutaneous spinal cord stimulation, or tSCS. Unlike epidural stimulation, tSCS does not require surgery. Electrical stimulation is delivered through the skin, with the aim of influencing spinal networks below the level of injury.

In recent years, tSCS has gained attention mainly for motor recovery and upper-limb function. This protocol is interesting because it shifts the focus to autonomic function, especially cardiovascular and pelvic-organ control.

The target group is adults within six months of injury who have cervical or upper thoracic SCI at or above T6 and AIS grades A to C. That timing matters because the subacute period is biologically active, but also medically delicate. The authors note that the safety of tSCS in this early phase remains uncertain, which is one reason the study is framed around feasibility first.

How the trial is structured

The protocol has two parts.

Project A is a pilot randomised controlled trial during inpatient rehabilitation. It plans to enrol 26 adults, randomly assigning them to receive either tSCS or sham stimulation for five sessions alongside standard care.

Project B is a post-discharge outpatient phase with a single-arm quasi-experimental design. Participants can continue into it after inpatient rehab, and additional eligible participants can also be recruited directly into that phase. They will receive 18 tSCS sessions over six weeks in the lab.

The primary outcomes are feasibility outcomes, not definitive efficacy outcomes. That means recruitment, retention, and stimulation-related adverse events are the main early targets. The team will also collect exploratory autonomic outcome data, which may help estimate whether the intervention is producing meaningful physiological responses worth testing in a larger trial.

Why autonomic recovery matters so much

The paper's background section lays this out clearly. Cardiovascular instability after SCI can include neurogenic shock early on, then longer-lasting problems such as orthostatic hypotension and autonomic dysreflexia. These are not minor side issues. They can cause severe blood-pressure swings and are tied to morbidity and mortality after SCI.

Pelvic-organ dysfunction is also central, affecting bladder and bowel function, dignity, independence, infection risk, and daily routine. A treatment that could stabilise even part of this system would matter greatly.

Why this is a useful story even without results

Protocol papers can look less exciting than outcome papers, but they tell us something important: where the field is moving next. This one shows that stimulation research is starting to take autonomic recovery more seriously as a first-order target rather than an afterthought.

It also shows a shift toward earlier intervention. Much of the stimulation literature in SCI has focused on chronic injury. Studying subacute SCI is harder, but it may also be where some of the biggest gains are possible if the intervention is safe enough.

Perspective

This is a planning paper, not a proof-of-concept success story. No one should read it as evidence that tSCS has already been shown to restore autonomic function after subacute SCI. But it is still important because it formalises a clear next step: a structured attempt to test whether non-invasive stimulation can safely target the cardiovascular and pelvic-organ complications that matter so much after high-level SCI.

Neuropathic pain is one of the most disabling problems in neurology and rehabilitation. For people with spinal cord injury, it is also one of the most frustrating. It can be severe, persistent, hard to describe, and often poorly controlled even when several drugs have been tried.

A new clinician-focused overview in the Medical Independent looks at where the field stands as part of the 2026 International Association for the Study of Pain Global Year of Neuropathic Pain. It is not a new trial or a single breakthrough paper. Instead, it is a useful summary of why neuropathic pain remains such a difficult target, and where the next potential advances may come from.

Why neuropathic pain is so hard to treat

Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. That sounds neat on paper, but in real life it covers a wide range of conditions and mechanisms. Peripheral nerve injury, diabetic neuropathy, postherpetic neuralgia, MS, stroke, and SCI can all produce neuropathic pain, but not necessarily through exactly the same biology.

That is part of the problem. The pain may feel similar to the patient, but the mechanisms underneath can differ. The article notes that trial outcomes for current drugs are usually modest, placebo effects are large, diagnostic criteria are often messy, and the evidence base is heavily weighted toward a few conditions such as diabetic neuropathy and postherpetic neuralgia. That means treatments are often borrowed across syndromes even when the fit is imperfect.

The newer areas attracting attention

The article highlights four broad areas of interest.

The first is anti-nerve growth factor antibodies. These were once seen as highly promising target-specific analgesics, but the more advanced agents ran into safety problems that outweighed the benefits, especially at higher doses.

The second is microglia. These immune-related cells in the central nervous system have become a major focus because they are deeply involved in neuroplasticity and in the changes that occur after nerve injury. For SCI readers, this is especially relevant because microglia are also central to the secondary injury response after spinal cord trauma.

The article notes that electrical currents can now be used to influence microglia-related pathways, which is one of the rationales behind differential target multiplexed spinal cord stimulation, or DTM-SCS. According to the piece, human studies targeting glia-rich thoracic regions have shown improved analgesic outcomes over conventional spinal cord stimulation for back and leg pain.

The third area is AMPK activation. AMPK is a cellular energy regulator, and preclinical work suggests that activating it may damp down pathways involved in chronic pain and even reduce allodynia after peripheral nerve injury.

The fourth area is genetics. The field is still early, but there is growing interest in whether some people may be genetically more vulnerable to neuropathic pain or more likely to respond to certain treatments.

What the article says about present-day treatment

The piece is frank that current drug options are limited. It points to evidence reviews suggesting that the overall effects of common neuropathic pain drugs are generally modest, and that no single class has clearly proven superior across all neuropathic pain syndromes.

In practice, the article recommends using recognised screening tools to confirm that the pain really is neuropathic, then using guideline-based prescribing while paying close attention to comorbidities, adverse effects, and whether the treatment is actually helping the patient in a meaningful way. It also warns about the downsides of gabapentinoids, including neurocognitive effects, weight gain, falls risk, and growing concerns about pregabalin misuse.

Why SCI readers should care

Although the article is not written specifically about SCI, its message applies strongly to the SCI community. Neuropathic pain after spinal cord injury can be severe, difficult to classify, and highly resistant to treatment. The standard medication lists are familiar, but many people find the relief incomplete and the side effects significant.

That is why the most interesting part of this article is not a new pill recommendation. It is the shift in emphasis toward mechanisms beyond neurons alone: glia, inflammation, plasticity, electrical modulation, and eventually genetics. Those are all areas already relevant to SCI research more broadly.

Perspective

This is best read as a reality-check story, not a breakthrough story. The field is advancing, but slowly. There are good reasons to think future neuropathic pain treatments will become more precise and more biologically informed. But for now, the article's central message is that neuropathic pain remains a major unmet need, and that smarter, more mechanism-based treatment is still urgently needed.

Repairing the injured spinal cord is difficult because the problem is not only a break in tissue. After severe SCI, nerve cells die, nerve fibers lose their route across the injury site, scar tissue and inflammation make regrowth harder, and the brain's signals can no longer pass cleanly to the spinal circuits below.

A University of Minnesota Twin Cities team has been working on a physical and biological bridge for that gap. Their study, published in Advanced Healthcare Materials, uses a 3D-printed "organoid scaffold" loaded with human induced pluripotent stem cell-derived spinal neural progenitor cells, known as sNPCs.

The scaffold idea

A scaffold is a support structure. In this study, the scaffold was printed with microscopic channels. Those channels matter because regenerating nerve fibers need direction. If new cells grow randomly, they may survive but fail to create a useful relay across the injured area.

The researchers placed spinal neural progenitor cells inside those channels. These cells are not fully mature neurons at the start. They are immature spinal-cord-like cells that can develop into more specialised nerve cells. The 3D-printed architecture helps guide their growth so that the new axons, the long cable-like parts of neurons, extend along the intended path.

In plain terms, the scaffold works like a roadbed. The stem-cell-derived neural cells are the traffic system being rebuilt on top of it. The aim is to create a living relay that can connect tissue above the injury to tissue below it.

What the animal study found

The team transplanted the cell-filled scaffolds into rats with completely transected spinal cords. A transection model is severe: the cord is cut through rather than partially bruised. Over time, many of the transplanted cells differentiated into neurons.

The important finding was direction and integration. The new cells extended nerve fibers both rostrally, meaning toward the head, and caudally, meaning toward the tail. That suggests the scaffold did not simply keep cells alive; it helped orient growth toward host spinal tissue on both sides of the injury.

At 12 weeks after transplantation, the published abstract reports that most cells inside the scaffolds had differentiated into neurons and integrated into the host spinal cord tissue. The University of Minnesota release also reports significant functional recovery in the rats.

Why organoid scaffolds are different

Stem-cell transplantation for SCI has been explored for years, but a major problem is organisation. Injecting cells into an injury site does not guarantee that they mature correctly, line up with the spinal cord's structure, or form connections that carry useful signals.

Organoid scaffolds try to solve this by combining living cells with engineered architecture. "Organoid" means a lab-grown tissue structure that mimics some features of an organ or region of tissue. Here, the goal is not to grow a whole spinal cord in the lab. The goal is to build a small spinal-cord-like relay that can be placed into the damaged area.

This approach sits at the intersection of regenerative medicine, bioengineering, and neural repair. It is not just a cell therapy and not just a device. It is a living, structured transplant.

Analysis

The exciting part of this work is the attempt to control direction. SCI repair is not simply about making neurons grow. It is about making the right cells grow in the right place, in the right direction, and then connect to the right circuits. Without that organisation, regeneration may not translate into function.

The study also uses clinically relevant human stem-cell-derived spinal neural progenitor cells, which makes the research more relevant than work using only generic cell lines or non-human cells. That does not mean it is ready for patients, but it does mean the researchers are thinking about translation from the start.

The rat findings are important because the transplanted cells matured, extended axons in both directions, and appeared to integrate with host tissue. Functional improvement in a severe injury model makes the result more interesting for SCI research.

What still needs to be solved

This is still preclinical research. Rat spinal cords are much smaller than human spinal cords, and a controlled laboratory transection is not the same as a real-world human SCI, where injury patterns vary widely. Human injuries may involve bruising, bleeding, compression, bone damage, scar tissue, cysts, chronic inflammation, and years of tissue change.

Scaling the scaffold is another challenge. A human implant would need to match the size and shape of the lesion, survive in the injury environment, avoid harmful overgrowth, connect appropriately, and work alongside rehabilitation. Safety questions would include immune response, tumor risk, abnormal pain signaling, spasticity, and whether new connections are useful rather than noisy.

Perspective

The study is best understood as an early but serious step toward structured spinal cord repair. It shows that 3D printing can do more than make a passive implant. It can shape how living neural cells organise and grow.

For people with SCI, this is not a near-term treatment. But it is a strong example of where regenerative medicine is heading: away from simply adding cells, and toward building guided, living repair systems that are designed to reconnect damaged circuits.

Alzheimer's disease is usually described as a brain disease. That is accurate, but it may not be the full story. Many people with Alzheimer's also develop movement-related problems, including changes in balance, walking, coordination, and physical endurance. The usual assumption is that these problems come from brain degeneration.

A new study asks a sharper question: could some of those movement problems begin outside the brain and spinal cord, in the peripheral nerves that connect to muscles?

The study, published in Alzheimer's & Dementia, used a functional human neuromuscular junction microphysiological system. In more everyday language, the researchers built a human nerve-muscle model on a chip.

What the researchers modelled

The neuromuscular junction is the point where a motor nerve tells a muscle to contract. It is essential for movement. If that connection fails, the brain may still send a command, but the muscle will not receive it properly.

The researchers used induced pluripotent stem cell-derived motor neurons carrying familial Alzheimer's disease mutations. Familial Alzheimer's is a rare inherited form of the disease that usually appears earlier in life than typical Alzheimer's. They paired those motor neurons with healthy human skeletal muscle cells in a two-chamber chip system.

The key design feature is what the system leaves out: the brain and spinal cord. By isolating the motor neuron-muscle connection, the researchers could test whether Alzheimer's-related mutations could directly harm peripheral motor function.

What they found

The study reported that neuromuscular junctions formed with familial Alzheimer's motor neurons showed impaired function. The PSEN1 A246E mutation produced severe deficits, while the APP K595N/M596L mutation produced moderate deficits.

That matters because it suggests movement-related problems can arise from the nerve-to-muscle circuit itself, not only from loss of brain control. In other words, the peripheral nervous system may be part of the disease process.

The researchers measured functional outputs such as how reliably nerve activity triggered muscle contraction and how the muscle response behaved over time. These are practical, movement-related readouts rather than only molecular markers.

Why this appeared in a spinal cord alert

This is not an SCI study. It does not involve spinal cord injury repair, paralysis treatment, or spinal cord stimulation. It appeared in the spinal cord alert because the story discusses whether movement deficits can arise outside the brain and spinal cord.

It is still relevant to a neurorehabilitation audience because it highlights an important principle: movement disorders may involve the whole motor pathway, not only the brain. For SCI, peripheral nerves, muscles, neuromuscular junctions, spinal circuits, and brain control all shape functional outcomes.

Analysis

The most interesting idea is the shift from a top-down view to a whole-system view. If movement problems in Alzheimer's can begin at the neuromuscular junction, then treatments aimed only at plaques, tangles, or brain inflammation may miss an important part of the disability.

This does not redefine Alzheimer's as a muscle disease. It remains a neurodegenerative condition. But it suggests that some symptoms may reflect a broader nervous-system disorder that includes the peripheral motor circuit.

The use of human-on-a-chip technology is also important. Animal models often fail to reproduce the full human biology of neurodegenerative disease. A chip model built from human cells can isolate specific mechanisms and test drugs in a more controlled way.

What this does not prove yet

This is a lab model, not a patient trial. It shows that familial Alzheimer's mutations can impair human-cell-derived neuromuscular junction function in vitro. It does not prove that most Alzheimer's patients develop motor symptoms through this exact mechanism.

It also focuses on familial Alzheimer's mutations, which represent a rare form of the disease. Typical late-onset Alzheimer's may involve different combinations of risk factors and mechanisms.

Perspective

For SCI readers, the story is adjacent rather than central. It is not about spinal cord injury, but it reinforces a concept that matters in SCI rehabilitation: movement depends on the entire circuit. Brain, spinal cord, peripheral nerves, neuromuscular junctions, and muscles all contribute.

If researchers can better model each part of that circuit using human cells, future therapies for neurological disability may become more precise. The lesson is not that Alzheimer's begins in the nerves for everyone. The lesson is that movement symptoms may have peripheral roots that deserve more attention.

Aneuvo has received U.S. Food and Drug Administration clearance for ExaStim, its non-invasive spinal cord stimulation system for neurorehabilitation after spinal cord injury. This is a regulatory milestone because it moves the system from investigational status toward U.S. market availability for a defined SCI indication.

The device is not implanted. It delivers electrical pulses through electrodes placed on the skin over the spine, stimulating nerves along the spinal cord and dorsal roots. The system is controlled through software on a mobile digital device and is designed for use in both clinic and home settings.

What was cleared

FDA's public 510(k) database lists ExaStim under 510(k) number K252893. The device classification is "Transcutaneous Electrical Spine Stimulator To Improve Skeletal Muscle Strength And Sensation." The FDA decision date was March 27, 2026, and the clearance type was a traditional 510(k) with a substantially equivalent decision.

Aneuvo announced the clearance on April 16, 2026. According to the company, ExaStim is indicated to improve hand sensation and strength in individuals aged 18 to 75 with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injury, when used together with functional task practice.

That last phrase is important. The device is not being positioned as a stand-alone cure. It is meant to be paired with task-specific rehabilitation, where stimulation is delivered alongside repeated practice of useful movements.

Why non-invasive spinal stimulation matters

Spinal cord stimulation has become one of the most active areas of SCI research. Some approaches use implanted epidural electrodes placed surgically near the spinal cord. ExaStim uses a transcutaneous approach, meaning stimulation is delivered through the skin.

Non-invasive stimulation has tradeoffs. It may be less precisely targeted than an implanted system, but it avoids surgery and may be easier to scale across clinics and home programs. For people with SCI, that difference matters. A therapy that can be used repeatedly without implantation could reach more patients if it proves useful, practical, and affordable.

In incomplete SCI, some neural pathways remain physically intact but underused, weak, or poorly coordinated. Stimulation may help raise the excitability of spinal networks so that rehabilitation practice can make better use of surviving pathways. In simple terms, the device may help the nervous system become more responsive while the person practices specific tasks.

What the clearance does and does not mean

FDA clearance is not the same as saying a device reverses paralysis. A 510(k) clearance means the FDA found the device substantially equivalent to a legally marketed predicate device for the stated use. It is a regulatory clearance for a defined indication, not a broad claim that the technology restores normal function after SCI.

The cleared indication is specific: adults with chronic, non-progressive neurological deficits from incomplete SCI, focused on improving hand sensation and strength, with functional task practice. It does not cover every injury type, every stage of SCI, or every body function.

That specificity is useful. It tells clinicians and patients where the evidence and regulatory pathway are currently focused.

Analysis

The most newsworthy part of this story is access. Neuromodulation has produced exciting SCI research, but many approaches remain limited to specialised trials or surgical implantation. A cleared, non-invasive system for both clinic and home use could make spinal stimulation more available as part of real rehabilitation programs.

The focus on hand sensation and strength is also important. For people with cervical incomplete SCI, even small improvements in hand function can affect independence: feeding, phone use, transfers, grooming, wheelchair control, dressing, bladder and bowel routines, and work tasks.

The home-use component could be meaningful if it allows higher-dose practice outside clinic hours. SCI rehabilitation often depends on repetition, and repetition is hard when therapy is limited to short clinic sessions. A portable system may help bridge that gap, though real-world adherence, training, support, cost, and safety monitoring will matter.

Questions still to watch

The next stage is not only commercial launch. The field will need practical evidence: who responds best, how large the gains are, how long benefits last, how much task practice is needed, and whether home use can be delivered safely and consistently.

It will also be important to compare ExaStim with other neuromodulation approaches, including implanted stimulation, other transcutaneous systems, functional electrical stimulation, robotic training, and intensive task-based therapy. The strongest future protocols may combine several tools rather than relying on stimulation alone.

Perspective

This is a meaningful regulatory milestone, especially because it concerns non-invasive stimulation and upper-limb function after incomplete SCI. It should be reported carefully: not as a cure, not as proof of broad recovery, but as a cleared neurorehabilitation tool that may expand access to spinal stimulation when paired with functional practice.

For the SCI community, the practical hope is straightforward. If stimulation can make surviving pathways easier to recruit, and if people can practice meaningful tasks at enough intensity, some patients may gain useful improvements in hand strength and sensation.

Walking is not just movement. It is also sensation. A person needs to know where the legs are, when the feet contact the ground, how weight is shifting, and whether the next step is safe. After spinal cord injury, the loss of sensation can make assisted walking less natural and more risky, even when robotic exoskeletons provide mechanical support.

A UC Irvine-led study, with collaborators from Caltech and the Keck School of Medicine of USC, tested a bidirectional brain-computer interface for walking. "Bidirectional" means information travels both ways: brain signals are decoded to control movement, and artificial sensory feedback is sent back into the brain.

How the system worked

The system used electrocorticography, or ECoG, which records electrical activity from electrodes placed on the surface of the brain. The researchers recorded from leg motor cortex regions to decode the participant's walking intent.

Those decoded signals were used to control a robotic walking exoskeleton. At the same time, the system delivered artificial leg sensation by electrically stimulating the somatosensory cortex, the brain area involved in body sensation.

This creates a closed loop. The participant does not simply send a command to a machine. The system also sends back sensory information that can help the brain interpret the walking movement.

The study participant

The participant was a 50-year-old woman undergoing epilepsy evaluation who already had bilateral interhemispheric subdural ECoG implants. That detail matters. This was not yet a chronic implant trial in a person with complete paraplegia. It was a proof-of-concept study using a clinical opportunity to test whether the approach could work.

The participant operated the BDBCI-controlled exoskeleton across 10 exercises and quickly achieved high performance. To test whether the sensory feedback was meaningful, she completed a blind step-counting task and identified steps with nearly 93 percent overall accuracy. In a separate sensory discrimination task, she identified right-leg, left-leg, and no-stimulation sensations with high accuracy. No adverse events were reported in the study.

Why sensory feedback is a big deal

Most exoskeleton systems depend heavily on manual controls, preset movement programs, and visual monitoring. That can help a person move upright, but it is not the same as natural walking. Without body feedback, the user may need to watch each movement and rely on external cues.

In intact walking, sensory information is continuous. It helps the nervous system correct balance, adjust timing, and respond to the environment. For people with SCI using assistive devices, restoring even artificial feedback could make movement feel more connected and potentially safer.

The study is therefore not only about controlling a robot with thoughts. It is about rebuilding part of the sensorimotor loop that SCI interrupts.

Analysis

This is an important engineering and neuroscience milestone because it brings together several hard problems: decoding leg movement intent from the brain, controlling a powered exoskeleton in real time, stimulating the sensory cortex to create leg sensations, and packaging the system into a compact embedded platform.

The researchers describe this as a step toward future fully implantable systems. A future version might use a skull-mounted component connected under the skin to implanted electronics, removing transdermal wires that can raise infection risk. That is still future work, but the direction is clear: a system that could one day be used outside the lab and over longer periods.

What this does not prove yet

This was not a large clinical trial, and it did not show independent walking restoration in people with chronic complete SCI. The participant was not described as the final target population for the technology. The result is best understood as a proof of concept that a two-way brain interface can combine walking control with artificial leg sensation.

The next steps will need to test safety, stability, decoding accuracy, sensory usefulness, training burden, implant durability, and real-world performance in people with paralysis.

Perspective

SCI technology is increasingly moving from one-way assistance to closed-loop systems. One-way systems push stimulation, robotic movement, or commands into the body. Closed-loop systems listen, respond, and feed information back.

That shift matters because natural movement depends on feedback. A future walking system for SCI may need to combine brain intent, spinal stimulation, robotic support, muscle activation, and sensory feedback. This study shows one piece of that future: the brain can both command a walking device and receive artificial sensations tied to its movement.

Neuropathic pain is usually discussed as a nerve problem. That is true, but it is incomplete. Nerves do not work alone. They depend on support cells that wrap, insulate, feed, and regulate them. A new study in Advanced Science focuses on one of those support cell families: oligodendrocytes.

Oligodendrocytes are cells in the central nervous system that make myelin, the insulating layer around nerve fibers. Myelin helps electrical signals travel quickly and reliably. When myelin is damaged or poorly maintained, nerve signaling can become unstable, inefficient, or abnormal.

The paper, "Targeting the PDK1/c-Myc/SOX10 Signaling in Oligodendrocytes Alleviates Neuropathic Pain", investigates how oligodendrocyte homeostasis contributes to neuropathic pain.

The pathway under study

The researchers focused on PDK1, short for 3-phosphoinositide-dependent kinase 1. In this study, PDK1 appears to help maintain healthy oligodendrocyte function and myelination.

They also studied a signaling axis involving c-Myc and SOX10. SOX10 is important for oligodendrocyte development and myelin-related function. c-Myc is a powerful regulator of cell growth and gene expression. The paper reports that PDK1 deficiency impaired myelination through the c-Myc/SOX10 axis.

In simple terms, when this molecular control system was disrupted, the myelin-maintaining cells did not do their job properly.

What the mouse experiments showed

The study used chronic constriction injury, a standard mouse model of neuropathic pain caused by peripheral nerve injury. The researchers observed deficient myelination and downregulation of PDK1 in oligodendrocyte-lineage cells in the spinal cord.

They then used inducible oligodendrocyte-lineage-specific Pdk1 conditional knockout mice. Removing PDK1 in these cells produced mechanical allodynia and thermal hyperalgesia. Mechanical allodynia means normally non-painful touch becomes painful. Thermal hyperalgesia means heat sensitivity becomes exaggerated.

Those pain-like behaviours resembled what is seen after chronic constriction injury.

The team also reported that pharmacologically enhancing remyelination or knocking down c-Myc using an AAV-based approach restored nodal integrity and reduced neuropathic pain behaviours in the Pdk1-deficient mice.

Why myelin matters for pain

Myelin is often thought of as insulation, but it is more than wrapping. It helps organise nodes of Ranvier, the small exposed gaps along a nerve fiber where electrical signals are regenerated. If nodes are disrupted, nerve signals can become abnormal.

In pain circuits, abnormal signaling can mean that harmless touch is interpreted as pain, or that pain pathways become easier to activate. This study suggests that impaired myelin support in spinal cord circuits may contribute to that shift.

For SCI readers, this is relevant because neuropathic pain after spinal cord injury also involves central nervous system changes, glial cells, demyelination, inflammation, and disrupted sensory processing. This study is not an SCI-specific trial, but it adds to the larger picture of how support cells shape chronic pain.

Analysis

The useful message is that neuropathic pain is not only a neuron problem. It can also be a myelin-maintenance problem. If oligodendrocytes fail to preserve the structure needed for clean signal transmission, pain circuits may become unstable.

That opens a different kind of treatment thinking. Instead of only blocking pain signals after they appear, future therapies might try to restore the cellular environment that prevents pain circuits from becoming pathological in the first place.

The study also highlights remyelination as a pain target. Remyelination is usually discussed in diseases such as multiple sclerosis, but this work suggests that promoting myelin repair may also reduce neuropathic pain under some conditions.

What this does not mean yet

This is preclinical mouse research. It does not show that targeting PDK1, c-Myc, or SOX10 is safe or effective in people with neuropathic pain, SCI pain, or peripheral nerve injury. These pathways are biologically powerful, so any future therapy would need careful targeting and safety testing.

It also does not prove that all neuropathic pain is caused by demyelination. Neuropathic pain is diverse. It can involve peripheral nerves, spinal cord circuits, brain networks, immune cells, and psychological stress systems. But the study adds an important piece: oligodendrocyte health may be one of the mechanisms that decides whether nerve injury becomes chronic pain.

Perspective

For the SCI community, this is worth watching because central neuropathic pain remains one of the hardest long-term complications to treat. The more researchers understand the support-cell biology behind pain, the more realistic it becomes to design treatments that change the disease process rather than only dull the symptoms.

Neuropathic pain after spinal cord injury is one of the most difficult complications of SCI. It can feel burning, stabbing, electric, freezing, crushing, or hypersensitive to ordinary touch. It may occur below the level of injury, at the level of injury, or in areas where sensation is already altered. For many people, it becomes a daily problem that is separate from the original trauma.

The paper "Imbalance of nociceptive homeostasis drives spinal cord injury pain", published in Experimental Neurology, focuses on a useful idea: pain circuits are supposed to maintain balance. That balance is called homeostasis. In plain terms, the nervous system should be able to turn danger signals up when tissue is threatened, and turn them back down when the threat has passed.

What nociceptive homeostasis means

Nociception is the nervous system's detection of potentially harmful input. It is not exactly the same as pain, because pain is the conscious experience that the brain builds from many signals. But nociception is one of the main signal streams that can become pain.

In a healthy system, nociceptive pathways are regulated by several layers of control. Sensory nerves bring warning signals into the spinal cord. Local spinal circuits decide whether those signals should be amplified or dampened. Inhibitory neurons act like brakes. Glial and immune cells help shape inflammation and repair. The brain also sends descending signals back down to the spinal cord, either suppressing or facilitating pain transmission depending on context.

Homeostasis means these parts keep each other in check. The system is not silent, and it is not permanently switched on. It adjusts.

How SCI can break the balance

A spinal cord injury damages more than motor pathways. It also disrupts sensory traffic, local spinal circuitry, immune signaling, and the communication loops between the brain and spinal cord. After injury, some pain-processing neurons may become easier to activate. Inhibitory circuits may weaken. Glial cells can remain activated and release inflammatory signals. The balance between excitation and inhibition can shift.

The result is not simply "more pain signal." It is a changed network. The spinal cord can begin treating ordinary input as threatening, and the brain may receive distorted information from below the injury. This helps explain why SCI neuropathic pain can persist even when there is no ongoing tissue damage in the painful area.

A helpful comparison is a smoke alarm that has lost its calibration. The alarm still serves an important purpose, but after damage to the wiring, it may trigger from steam, dust, or nothing obvious at all. In SCI neuropathic pain, the problem is not imaginary pain. The problem is a real nervous system circuit that has become poorly regulated.

Analysis

The important shift in this story is that the target is not one single molecule, one nerve, or one pain receptor. The target is a state of imbalance. That matters because SCI pain is rarely caused by one isolated mechanism. It can involve spinal neurons, brain-spinal communication, inflammatory signaling, sensory rewiring, and loss of inhibitory control all at the same time.

A homeostasis model also helps explain why current treatments are often incomplete. Drugs that reduce nerve firing, such as gabapentinoids, may help some people but may not restore the broader circuit balance. Anti-inflammatory strategies may address one part of the picture but not descending control. Neuromodulation may change network activity but may need to be paired with rehabilitation or other treatments to produce durable change.

In other words, the paper points toward combination thinking: therapies that reduce pathological excitation, strengthen inhibitory control, calm maladaptive inflammation, and retrain circuits may be more realistic than expecting one drug to solve all SCI pain.

What this does not mean yet

This is not a new pain treatment ready for clinical use. The public metadata available for this article identifies a mechanistic SCI pain paper, not a human clinical trial. It should be read as a framework for understanding and targeting SCI neuropathic pain, rather than proof that a specific therapy works in patients.

The next step for the field is to turn this type of circuit-level understanding into testable interventions. That could include drugs, spinal stimulation, brain stimulation, rehabilitation-linked neuromodulation, immune-modulating approaches, or combinations designed around the person's pain type and injury pattern.

Perspective

SCI neuropathic pain is often described by patients as one of the most life-changing parts of injury. A homeostasis view respects the complexity of that pain. It says the pain is not just a symptom to be muted; it is a sign that protective neural systems have lost their normal balance. Restoring that balance may become a more precise goal for future SCI pain research.

ONWARD Medical has raised EUR 40.6 million in gross proceeds to support its spinal cord stimulation programs. The financing came through an accelerated bookbuild private placement with institutional investors, with new shares issued at EUR 3.00 per share. EQT Life Sciences invested EUR 25 million as part of the transaction.

For the SCI community, the key part is not the finance structure itself. It is what the money is intended to support: ONWARD's implantable ARC-IM platform, its already cleared non-invasive ARC-EX system, and the company's transition into a commercial-stage neurotechnology business.

What ONWARD is building

ONWARD's ARC Therapy is spinal cord stimulation designed to restore or improve movement, function, and independence after spinal cord injury. The company has two main platforms.

ARC-EX is an external, non-invasive system that delivers stimulation through the skin. It has already received clearance for commercial sale in the United States and Europe. ARC-IM is an investigational implantable system designed to deliver more targeted stimulation from inside the body.

The capital raise is especially relevant to ARC-IM because ONWARD says part of the proceeds will fund development, clinical studies, and regulatory work for the implantable system.

Why blood pressure instability matters after SCI

The specific ARC-IM program highlighted in the company's announcement is Empower BP, a pivotal trial evaluating whether the implantable system can address blood pressure instability after spinal cord injury.

Blood pressure problems are common after higher-level SCI because injury can disrupt autonomic nervous system control. The autonomic system regulates functions that happen automatically, including blood vessel tone, heart rate responses, sweating, digestion, bladder control, and temperature regulation.

When that system is disrupted, people may experience orthostatic hypotension, where blood pressure drops when sitting or standing, causing dizziness, weakness, fainting, fatigue, or inability to tolerate upright activity. Others may experience autonomic dysreflexia, a sudden dangerous rise in blood pressure triggered by pain, bladder issues, bowel problems, skin irritation, or other stimuli below the injury level.

These are not minor quality-of-life issues. Poor blood pressure control can limit rehabilitation, wheelchair tolerance, standing, exercise, social activity, and safety.

What the funding changes

ONWARD says the net proceeds, together with existing cash, are expected to extend its runway into Q1 2028, assuming no drawdown of the company's debt facility. The company described its intended use of proceeds as funding ARC-IM development and trials, expanding commercial support for ARC-EX, scaling quality and administrative functions, and supporting working capital and existing debt obligations.

In practical terms, this gives ONWARD more time and capital to move both product lines forward. ARC-EX is already in the commercial phase, while ARC-IM remains investigational and needs clinical and regulatory progress.

Analysis

This is a business news story, but it has direct SCI relevance because ONWARD is one of the most visible companies trying to turn spinal cord stimulation research into regulated therapies.

The most important scientific point is that SCI recovery is not only about voluntary walking. Autonomic function matters. Blood pressure stability can affect whether someone can sit up, train, transfer, exercise, attend therapy, or avoid medical emergencies. A therapy aimed at autonomic instability would therefore address a major unmet need.

The second important point is the split between external and implantable stimulation. Non-invasive stimulation may be easier to access and deploy, while implantable stimulation may offer more precise and durable targeting. The field is likely to need both approaches, depending on injury type, treatment goal, risk tolerance, and clinical setting.

What this does not mean yet

A capital raise is not a clinical result. It does not prove that ARC-IM works for blood pressure instability, and it does not change the investigational status of the implantable platform. The useful interpretation is that ONWARD now has more financial runway to continue the trials and regulatory work needed to answer those questions.

The next milestones to watch are Empower BP trial progress, safety data, durability of effect, regulatory submissions, and whether autonomic benefits translate into daily life improvements for people with SCI.

Perspective

SCI neurotechnology is moving from one-off laboratory demonstrations toward regulated devices, commercial rollout, and larger trials. That transition requires capital, manufacturing, quality systems, clinical infrastructure, and reimbursement work as much as it requires good science.

ONWARD's raise is a sign that investors still see spinal cord stimulation as a serious therapeutic area. For people living with SCI, the important question remains whether these platforms can deliver meaningful, repeatable gains in the functions that shape daily independence.

Spinal cord injury often causes changes far beyond paralysis. Muscles below the injury can shrink because they are no longer used normally. Fitness can fall because walking, standing, and whole-body exercise become harder or impossible. Metabolic health can also change, increasing risks around body composition, insulin sensitivity, cardiovascular health, and fatigue.

Exercise is one of the most important tools for protecting long-term health after SCI, but exercise alone can have limited effects when large muscle groups are weak, paralyzed, or difficult to activate. This randomized controlled trial asked whether adding testosterone to a structured home exercise program could improve the body's response.

The study setup

The trial enrolled 84 adults with SCI, aged 19 to 70. Most participants were male, but the study also included eight female participants. Injury levels ranged from C4 to T12, and participants included AIS grades A to D. On average, participants had been living with SCI for nearly 14 years, so this was largely a chronic SCI population rather than an acute recovery study.

Everyone received a home-based multimodal exercise program. That program included functional electrical stimulation-assisted leg cycling, often shortened to FES leg cycling, plus arm ergometry. FES cycling uses electrical stimulation to activate muscles in the legs so they can contribute to cycling movement. Arm ergometry is upper-body cycling, which can train cardiovascular fitness through the arms and shoulders.

Participants were randomized into two groups. One group received the exercise program plus intramuscular testosterone undecanoate. The control group received the same exercise program plus placebo. The trial was double-blind and placebo-controlled, meaning participants and study staff were protected from knowing which treatment was given during the trial.

What the researchers measured

The main outcome was aerobic capacity, measured as peak VO2 during arm exercise testing. Peak VO2 is a measure of how much oxygen the body can use during hard exercise. It is a standard way to assess cardiovascular fitness.

The researchers also measured lean mass, lower-extremity lean mass, hemoglobin, cardiometabolic markers, and safety. Lean mass matters in SCI because muscle loss is not only a strength issue. Muscle is metabolically active tissue. Losing it can affect glucose control, energy use, pressure injury risk, circulation, and daily function.

What they found

The primary result was cautious. The testosterone-augmented group improved more within the group than the control group did, with an approximate 19 percent increase in peak VO2 compared with about 6 percent in controls. However, the between-group difference in peak VO2 was not statistically significant. In a clinical trial, that distinction matters. It means the study cannot claim clear proof that testosterone added to exercise improved aerobic capacity more than exercise plus placebo.

The body composition results were stronger. The testosterone-augmented group gained significantly more lean mass. Whole-body lean mass increased by about 1.84 kg more than controls, and lower-extremity lean mass increased by about 0.92 kg more. The treatment group also corrected anemia in a greater proportion of participants. Adverse event rates were similar between groups over the 16-week trial.

Analysis

The most important takeaway is not that testosterone is a shortcut for recovery. It is not. The study tested testosterone as an enhancer of a structured exercise program, not as a stand-alone therapy and not as a treatment to reverse paralysis.

The results suggest that, in medically selected adults with SCI, testosterone may help the body build or preserve lean tissue when paired with FES cycling and arm exercise. That is meaningful because muscle loss after SCI is difficult to reverse. Even modest increases in lean mass could matter for metabolism, strength reserve, fatigue, transfer ability, skin protection, and general health.

The aerobic capacity result is more uncertain. Because the between-group peak VO2 difference did not reach statistical significance, the trial does not prove a cardiovascular fitness advantage. It does, however, provide a signal that may justify a larger or longer trial.

Why testosterone is medically sensitive

Testosterone affects muscle, red blood cell production, sexual function, mood, body composition, and metabolism. It can also carry risks and requires medical monitoring. It is not suitable for everyone, and the risks may differ depending on age, sex, fertility goals, cardiovascular history, prostate health, baseline hormone levels, and other medical factors.

For SCI readers, the practical message is not to self-medicate. The message is that hormone status and anabolic support may deserve more serious clinical research as part of whole-body rehabilitation after SCI.

Perspective

This is a human randomized controlled trial, which gives it more clinical weight than a small observational study or animal experiment. Still, it lasted only 16 weeks and did not prove superiority for the primary aerobic outcome. The strongest signal was improved lean mass and hemoglobin.

Future studies will need to test whether those body composition gains translate into outcomes people can feel: better endurance, easier transfers, improved metabolic health, fewer complications, or better quality of life. For now, the study supports testosterone-augmented exercise as a promising but medically supervised research direction, not a general recommendation for everyone with SCI.

After spinal cord injury, one of the biggest biological problems is that long nerve fibers in the central nervous system do not regrow well. Damage to descending pathways, the pathways that carry movement-related commands from the brain down the spinal cord, can leave the body below the injury disconnected from voluntary control.

This study, published in Neurobiology of Disease, focuses on a strategy called transneuronal cytokine delivery. In plain language, that means delivering a biological growth signal into one part of a connected neural network so the signal can influence other neurons across synaptic connections.

The core idea

Cytokines are signaling proteins. Many people hear about them in the context of inflammation, but some cytokine-related pathways can also influence neuron survival, growth, and plasticity. The challenge is getting the right signal to the right cells at the right time without causing broad unwanted effects.

The email alert identifies intracortical delivery of an AAV2 vector. AAV2 is a viral vector often used in gene therapy research to deliver genetic instructions into cells. "Intracortical" means the vector is delivered into the brain's cortex. The goal is not to replace the damaged spinal cord directly. Instead, the approach tries to make connected descending circuits more capable of adapting after injury.

The title reports recovery across spinal cord contusion severities. That is important because contusion injuries, where the cord is bruised or crushed rather than cleanly cut, are closer to many real-world traumatic SCI patterns. Different severities leave different amounts of spared tissue, and spared tissue is often where recovery-focused therapies try to work.

What descending circuit plasticity means

Descending circuits are routes from the brain and brainstem to the spinal cord. They help control movement, posture, muscle tone, and coordinated action. After SCI, some fibers are destroyed, while others may remain but become insufficient or poorly connected.

Plasticity means the nervous system changes its structure or function. In this context, descending circuit plasticity could include sprouting of spared fibers, stronger connections, rerouting through alternative pathways, or improved use of circuits that survived the injury.

The key point is that recovery may not require rebuilding the spinal cord exactly as it was before injury. If enough pathways remain, the nervous system may be pushed to reorganize around the damage. This study suggests cytokine delivery may help create that growth-permissive state.

Analysis

This is an ambitious approach because it combines gene delivery, growth biology, and circuit-level recovery. Rather than treating SCI only at the lesion site, it targets the command network above the injury and its connected descending pathways.

That matters because the brain and spinal cord are not separate repair targets. Movement recovery depends on the entire pathway: cortical command, brainstem relay, spinal interneurons, motor neurons, sensory feedback, and muscles. A therapy that strengthens descending plasticity could potentially make rehabilitation or stimulation more effective by giving the nervous system more usable wiring to train.

The phrase "across contusion severities" is also important. Many preclinical therapies look promising in one injury model but fail when the injury is more severe, more variable, or more clinically realistic. Testing across severities is a step toward understanding where a treatment might work and where biological limits remain.

Why this is not yet a human therapy

This should be viewed as preclinical research. AAV-based cytokine delivery raises major translational questions: dosing, targeting, timing after injury, reversibility, immune response, long-term safety, and whether the same circuits can be safely modified in humans. Growth-promoting signals can be powerful, but powerful biology needs tight control.

There is also a difference between improved movement in an animal model and meaningful recovery in people. Human SCI is more variable in injury level, severity, time since injury, medical complications, age, and rehabilitation access. A therapy that promotes circuit plasticity would likely need to be combined with intensive rehabilitation and careful outcome testing.

Perspective

The value of this study is that it treats SCI recovery as a circuit problem, not only a lesion problem. The damaged area matters, but so do the surviving pathways above and below it. If future research can safely guide those pathways to sprout, strengthen, or reroute, gene-delivered growth signals may become part of a larger recovery strategy.

For now, the finding is best understood as a promising laboratory step toward making the injured nervous system more adaptable after contusion SCI.

Robotic-assisted gait training is often used in SCI rehabilitation because it can deliver repeated stepping practice with body-weight support and controlled leg movement. For people with significant weakness or paralysis, the robot can move the legs through a walking pattern even when the person cannot generate that movement independently.

A common question is whether passive robotic walking is meaningful for the nervous system, or whether it is mainly a mechanical exercise for the legs. This study, published in Gait & Posture, looked directly at the brain during passive robotic-assisted gait training in individuals with spinal cord injury.

The study question

The researchers used EEG, a method that records electrical activity from the scalp, to study cortical connectivity during passive robotic gait. "Cortical" refers to the cerebral cortex, the outer part of the brain involved in movement planning, sensation, attention, and voluntary control. "Connectivity" refers to how strongly different brain regions appear to communicate or coordinate their activity.

The title of the paper reports enhanced cortical connectivity during passive robotic-assisted gait training. In plain language, that suggests the brain was not simply idle while the robot moved the legs. The movement, sensory feedback, body position, and rhythm of stepping may have activated or synchronized parts of the brain involved in locomotion.

Why passive movement can still matter

Walking is not controlled only by the legs. It is a loop involving the brain, spinal cord, sensory nerves, muscles, joints, balance systems, and vision. Even when a robot supplies the movement, the body still sends information back to the nervous system: hip angle, knee movement, foot loading, stretch, rhythm, and posture.

For a person with SCI, those signals may be reduced, distorted, or partly disconnected, but they may not be absent. Passive robotic stepping could provide repeated, structured sensory input to remaining pathways. If the brain responds to that input, passive gait training may help keep locomotor networks engaged, especially for people who cannot yet contribute much active movement.

What EEG adds

Traditional rehab outcomes often focus on visible performance: walking speed, distance, assistance level, or step quality. EEG adds another layer. It asks what the nervous system is doing during training.

Enhanced cortical connectivity does not automatically mean improved walking. It is a biological signal, not a functional outcome by itself. But it can help researchers understand whether a therapy is engaging the intended neural systems. If passive robotic gait activates motor and sensorimotor networks, clinicians and researchers may be able to design better protocols around intensity, timing, attention, active participation, and stimulation.

Analysis

The important idea here is that passive does not necessarily mean neurologically passive. A person may not be voluntarily driving the step, but the brain can still receive rhythmic movement information and may still organize around it.

That matters for people with more severe SCI, who are often excluded from active gait approaches because they cannot produce enough movement. If passive robotic training can engage cortical networks, it may have a role earlier in rehabilitation or in people with limited voluntary control. It may also pair well with other tools, such as functional electrical stimulation, brain-computer interfaces, transcranial stimulation, epidural stimulation, or task-specific practice.

The study also fits a broader trend in neurorehabilitation: researchers are moving beyond asking whether a device moves the body, and toward asking whether the device drives useful nervous system activity.

What this does not prove yet

EEG connectivity is not the same as recovery. The public metadata for this article does not provide enough detail to judge sample size, injury mix, training dose, or whether connectivity changes predicted functional improvement. The study should therefore be read as a neurophysiology finding rather than proof that passive robotic gait training restores walking.

It also does not mean passive movement is always better than active training. In rehabilitation, active effort usually matters. The more useful question may be how passive robotic stepping can be used when active movement is limited, and how clinicians can gradually increase participation as neural and muscular capacity allows.

Perspective

For SCI rehabilitation, this is an encouraging mechanistic story. It suggests that the brain may still be part of the walking conversation even when a robot is doing much of the work. The next step is to connect these EEG changes to outcomes people care about: standing, stepping, endurance, balance, spasticity, fatigue, and independence.

For years, clinical guidelines for acute traumatic SCI have recommended maintaining a mean arterial pressure [MAP — a measure of average blood pressure] of 85–90 mmHg or higher for the first 3–7 days after injury. The reasoning: the injured cord is vulnerable to secondary ischaemia [damage from reduced blood supply], and higher perfusion pressure [the force driving blood into the tissue] might limit that damage. A review on First10EM — a point-of-care emergency medicine resource — analyses the evidence behind this practice, specifically examining a randomised clinical trial published in JAMA Network Open that directly compared augmented versus conventional blood pressure targets in acute SCI. The trial's findings are striking: augmented blood pressure [MAP >85–90 mmHg] produced no better neurological scores at 6 months than conventional management. The augmented group experienced higher rates of respiratory complications, longer mechanical ventilatory support, and greater overall organ dysfunction. The reviewers note that avoiding frank hypotension [a dangerous drop in blood pressure] does remain beneficial — the concern is with aggressively elevated targets rather than simply preventing dangerous lows. Observational data shows that even transient hypotensive episodes in the first 72 hours worsen recovery, suggesting the optimal approach sits between the extremes. The First10EM review recommends treating the patient's clinical picture rather than chasing numerical targets — aligning with 2024 AO Spine and Praxis guideline recommendations of MAP ≥75–80 mmHg as a floor, not an aggressive ceiling. This has direct implications for emergency and intensive care management of acute SCI.

Why don't nerve fibres in the spinal cord simply regrow after injury? A 2026 study published in Nature by researchers at the Icahn School of Medicine at Mount Sinai identifies the aryl hydrocarbon receptor [AHR] — a protein found in neurons that normally senses environmental signals — as a key molecular brake on axonal regeneration [the regrowth of nerve fibres after damage]. After injury, AHR activates a protective stress response in damaged neurons, tightening protein quality control [proteostasis — the cell's system for managing its protein inventory]. While this protects neurons from immediate stress-induced death, it also downregulates [reduces production of] the growth-promoting proteins that axons need to extend. The research team removed or blocked AHR in mouse models of both peripheral nerve injury and spinal cord injury — either genetically or with pharmacological [drug-based] agents — and found that axons regrew more effectively and motor and sensory function recovered measurably better. Crucially, several AHR-blocking drugs are already in clinical trials for other diseases, including certain cancers, meaning a potential translational pathway may already be partially established. This is currently mouse research; human SCI clinical trials targeting AHR would still be needed. The Mount Sinai team plans to test both AHR-blocking drugs and gene-therapy strategies designed to reduce AHR activity in neurons, in further preclinical and eventually clinical work.

Note: This paper was published in 2007 in the Journal of Neurotrauma and represents foundational research rather than a new finding. It has resurfaced in today's alert feeds via Semantic Scholar indexing and is covered here as a research primer underpinning ongoing 2026 work on blood-spinal cord barrier [BSCB] therapeutics. The BSCB is a specialised lining of blood vessels in and around the spinal cord that strictly controls what passes between the bloodstream and the cord's delicate neural tissue — analogous to the blood-brain barrier. After injury, disruption of this barrier allows immune cells, inflammatory proteins, and blood-borne substances to flood the cord, causing secondary damage that is often more severe than the initial trauma. Maikos and Shreiber (2007) conducted the first systematic, quantitative study of how quickly and severely this breach occurs. Using a rat weight-drop contusion model [dropping weights of increasing height onto the exposed thoracic spinal cord], they measured the extravasation [leakage through vessel walls] of three molecular tracers of different sizes — a small molecule, a protein [bovine serum albumin, ~70 kDa], and red blood cells — just five minutes post-injury. BSCB disruption was immediate and non-selective, present within five minutes. Larger drop heights produced greater leakage volumes; grey matter [where nerve cell bodies concentrate] was more vulnerable than white matter [where nerve fibres run]. The study established a clear, biomechanical relationship between injury severity and vascular damage that has underpinned decades of subsequent research into BSCB-protective interventions in acute SCI.

Respiratory failure is the leading cause of death after cervical spinal cord injury. Most people with high cervical SCI require ventilator support because nerve pathways from the brainstem's breathing rhythm generators to the diaphragm are interrupted. Epidural stimulation — delivering electrical pulses to the spinal cord via electrodes implanted on the epidural surface [the space between the vertebra and the spinal cord membrane] — has shown remarkable results for motor recovery, but its application to breathing has been far less explored. A 2026 preprint by Dale, Mickle, Peñaloza-Aponte, and Brennan argues that current pacing strategies override brainstem rhythm generators rather than working with them, limiting adaptability and rehabilitation potential. Their work maps ascending spinal pathways and peripheral sensory feedback mechanisms that connect cervical spinal cord stimulation to the hypoglossal motor nucleus [the brainstem region controlling upper airway muscles] and other respiratory circuits. A key finding from the same research group shows that C4 epidural stimulation alters motor output at the hypoglossal level through both excitatory ascending pathways and inhibitory peripheral sensory feedback — meaning the response is bidirectional and complex, not simply a one-way signal boost. This is a preprint [not yet peer-reviewed] and animal work. The findings have direct implications for designing closed-loop stimulation systems [devices that sense breathing signals and adjust stimulation in real time] that could eventually restore more natural, adaptable breathing in people with cervical SCI.

Transplanted cells for spinal cord injury often fail to survive long enough or integrate well enough to make a meaningful difference. A 2026 study in Science China Life Sciences by Yunlong et al. tested whether adding electroacupuncture [electrical stimulation delivered through acupuncture needles] and ordered collagen scaffolds [a structured biological framework that mimics the natural architecture of spinal cord tissue] to neural progenitor cell [NPC] transplantation could change that. Neural progenitor cells are immature cells with the potential to develop into neurons [nerve cells], astrocytes [support cells], or oligodendrocytes [the cells that insulate nerve fibres with myelin]. The study found that electroacupuncture increased local production of neurotrophic factors [growth-promoting proteins such as NT-3 and BDNF] that helped transplanted cells survive and integrate. The ordered collagen scaffold provided a physical roadmap for new nerve fibres to grow along — addressing the disorganised injury environment that usually causes transplanted cells to fail. Together, the three-component approach achieved significantly better motor function recovery in rat SCI models than any single treatment alone. This is an animal study — all results are in rats. Translation to human use would require substantial further development, and the regulatory complexity of combination therapies involving both a device and a cell product adds additional hurdles. It is notable, however, that this directly targets the survival-and-integration failure that has limited cell therapy for SCI.

SCI triggers two successive crises: an acute inflammatory storm in the first days, followed by chronic failure of neural repair. Most treatments address one phase or the other — not both in sequence. A 2026 study in Chemical Engineering Journal by Ju et al. describes a microenvironment-responsive exosome-hydrogel hybrid system designed to tackle both. Exosomes [tiny vesicles naturally produced by cells, packed with signalling proteins and RNA] are released from the hydrogel in response to the inflammatory signals present at the acute injury site. Once released, they act on immune cells to shift them from a damaging M1 phenotype [attack mode] to a healing M2 phenotype [repair mode]. As inflammation subsides, the hydrogel scaffold continues to support neural regeneration by providing a physical structure for nerve cells to grow along. The study was conducted in animal models, with authors reporting improvements in functional recovery scores. This remains a preclinical study — no human trials have been conducted. Substantial safety testing and clinical development would be needed before use in people. However, this dual-function, sequenced delivery approach is increasingly viewed as the correct strategy in SCI, as single-target treatments have consistently underperformed in clinical translation.

When spinal cord cells are destroyed by injury, they spill their contents — including their DNA — into surrounding tissue. This loose genetic material, known as cell-free DNA [cfDNA], doesn't sit inertly; it triggers the immune system to mount a prolonged inflammatory response that accelerates neuronal apoptosis [programmed nerve cell death] and makes recovery progressively harder. In a study published in ACS Applied Materials & Interfaces, a Chinese research team led by Z. Wang developed a spatiotemporally delivered scavenger — a material that acts like a molecular sponge for cfDNA, intercepting it before it can bind to the immune receptors that kick off this destructive cascade. The delivery system was designed to release the scavenger at the right location and the right time after injury to maximise impact. Testing was conducted in cell models [in vitro] and animal models [in vivo], where the approach significantly reduced neuroinflammation [nerve-damaging immune activity] and cell death at the injury site. This is a lab and animal study; no human trials have been conducted, and clinical translation remains a long step away. However, targeting the cfDNA pathway represents a novel approach to the inhibitory post-injury microenvironment — the hostile chemical environment that has undermined most SCI treatments tested to date.

Spinal cord injury doesn't only damage the cord itself — it sets off a chain reaction that disrupts the gut, derails the immune system, and throws metabolism into disorder. A review paper by Huang et al. in International Immunopharmacology describes the emerging concept of the gut-spinal axis: the two-way communication network connecting the gut's microbial ecosystem and the injured cord. After SCI, loss of normal nerve signals to the gut — known as neurogenic bowel — causes dysbiosis [disruption of the normal gut bacterial community]. This disruption allows harmful bacterial fragments to leak into the bloodstream, triggering systemic immune activation that then worsens neuroinflammation [damaging immune activity] at the injury site. Simultaneously, disruption of metabolic homeostasis [the body's chemical balance], including changes in how fats, sugars, and immune signals are processed, creates conditions hostile to nerve repair. The authors review evidence that restoring gut microbial health — through targeted probiotics, dietary intervention, or faecal microbiota transplant [transferring healthy gut bacteria from a donor] — may reduce neurological damage and improve recovery outcomes. This is a review paper synthesising existing research, not a new experimental study. It points to the gut microbiome as a genuinely underexplored therapeutic target in SCI, though direct human trials of gut-targeted SCI therapies remain in early stages.

Healing after SCI is a sequence problem: the body needs different treatments at different times, but conventional single-dose therapies can't adapt to an evolving injury environment. A 2026 study in Materials Today Bio by Zhang et al. introduces a spatiotemporal liposome-zwitterionic nanohydrogel system. In practical terms, this is a gel studded with tiny fat-coated capsules that carry therapeutic molecules and release them on a pre-programmed schedule. Zwitterionic materials [materials that carry both positive and negative electrical charges] are notable for biocompatibility and resistance to triggering unwanted immune reactions. The liposomes first release anti-inflammatory compounds in response to the acute-injury microenvironment. As conditions shift over days, the system transitions to deliver immunomodulatory [immune-steering] and neurogenesis-promoting [new neuron growth] signals. The study was conducted in preclinical animal models and reports that the sequential approach addresses the two-phase problem more effectively than single-phase treatments. This is an animal study only — no human trials have been conducted. The complexity of the system is both its therapeutic promise and its regulatory challenge: more components mean more interactions to characterise before clinical use becomes possible.

Paralysis after SCI doesn't only affect the limbs — the loss of nerve control extends to internal organs including the bowel, bladder, and stomach, causing significant health complications that represent some of the most debilitating aspects of living with SCI. A 2026 study from MIT's McGovern Institute, published on 31 March, introduces the myoneural actuator [MNA] — a biohybrid device that uses living skeletal muscle [the type that normally moves limbs] surgically rewired so that a computer, rather than the brain, controls it. The MNA is implanted and wrapped around an organ. When the computer sends a signal, the muscle squeezes the organ, restoring a facsimile of normal movement — a process analogous to peristalsis [the rhythmic gut contractions that move food and waste]. In rodent experiments, the team restored squeezing motion in the small intestine. Critically, the system also transmitted sensory signals back toward the brain, suggesting a future implant could allow paralysed organs to communicate their state — such as a stomach conveying hunger or fullness. The authors identify potential applications in neurogenic bowel [loss of gut nerve control in SCI], ileus [post-surgical bowel paralysis], and diabetic enteropathy [gut damage from diabetes]. This is a rodent study; larger-animal and human studies are needed before clinical use. The proof of concept — that living muscle can serve as a fatigue-resistant, computer-controlled actuator inside the body — is genuinely novel and opens a new category of organ restoration technology.

Neuropathic pain — persistent, often burning or stabbing pain caused by nerve damage rather than ongoing tissue injury — affects up to 80% of people living with SCI. A February 2026 review in Experimental Neurology, part of a special issue on central neuropathic pain in SCI, maps the mechanisms driving this condition and critically examines the animal models used to study it. The authors identify several converging mechanisms: central sensitisation [a state in which the spinal cord's pain-processing circuits become abnormally amplified, responding to non-painful signals as if they were painful], neuroinflammation driven by glial cell activation [where microglia and astrocytes shift into inflammatory mode], hyperexcitability of primary sensory neurons [peripheral pain-detecting nerve cells that fire too readily after injury], and structural remodelling of pain circuits in the brain itself. Animal models reviewed include contusion, compression, and transection SCI models in rodents, using von Frey filaments [fine calibrated fibres used to measure mechanical pain sensitivity], thermal testing, and electrophysiological recordings [electrical measurements of pain-processing neuron activity]. The paper flags a critical translational gap: in humans, SCI neuropathic pain is primarily spontaneous or tonic [constant background pain], but animal model measurements almost exclusively use evoked responses [triggered by applied stimuli]. This fundamental mismatch may help explain why so many animal-model successes have failed to produce effective human treatments. This is a review paper — it synthesises existing research rather than presenting new data — but it functions as an important calibration exercise for the field.

In February 2026, Rooprai — a woman with paraplegia [paralysis of the lower body, typically caused by SCI] — took her first steps along a Fort Lauderdale beach wearing an advanced AI-powered robotic exoskeleton. Exoskeletons are wearable robotic frames that support and move the legs through normal walking motions, enabling people with lower-body paralysis to stand upright and walk. The device incorporates artificial intelligence that reads residual nerve and muscle signals, synchronising hip and knee movements to mimic natural gait [the walking pattern]. Unlike earlier exoskeletons that used fixed programmed movements, AI-integrated systems adapt in real time to the user's own signals and terrain. Exoskeletons do not repair the spinal cord; they bypass it by providing external mechanical actuation. Regular exoskeleton use has been shown in some studies to deliver secondary benefits including reduced spasticity [involuntary muscle stiffness and spasms], improved bowel and bladder function, and better cardiovascular fitness — though study quality varies and these benefits are not universal. The technology remains expensive and requires significant training, limiting access. Regulatory approvals for personal exoskeleton use outside clinical settings have expanded in recent years in the US, Australia, and Europe, moving the technology closer to daily-life use for eligible patients.

After spinal cord injury, a dual scar forms at the injury site: a glial scar [made of reactive astrocytes and other support cells] and a fibrotic scar [made of collagen-depositing connective tissue cells]. While these scars initially seal off damage, they quickly become the primary barrier to axonal regeneration [the regrowth of nerve fibres]. A 2026 review by Zhang, Jin, and Ning in Frontiers in Neurology examines growing evidence that mitochondrial dysfunction [failure of the cell's energy-producing organelles] is a key upstream driver of this scarring process. When mitochondria fail after SCI, cells experience energy depletion and a surge of reactive oxygen species [ROS — chemically unstable molecules that damage proteins, fats, and DNA]. This metabolic crisis triggers reactive gliosis [the abnormal over-activation of glial cells], amplifies the inflammatory cascade, and ultimately leads to the dense, inhibitory scar matrix surrounding chronic SCI injury sites. The authors review therapeutic approaches targeting mitochondrial function — including antioxidants [ROS-neutralising molecules], mitochondrial transplantation [an experimental approach to replacing damaged mitochondria with healthy ones], and metabolic modulators. This is a review paper drawing on existing experimental literature, not new experimental data. It frames mitochondrial health as a tractable and time-sensitive therapeutic target, particularly in the acute and subacute injury phases when intervention might prevent scar formation from becoming permanent.

Note: This study addresses Persistent Spinal Pain Syndrome [PSPS — chronic back and leg pain following spinal surgery that didn't resolve the problem, previously called Failed Back Surgery Syndrome]. While not exclusively an SCI population, spinal cord stimulation [SCS] is a primary treatment modality for SCI-related neuropathic pain, and long-term efficacy and age-related outcome data are directly relevant to the SCI community. SCS involves implanting thin electrode leads near the spinal cord that deliver electrical pulses to modulate pain signals before they reach the brain — essentially interrupting the misfiring pain circuits that produce neuropathic pain. The EV187 study, published in the Neuromodulation journal, assessed 40 patients with PSPS who received SCS therapy, tracking subjective sensory responses using Quantitative Sensory Testing [QST — standardised measurements of response to electrical and mechanical pressure stimuli] at multiple time points. Follow-up ranged from 5 to 11 years — unusually long for this type of study. Pain levels, drug use, and quality of life were assessed throughout. The study found that pain relief persisted over this extended period, and that outcomes were equivalent or better in older patients — countering a clinical concern that SCS is less suitable for elderly patients due to comorbidities or reduced physiological adaptability. Broader data from the US show a 115% increase in SCS trials and a 324% increase in permanent SCS placement in patients over 85 between 2009 and 2018. The EV187 report is a conference abstract-level study; full peer-reviewed data should be consulted for complete conclusions.

Manufacturing consistency is one of the most overlooked but absolutely critical steps between a promising lab therapy and one that can be tested in humans. NurExone Biologic — a Canadian company developing an exosome-based therapy for acute spinal cord injury — announced results from an independent proteomic analysis [a comprehensive study of the protein content of each production batch] conducted at the Technion – Israel Institute of Technology. The analysis evaluated multiple batches of their ExoPTEN exosomes [nano-scale vesicles derived from cells, engineered to carry a genetic payload that suppresses the PTEN gene]. PTEN normally acts as a brake on axon regrowth; suppressing it has been shown in preclinical studies to dramatically enhance nerve regeneration after SCI. The independent analysis confirmed that batches were consistent in composition and biological activity — a requirement of Chemistry, Manufacturing and Controls [CMC] readiness, the regulatory framework governing what must be demonstrated before a drug can be tested in humans. NurExone's planned Phase 1/2a clinical trial is targeted for 2026 and will enrol adult patients with traumatic SCI between spinal levels C5 and T10, classified as ASIA Grade A or B [indicating complete or near-complete injury]. This is a pre-trial announcement — no human data exists yet, and Phase 1 primarily assesses safety rather than efficacy. However, for a therapy with strong preclinical results, clearing the manufacturing consistency hurdle is a meaningful and necessary step toward that first human trial.

The spinal cord is an electrical organ. Nerve signals travel as precisely timed pulses of electrical charge, and the tissue itself maintains a carefully calibrated bioelectrical environment that keeps neurons alive and communicating. When a spinal cord injury occurs, that environment collapses — cells stop firing, the electrical balance breaks down, and a destructive cycle sets in: electrical silence leads to neuronal degeneration, which triggers scar-forming glial cells, which further blocks recovery. A new review in the Journal of Functional Biomaterials asks whether purpose-built biomaterials can reverse this cycle by physically rebuilding the injured cord's electrical environment. What electroconductive biomaterials are The review by Zhang and colleagues focuses on a class of engineered materials called electroconductive biomaterials — substances that conduct electrical signals while remaining safe to implant in living tissue. The most discussed approach involves injectable electroconductive hydrogels: gel-like substances delivered into the injury site by syringe that, once in place, form a matrix conducting electrical signals between surviving nerve cells. The idea is that re-establishing electrical continuity across the injury zone could encourage surviving neurons to fire again and support the regrowth of nerve fibres. How they work Applying controlled electrical signals through the material — exogenous electrical stimulation — can reverse the electrically silent state of neurons and switch on molecular programmes associated with regeneration. The conductive scaffolds can also act as carriers for drugs, growth factors, or transplanted cells, combining physical and biochemical repair approaches in a single implant. Researchers are developing smart versions that respond to the injury environment, releasing therapeutic signals in response to chemical cues. Where this stands For people living with SCI, this field represents a longer-term horizon rather than an imminent clinical option. Most work is preclinical — cell cultures and animal models. The challenge of safely implanting materials into the damaged spinal cord without causing additional harm remains significant, as does demonstrating that any electrical recovery translates to meaningful function in humans. No approved clinical therapies based on electroconductive biomaterials for SCI currently exist, but the field is advancing rapidly.

After a spinal cord injury, the initial physical trauma triggers a secondary injury — a wave of inflammation that continues destroying tissue for hours and days after the event. Controlling this cascade is one of the central challenges in acute SCI treatment. A new systematic review in Brain Sciences examines one promising candidate: etanercept (brand name Enbrel), a drug that blocks TNF-α (tumour necrosis factor-alpha), a key driver of that inflammatory wave. What TNF-α does and how etanercept stops it TNF-α is a protein the body releases in response to injury or infection. After SCI it spikes rapidly, driving secondary damage — activating immune cells, disrupting the blood-spinal cord barrier, and triggering cell death. Etanercept binds to TNF-α and neutralises it before it activates its targets, intercepting the signal before damage escalates. It has been used safely in humans for decades in conditions like rheumatoid arthritis and psoriasis. What the review found The systematic review by Garmo and colleagues, searching studies through December 2025, synthesised preclinical studies of etanercept after SCI. Across included studies, treatment was consistently associated with reduced inflammation, lower levels of TNF-α and IL-1β in tissue and blood, preserved myelin, and improved hindlimb motor function. Some studies found reductions in cell death and neutrophil infiltration — an immune cell type that contributes significantly to secondary injury. The repurposing appeal Etanercept is already approved, well-studied for safety, and available. Drug repurposing can dramatically shorten the path to clinical availability compared to developing a new compound from scratch. However, this review covers animal research only, and the leap from rat SCI models to human trials remains substantial. Timing, dosage, and route of administration in the acute setting would all need to be established before trials could proceed. No human trials of etanercept specifically for SCI are yet underway.

People with spinal cord injury face significantly elevated risk of cardiovascular disease and metabolic conditions like type 2 diabetes. Paralysis reduces active muscle mass, lowering the body's ability to burn glucose and regulate blood fats. Combined with reduced mobility and the physiological changes that follow SCI, this creates a cluster of risk factors — high blood glucose, abnormal lipids, cardiovascular stress — that can develop years before symptoms appear. A new systematic review and meta-analysis in BMC Sports Science Medicine and Rehabilitation examined the full body of evidence on exercise training as a countermeasure. What the analysis covered Khalafi and colleagues searched PubMed, Web of Science, and Scopus from inception to January 2025 — one of the most up-to-date syntheses of this field to date. The analysis examined effects of exercise on glycaemic markers (blood sugar regulation), lipid profiles (cholesterol and triglycerides), and broader cardiometabolic outcomes in adults with SCI. What the evidence shows Exercise training improved multiple markers of metabolic health. Aerobic exercise was particularly effective at improving insulin sensitivity — the body's ability to respond to insulin and clear glucose from blood. Resistance training showed stronger effects on lipid profiles, including reductions in harmful LDL cholesterol and triglycerides. Functional electrical stimulation (FES) cycling, which uses electrical pulses to activate paralysed leg muscles, showed benefits for peripheral insulin sensitivity specifically — engaging metabolic pathways that upper-body exercise alone does not reach. Practical implications The type of exercise matters, and benefits don't require a one-size-fits-all approach. A programme combining aerobic and resistance elements — tailored to injury level and capacity — appears to offer the broadest metabolic benefit. For higher-level injuries where voluntary lower-body exercise isn't possible, FES-based options add a meaningful complement. This is a meta-analysis of existing human clinical studies — a higher level of evidence than single studies alone. Structured exercise programmes should be viewed as a genuine health-protective intervention, not an optional extra.

Chronic pain is one of the most common and persistent challenges after spinal cord injury, and opioid medications are frequently prescribed to manage it. But the relationship between pain, opioid use, and mental health in SCI is complex — and a new study in Spinal Cord (Nature) provides some of the clearest data yet on how opioid misuse connects to suicidal ideation in this population. The study and sample Led by James Krause and colleagues at the Medical University of South Carolina, the study drew on self-report data from 1,253 participants enrolled in a longitudinal health outcomes study — one of the largest datasets of its kind in SCI research. Participants answered detailed questions about prescription opioid use, any misuse of opioids, binge drinking, pain levels, depression, and suicidal ideation. The numbers The findings were striking. Self-reported misuse of prescription opioids was associated with 3.51 times the odds of suicidal ideation (OR = 3.51, CI = 1.83–6.72). Using three or more prescription opioids concurrently was associated with 3.53 times the odds (OR = 3.53, CI = 1.50–8.31). For comparison, depression was associated with nearly 6 times the odds (OR = 5.98, CI = 3.60–9.92), and 15 or more painful days per month with more than double the odds (OR = 2.15, CI = 1.24–3.73). Binge drinking did not show a statistically significant relationship with suicidal ideation in this sample. What it means for care These figures highlight an underappreciated compounding risk: chronic pain drives opioid use, opioid misuse compounds psychological distress, and psychological distress elevates suicide risk — all within a population already facing elevated rates of depression and social isolation. The study cannot establish causation, but the associations are robust. The authors argue that pain management, mental health, and suicide risk must be treated as interconnected in SCI care — not as separate concerns. Routine screening for opioid misuse and suicidal ideation, particularly in patients on multiple opioids or with high pain burden, appears warranted.

Respiratory failure is the leading cause of death in people with cervical spinal cord injuries, and breathing difficulties remain one of the most life-altering consequences of high-level SCI even in those who survive. The phrenic nerve — which drives the diaphragm — receives signals from the brainstem that travel through the spinal cord. When the cord is injured in the cervical region, that pathway is disrupted, weakening or eliminating automatic breathing control. A new study in Experimental Neurology investigated whether targeting specific nerve cells within the spinal cord could strengthen the breathing response in chronic cervical SCI. The cells in question The study by Brezinski and colleagues focused on spinal excitatory interneurons — nerve cells within the cord that don't directly control the diaphragm, but act as amplifiers and relay stations for incoming respiratory signals. When the brainstem sends a breathing signal down the cord, these interneurons boost and shape it before it reaches the motor neurons that drive the breathing muscles. Previous research identified certain cholinergic (acetylcholine-releasing) interneurons as particularly active during hypercapnic ventilatory response — the automatic increase in breathing triggered when blood CO2 rises, a critical safety mechanism. What the researchers found Selectively activating spinal excitatory interneurons enhanced the hypercapnic ventilatory response in chronic cervical SCI. In other words, stimulating these relay cells strengthened the automatic drive to breathe more when CO2 builds up — a response typically blunted after high-level injury. Critically, the approach sustained ventilation improvements in the chronic phase of injury, not just acutely. Why it matters For people with cervical injuries who rely on ventilators or experience breathlessness during exertion, this research points toward a therapeutic target. If specific interneuron populations can be reliably activated — through pharmacology, electrical stimulation, or future optogenetic tools — it may be possible to partially restore respiratory drive without external ventilation. The finding that this works in the chronic phase is particularly relevant for the large population living long-term with cervical SCI. This is preclinical research in an animal model; considerable work remains to translate interneuron activation into clinical practice.

One of the most persistent obstacles to recovery after spinal cord injury is the secondary injury cascade — a prolonged inflammatory response that continues well beyond the initial trauma. While some immune activity is necessary for repair, in SCI this frequently becomes chronic and destructive. Immune cells called myeloid cells — including macrophages and microglia, the spinal cord's resident immune cells — can persist in an inflammatory state that damages surrounding tissue and limits new connections from forming. A new study in Cells tested whether a two-drug combination could shift this balance. The two agents Propentofylline is a xanthine derivative — related to caffeine — shown in previous research to suppress inflammatory signalling in glial cells. It works by inhibiting pathways that keep immune cells in a pro-inflammatory mode. Interleukin-4 (IL-4) is a naturally occurring cytokine — a chemical messenger — that the body uses to switch immune responses from inflammatory to repair-promoting, previously studied in SCI models as a way to drive macrophages toward a healing rather than destructive state. What the study found Ghosh and colleagues evaluated systemic combination treatment of propentofylline and IL-4 in a spinal cord injury model, measuring effects on myeloid cell populations at the injury site and on functional outcomes. The combination was associated with modulation of lesion-associated myeloid responses — immune cells at the injury site shifted toward a less damaging state — and with improved functional recovery compared to untreated controls. Where this fits Both compounds are known with established research histories, making their combination a relatively straightforward target for further development. However, this is animal research. Translation to human trials would require safety profiling of the combination, dose optimisation, and identification of the treatment window after injury when intervention would be most effective. The findings add to a growing literature on immunomodulation as a strategy for improving SCI outcomes — using drugs or biological signals to deliberately reshape the immune response, rather than blocking it entirely.